ID,Title,Start_Date,Completion_Date,Actual_Duration,Status,Study_Type
BTX-BCI-016-PRT,Breast Cancer Index (BCI) Registry,2021-04-14,2028-12-01,2788 days,Recruiting,Observational
2018-TJ-BCD,Diagnosis Value of SEMA4C in Breast Cancer,2023-09-01,2024-09-01,366 days,Not yet recruiting,Observational
Breast cancer,Role of Sorcin and Annexin A3 in Breast Cancer Patients,2019-01-20,2019-09-30,253 days,Unknown status,Observational
BC-BOMET,Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases,2020-01-13,2024-11-12,1765 days,Recruiting,Observational
241391,A Study to Identify Breast Cancer (IDBC),2019-01-24,2022-12-31,1437 days,Unknown status,Observational
IL-TM-B1-01,Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay,2018-01-22,2019-07-01,525 days,Unknown status,Observational
FH-Risk 2.0 Research Protocol,FH-Risk 2.0: Updating Breast Cancer Risk Estimates,2022-03-01,2024-10-31,975 days,Recruiting,Observational
ID-RPSBC-01-20201012,Genetic and Non-Genetic Breast Cancer Risk Prediction Evaluation in Indonesian Samples,2020-10-13,2023-06-30,990 days,Recruiting,Observational
IRST174.22,What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer?,2020-02-06,2026-02-01,2187 days,Recruiting,Interventional
ANILERGÄ°NN,Weight Loss and Breast Cancer,2022-12-15,2026-05-01,1233 days,Not yet recruiting,Observational
32155120.7.0000.0072,Breast Cancer Survivors: Main Physical and Psychosocial Problems After Completion of Treatment,2020-10-05,2022-11-01,757 days,Unknown status,Observational
GCO 17-2188,Increasing African Immigrant Womens Participation in Breast Cancer Screening,2020-02-05,2023-06-01,1212 days,Recruiting,Interventional
233756,The HIFUB Study (HIFU in Breast Cancer),2022-05-01,2022-11-01,184 days,Not yet recruiting,Interventional
D16196,A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers,2018-05-24,2021-04-05,1047 days,Completed,Interventional
RO1912-30902,RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients,2020-01-01,2022-02-01,762 days,Unknown status,Interventional
UMCC 2021.087,Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid,2022-05-12,2023-05-01,354 days,Recruiting,Interventional
LNs Staging of Breast cancer,Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Breast Cancer.,2018-10-01,2021-12-01,1157 days,Unknown status,Interventional
SA18i0002,The Effect of a Patient Decision Aids for Breast Cancer Screening,2021-07-01,2022-10-31,487 days,Recruiting,Interventional
494936,Clinical Pilot Study for Personalized Risk-based Breast Cancer Screening,2023-02-01,2035-11-11,4666 days,Recruiting,Interventional
042210,Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer,2023-06-15,2028-06-30,1842 days,Not yet recruiting,Interventional
Yuan Shifang-1,Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device,2020-01-01,2022-12-01,1065 days,Unknown status,Observational
(818)109A-57,Mobile Application Support for Women With Breast Cancer Undergoing Chemotherapy,2021-05-16,2023-12-31,959 days,Recruiting,Interventional
21 SEIN 01,Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer.,2021-03-31,2022-07-29,485 days,Completed,Interventional
18-181,Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening,2019-01-30,2026-05-30,2677 days,Recruiting,Interventional
catheter guided chemo-infusion,Catheter Guided Chemo-infusion in Breast Cancer,2023-04-01,2025-05-01,761 days,Not yet recruiting,Interventional
2020/132,Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS),2021-06-01,2022-02-01,245 days,Completed,Interventional
17-689,Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening,2018-05-17,2023-08-30,1931 days,"Active, not recruiting",Interventional
831804,[18F] F-GLN by PET/CT in Breast Cancer,2019-04-05,2024-12-01,2067 days,Recruiting,Interventional
PI-2842,Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women,2018-07-01,2019-12-31,548 days,Completed,Observational
NCC2985,Characteristics and Treatment Trends of Young Breast Cancer in China,2021-11-01,2024-10-01,1065 days,Not yet recruiting,Observational
260281,Sodium (23Na) MRI for Tumour Characterisation and Assessment of Therapy Response in Breast Cancer,2020-08-13,2025-12-31,1966 days,Recruiting,Observational
V1 11.12. 2020 (C.I.R.E.C.),Onco-liq: Kit for Breast Cancer Diagnosis.,2021-09-01,2023-08-01,699 days,Recruiting,Observational
154/2019,Short and Long Term Effects of a Physical Therapy Program After Breast Cancer Surgery,2019-12-02,2024-02-25,1546 days,Suspended,Interventional
Amr Ahmed,"The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism",2023-01-01,2024-01-31,395 days,Not yet recruiting,Interventional
CLM-INS-004,PERSONAL - Sleep In Breast Cancer,2022-01-15,2022-08-03,200 days,Completed,Observational
2022-11-076-002,Comparison of Ultrasound and Breast MRI for Breast Cancer Detection,2023-05-28,2028-05-28,1827 days,Not yet recruiting,Interventional
Health Literacy of Breast Ca,The Effect of Breast Cancer Screening Training,2023-02-15,2023-12-30,318 days,Not yet recruiting,Interventional
miRNA in breast cancer,Aberrant Expression of Micro RNA for Diagnosis of Breast Cancer,2021-12-01,2023-12-25,754 days,Not yet recruiting,Observational
MC1933,Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer,2021-01-13,2042-01-15,7672 days,Recruiting,Observational
RADIOVAL,Clinical Validation of Radiomics Artificial Intelligence: Application to Breast Cancer Treatment Planning,2023-06-01,2025-12-01,914 days,Recruiting,Observational
CE21096B,Factors Affecting Rehabilitation Time for Postoperative Complications Among Breast Cancer Patients,2021-05-01,2023-05-01,730 days,Recruiting,Observational
ZY(2018-2020)-CCCX-2005-04,Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer,2020-05-25,2024-05-31,1467 days,Recruiting,Interventional
MicroRNA in breast cancer,Diagnostic and Prognostic Value of MicroRNA in Breast Cancer Patients,2022-03-01,2024-03-01,731 days,Not yet recruiting,Observational
GEICAM/2016-04,Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk,2018-09-14,2024-12-31,2300 days,"Active, not recruiting",Observational
22IC7498,Behavioural Science Messages in Breast Cancer Screening,2022-07-15,2023-01-15,184 days,Completed,Interventional
BMIBC,Impact of Body Mass Index on Outcomes of Breast Cancer Management,2018-02-12,2019-08-12,546 days,Unknown status,Observational
3.0840453,Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53,2018-12-02,2022-02-22,1178 days,Completed,Observational
18 SEIN 11,"Prospective, Multicentric Study Evaluating the Surgical Treatment by Mastectomy With Immediate Prosthetic Breast Reconstruction in Patients With Breast Cancer and Receiving Adjuvant Therapy by TomoTherapy +/-Chemotherapy.",2019-06-07,2025-12-01,2369 days,Recruiting,Interventional
HKG-KZ-BrCa-101,"Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC",2018-06-01,2021-09-01,1188 days,Terminated,Observational
Hibiscuss,"Breast Cancer Detection in Breast Surgical Specimens With the Histolog Scanner, Slide-free Confocal Microscope",2019-06-26,2021-12-31,919 days,Completed,Observational
Pro00107118,A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer,2022-04-07,2024-10-01,908 days,Recruiting,Observational
SNAPS Breast Cancer,SNAPS Breast Cancer Patient Study Breast Cancer Patients,2024-09-01,2026-12-31,851 days,Suspended,Observational
17-447,Imaging With [11C]Martinostat in Breast Cancer,2020-02-01,2024-10-31,1734 days,Withdrawn,Interventional
22-509,Breast Cancer Survivor Educational Intervention,2023-02-28,2023-08-31,184 days,Recruiting,Interventional
ZCHBC022,Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC,2022-09-16,2025-12-30,1201 days,Recruiting,Observational
R.18.02.34.R1.R2,Association of Hepatitis C Virus With Breast Cancer,2019-09-01,2020-06-01,274 days,Completed,Observational
ID-BCRPS-02-20220913,The Perspective of Healthy Individuals on Breast Cancer Risk Prediction Report In The Indonesian Population,2022-09-14,2022-12-31,108 days,Recruiting,Interventional
112991,Hybrid PET/MR Imaging of Acute Cardiac Inflammation After Left-Sided Breast Cancer Radiotherapy,2019-01-01,2021-12-31,1095 days,Unknown status,Observational
17-01549,Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer,2018-07-23,2025-01-23,2376 days,Recruiting,Interventional
TET-21-001,Identification of Breast Cancer Specific Markers in Patients Compared to Healthy Participants,2021-10-04,2023-10-01,727 days,Recruiting,Observational
202101073,Project Insight: Feasibility of a Breast Cancer Screening Decision Support Tool,2021-04-19,2021-08-30,133 days,Completed,Interventional
"estPerMed 1, Breast",Personalised Risk-based Breast Cancer Prevention and Screening,2018-10-01,2020-12-01,792 days,Unknown status,Interventional
68824072019,Risk Reduction Program for Women Having High Risk of Breast Cancer,2018-04-01,2021-09-01,1249 days,Completed,Interventional
3055,Correlation of Predictive Accuracy of PREDICT Version 2.2 of Indian Women With Operable Breast Cancer,2018-11-15,2022-12-31,1507 days,"Active, not recruiting",Observational
20220303swj0211,The Psychology Intervention on Disease Acceptance and Quality of Life in Breast Cancer Patients,2022-10-20,2024-10-20,731 days,Not yet recruiting,Interventional
RC20_0532,Breast Cancer Screening Uptake: a Randomized Controlled Trial Assessing the Effect of a Decisional Aid,2023-01-01,2025-01-01,731 days,Not yet recruiting,Interventional
Breast Cancer Risk,Breast Cancer Risk From Sonographic Glandular Tissue Component (or International GTC Study),2022-11-01,2029-12-30,2616 days,Recruiting,Observational
KMUHIRB-E(I)-20200041,"Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment",2020-09-18,2022-08-15,696 days,Completed,Interventional
VGHKS18-CT11-17,CEDM as a Screening Tool for Breast Cancer in Higher-risk Women: A Prospective Study,2019-01-01,2021-12-31,1095 days,Completed,Observational
832165,Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT,2019-02-11,2027-02-01,2912 days,Recruiting,Observational
ICO-2019-08,Interest of Touch-massage in Hospital Day Care,2019-10-07,2020-05-12,218 days,Completed,Observational
biomarkers in breast cancer,Circular RNA and Chemerin in Breast Cancer Patient,2023-10-01,2025-12-01,792 days,Not yet recruiting,Observational
GEICAM/2017-07,Registry Study of Pregnancy and Breast Cancer,2019-11-18,2040-01-01,7349 days,Recruiting,Observational
LCCC2207,"Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians",2022-07-15,2025-07-15,1096 days,Recruiting,Observational
4452,Development of a Horizontal Data Integration Classifier for Noninvasive Early Diagnosis of Breast Cancer,2021-01-19,2024-12-01,1412 days,"Active, not recruiting",Interventional
MCC-21448,Study of Screening Brain MRIs in Stage IV Breast Cancer,2021-12-21,2023-08-31,618 days,Recruiting,Observational
2017-0588,Implementation of a Web-based Decision Aid for Breast Cancer Surgery,2019-04-04,2020-05-12,404 days,Completed,Observational
SK-421-BRCA,A Digital Solution for Breast Cancer Patients,2022-07-15,2023-09-01,413 days,Recruiting,Interventional
autotaxin1,Autotaxin: a Potential Biomarker for Breast Cancer.,2019-01-01,2021-03-15,804 days,Completed,Interventional
UPCC 19121,Role of the Immune Environment in Response to Therapy in Breast Cancer,2022-10-03,2032-12-31,3742 days,Recruiting,Observational
DS8201-A-U302,"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]",2018-08-09,2024-04-01,2062 days,"Active, not recruiting",Interventional
CCR 5113,PIONEER Study of Lifestyle Intervention to Reduced Breast Cancer Risk,2020-09-16,2023-12-01,1171 days,"Active, not recruiting",Interventional
21-480,A Formative Evaluation For Improving Breast Cancer Hormone Receptor Testing in Tanzania,2023-04-01,2023-05-01,30 days,Not yet recruiting,Observational
LQ005,Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer,2019-02-14,2022-04-01,1142 days,Unknown status,Observational
ICO-N-2017-02,Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse,2018-05-29,2020-12-03,919 days,Terminated,Interventional
medicin,Autotaxin (ATX) as a Marker for Breast Cancer,2021-05-01,2022-11-01,549 days,Unknown status,Interventional
METCZ20200211,Magnetic Tracer in the Sentinel Node Procedure in Breast Cancer: the Non-radioactive Alternative for Radio-isotopes,2021-08-01,2022-02-09,192 days,Completed,Interventional
2021LC2210,Remote Breast Cancer Screening Study,2021-09-01,2025-08-01,1430 days,Recruiting,Observational
17-581,Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds,2018-03-09,2018-08-27,171 days,Completed,Observational
2020-A00058-31,Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening,2021-05-31,2027-05-01,2161 days,Recruiting,Interventional
NCC3299,Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology,2022-04-01,2022-12-31,274 days,Recruiting,Observational
351-19,mULM to Support Breast Cancer Diagnosis and Therapy,2021-04-26,2023-12-01,949 days,Recruiting,Interventional
ESR-21-21505,The Treatment Situation of Chinese County Population With Breast Cancer,2022-09-29,2024-09-01,703 days,Recruiting,Observational
LUMHS/REC/-17,Association of Tumour Grade and Sex Steroid Receptor as a Prognostic Index in Breast Cancer,2020-07-01,2021-01-15,198 days,Unknown status,Observational
PekingUPH10B004,Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients,2021-04-02,2026-12-31,2099 days,Recruiting,Interventional
2014P002688a,Promoting Earlier Detection of Breast Cancer in Rwanda: Scaleup in the National Health Care System,2020-07-01,2022-03-25,632 days,Completed,Observational
ODELIA,A Retrospective Analysis of Magnetic Resonance Imaging Data for Breast Cancer Screening in the Open Consortium for Decentralized Medical Artificial Intelligence,2023-01-01,2027-12-31,1825 days,"Active, not recruiting",Observational
CD3-MUC1 in breast cancer,Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer,2019-05-20,2020-07-05,412 days,Withdrawn,Interventional
LCCC 1829,Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA,2018-11-06,2030-12-15,4422 days,Recruiting,Interventional
2022-080,"Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer",2022-08-04,2025-07-30,1091 days,Recruiting,Interventional
2018-TJ-BCP,SEMA4C as a Relapse Biomarker in Breast Cancer,2022-09-01,2026-08-01,1430 days,Not yet recruiting,Observational
20218,A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy,2019-01-29,2022-11-01,1372 days,Completed,Interventional
2017-03-002A,PET/MR Radiomics for Breast Cancer Diagnosis,2018-07-06,2022-12-31,1639 days,Recruiting,Observational
LA LEAST,Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer,2019-09-23,2029-05-01,3508 days,Recruiting,Interventional
1905795920,Breast Cancer Self-Efficacy Scale for Partners,2019-09-01,2022-03-01,912 days,Terminated,Observational
2015-004027-31,HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer,2019-03-08,2023-12-31,1759 days,Recruiting,Interventional
4-2018-0254,Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer,2018-10-02,2023-06-03,1705 days,Recruiting,Observational
BREACE,Exercise in Older Women With Breast Cancer During Systemic Therapy,2018-11-15,2023-12-01,1842 days,Recruiting,Interventional
495077,18F-FDG PET/CT Imaging for Breast Cancer,2023-02-16,2032-12-31,3606 days,Recruiting,Interventional
CCR4684,"Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours",2019-05-09,2024-07-01,1880 days,Recruiting,Interventional
211753,BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity,2022-03-09,2024-08-01,876 days,Recruiting,Interventional
1705018188,Dedicated Breast PET/MRI in Evaluation of Extent of Disease in Women With Newly Diagnosed Breast Cancer,2018-03-15,2022-03-04,1450 days,Terminated,Interventional
22-136,"A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer",2022-06-06,2025-06-06,1096 days,Recruiting,Interventional
CDK-HeCOG-2019,Clinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With CDK Inhibitors Combined With Endocrine Therapy,2019-01-01,2021-01-02,732 days,Completed,Observational
2020-0327,Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer,2018-01-01,2020-08-01,943 days,Completed,Observational
RECO_CT29B,Investigation of Urinary Biomarkers for the Detection of Breast Cancer,2022-12-21,2024-04-01,467 days,Recruiting,Interventional
SH ABCD,Autoantibodies in Breast Cancer Detection,2018-07-24,2028-11-01,3753 days,Recruiting,Observational
D8531C00002,A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy,2023-03-31,2036-05-29,4808 days,Recruiting,Interventional
SOLTI-1910,Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.,2022-03-25,2024-06-01,799 days,Recruiting,Interventional
1905202-3,ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies,2019-07-01,2023-07-01,1461 days,Recruiting,Observational
Targeted axillary dissection,Evaluation of Targeted Axillary Lymph Node Dissection in Node Positive Breast Cancer Patients Post Neo Adjuvant Therapy,2023-12-01,2025-08-01,609 days,Not yet recruiting,Interventional
2021-0215,BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer,2022-01-10,2024-05-01,842 days,Recruiting,Interventional
2022-8048-23560,Frequency of Occult Breast Cancer After Prophylactic Mastectomy Among High-Penetrance Breast Cancer Gene Positives,2023-01-01,2023-03-30,88 days,Recruiting,Observational
GFY202001,Study of Prediction of Ovarian Reserve in Yong Breast Cancer Patients Treated With Chemotherapy,2020-01-01,2023-06-30,1276 days,Recruiting,Observational
2019-A01861-56,Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients,2019-12-04,2027-10-01,2858 days,Recruiting,Observational
18-634,Elevate! : An Elderly Breast Cancer Cohort Study,2019-02-19,2028-11-01,3543 days,Recruiting,Observational
20 KHCC 202,Universal Genetic Testing Versus Guidelines-Directed Testing for Germline Pathogenic Variants Among Non-Western Patients With Breast Cancer,2021-04-01,2023-07-01,821 days,Recruiting,Observational
IRB # 21-0026,Tear Based Sample Collection Breast Cancer Detection,2021-04-28,2025-09-15,1601 days,"Active, not recruiting",Observational
IRB00002991,Implementation of Online Adaptive Radiotherapy for Breast Cancer Patients on Ethos (BREAST-ART),2021-12-10,2024-03-01,812 days,Recruiting,Observational
17-398,Feasibility of an Individualized Goals of Care Discussion Guide for Advanced Breast Cancer,2018-01-22,2019-04-29,462 days,Completed,Interventional
ESR-17-12934,Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer,2018-01-01,2019-07-01,546 days,Unknown status,Observational
LCCC 1954,Patient-centered Communication About Healthy Weight in Early Breast Cancer,2020-06-15,2020-09-29,106 days,Completed,Observational
69HCL22_0613,Effect of Physical Activity in Patients With Breast Cancer.,2022-09-01,2023-02-01,153 days,Withdrawn,Observational
LCCC2213,Metastatic Breast Cancer-Specific Prognostic Tool,2022-09-20,2024-10-01,742 days,Recruiting,Observational
IC 2018-01,Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer,2018-07-25,2020-09-20,788 days,Completed,Interventional
IC 2020 08,Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer.,2021-01-25,2021-12-20,329 days,Completed,Interventional
PI17/00834,Assessment of Feasibility and Acceptability of Personalized Breast Cancer Screening,2019-01-30,2021-12-31,1066 days,Completed,Interventional
PekingUMCH-FAPI-BC-1,Characterizing Breast Cancer With 68Ga-FAPI PET/CT,2021-05-01,2023-12-31,974 days,Recruiting,Interventional
PekingUMCH-FAPI-BC-2,Characterizing Breast Cancer With Al18F-NOTA-FAPI-04 PET/CT,2022-05-10,2023-06-30,416 days,Recruiting,Interventional
FMASUMD232/2021,Circulating microRNA 21 Expression Level Before and After Neoadjuvant Systemic Therapy in Breast Carcinoma,2021-12-01,2024-01-01,761 days,Not yet recruiting,Observational
Breast immune checkpoint,Relationship Between Breast Cancer Subtypes and Immune Checkpoints,2022-05-01,2022-12-15,228 days,Completed,Observational
IRB00283392,Messaging Strategies to Reduce Breast Cancer Over-screening in Older Women,2023-07-01,2023-12-31,183 days,Not yet recruiting,Interventional
IRB17-0721,Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer,2018-02-12,2022-09-01,1662 days,"Active, not recruiting",Interventional
180034,ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma,2018-01-17,2021-10-07,1359 days,Completed,Interventional
BCL IDE,Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer,2020-12-23,2023-07-01,920 days,Recruiting,Interventional
REO 027,A Window-of-opportunity Study of Pelareorep in Early Breast Cancer,2019-03-29,2022-04-20,1118 days,Terminated,Interventional
CentroHLO_EFBreastCancer,Evaluating and Following Breast Cancer Patients in a Better Way,2019-06-01,2020-12-31,579 days,Unknown status,Observational
elastography in breast cancer,Shear Wave Elastography Assessment of Neoadjuvant Chemotherapy Response in Patients With Invasive Breast Cancer,2021-12-01,2023-03-01,455 days,Not yet recruiting,Observational
2018-177-IMP-EXP-4,Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer,2019-01-19,2022-09-30,1350 days,Recruiting,Observational
V3-MOMMO-01,Open Label Immunotherapy Trial for Breast Cancer,2018-07-01,2019-12-31,548 days,Unknown status,Interventional
PROICM 2020-01 OST,Evaluation of the Prevalence of Pelvic Static Disorders in Women With Localized Breast Cancer,2020-09-18,2021-07-06,291 days,Completed,Observational
077-2019,Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Chest-wall and Locally-Advanced Breast Cancer,2020-07-31,2024-06-30,1430 days,Recruiting,Interventional
18-281,Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer,2019-03-21,2024-01-31,1777 days,Recruiting,Observational
2021-A02676-35,Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment,2023-01-09,2026-12-01,1422 days,Recruiting,Observational
84434789,Looking At Triple Negative Breast Cancer Patient Experience Patterns in Medical Trials,2024-04-01,2026-04-01,730 days,Not yet recruiting,Observational
2021-004,Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study,2021-11-04,2022-09-28,328 days,Recruiting,Observational
CBS-PIK3CA,Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC,2019-10-11,2023-06-11,1339 days,"Active, not recruiting",Observational
JuÃ§ara Phd Thesis,Emotional Evaluation and Reconstructed Breast Satisfaction,2019-07-01,2022-02-28,973 days,Unknown status,Interventional
18 SEIN 08,The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-Î± Status in Patients With Metastatic Breast Cancer HER2 + and ERÎ± Neg Treated With Trastuzumab + Pertuzumab + Taxane.,2020-08-28,2021-07-09,315 days,Terminated,Interventional
ARNA Breast 2021,"In Vitro Study of the Liquid Biopsy Test System of the Diagnostic Value, in Women With Various Forms of Breast Cancer",2021-05-21,2021-12-31,224 days,Unknown status,Observational
SNP-17-001,Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer,2018-09-21,2020-11-11,782 days,Completed,Observational
2021-012,Efficacity of Deep Inspiration Breath Hold and Intensity-modulated Radiotherapy in Preventing PErfusion Defect for Left Sided Breast Cancer (EDIPE),2022-10-27,2024-10-27,731 days,Recruiting,Interventional
69HCL18_0769,Awareness About Breast Cancer Screening,2019-01-24,2019-02-07,14 days,Completed,Observational
2394,Predictive Model of Axillary Nodal Status After Neoadjuvant Chemotherapy in Breast Cancer Patients,2020-02-04,2024-01-31,1457 days,"Active, not recruiting",Observational
CASE12119,Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer,2021-06-29,2024-06-01,1068 days,Recruiting,Interventional
18-124,ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer,2018-08-22,2029-08-30,4026 days,"Active, not recruiting",Interventional
18-461,Decisions of Young Women With Breast Cancer Regarding Fertility Preservation Before Cancer Treatment and Family Building After Treatment,2019-01-18,2024-01-01,1809 days,"Active, not recruiting",Observational
2020-KY-064,Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer,2020-12-01,2023-12-31,1125 days,Recruiting,Observational
3049,Evaluating Breast Cancer Patients Modesty During Radiotherapy. A Multicentric Study,2020-06-03,2022-09-28,847 days,Completed,Observational
EFC16133,"Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity",2022-02-17,2022-10-13,238 days,Terminated,Interventional
CLEE011O12001,Phase IIIb Study of Ribociclib + ET in Early Breast Cancer,2023-09-29,2030-06-28,2464 days,Not yet recruiting,Interventional
82944089,Discovering Factors in Metastatic Breast Cancer Patients Clinical Trial Experiences,2023-03-25,2025-03-25,731 days,Not yet recruiting,Observational
NewGiza University Protocol 1,The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study,2021-11-16,2022-03-31,135 days,Not yet recruiting,Observational
s66248,Identifying Prognostic Variables for Persistent Upper Limb Dysfunctions After Breast Cancer Treatment,2022-04-26,2025-02-01,1012 days,Recruiting,Interventional
964635,The Benefit of Surgery in Stage IV of Breast Cancer,2020-11-20,2021-12-20,395 days,Unknown status,Interventional
3/19,Multidisciplinary Approach to Breast Cancer Through the Study of Altered Transcriptomic and Immune Accompanied by the Identification of Extractable Markers From the Radiodiagnostic Bioimaging,2019-05-29,2023-05-28,1460 days,Recruiting,Observational
SCCC-11118; STU-2018-0015,Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer,2018-11-27,2024-11-30,2195 days,"Active, not recruiting",Interventional
2019402,Supportive Effects of Craniosacral Therapy for Female Patients With Breast Cancer and Their Partners,2023-05-01,2024-12-01,580 days,Not yet recruiting,Interventional
19-003085,"GENetic Risk Estimation of Breast Cancer Prior to Decisions on Preventive Therapy Uptake, Risk Reducing Surgery or Intensive Imaging Surveillance",2019-10-17,2024-12-31,1902 days,Enrolling by invitation,Observational
RADIO-SLEEP,Sleep Disorders Prior to and During a Course of Radiotherapy for Breast Cancer,2021-06-01,2022-06-30,394 days,Not yet recruiting,Interventional
Protocol EMIT-1,Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer,2018-10-29,2043-12-31,9194 days,"Active, not recruiting",Observational
17/09/621_Myosin VI,Nuclear Myosin VI - a Therapeutic Target in Breast Cancer,2019-05-05,2020-12-01,576 days,Unknown status,Observational
2017/1356,Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Adherence and Clinical Outcome,2019-08-01,2021-04-01,609 days,Completed,Observational
IC 2016-07,"FErtility, PrEgnancy, contRaceptIon After Breast Cancer in France",2018-03-08,2021-03-01,1089 days,Unknown status,Observational
left breast cancer,Cardiac Toxicity of Hypo Fractionated Radiotherapy in Left Breast Cancer,2022-04-27,2023-11-30,582 days,Not yet recruiting,Observational
180212-1,IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry,2018-02-27,2028-02-27,3652 days,Recruiting,Observational
19-001,Individualizing Surveillance Mammography for Older Breast Cancer Survivors,2019-05-16,2021-07-01,777 days,Completed,Interventional
CTRP6 in Breast Cancer,The Role of C1q Tumor Necrosis Factor-related Protein 6 in Breast Cancer,2020-11-01,2022-10-01,699 days,Unknown status,Observational
CESM in breast cancer,Accuracy Of Contrast Enhanced Mamography in Predicting Response of Breast Cancer Post Neoadjuvant Chemotherapy,2021-12-01,2024-01-01,761 days,Not yet recruiting,Observational
UCaenNormandie,A Randomized Cluster Trial to Evaluate a Mobile Mammography Unit in Breast Cancer Screening in France (Mammobile),2022-02-14,2024-09-01,930 days,Enrolling by invitation,Interventional
SOLTI-1903,Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer,2020-10-20,2024-07-30,1379 days,"Active, not recruiting",Observational
Vitamin D in breast cancer,Prognostic Value of Vitamin D Levels in Egyptian Females With Breast Cancer,2018-09-01,2021-09-01,1096 days,Unknown status,Observational
17-552,Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening,2018-04-18,2023-12-30,2082 days,"Active, not recruiting",Interventional
CCR5348,Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer,2021-11-01,2027-11-01,2191 days,Not yet recruiting,Interventional
19HLSEIN02,Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC,2020-06-15,2021-01-31,230 days,Completed,Observational
STUDY00011606,Design of Chatbot Persona for Breast Cancer Screening Outreach Among Black Women,2022-08-22,2022-11-15,85 days,Recruiting,Interventional
03/21,"A Prospective Single-center Cohort Study ""Preoperative Identification of Sentinel Lymph Nodes Using Contrast-enhanced CT Lymphography in Breast Cancer Patients""",2022-10-01,2023-08-01,304 days,Not yet recruiting,Interventional
AHQU-2021007,Genetic Predictors of Response to Acupuncture for Cancer-related Fatigue Among Breast Cancer Patients After Chemotherapy,2022-04-01,2023-10-31,578 days,Recruiting,Interventional
D8530C00003,"A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer",2020-11-02,2023-06-09,949 days,Recruiting,Interventional
2019-05-157,Genetic Characteristics of Metastatic Breast Cancer Patients,2019-07-17,2024-07-31,1841 days,Recruiting,Interventional
200056,"BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)",2021-05-04,2021-10-22,171 days,Terminated,Interventional
182-20-CA,18F-fluoroestradiol (FES) PET/CT for Breast Cancer,2021-01-15,2023-12-15,1064 days,Recruiting,Interventional
Shengjing-LCG008,Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy,2021-08-01,2027-08-01,2191 days,Not yet recruiting,Interventional
NeoRadUKD,NeoRad Breast Cancer Study,2020-07-01,2030-12-31,3835 days,Not yet recruiting,Interventional
KY20192114-C-1,Sentinel Lymph Node Biopsy in Early Breast Cancer: a Real-world Multicenter Cross-sectional Study (CABS001 Study),2019-08-01,2021-12-31,883 days,Unknown status,Observational
STUDY19060359,Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania,2019-10-23,2026-03-28,2348 days,Recruiting,Interventional
2019.089,Using Imaging Data and Genomic Data to Predict Metastasis of Breast Cancer After Treatment,2019-09-01,2023-06-01,1369 days,Recruiting,Observational
Xist,XIST Gene Deletion in Breast Cancer Therapy,2020-03-01,2022-03-01,730 days,Unknown status,Observational
UEM0002,Synergic Effects of Physical Activity and Probiotic on Gut Immune System and Quality of Life of Breast Cancer Survivors.,2018-10-01,2019-12-31,456 days,Withdrawn,Interventional
004181,Together After Cancer,2023-01-01,2026-03-01,1155 days,Recruiting,Interventional
HERMIONE 13,Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer,2021-09-24,2023-09-30,736 days,Recruiting,Observational
STANDPOINT,Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer,2020-12-31,2022-12-31,730 days,Recruiting,Observational
NL75855.091.21,Evaluation of Contrast Enhanced Breast CT for Diagnosis and Staging of Breast Cancer,2022-08-01,2025-08-01,1096 days,Not yet recruiting,Observational
CASE5118,Assessing the Impact of the Microbiome on Breast Cancer Radiotherapy Toxicity,2019-03-21,2023-12-01,1716 days,Recruiting,Observational
21 SEIN 09,"Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.",2022-06-23,2025-06-01,1074 days,Recruiting,Interventional
CINEICC-3-IAT,Mind Programme for Women With Breast Cancer,2023-01-02,2025-08-31,972 days,Recruiting,Interventional
Bakircay University,Training With Mobile Application in Breast Cancer,2018-01-10,2018-04-17,97 days,Completed,Interventional
HR-HER2-RWS-01,The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.,2022-08-01,2026-12-31,1613 days,Recruiting,Observational
01-BR-003,Guardant360Â® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer,2020-07-02,2022-03-17,623 days,Completed,Observational
21149002,The Effect of Virtual Reality on Anxiety and Fatigue in Women With Breast Cancer Receiving Adjuvant Chemotherapy,2022-04-04,2022-11-30,240 days,Completed,Interventional
21-528,Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment,2021-05-07,2023-12-01,938 days,"Active, not recruiting",Observational
DS8201-0002-EAP-MA,EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan,2022-11-11,2023-04-01,141 days,Recruiting,Observational
AAAU1629,FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments,2023-05-01,2024-07-01,427 days,Not yet recruiting,Interventional
BC-NEO-IIT-SHR1316-SHR6390-RT,Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment,2021-11-12,2023-10-15,702 days,"Active, not recruiting",Interventional
2020-12/898,Metabolomic Profiling of Erector Spinae Plane Block* for Breast Cancer Surgery,2021-02-01,2021-10-01,242 days,Completed,Observational
CHUBX 2016/19,Adaptation of a Knowledges Exchange Portal Between (KEP) Healers and Patients : Obstacles and Sources to KEP Use for Breast Cancer Women,2018-03-16,2019-06-17,458 days,Completed,Observational
IRB202100182 -N,All-extremity Exercise During Breast Cancer Chemotherapy,2023-05-01,2024-05-31,396 days,Recruiting,Interventional
PI-0538-2017,Breast Cancer and Its Relationship With the Microbiota,2018-01-01,2022-12-31,1825 days,"Active, not recruiting",Observational
21/4657,Health Technologies Readiness in Breast Cancer Patients,2021-03-01,2021-08-31,183 days,Completed,Observational
2019-KY-001-003,PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer,2019-05-17,2022-11-16,1279 days,Completed,Interventional
AbantIBU,Early Detection of Lymphedema With Bio-Electrical Impedance Analysis in Patients After Breast Cancer Surgery,2018-08-01,2019-11-01,457 days,Withdrawn,Interventional
121K686,Online Group Therapy for Breast Cancer,2022-01-15,2022-10-01,259 days,Recruiting,Interventional
06-2020,Prevalence of Depression and Anxiety Among Breast Cancer Patients,2021-05-17,2022-03-10,297 days,Completed,Observational
NADOPTIC,Monitoring Response to NAC and Prediction of pCR in Breast Cancer Patients Using Optical Imaging,2020-01-27,2023-01-27,1096 days,Unknown status,Interventional
CHIR-07-Sentimag,Magseed and Magtrace Localization for Breast Cancer,2020-05-04,2023-12-31,1336 days,Recruiting,Observational
Pro00020917,Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer,2020-03-03,2025-02-01,1796 days,Recruiting,Interventional
Breast Cancer,"Effects of Continuous and Interval Physical Training Through the Intensity of the Incremental Shuttle Walk Test, on Functional Capacity and Quality of Life in Women With Malignant Breast Cancer During Chemotherapy Treatment",2023-01-20,2025-12-30,1075 days,Not yet recruiting,Interventional
BSU,The Effect of Metformin on Breast Cancer Patients,2019-06-01,2020-10-01,488 days,Unknown status,Interventional
URomLS Prot.0930/2021Rif. 6528,To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study),2022-09-01,2023-01-27,148 days,Completed,Interventional
SOLTI-1716,Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression,2020-07-21,2024-11-01,1564 days,"Active, not recruiting",Interventional
2020-0724,"Droplet-BC Screening Test for the Detection of Breast Cancer, the DROPLET-BC Study",2020-11-03,2022-12-31,788 days,Recruiting,Observational
LCCC 1749,Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging,2018-02-28,2025-11-15,2817 days,Recruiting,Interventional
GIMI-IRB-20005,Multi-4SCAR-T Therapy Targeting Breast Cancer,2020-06-01,2023-12-31,1308 days,Recruiting,Interventional
202302017,Cryoablation vs Lumpectomy in T1 Breast Cancers,2023-06-30,2030-12-31,2741 days,Not yet recruiting,Interventional
17-PP-19,Peri-gravidic Exposure to Endocrine Disrupting Persistent Organic Pollutants,2019-04-15,2021-11-15,945 days,Recruiting,Observational
2015-4-6-003,Prevention of Sequelae Pain After Breast Cancer Surgery by Self-massages and Self Stretching. Impact of Learning Workshops.,2020-01-13,2024-06-15,1615 days,Recruiting,Interventional
FIRST,FreezIng bReaST Cancer in Brazil: a Before-after Study,2022-09-15,2024-07-15,669 days,Not yet recruiting,Interventional
PUMCH-BREAST-ctDNA screening,Clinical Application of ctDNA in Early Screening of Breast Cancer,2019-06-01,2021-06-01,731 days,Unknown status,Observational
147/19,Breast Cancer: Feasibility of an Educational Intervention,2019-12-01,2020-11-09,344 days,Completed,Interventional
STUDY00001641,Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women,2022-07-16,2024-12-01,869 days,Recruiting,Interventional
PetrovRIO,Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB),2019-10-08,2028-12-10,3351 days,Recruiting,Interventional
MD 177/2021,Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer,2022-08-01,2023-08-01,365 days,Not yet recruiting,Observational
A5481177,A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting,2021-11-22,2022-12-02,375 days,Recruiting,Observational
2017-KY-19,The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer,2020-01-01,2024-12-31,1826 days,Recruiting,Observational
Radiotherapy in breast cancer,Efficacy of Capecitabine With Adjuvant Radiotherapy in Treatment of Early Stages Breast Cancer (Retrospective Study).,2023-04-01,2023-04-01,0 days,Not yet recruiting,Observational
19-001004,Brain Health in Breast Cancer Survivors,2020-03-11,2025-03-15,1830 days,Recruiting,Observational
19049,Specialist Recommendation on FBC (Familial Breast Cancer) Chemoprevention Prescribing,2019-07-22,2019-12-31,162 days,Completed,Observational
Z211100002921033,The Detection of Cell-in-cell Structure (CICs) in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy,2021-10-01,2024-10-01,1096 days,Recruiting,Observational
CFDAIIUASABFDOBC,Cell Free DNA and Its Integrity Using ALU Sequences as a Biomarker for Diagnosis of Breast Cancer,2018-07-01,2020-07-01,731 days,Unknown status,Observational
Breast cancer neoadjuvant,Evaluation of the Role of Immune Checkpoints in Response to Breast Cancer Neoadjuvant Therapy,2022-03-01,2023-01-01,306 days,Recruiting,Observational
wanghaibo,Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer,2022-10-08,2027-03-31,1635 days,Not yet recruiting,Interventional
2020-KY-063,Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer,2020-07-01,2022-07-01,730 days,Unknown status,Observational
PUMCH-BC502,Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients,2019-04-25,2025-03-01,2137 days,Recruiting,Observational
852-20,"Breast Cancer, Reasoning, and Activity Intervention",2021-11-03,2026-03-31,1609 days,Withdrawn,Interventional
2020[84],HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody,2020-08-24,2024-09-30,1498 days,Recruiting,Interventional
SYSEC-KY-2018-018,Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients,2019-09-01,2021-07-30,698 days,Unknown status,Observational
19-045,A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients,2019-03-22,2024-03-01,1806 days,"Active, not recruiting",Observational
PROICM 2019-16-BCU,Evaluation of Sexual Quality of Life for Breast Cancer,2020-02-10,2020-07-31,172 days,Completed,Observational
IBCSG 59-19,Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer,2019-08-27,2026-11-01,2623 days,Recruiting,Interventional
33293720.9.0000.5505,Tele-rehabilitation in Women With Breast Cancer During COVID-19 Pandemic.,2020-03-02,2022-12-02,1005 days,"Active, not recruiting",Interventional
199080,Prospective Trial of Digital Breast Tomosynthesis (DBT) in Breast Cancer Screening.,2018-12-17,2024-07-01,2023 days,Recruiting,Interventional
SLN SPECT,Sentinel Lymph Node Identification in Patients With Breast Cancer Using SPECT/CT,2018-07-01,2022-09-01,1523 days,Unknown status,Interventional
SOLTI-1907,Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer,2021-03-15,2025-02-24,1442 days,Recruiting,Interventional
SDS-HER-01-2018,Safety and Efficacy Assessment of Diagnostic Microprobe (inPROBE) in Women at High Risk of Breast Cancer,2022-08-24,2023-03-02,190 days,Completed,Interventional
APHP211502,Breast Cancer Prevention and Screening Membership,2022-05-31,2032-04-01,3593 days,Recruiting,Interventional
ISTMET-BHWGI2022-1,Preoperative Radiotherapy and Systemic Therapy Following Surgery in de Novo Metastatic Breast Cancer,2022-03-01,2028-03-31,2222 days,Recruiting,Observational
SCHBCC-N024,Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer,2020-05-01,2025-05-01,1826 days,Recruiting,Interventional
4817,Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation,2022-03-01,2023-06-01,457 days,Recruiting,Observational
Cpetptmrbc,Correlation Between PET/CT Parameters and Tumor Markers in Recurrent Breast Cancer,2021-10-01,2023-05-01,577 days,Not yet recruiting,Observational
EEBC,Prospective Research for Elderly (â¥65 Years Old) Early Breast Cancer Patients,2022-04-01,2025-12-01,1340 days,Recruiting,Observational
symptom of breast cancer,Trajectory Analysis of Symptom Distress and Cancer-related Fatigue After Adjuvant Chemotherapy in Breast Cancer Female,2021-05-29,2024-07-31,1159 days,Not yet recruiting,Observational
IEO 0761/,Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer,2018-06-01,2022-12-31,1674 days,Recruiting,Observational
CELC-G-301,Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1),2022-09-30,2026-09-30,1461 days,Recruiting,Interventional
CARMA-2101,Cohort Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients Derived Organoids,2021-09-01,2023-09-01,730 days,Not yet recruiting,Observational
RWD_abemaciclib,Real-world Data in Patients With Breast Cancer Treated With Abemaciclib,2021-10-06,2024-12-01,1152 days,Recruiting,Observational
Tiresias,To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer,2020-09-01,2025-09-01,1826 days,Recruiting,Observational
A5481125,Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.,2019-05-15,2021-03-12,667 days,Completed,Observational
20-1789.cc,Sexual Health in Breast Cancer Patients,2020-12-01,2024-12-01,1461 days,Recruiting,Observational
ML40952,Tw HER2 Positive Breast Cancer Productivity & Utility Study,2018-12-24,2019-12-31,372 days,Unknown status,Observational
DBCG Proton trial,The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer,2020-06-01,2037-06-01,6209 days,Recruiting,Interventional
OOTR-N016/KBCRN-B-003/HT-PAB,"Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer",2019-07-16,2021-12-23,891 days,Completed,Interventional
710/2021,The Effect of Arm Exercises on Arm Oedema After Breast Cancer Surgery,2022-04-18,2024-05-30,773 days,Recruiting,Interventional
19-003028,Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring,2019-09-01,2028-11-29,3377 days,Recruiting,Observational
KL166-IIS-001,HER2-positive Breast Cancer Project Initiated by Investigators,2022-06-01,2024-12-31,944 days,Not yet recruiting,Interventional
V2_16-04-2020,Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy,2020-05-14,2022-12-31,961 days,Recruiting,Observational
N19ASC,Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy,2020-01-01,2027-07-01,2738 days,Not yet recruiting,Interventional
SNBvsPET/MRI 2,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,2020-07-03,2025-02-14,1687 days,Recruiting,Interventional
dingxwyh01,Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer,2018-12-01,2020-09-30,669 days,Unknown status,Interventional
SNUH_FMI,Molecular Profiling in Young (<50 Years of Age) Patients With Metastatic Breast Cancer,2019-09-01,2021-07-01,669 days,Unknown status,Interventional
2022/0035986,Vocational Rehabilitation for the Return to Work of Breast Cancer Patients: a Feasibility Study,2022-05-09,2024-05-01,723 days,Recruiting,Interventional
RF-2013-02358165,Axillary Reverse Mapping (ARM) in Breast Cancer Surgery to Prevent Lymphedema. (ARMtrial),2018-01-17,2020-12-01,1049 days,Unknown status,Interventional
18-516,GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases,2019-02-11,2025-11-30,2484 days,Recruiting,Interventional
2022106,Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer,2022-10-26,2026-12-01,1497 days,Not yet recruiting,Observational
19-147,Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer,2019-08-09,2020-09-18,406 days,Completed,Interventional
dingxwyh02,The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer,2018-12-01,2020-09-30,669 days,Unknown status,Interventional
19 SEIN 14,E-monitoring of Patients Under Adjuvant Hormonotherapy for Breast Cancer.,2020-02-28,2021-07-21,509 days,Completed,Interventional
AURORA,New Techniques to evAlUate Response to neOadjuvant Treatments in bReast cAncer (AURORA),2020-12-01,2022-12-01,730 days,Unknown status,Interventional
17/0765,Enabling the Study of Metabolism in Breast Cancer Through Collection of Fresh-tissue Biopsies,2019-04-01,2027-02-28,2890 days,Not yet recruiting,Observational
BR02/03/21,Quadratic Phenotypic Optimisation Platform (QPOP) Utilisation to Enhance Selection of Patient Therapy Through Patient Derived Organoids in Breast Cancer,2021-12-06,2025-12-31,1486 days,Recruiting,Interventional
2018-9529,TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer,2018-12-12,2024-06-01,1998 days,Recruiting,Interventional
1186,The Role of Genetic Factors in the Development of Breast Cancer in the Kazakh Population,2022-03-30,2023-01-20,296 days,Completed,Observational
REaCT-HER TIME,Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy,2021-12-13,2023-09-01,627 days,"Active, not recruiting",Interventional
01-2021,"Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.",2021-01-01,2021-12-01,334 days,Unknown status,Observational
D9673R00011,Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients,2022-02-24,2023-05-31,461 days,Recruiting,Observational
SOLTI-1911,Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer,2022-05-03,2030-07-01,2981 days,Recruiting,Interventional
APHP211593,Molecular Signature for Breast Cancer,2023-03-01,2023-12-01,275 days,Not yet recruiting,Observational
IC 2018-08,Breast Cancer Risk After Diagnostic Gene Sequencing,2019-10-22,2022-03-03,863 days,Completed,Interventional
AHQU-2021006,Genetic Predictors to Acupuncture Response for Arthralgia Induced by Aromatase Inhibitors in Patients With Breast Cancer,2021-11-25,2023-11-30,735 days,Recruiting,Interventional
2540,Extracellular Vesicles in Breast Cancer Patientsin Undergone Neoadjuvant Chemotherapy,2021-05-11,2027-12-21,2415 days,Recruiting,Observational
FLA 18-057,Effects of Bariatric Surgery on Breast Density Improvement and Impact on Breast Cancer Risk in Severe Obese Patients,2021-02-22,2023-12-31,1042 days,Recruiting,Observational
V2011201,Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer,2023-03-15,2024-05-26,438 days,Withdrawn,Interventional
HERdi PREDICT,A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies,2019-12-20,2023-06-01,1259 days,Recruiting,Observational
HCB-ONC001 (ML41519),Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy,2020-09-23,2026-12-01,2260 days,Recruiting,Interventional
IRB-300002157,RAD 1802: Pilot Trial of Dose Adapted Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI),2019-08-20,2025-12-01,2295 days,Recruiting,Interventional
IAyas2,The Validity and Reliability of FIT-HaNSA in Breast Cancer Patients,2021-02-01,2022-09-01,577 days,Unknown status,Observational
A5481176,A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark,2022-02-24,2022-08-01,158 days,Completed,Observational
Shengjing-LCG009,Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients,2021-08-01,2027-08-15,2205 days,Recruiting,Interventional
OTT-19-06,"A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer",2021-06-08,2022-08-15,433 days,Completed,Interventional
20210312,Personalized Evidence-based Treatment in Patients With Invasive Breast Cancer,2021-03-01,2021-05-30,90 days,Unknown status,Observational
FAST feasibility in CU,Weekly Single Fraction Hypofractionated Adjuvant Radiotherapy for Early Stage Breast Cancer,2018-12-10,2024-05-01,1969 days,Recruiting,Interventional
Sentinel lymph node biopsy,Oncologic Safety of Sentinel Lymph Node Biopsy in Clinically Palpable Axillary Lymph Node in Breast Cancer Patients,2023-02-01,2025-03-01,759 days,Not yet recruiting,Observational
BC001,Moving on After Breast Cancer Plus- for Breast Cancer Survivors,2019-03-10,2022-07-05,1213 days,Completed,Interventional
SOC.04/20-21,Breast Screening Atypia and Subsequent Development of Cancer in England,2021-12-01,2022-11-30,364 days,Enrolling by invitation,Observational
UT BCS ECS Study,Feasibility and Effectiveness of an Internet-based Intervention to Manage Fatigue in Breast Cancer Survivors,2020-01-27,2020-09-01,218 days,Withdrawn,Interventional
oddie2,Artificial Intelligence for breaST canceR scrEening in mAMmography (AI-STREAM),2021-02-01,2024-12-31,1429 days,Recruiting,Observational
FMASU R61/2020,Knowledge and Perception of Clinical Trial Participation in Breast Cancer Patients in Egypt,2020-07-20,2020-12-01,134 days,Unknown status,Observational
18-109,A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors,2018-09-14,2023-09-01,1813 days,Recruiting,Observational
19-509,Genetic Testing for All Breast Cancer Patients (GET FACTS),2020-01-31,2023-11-01,1370 days,"Active, not recruiting",Interventional
19-277,Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients,2019-11-26,2023-05-01,1252 days,"Active, not recruiting",Interventional
UW 20-064,Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy,2020-10-15,2028-12-31,2999 days,Recruiting,Interventional
UC-0105/1701,SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer,2018-03-15,2022-11-18,1709 days,Terminated,Interventional
20-1039,Couples QOL in Metastatic Breast Cancer,2021-01-01,2024-08-31,1338 days,Recruiting,Interventional
BRAR1,of Androgen Receptor Expression in Breast Cancer With or Without BRCA Mutation,2021-07-01,2024-12-31,1279 days,Recruiting,Observational
18-1025,Coping Together After Breast Cancer,2019-05-24,2023-05-01,1438 days,"Active, not recruiting",Interventional
IRB16-0396,"Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening",2020-09-17,2021-09-14,362 days,Recruiting,Observational
09.2019.984,Effectiveness of Stellate Ganglion Block in Breast Cancer Related Lymphedema,2020-01-07,2020-04-01,85 days,Unknown status,Interventional
O4M-B001,Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients,2020-06-01,2020-10-01,122 days,Unknown status,Interventional
TaiHao TVGH2020-07-006AC#1,Evaluation of TaiHao Breast Ultrasound Diagnosis Software RN-CES Descartes,2023-01-30,2023-03-31,60 days,"Active, not recruiting",Interventional
STGKS001,Artificial Intelligence in Large-scale Breast Cancer Screening,2021-04-01,2024-12-01,1340 days,"Active, not recruiting",Interventional
19-086,"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)",2019-05-30,2024-12-01,2012 days,"Active, not recruiting",Interventional
CNER 202107/05,eHealth Intervention for Medication Adherence in Breast Cancer Survivors,2021-10-04,2023-02-28,512 days,Recruiting,Interventional
Optimune Trial,Evaluating a Novel Web-based Intervention for Breast Cancer Survivors,2018-03-16,2022-04-30,1506 days,Terminated,Interventional
1808019498,Converting HR+ Breast Cancer Into an Individualized Vaccine,2020-03-17,2027-12-01,2815 days,Recruiting,Interventional
Emotional security&mastectomy,Emotional Security and Quality of Life Among Breast Cancer Patient Who Have Undergo Mastectomy,2021-06-01,2021-12-31,213 days,Unknown status,Observational
HYGEE,Evaluation of the Impact of the Use of Hypnotherapy Performed by a Virtual Reality Toolalong the Care Pathway of Patients Undergoing Breast Cancer Treatment.,2020-09-24,2023-09-09,1080 days,"Active, not recruiting",Interventional
A5481115,Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan,2019-08-31,2023-11-30,1552 days,Recruiting,Observational
Breast Audit,The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study,2022-02-28,2022-05-01,62 days,Completed,Observational
STU-2018-0370,Infrared Imaging for Breast Cancer Modeling,2019-06-13,2022-06-01,1084 days,Completed,Interventional
MRI in breast cancer,Breast MRI in Evaluation of Pathologic Response in Patients With Breast Cancer With Neoadjuvent Chemotherapy,2022-05-01,2024-12-01,945 days,Not yet recruiting,Observational
Prix Ruban Rose/2021/FF-01,Personalized Follow-up After Breast Cancer Surgery Via Electronic Patient Reported Outcomes,2021-04-01,2022-06-30,455 days,Completed,Interventional
FUSCC-OMIT,A Trial Evaluating the Efficacy of Metastasectomy in Patients With Oligo-Metastatic Breast Cancer(OMIT),2019-12-10,2025-03-10,1917 days,Recruiting,Interventional
Pyrotinib neoadjuvant,Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer,2023-04-15,2025-09-30,899 days,Not yet recruiting,Interventional
SMC 2021-02-102,"Selective Omission of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm studyTrial",2021-09-27,2028-12-31,2652 days,Enrolling by invitation,Interventional
BSMMU/2019/8874,Effect of Vitamin C and E in Breast Cancer Patients Undergoing Chemotherapy,2019-10-10,2020-09-15,341 days,Unknown status,Interventional
20210601,Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective Study,2022-07-01,2025-06-01,1066 days,Recruiting,Observational
99mTc-ADAPT6 vs 99mTc-DARPinG3,Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3,2022-05-01,2023-01-21,265 days,Completed,Interventional
Telemonitoring BCS,"Effect of Telemonitoring on Functionality, Quality of Life and Risk of Lymphedema in Breast Cancer Survivors",2021-08-01,2021-12-01,122 days,Recruiting,Interventional
CCTG MA.39,Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer,2018-05-30,2027-12-30,3501 days,Recruiting,Interventional
IRB-2022-166,"Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world Study",2022-08-30,2027-03-31,1674 days,Not yet recruiting,Observational
2490,Characterization of Extracellular Vesicles in Breast Cancer Patients,2020-12-01,2023-09-01,1004 days,Recruiting,Observational
19/317-2101,Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients,2020-05-08,2024-05-01,1454 days,Recruiting,Interventional
2021-1116,Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks,2023-03-15,2029-12-01,2453 days,Recruiting,Interventional
SPT-2021-002,Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer,2022-03-12,2025-12-31,1390 days,Not yet recruiting,Interventional
s66248-aim2,Identifying Prognostic Variables for Persistent UL Dysfunctions After Breast Cancer Treatment -Reliability and Validity,2022-04-26,2025-02-01,1012 days,Recruiting,Interventional
Cardiac safety study,Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab,2019-07-05,2021-12-30,909 days,Recruiting,Observational
BGB-290-201,Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China,2018-06-22,2021-04-14,1027 days,Completed,Interventional
10038,Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*),2020-01-15,2035-01-15,5479 days,Recruiting,Interventional
Pro00085352,Examining Bioactivity of PVSRIPO in Invasive Breast Cancer,2019-06-30,2022-12-01,1250 days,Recruiting,Interventional
EORTC 1745-ETF-BCG,Adjuvant Palbociclib in Elderly Patients With Breast Cancer,2019-06-14,2032-09-30,4857 days,"Active, not recruiting",Interventional
4523,Acupuncture Treatment of Vasomotor Symptoms in Breast Cancer Patients,2021-11-25,2024-12-25,1126 days,Recruiting,Interventional
17-455,The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer,2018-06-21,2025-05-31,2536 days,"Active, not recruiting",Interventional
01AB21- PIK3CA,Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.,2022-08-25,2025-06-30,1040 days,Recruiting,Interventional
ICO-N-2017-12,Clinico-biological Data Collection Study of Metastatic Breast Cancer,2018-12-24,2036-12-30,6581 days,Recruiting,Interventional
Optimune Trial Add-on,Evaluating a Novel Web-based Intervention for Breast Cancer Survivors,2018-09-01,2020-09-01,731 days,Completed,Interventional
2018396H,TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer,2019-09-17,2022-09-17,1096 days,Unknown status,Interventional
PROICM 2020-05 SKY,Evaluation of the Efficacy of a Physical Therapy-yoga-patient Educational Program for Breast Cancer Patients With Pain Due to Hormonal Therapy Treatment.,2021-02-11,2025-08-01,1632 days,Recruiting,Interventional
GEICAM/2019-01,Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients,2020-10-02,2033-02-28,4532 days,"Active, not recruiting",Interventional
69HCL18_0310,Descriptive Observational Study of the Evolution of the Lifestyle Alteration in Patients With Breast Cancer,2018-11-27,2020-10-19,692 days,Completed,Observational
2004-261-112,Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer,2020-10-01,2020-12-16,76 days,Terminated,Observational
MA-BC-â¡-040,Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer,2022-08-01,2024-05-01,639 days,Not yet recruiting,Interventional
APHP190505,Circulating Fetal Cells and Breast Cancer,2021-05-14,2025-05-01,1448 days,"Active, not recruiting",Observational
2019-1183,A Phase I Dose Escalation Study of Single Fraction Ablative Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer,2019-12-25,2025-08-01,2046 days,Recruiting,Interventional
IJB-NERABRAIN-ODN-007,Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer,2021-11-24,2021-11-24,0 days,Withdrawn,Interventional
19-066,Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer,2019-07-26,2025-02-01,2017 days,Recruiting,Interventional
EH18-203,The MEDITATE-BC Study: Mindfulness-Enhanced Decision Intervention To Aid Treatment Election - Breast Cancer,2018-11-08,2020-02-10,459 days,Completed,Interventional
22-280,Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors,2022-10-18,2024-10-18,731 days,Recruiting,Observational
BakircayU,Factors Affecting Functionality in Breast Cancer Survivors,2019-12-17,2021-09-30,653 days,Completed,Observational
A211801,Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation,2022-02-23,2033-12-01,4299 days,Recruiting,Interventional
SGK-SFC-001,Susan G. Komens ShareForCures,2022-11-17,2032-11-01,3637 days,Enrolling by invitation,Observational
CAAE: 39277420.8.0000.5313,Adaptations to Breast Cancer and Exercise Using Telehealth (ABRACE: Telehealth),2021-02-01,2023-03-01,758 days,Unknown status,Interventional
D361DC00001,Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292),2021-05-10,2029-01-05,2797 days,Recruiting,Interventional
PekingUMCH-NM25,99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer,2019-12-07,2020-12-31,390 days,Completed,Interventional
5354-CL-1201,A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery,2022-08-10,2023-09-30,416 days,Recruiting,Interventional
MO39485,"A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America",2020-02-21,2025-11-28,2107 days,"Active, not recruiting",Observational
SOC.03/20-21,"English Mammography Screening Outcomes by Age, Frequency and Test Threshold",2021-01-01,2023-12-30,1093 days,Enrolling by invitation,Observational
2019-228,Prophylactic Irradiation to the Contralateral Breast for BCAs Patients,2023-01-01,2029-12-01,2526 days,Recruiting,Interventional
800646,Intervening on Womens Health for Rural Young Breast Cancer Survivors,2021-10-15,2024-04-30,928 days,Recruiting,Interventional
NP 1521/19,Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer,2020-03-27,2025-03-27,1826 days,"Active, not recruiting",Interventional
DARE,"DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer",2021-02-09,2026-12-15,2135 days,Recruiting,Interventional
M2020 UK01,Breath Test to Predict Breast Cancer and Outcome of Mammography,2021-03-01,2023-03-01,730 days,Unknown status,Observational
[2019]52,HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02,2019-07-29,2022-03-30,975 days,Completed,Interventional
TRA05-GEFPICS,Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast Cancer,2020-04-24,2023-06-30,1162 days,"Active, not recruiting",Observational
NOV2016PhD818,Living Better With Advanced Breast Cancer: Feasibility Evaluation of an Online Supportive Intervention.,2020-06-06,2021-03-31,298 days,Completed,Interventional
BCP28,CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC,2020-11-01,2022-12-30,789 days,Recruiting,Observational
GEICAM/2017-01_IBCSG 62-20_BIG,Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET),2021-09-14,2026-09-01,1813 days,Recruiting,Interventional
GCO 17-00563,Integrated Intervention for Breast Cancer Survivors With Diabetes,2022-01-27,2023-09-01,582 days,Recruiting,Interventional
PekingUMCH-FES-BC-1,Characterizing Breast Cancer With 18F-FES PET/CT,2021-05-01,2024-12-31,1340 days,Recruiting,Interventional
EudraCT 2020-005200-19,Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC),2023-02-06,2024-12-31,694 days,Not yet recruiting,Interventional
D9673C00007,A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer,2021-06-22,2024-02-09,962 days,Recruiting,Interventional
LY2022-028-B,Pre-operative Therapy in Breast Cancer,2022-11-01,2030-11-01,2922 days,Recruiting,Observational
ATADEK-2021/14/16,Breast Cancer and Kinesiophobia and Physical Activity,2021-08-01,2022-05-15,287 days,Completed,Observational
J21125,Cardiometabolic Screening Program,2022-06-03,2027-06-01,1824 days,Recruiting,Interventional
2018-9567,Pilot Study Assessing the Effect of Cyclin-dependent Kinase 4/6 Inhibitors on Body Composition in Patients With ER+/HER2- Metastatic Breast Cancer,2019-01-08,2025-12-01,2519 days,Recruiting,Observational
UBRS20139,Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling,2022-09-23,2025-09-01,1074 days,Recruiting,Interventional
20 SEIN 13,Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer,2021-02-12,2024-02-01,1084 days,Recruiting,Interventional
TQB3616-III-03,Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer,2023-03-30,2027-01-01,1373 days,Recruiting,Interventional
MD.21.09.521.R,The Significance of Radiologically Detected Intramammary Lymph Nodes in Prediction of Axillary Lymph Nodes Status in Breast Cancer Patients,2021-09-14,2023-03-04,536 days,"Active, not recruiting",Observational
20190283,SABER Study for Selected Early Stage Breast Cancer,2020-08-05,2025-08-01,1822 days,Recruiting,Interventional
FISH in breast cancer,Partial PTEN Deletion in Breast Cancer,2021-11-01,2025-01-30,1186 days,Not yet recruiting,Observational
NCC3075,Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer,2022-01-01,2024-12-31,1095 days,Not yet recruiting,Interventional
CSPC-DMS-BC-13,Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.,2019-07-07,2020-05-01,299 days,Completed,Observational
19900601,Effect of Lymphedema Prevention Program Based on Theory of Knowledge-attitude-practice on Postoperative Breast Cancer Patients,2020-03-01,2020-12-08,282 days,Completed,Interventional
DBCG RT Recon,Delayed-immediate Versus Delayed Breast Reconstruction in Breast Cancer Patients With Mastectomy and Radiation Therapy,2020-01-01,2033-11-01,5053 days,Recruiting,Interventional
PROICM 2019-11 PRA,A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer,2020-12-04,2032-12-01,4380 days,Recruiting,Interventional
201819010.4,Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients,2020-10-15,2021-01-15,92 days,Unknown status,Observational
2018NTLS176,Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer,2019-08-08,2025-01-01,1973 days,Recruiting,Observational
SPHIC-TR-BCa2022-01,A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer,2023-01-10,2026-01-10,1096 days,Recruiting,Interventional
C3441020,Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer,2018-08-27,2020-09-23,758 days,Terminated,Interventional
SRMBCNabP2022,Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer,2022-04-20,2023-06-30,436 days,Not yet recruiting,Interventional
18ON009,Developing a Diagnostic Tool to Predict Response to Chemotherapy,2019-11-07,2021-05-31,571 days,Unknown status,Observational
FDRT-BC009,FSRT in Breast Cancer Patients With Brain Metastases,2019-07-01,2022-07-01,1096 days,Unknown status,Interventional
18-223,Olaparib + Sapacitabine in BRCA Mutant Breast Cancer,2018-10-01,2025-06-22,2456 days,"Active, not recruiting",Interventional
MCC-20897,DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer,2022-08-11,2025-04-01,964 days,Recruiting,Interventional
21-3576.cc,Interpretations and Predictions of Patient Reported Outcomes by Breast Cancer Patients,2021-06-29,2025-06-01,1433 days,Recruiting,Observational
IIT2018-01-McArthur-IPI,Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer,2019-11-12,2026-06-01,2393 days,Recruiting,Interventional
BCHRD201,AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer,2020-08-01,2021-08-01,365 days,Unknown status,Interventional
BrIMA,Specimen PET-CT Imaging for Intraoperative Margin Assessment in Breast Cancer,2022-06-17,2023-07-01,379 days,Recruiting,Interventional
ChanghaiHTB,Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy,2022-08-01,2031-05-01,3195 days,Not yet recruiting,Interventional
2018-00838; ch20Weber2,Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS),2018-08-07,2036-12-01,6691 days,Recruiting,Interventional
WSG-AM09,A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1),2020-08-18,2022-05-31,651 days,Completed,Interventional
UC-0107/1903,Patients Choice in the Reduction of Their Treatment in Women Over 65 Year With Breast Cancer,2021-10-01,2025-09-01,1431 days,Recruiting,Interventional
PANONC-1 Version: 1.1,Neoadjuvant Treatment of Breast Cancer,2022-03-01,2031-12-01,3562 days,Not yet recruiting,Observational
AB-MR for Second Breast Cancer,Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing,2018-05-01,2022-06-01,1492 days,Unknown status,Observational
AHQU-2021005,Precision Acupuncture in the Treatment of Peripheral Neuropathy After Taxanes Chemotherapy in Breast Cancer,2021-12-01,2023-12-01,730 days,Recruiting,Interventional
2019/FO244363,Long-term Effects of Breast Cancer Treatment,2019-07-01,2022-06-30,1095 days,Unknown status,Observational
BC-2019,The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Target,2019-01-01,2023-11-01,1765 days,Recruiting,Interventional
18-058,"Exercise, Fitness and Tumor Profiling in Breast Cancer Patients",2018-01-31,2024-01-01,2161 days,"Active, not recruiting",Observational
KYJJ-2021-186,Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients,2019-03-01,2029-03-01,3653 days,Recruiting,Observational
19-188,"Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial",2021-11-18,2024-07-31,986 days,Recruiting,Interventional
BCSCO003,Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China,2019-09-05,2025-12-01,2279 days,Not yet recruiting,Observational
SP00049673,Technology-Supported Physical Activity Intervention for Metastatic Breast Cancer Survivors: Fit2ThriveMB,2019-11-26,2021-05-01,522 days,Completed,Interventional
DSCN-EHT-NIS-BC001,A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer,2023-03-15,2023-05-31,77 days,Recruiting,Observational
17-512,Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer,2018-01-30,2025-06-30,2708 days,"Active, not recruiting",Interventional
SCBCS025,"Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China",2020-12-04,2024-12-31,1488 days,Recruiting,Interventional
19-239,Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.,2019-10-09,2024-12-01,1880 days,Recruiting,Interventional
LC2019L06,Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy,2020-02-01,2027-12-01,2860 days,Recruiting,Interventional
GEICAM/2016-03,Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies,2018-01-18,2048-01-01,10940 days,Recruiting,Observational
Breast Screening with DWI,Breast Cancer Screening With Diffusion-weighted MRI in Women at High Risk for Breast Cancer,2019-04-03,2022-12-01,1338 days,Unknown status,Observational
HNCH-BC003,Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients,2020-04-15,2022-05-01,746 days,Withdrawn,Interventional
21-183,"Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation",2021-04-20,2024-04-01,1077 days,Recruiting,Observational
02AB21-TucErBit,"A Phase II Study of the Safety, Tolerability and Antitumor Activity of Tucatinib in Combination With Eribulin and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer",2022-11-17,2025-05-26,921 days,Recruiting,Interventional
IRB-48150,68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer,2019-03-19,2024-06-18,1918 days,Suspended,Interventional
ICO-2019-03,Bringing of PET-TDM FDG in the Determination of the Characteristics of Primary Mammary Tumors TrIple Negatives,2019-11-05,2024-10-22,1813 days,"Active, not recruiting",Observational
Soh-Med-23-01-07,Prognostic Value of Some Biochemical Markers in Breast Cancer,2023-02-01,2023-12-01,303 days,Not yet recruiting,Observational
IUSCC-0613,An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer,2018-01-19,2020-05-27,859 days,Completed,Interventional
Breast Cancer Screening,Diffusion-Weighted MRI for Breast Cancer Screening in Women With a Personal History of Breast Cancer,2021-06-30,2024-11-30,1249 days,Not yet recruiting,Observational
16-145,Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy,2019-07-17,2024-08-01,1842 days,Recruiting,Interventional
A5481144,HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes,2019-11-18,2021-02-12,452 days,Terminated,Observational
D133FR00138,ALEXANDRIA Study Egypt,2018-10-29,2021-01-24,818 days,Completed,Observational
State University of SÃ£o Paulo,Aerobic Training in Treatment for Breast Cancer,2018-07-01,2020-11-30,883 days,Completed,Interventional
21-440,Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer,2022-07-13,2023-11-01,476 days,Recruiting,Interventional
YM107109E,Breast Cancer Self-Management Mobile Care Application Intervention in the Quality of Life,2019-01-11,2019-07-06,176 days,Completed,Interventional
GEICAM/2020-08,Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer,2023-03-08,2026-08-01,1242 days,Recruiting,Interventional
2023-09,Feasibility of Carbon-Dye Marking of Axillary Lymph Nodes Before Neoadjuvant Chemotherapy in Patients With Breast Cancer,2023-02-07,2024-03-01,388 days,Recruiting,Interventional
ARV-471-BC-201,A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery,2023-02-15,2024-06-01,472 days,Recruiting,Interventional
grid.412416.4,The Role of Interleukin-7 Serum Level as Biological Marker in Breast Cancer,2018-06-05,2019-12-20,563 days,Completed,Observational
18-333,A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy,2019-02-01,2024-12-31,2160 days,"Active, not recruiting",Interventional
MA-BC-II-024,Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC),2021-06-15,2025-06-30,1476 days,Not yet recruiting,Interventional
intestinal flora study,A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer,2021-01-18,2022-12-30,711 days,Recruiting,Observational
ML42450,"Real-World Data on Clinical Characteristics, Demographics, and Outcomes of Patients With Metastatic Breast Cancer in Turkey",2021-03-22,2022-08-08,504 days,Completed,Observational
GNC-035-103,"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer",2021-11-26,2023-11-30,734 days,Recruiting,Interventional
DS8201-A-U301,DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02],2018-08-01,2024-09-01,2223 days,"Active, not recruiting",Interventional
2018-09-007A,Research on the Heterogeneity of Taiwanese Breast Cancer Patients by Next Generation Sequencing (NGS) Tools,2018-11-22,2026-08-31,2839 days,Recruiting,Observational
M18DMB,ModraDoc006/r in Patients With Breast Cancer,2019-01-30,2020-11-09,649 days,Completed,Interventional
Microbiome_BC&PnC,Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients,2022-05-12,2025-08-01,1177 days,Recruiting,Observational
R148/2021,TIL Relation to pCR After Neoadjuvant Therapy in Breast Cancer Patients,2022-07-24,2023-09-01,404 days,Recruiting,Observational
ZNJC201935,Nomogram to Predict Breast Cancer Related Lymphedema,2020-12-11,2027-12-31,2576 days,Recruiting,Interventional
SCHBCC0N026,A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC,2020-01-20,2021-12-31,711 days,Recruiting,Interventional
MUKDEN-09,"Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer",2022-12-20,2027-12-10,1816 days,Recruiting,Interventional
NACAGEP,"Gene Expression Profiling to Help Define the Need for Neo-Adjuvant Chemotherapy in HR+, HER- Breast Cancer Patients",2022-11-14,2024-11-14,731 days,Recruiting,Observational
2017MayPR898,A Communication Skills Package to Prevent Fear of Cancer Recurrence,2018-09-01,2020-02-01,518 days,Unknown status,Observational
RGT-419B_01-101,"First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer",2022-03-04,2024-08-28,908 days,Recruiting,Interventional
NCC 2019-0098,Life Style Modification for Breast Canccer Survivors Using Mobile App-based Human Coaching Program,2019-05-14,2022-06-30,1143 days,Completed,Observational
21-003046,"Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer",2022-07-21,2024-06-15,695 days,Recruiting,Interventional
SSGJ-302H-mBC-IIT-01,Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC,2021-01-04,2022-12-30,725 days,Recruiting,Interventional
KY2019-070,Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer,2019-12-16,2028-08-01,3151 days,Recruiting,Interventional
A5481155,"Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy",2020-06-30,2020-12-31,184 days,Completed,Observational
D8530C00001,Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.,2018-10-11,2024-04-15,2013 days,Recruiting,Interventional
APHP191059,BIOPSY SCANNER LLTECHÂ© Technology for Diagnosis of Breast Cancer,2020-04-28,2021-09-15,505 days,Unknown status,Observational
1R01CA236860-01A1,Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors,2021-02-01,2025-12-31,1794 days,Recruiting,Interventional
BT006,Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases,2019-09-18,2022-03-01,895 days,Recruiting,Interventional
310-17-SZMC,Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer,2019-04-18,2021-06-15,789 days,Unknown status,Interventional
2017-01282 (BASEC),Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer,2020-01-13,2020-02-05,23 days,Terminated,Interventional
CINDERELLA,Comparing Decision on Aesthetics After Breast Cancer Locoregional Treatment.,2023-06-01,2025-12-01,914 days,Not yet recruiting,Interventional
CCR5214,"Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression",2021-08-01,2024-08-01,1096 days,Not yet recruiting,Interventional
MCC-21757,Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer,2022-11-04,2026-11-01,1458 days,Recruiting,Interventional
K2022-025-01,A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer,2022-12-10,2025-12-10,1096 days,Not yet recruiting,Interventional
PUMCH-MUSD,A Comparative Study of Mammography and Ultrasound for Breast Cancer Screening and Early Diagnosis,2020-06-12,2023-06-01,1084 days,Recruiting,Observational
0720222005,The Postoperative Radiotherapy in N1 Breast Cancer Patients,2022-08-01,2033-12-31,4170 days,Recruiting,Interventional
D967UC00001,"Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)",2021-04-26,2029-12-30,3170 days,Recruiting,Interventional
PLEASURABLE,"Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer",2019-05-12,2025-12-10,2404 days,"Active, not recruiting",Interventional
21822,"COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer",2019-10-18,2023-04-30,1290 days,Withdrawn,Interventional
CTNZ-2017-01,Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy,2019-06-10,2021-10-15,858 days,Completed,Interventional
20-649,"Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer",2021-07-21,2029-12-01,3055 days,Recruiting,Interventional
2020-08-06R,Early Detection of CMP in Patients With Breast Cancer Using Cardiac Magnetic Resonance,2020-10-30,2023-09-01,1036 days,Recruiting,Observational
Qassim QDs-VELD,Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer,2019-09-15,2022-12-13,1185 days,Unknown status,Interventional
HR-BLTN-III-EBC,A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,2019-07-12,2024-07-31,1846 days,"Active, not recruiting",Interventional
COV-19 BUMDC,COVID-19 Pandemic: Effect on Management of Patients With Breast Cancer,2020-01-01,2021-01-31,396 days,Completed,Observational
14-833-02,Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study,2018-05-27,2019-12-31,583 days,Completed,Interventional
17-519,Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis,2018-05-01,2025-09-30,2709 days,"Active, not recruiting",Interventional
Radiotherapy in Breast Cancer,Accelerated Hypofractionated 1 Week Radiotherapy in Breast Cancer Patients,2018-01-01,2019-06-30,545 days,Completed,Interventional
2020-A01423-36,Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients,2020-11-27,2029-11-09,3269 days,Recruiting,Observational
STML-ELA-0222,Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer,2023-01-24,2026-08-31,1315 days,Recruiting,Interventional
C3441055,Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m,2021-12-17,2022-06-30,195 days,Completed,Observational
CRF-NHI01,Real-world Clinical Benefit Evaluation in Breast Cancer Patients With Pharmaceutical Interventions for Cancer-related Fatigue,2021-09-08,2023-12-31,844 days,Recruiting,Observational
H-41818,Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer,2020-03-04,2030-12-01,3924 days,Recruiting,Interventional
CLUE-BCL,Evaluation of the Treatment Response in Breast Cancer Related Lymphedema,2019-07-11,2019-12-11,153 days,Completed,Interventional
nihan25,Women on Breast Cancer Health BelÄ±efs and ScreenÄ±ng BehavÄ±ors,2022-08-15,2023-05-15,273 days,Recruiting,Interventional
2020-0927,Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer,2021-12-13,2024-12-31,1114 days,Recruiting,Interventional
2020FES,16Î±-18F-fluor-17Î²-estradiol PET/CT for Visualisation of Estrogen Receptor Positive Liver Metastases From Breast Cancer,2020-03-01,2021-03-01,365 days,Unknown status,Interventional
PRO00034502,Tell us Your Food Story,2019-10-01,2020-11-20,416 days,Withdrawn,Observational
Breast cancer in females,Concurrent Paclitaxel and Radiotherapy After Adjuvant Doxorubicin and Cyclophosphamide for Stage 2 or 3 Breast Cancer,2023-09-01,2023-12-01,91 days,Not yet recruiting,Observational
SCLND0919,Clinical Significance of Supraclavicular Lymph Node Dissection for Breast Cancer Patients With Ipsilateral Supraclavicular Lymph Node Metastasis,2019-02-27,2022-04-30,1158 days,Unknown status,Interventional
PUMA-NER-6203,A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib,2020-06-30,2021-12-28,546 days,Completed,Interventional
KBCSG-24,Omission of Breast Surgery for Breast Cancer Patients With pCR on MRI and Vacuum-assisted Biopsy After NAC (OPTIMIST),2022-09-22,2031-03-01,3082 days,Recruiting,Interventional
AHQU-2021001,Effect of Oxygen Inhalation on Fatigue After Chemotherapy of Breast Cancer in High Altitude Area,2021-03-01,2022-12-31,670 days,Recruiting,Interventional
Fenofibrate in Breast Cancer,Fenofibrate Role in Breast Cancer Patients,2023-01-01,2024-02-01,396 days,Recruiting,Interventional
AHQU-2021003,Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer,2021-02-01,2023-01-31,729 days,Recruiting,Interventional
2018LS148,BAriaTric Surgery After Breast Cancer Treatment (BATS),2023-04-01,2025-02-01,672 days,Not yet recruiting,Interventional
PekingUMCH-BCa093,68Ga PET/CT Imaging in Breast Cancer Patients,2022-11-15,2024-12-31,777 days,Recruiting,Interventional
ADA,"An Integrative Intervention Based on Physical Activity, Nutrition and Supportive Care (the ADA Program) to Improve the Quality of Life of Breast Cancer Survivors",2022-12-01,2025-11-01,1066 days,Not yet recruiting,Interventional
514-0213/21-5000,Insulin Sensitivity After Breast Cancer,2021-08-01,2026-09-01,1857 days,Recruiting,Interventional
CentroHLOBreastUnit,HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer,2018-05-01,2020-05-01,731 days,Unknown status,Interventional
CCR4965,Evaluating a Digital Tool for Supporting Breast Cancer Patients,2019-10-01,2022-12-30,1186 days,"Active, not recruiting",Interventional
GCO 21-0699,"Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer",2021-09-29,2024-09-01,1068 days,Recruiting,Interventional
DBCG RT Natural Trial,Partial Breast Versus no Irradiation for Women With Early Breast Cancer,2018-09-05,2035-09-01,6205 days,Recruiting,Interventional
IPNCb-01,Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer,2021-11-01,2023-12-01,760 days,Recruiting,Interventional
CSPC-KAL-BC-12,Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer,2019-06-01,2024-12-01,2010 days,Not yet recruiting,Interventional
003-2017,Stereotactic Body Radiation Therapy for Breast Cancer,2018-07-17,2023-07-17,1826 days,Recruiting,Interventional
Breast cancer treatment,The Anti-tumor Effect of Metformin And Atorvastatin in Breast Cancer,2022-10-01,2023-09-01,335 days,Not yet recruiting,Interventional
18-561,NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer,2019-03-08,2023-04-19,1503 days,"Active, not recruiting",Interventional
E19137,Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile,2019-07-02,2021-05-01,669 days,Suspended,Observational
Vitamin D and breast cancer,Vitamin D and Calcium Supplementation in Breast Cancer,2022-11-01,2023-10-01,334 days,Not yet recruiting,Interventional
SYSEC-KY-KS-2021-182,Quantitative Assessment of Diffusion Spectrum Imaging in Breast Cancer,2021-08-20,2022-08-19,364 days,Recruiting,Interventional
CASE6119,Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer,2021-10-01,2023-09-01,700 days,Recruiting,Interventional
KX-ORAX-CN-007,A PK Study of Oraxol in Breast Cancer Patients,2019-04-22,2020-12-09,597 days,Completed,Interventional
NCC2018M-042,Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant ),2018-11-01,2021-09-01,1035 days,Unknown status,Interventional
CTO-IUSCCC-0803,Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis,2023-01-18,2023-07-31,194 days,Recruiting,Observational
55791222.0.0000.5313,Water and Land-based Aerobic Training in Breast Cancer Survivors,2022-09-01,2025-08-30,1094 days,Not yet recruiting,Interventional
UF-BRE-002,Phase I/IIa Study of Pharmacokinetics and Safety of Epidiferphaneâ¢ and Taxanes in Breast Cancer Patients,2020-03-01,2023-03-01,1095 days,Withdrawn,Interventional
18-010602,Screening CEDM in Intermediate and High-Risk Patient Populations,2019-02-15,2021-05-31,836 days,Completed,Observational
GIM21 - LiqERBcept,Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial),2018-11-07,2022-01-12,1162 days,Completed,Interventional
BREAST-SK-001,"Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.",2020-01-01,2023-01-01,1096 days,Unknown status,Interventional
LR19/011/50551,Increasing Knowledge of Alcohol as a Risk Factor for Breast Cancer Among Women Attending Breast Screening Services,2021-02-05,2021-12-02,300 days,Completed,Interventional
STU00201961A,A Research Study for Latina Women Undergoing Breast Cancer Treatment,2019-09-10,2022-07-01,1025 days,Completed,Interventional
18-641,"Young, Empowered & Strong (YES): The Young Womens Breast Cancer Study 2- Focus on Intervention Pilot",2019-05-23,2019-09-19,119 days,Completed,Interventional
CLEE011O12301C,A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer,2018-12-07,2026-05-29,2730 days,"Active, not recruiting",Interventional
HIRSLANDEN 01 SAKK 23/18,Intelligent Vacuum Assisted Biopsy Immediately Before Surgery as an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer,2020-08-17,2025-06-01,1749 days,Recruiting,Interventional
CCH-IRB-190414-P,Robotic Versus Conventional or Endoscopic Nipple Sparing Mastectomy in the Management of Breast Cancer-Prospective Study,2019-10-01,2022-02-28,881 days,Recruiting,Interventional
348455,Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer,2018-07-01,2023-12-31,2009 days,"Active, not recruiting",Interventional
SOLTI-2101,Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype,2022-03-28,2027-03-01,1799 days,Recruiting,Interventional
Zz123456.,The Effect of the Mobile Application-based Support Program on the Outcomes of Breast Cancer Patients in the Pandemic,2022-07-15,2024-02-15,580 days,Recruiting,Interventional
GBG102 - SASCIA,Sacituzumab Govitecan in Primary HER2-negative Breast Cancer,2020-10-28,2029-03-30,3075 days,Recruiting,Interventional
PROICM 2018-05 BCU,Sexual Quality of Life in Women During the First Year of Adjuvant Hormonal Treatment for Breast Cancer.,2018-05-02,2019-10-30,546 days,Completed,Observational
CAAE: 91570318.5.0000.5149,Nutritional Status and Pharmacological Treatment: Impact on the Toxicity and Quality of Life of Patients With Colorectal and Breast Cancer,2018-11-01,2019-12-01,395 days,Unknown status,Observational
FWA00015574/6-01-2019/korany,Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment,2019-10-20,2020-06-30,254 days,Completed,Interventional
SYSKY-2022-030-01,Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer,2022-07-15,2027-05-31,1781 days,Not yet recruiting,Observational
UI-ROD-OCTU02,MicroRNA Profiles in Triple Negative Breast Cancer,2021-11-29,2023-08-01,610 days,Recruiting,Interventional
KY20182079-F-1,Breast Cancer Treatment Based on Organ-like Culture,2019-01-02,2021-12-15,1078 days,Unknown status,Observational
PN-301-21,"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer",2022-02-28,2025-12-01,1372 days,Recruiting,Interventional
Radiation in breast cancer,Hypofractionated Radiotherapy Concomitantly With Weekly Boost for Breast Cancer Patients Treated With Conservative Breast Surgery,2021-12-01,2023-04-01,486 days,Unknown status,Observational
4-2018-0160,Impact of 5-fraction Stereotactic Partial Breast Irradiation and Whole Breast Irradiation on Cosmetic Outcome and Patient-reported Outcomes in Early-stage Breast Cancer,2018-04-11,2023-04-11,1826 days,Unknown status,Observational
ROCK,Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer,2018-05-01,2024-05-01,2192 days,Recruiting,Interventional
SOLTI-1805,"A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression",2020-12-22,2023-04-30,859 days,Recruiting,Interventional
KY20202075-F-2,Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer,2022-11-30,2025-07-30,973 days,Recruiting,Interventional
06805118.2.1001.5404,Sentinel Lymph Node Biopsy Versus no Axillary Surgery in Early Breast Cancer,2019-10-02,2030-10-02,4018 days,Recruiting,Interventional
ID4060,Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer,2019-11-01,2022-05-31,942 days,Completed,Observational
AN.MCME.CR.12,Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation,2019-08-01,2022-08-01,1096 days,Unknown status,Interventional
MedOPP293,Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer,2021-08-05,2028-03-01,2400 days,Recruiting,Interventional
iOM-110383,A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer,2019-01-01,2019-04-01,90 days,Withdrawn,Interventional
IRST174.25,Partial Breast Re-irradiation in Women in Women With Locally Recurrent Breast Cancer Previously Treated With Conservative Surgery and Whole Breast Irradiation,2023-03-31,2032-03-01,3258 days,Recruiting,Interventional
EUROPA,ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged â¥70 Years Early Stage Breast Cancer,2021-02-08,2030-02-08,3287 days,Recruiting,Interventional
HM022BC3C01,A Phase â¢ Study of the Efficacy and Safety of Hemay022+Aromatase Inhibitor(AI) in Participants With ER+/HER2+ Advanced or Metastatic Breast Cancer,2022-01-19,2024-06-01,864 days,Recruiting,Interventional
UF-BRE-007,Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients,2023-03-22,2026-01-01,1016 days,Recruiting,Interventional
SOLTI-2103,NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial,2022-11-25,2030-07-31,2805 days,Recruiting,Interventional
SOLTI-1503,Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer,2018-12-10,2025-04-27,2330 days,"Active, not recruiting",Interventional
0023041/i,MONOCENTRIC PERSPECTIVE STUDY: USE OF LIQUID BIOPSY WITH DIAGNOSTIC IMAGING,2022-09-12,2025-09-22,1106 days,Recruiting,Observational
LQ009,Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study,2022-03-01,2027-09-01,2010 days,Not yet recruiting,Interventional
BGB-900-2001-IIT,"A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)",2021-04-01,2023-06-30,820 days,Recruiting,Interventional
CLEE011H2301,Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer,2018-03-31,2025-11-17,2788 days,Withdrawn,Interventional
2020_61,Study of the Sexual Health of Patients Treated for Breast Cancer and Followed up in the Observatory of Fertility at Jeanne de Flandre Hospital.,2021-07-13,2025-07-01,1449 days,Recruiting,Observational
ONAWA (SOLTI-1802),Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer,2020-11-06,2021-04-30,175 days,Completed,Interventional
1,Hypofractionated Radiotherapy in Breast Cancer Patients With Prosthetic Reconstruction,2022-06-27,2029-05-01,2500 days,Recruiting,Interventional
STUDY00010776,REJOIN Trial for Older Breast Cancer Survivors,2021-06-15,2023-12-01,899 days,Recruiting,Interventional
CASE13119,Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer,2023-04-01,2024-12-01,610 days,Not yet recruiting,Interventional
ZX-2021-FES-ESTROTIMP-4,Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer,2022-02-08,2025-06-01,1209 days,Recruiting,Interventional
2017-0499,"Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer",2018-04-30,2022-02-10,1382 days,Completed,Interventional
IIT-UM2018001,Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation,2020-07-03,2023-12-01,1246 days,Recruiting,Interventional
Shengjing_002,Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer,2019-09-01,2022-09-30,1125 days,Recruiting,Interventional
UPCC 17120,Telehealth Weight Loss Program for Breast Cancer Survivors,2021-07-19,2023-12-01,865 days,"Active, not recruiting",Interventional
IRB-57723,Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer,2021-02-03,2026-02-01,1824 days,Recruiting,Interventional
D8530C00006,"A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer",2020-09-29,2023-12-29,1186 days,"Active, not recruiting",Interventional
3764,Stereotactic Body Radiotherapy for Patients With Breast Cancer Oligometastasis,2018-01-01,2021-04-01,1186 days,Unknown status,Interventional
115858,SIGNAL During a COVID-19 Pandemic,2020-05-01,2022-11-01,914 days,Withdrawn,Interventional
CCH-IRB-190414-R,Robotic Versus Conventional or Endoscopic Nipple Sparing Mastectomy for Breast Cancer,2019-08-22,2021-12-31,862 days,Unknown status,Interventional
UCCS20110,Development of a Personalized Discussion Prioritization Tool for Older Adults Considering Adjuvant Chemotherapy for Breast Cancer,2021-07-28,2023-07-01,703 days,"Active, not recruiting",Interventional
Shengjing-LJY04,Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer,2019-10-01,2029-09-30,3652 days,Recruiting,Observational
2019-004559-35,Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial),2020-06-15,2027-07-15,2586 days,Not yet recruiting,Interventional
GEICAM/2017-04,Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA),2018-06-12,2022-06-21,1470 days,Completed,Observational
KARMA Kontrast,KARMA Kontrast - a Controlled Trial Evaluating Contrast Enhanced Mammography in Early Detection of Breast Cancer,2020-11-09,2022-05-31,568 days,Unknown status,Interventional
ACE-Breast-03,"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)",2021-04-05,2025-12-01,1701 days,"Active, not recruiting",Interventional
BREAST,BRaziLian outcomE for metAStatic breasT Cancer,2021-09-13,2024-12-31,1205 days,Recruiting,Observational
FMBSUREC/10102021/Rabie,"Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients""",2021-10-30,2024-12-30,1157 days,Recruiting,Interventional
1808-42,Survey Study: Financial Impact of Breast Cancer Treatment,2018-09-04,2024-11-30,2279 days,"Active, not recruiting",Observational
2020-535,Targeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant Chemotherapy,2020-11-15,2025-07-15,1703 days,Recruiting,Interventional
RP-20-013,Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer,2022-10-01,2025-07-01,1004 days,Withdrawn,Interventional
EF141,Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy,2018-01-01,2019-10-01,638 days,Withdrawn,Interventional
STUDY00001225,The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project,2023-03-20,2027-06-01,1534 days,Recruiting,Interventional
CCR5119,KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer,2020-06-16,2026-12-31,2389 days,Recruiting,Interventional
3475-756,"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)",2018-12-27,2031-01-24,4411 days,"Active, not recruiting",Interventional
21-271,Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity,2021-08-27,2023-08-27,730 days,Recruiting,Observational
STUDY2019000317,Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer,2018-10-03,2028-10-03,3653 days,Recruiting,Observational
FirstHCMU_CB_001,Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast,2020-07-01,2021-01-15,198 days,Unknown status,Observational
2022-0055,A Study for the Neoadjuvant Treatment of Breast Cancer,2022-07-10,2027-12-20,1989 days,Recruiting,Interventional
WEFITTER,Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib,2022-04-22,2023-04-01,344 days,Recruiting,Interventional
A5481178,A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.,2022-10-12,2023-02-28,139 days,Completed,Observational
ARO-2015-1,Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer,2021-03-05,2025-06-30,1578 days,Recruiting,Interventional
HNCH-MBC11,Utidelone Combined With Bevacizumab in the Treatment of â¥ 2 Lines of HER-2 Negative Advanced Breast Cancer,2022-06-01,2024-12-30,943 days,Not yet recruiting,Interventional
SOLTI-1507,Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients,2020-02-25,2025-08-25,2008 days,Recruiting,Interventional
DKFZ-2019-008,Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE),2023-05-01,2029-12-01,2406 days,Not yet recruiting,Interventional
20170328,Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer,2018-08-01,2021-12-31,1248 days,Completed,Interventional
SHPD005,Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer,2018-10-16,2023-04-16,1643 days,Recruiting,Interventional
dAGEs,"Dietary Advanced Glycation End Products, Inflammation and Oxidative Stress in Breast Cancer Patients",2020-03-03,2023-06-30,1214 days,Recruiting,Observational
20-124,YES Study - Newly Diagnosed/Metastatic Intervention,2020-09-16,2028-03-01,2723 days,Recruiting,Interventional
LaPemERLA,Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole,2023-02-15,2026-12-31,1415 days,Recruiting,Interventional
NIR-THERMA-02,A Prospective Study to Evaluate Clinical Performance of Thermalytix in Detecting Breast Cancers,2018-12-15,2020-01-30,411 days,Completed,Observational
E7389-M082-602,A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants,2018-01-25,2018-06-30,156 days,Completed,Observational
Pro00020138,Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer,2019-06-11,2024-09-01,1909 days,Recruiting,Interventional
18-394,DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC,2018-11-05,2030-09-01,4318 days,"Active, not recruiting",Interventional
2019SABE028,The Effect of Early Rehabilitation After Breast Cancer Surgery on Physical and Psychosocial Functions,2020-07-01,2021-12-01,518 days,Recruiting,Interventional
IIBSP-PRO-2021-10,Prehabilitation for Breast Cancer Surgery,2021-11-01,2023-11-01,730 days,Recruiting,Interventional
SYSUCC-015,Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer,2021-11-11,2028-12-01,2577 days,Recruiting,Interventional
REO 026-1,Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer,2021-10-11,2023-07-01,628 days,"Active, not recruiting",Interventional
STUDY00001233,Novel Thermal Imaging Technique for Breast Screening,2022-11-15,2025-12-31,1142 days,Recruiting,Observational
2019.429,Effectiveness of Character Strengths-based Intervention Among Breast Cancer Patients,2020-05-04,2020-12-20,230 days,Completed,Interventional
CP7-005,A Study Comparing ImmunopheresisÂ® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients,2019-05-31,2023-07-31,1522 days,Recruiting,Interventional
LY2023-054-B,RC48-ADC in HER2-low Advanced Breast Cancer,2023-04-01,2026-08-01,1218 days,Not yet recruiting,Interventional
INCASE0518,Artificial Intelligence vs Physicians for Breast Cancer Patients Information,2018-11-01,2019-01-20,80 days,Completed,Observational
2021/193780(REK),Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole,2022-12-01,2024-12-01,731 days,Recruiting,Interventional
123123,Eurythmy Therapy (ERYT) as a Treatment Option for Fatigue in Metastatic Breast Cancer Patients,2020-03-10,2024-11-30,1726 days,Recruiting,Interventional
JTU-6H-20211011001,Effect of ALND With Vein Branches Reservation on Postoperative Upper Limb Edema and Dysfunction in Breast Cancer,2021-12-01,2024-03-01,821 days,Recruiting,Interventional
INST 1607,Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging,2018-04-16,2024-12-31,2451 days,Recruiting,Observational
CIMS-4FMFES-2021-3966,4FMFES-PET Imaging of ER+ Advanced Breast Cancers,2020-11-01,2023-12-31,1155 days,Recruiting,Interventional
SOLTI-1718,Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer,2020-07-23,2021-11-29,494 days,Terminated,Interventional
Yunwei Wei 2019-09-13,Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy,2019-09-12,2020-10-15,399 days,Unknown status,Observational
HLX11-BC301,A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-PerjetaÂ® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer,2022-04-25,2025-12-30,1345 days,Recruiting,Interventional
Zoledronic Acid In Breast Ca,Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole,2021-09-30,2023-09-30,730 days,Recruiting,Interventional
Tacrolimus_2020,Tacrolimus as Treatment of Breast Cancer-Related Lymphedema,2020-09-22,2022-01-06,471 days,Completed,Interventional
6788,Breast MRI for Neaodjuvant Chemotherapy Response Prediction and Evaluation in Breast Cancer,2018-01-01,2019-01-01,365 days,Unknown status,Observational
KSRAD001,Using AI to Select Women for Supplemental MRI in Breast Cancer Screening,2021-04-01,2025-07-01,1552 days,Recruiting,Interventional
Stage 2 compression therapy,Adjustable Compression Wrap Versus Compression Sleeve to Control Breast Cancer-related Lymphedema,2021-06-01,2022-12-31,578 days,Not yet recruiting,Interventional
CASE5120,Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer,2020-12-28,2023-12-01,1068 days,Recruiting,Interventional
PROICM 2020-07 VIS,Professional Life After Breast Cancer: Feasibility of a Coaching Program for an Adapted Return to Work,2021-09-13,2023-05-01,595 days,Recruiting,Interventional
CL1-81694-003,S 81694 Plus Paclitaxel in Metastatic Breast Cancer,2018-01-04,2020-06-08,886 days,Completed,Interventional
Shengjing-LCG005,Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer,2021-07-19,2026-11-30,1960 days,Recruiting,Interventional
2020.KB.SAG.069,The Effect of Mobile Lymphedema Self-Care Support Program on Self-Care in Women With Breast Cancer-related Lymphedema,2021-09-01,2021-12-01,91 days,Recruiting,Interventional
NCC1824,Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR,2018-09-17,2021-06-01,988 days,Unknown status,Observational
INNOVBC,A Guided Internet-delivered Individually-tailored ACT-influenced CBT Intervention to Improve Psychosocial Outcomes in Breast Cancer,2018-02-01,2019-12-01,668 days,Unknown status,Interventional
R20-003,Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Breast Cancer,2023-06-01,2025-07-01,761 days,Recruiting,Interventional
MedOPP319,CB-103 Plus NSAI In Luminal Advanced Breast Cancer,2021-05-06,2023-05-01,725 days,"Active, not recruiting",Interventional
WO39391,A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer,2018-08-02,2025-08-24,2579 days,"Active, not recruiting",Interventional
NCC1867,The Psychology of Chinese Breast Cancer Patients,2019-04-25,2021-12-31,981 days,Enrolling by invitation,Observational
20-157,Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD),2020-12-16,2023-12-01,1080 days,Recruiting,Interventional
2-102-21,Towards Early Detection of Breast Cancer in High Risk Population,2022-03-01,2024-05-01,792 days,Not yet recruiting,Observational
HunanCH-BC-001,Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer,2022-10-01,2025-10-01,1096 days,Not yet recruiting,Observational
2021.693,mHealth Usage Among Nigeria Women Diagnosed With Breast Cancer Receiving Chemotherapy,2022-09-01,2023-12-01,456 days,Recruiting,Interventional
GENEXAN,GENe EXpression After Regional or General ANesthesia in Patients Undergoing Breast Cancer Surgery,2021-03-01,2022-03-01,365 days,Unknown status,Interventional
HSC20160245H,Improving Adherence to EHT Among Breast Cancer Patients,2021-05-03,2025-06-01,1490 days,"Active, not recruiting",Interventional
GRO-06-001,ABUS for Early-stage Breast Cancer,2019-08-15,2022-08-15,1096 days,Unknown status,Interventional
Neveen,"Demographic , Clinicopathological Characteristics and Survival of Breast Cancer",2021-04-01,2024-12-31,1370 days,Not yet recruiting,Observational
Melody_002,"MelodyÂ®, a Lab Developed Test for Breast Cancer for Women With Dense Breast Tissue",2021-10-01,2024-10-01,1096 days,Recruiting,Observational
REC-H-PHBSU-21010,Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints,2021-04-26,2022-08-26,487 days,Completed,Interventional
YOUNGBC-22,"Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer",2022-09-01,2024-01-01,487 days,"Active, not recruiting",Interventional
16D.674,Prospective Breast Cancer Biospecimen Collection,2018-05-10,2021-01-22,988 days,Unknown status,Interventional
SMC- 5725-18,The Breast Cancer Personalized Nutrition Study,2019-07-17,2025-12-01,2329 days,Recruiting,Interventional
2000025837,Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer,2019-12-23,2023-07-01,1286 days,"Active, not recruiting",Interventional
DS8201-A-U305,A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05),2020-12-04,2030-12-31,3679 days,Recruiting,Interventional
2020/33,Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer,2021-07-16,2028-06-01,2512 days,Recruiting,Interventional
2018.016,Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA,2018-05-22,2024-12-01,2385 days,Recruiting,Interventional
HE071-CSP-021,A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer,2021-06-11,2024-05-30,1084 days,Recruiting,Interventional
Shengjing_001,Study on Bisphosphonates Targeting Triple-negative Breast Cancer,2019-09-01,2022-08-31,1095 days,Recruiting,Observational
PREDIX II HER2,Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer,2019-05-23,2021-06-30,769 days,Terminated,Interventional
ATADEK 2022-17/27,The Effect of Wearable Vibration Therapy on Shoulder Functionality in Individuals Receiving Adjuvant Radiotherapy After Breast Cancer Surgery,2022-11-01,2023-02-15,106 days,Recruiting,Interventional
CHIR-01-sentinel,Sentinel Lymph Node Biopsy in Patients With Breast Cancer After Neoadjuvant Therapy,2018-01-01,2020-11-30,1064 days,Completed,Interventional
R.20.05.834,Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.,2020-06-05,2023-05-01,1060 days,Recruiting,Interventional
MCC-20902,Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer,2021-10-12,2025-12-09,1519 days,"Active, not recruiting",Interventional
D3615C00001,Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer,2020-04-16,2024-06-07,1513 days,"Active, not recruiting",Interventional
SMC-2019-05-021 (2),Real-time Interactive Digital Healthcare System in Patients With Breast Cancer; Randomized Controlled Trial,2020-04-01,2021-11-17,595 days,Completed,Interventional
PUMCH-BC501,Evaluation of Prognostic Monitoring for Breast Cancer Patients With Recurrence and Metastasis After Surgery,2019-04-01,2025-03-01,2161 days,Recruiting,Observational
17/209,The Tomosynthesis Trial in Bergen - Part 2,2018-01-01,2023-06-01,1977 days,"Active, not recruiting",Interventional
2022-SR-494,Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer,2022-09-13,2025-12-01,1175 days,Recruiting,Interventional
PCS-001,Breast Cancer Liquid Biopsy Trial,2020-09-28,2023-07-31,1036 days,Recruiting,Observational
1563/2018,Randomized Clinical Trial Comparing Rehabilitation Robotic Versus Conventional After Breast Cancer Surgery,2019-07-20,2020-12-20,519 days,Unknown status,Interventional
C3441053,Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer,2021-08-20,2021-10-11,52 days,Completed,Observational
18-603,"Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors",2019-10-28,2021-12-01,765 days,Completed,Interventional
2021-0170,Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer,2022-01-31,2025-06-30,1246 days,Recruiting,Interventional
PUMCH-SBSBC,Survival Benefits of Statins in Breast Cancer Patients,2019-03-28,2024-06-28,1919 days,Recruiting,Interventional
B27IB3856,UCLA Breast Cancer Survivor Health Promotion Research Study,2022-04-01,2023-06-01,426 days,Recruiting,Interventional
2018.08.ST,Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma,2019-03-01,2022-03-09,1104 days,Terminated,Interventional
YYS-20200305,Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer,2020-10-09,2022-07-20,649 days,Completed,Interventional
CAN04CLIN005,Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.,2022-01-11,2026-08-01,1663 days,Recruiting,Interventional
YOUNGBC-7,18F-FES PET/CTs Additional Clinical Value in ER+ BC,2019-02-15,2019-06-20,125 days,Completed,Observational
ORIN1001-001,ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer,2019-05-25,2023-03-30,1405 days,"Active, not recruiting",Interventional
LUN_MMG_121,Study to Evaluate Effectiveness of Investigational Device in the Assistance of Detection and Diagnosis of Breast Cancer,2020-06-15,2021-01-13,212 days,Completed,Observational
Breast Cancer-RISS,Ultrasound Guided Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Surgeries,2020-08-31,2021-03-01,182 days,Completed,Interventional
STML-ELA-0322,"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study",2023-08-01,2025-08-01,731 days,Not yet recruiting,Interventional
LCCC2105,Transitioning Care: Perspectives of Older Women With Early Breast Cancer on Current Telemedicine Modalities,2021-07-02,2021-10-10,100 days,Completed,Observational
RJrapidplan,RapidPlan Models Establishment for Node-Positive Breast Cancer Treated With Hypofractionation Using Edge/Truebeam,2021-12-15,2024-12-15,1096 days,Recruiting,Observational
2-049-18,Randomised Controlled Study of Physical Exercise Intervention in Breast Cancer Patients at Risk of Anthracycline-induced Cardiomyopathy: The EMBRACE Study,2020-02-01,2030-08-30,3863 days,Recruiting,Observational
MIES-BCNAT,Multimodal Imaging Evaluation System of Axillary Lymph Node Staging and Treatment Strategy for Breast Cancer Neoadjuvant Therapy,2021-01-01,2023-12-31,1094 days,Not yet recruiting,Observational
MACSSI (ET18-150),MACSSI (MAstectomie Cellules Souches Surveillance Immunitaire),2021-02-22,2024-11-15,1362 days,Recruiting,Observational
HNCH-BC010,A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer,2022-05-11,2024-09-30,873 days,Recruiting,Interventional
22SCH740,STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER),2023-05-01,2027-05-01,1461 days,Not yet recruiting,Interventional
eMOUVOIR-1901,Impact of Personalized and Remote Support Centered on Exercise and Physical Activity for Breast Cancer Patients,2020-12-18,2024-12-01,1444 days,Recruiting,Interventional
NCC2019-0142,Prospective Cohort Study of Breast Cancer Patients Treated With Radiotherapy,2019-07-03,2034-06-30,5476 days,Enrolling by invitation,Observational
19-002792,Adipose-Induced Regeneration of Breast Skin to Treat Post-Mastectomy Radiation Injury in Breast Cancer Patients,2019-05-17,2026-08-01,2633 days,Recruiting,Interventional
20G.605,Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer,2020-11-24,2024-01-01,1133 days,Recruiting,Interventional
UT BCS Sleep Study,Feasibility and Effectiveness of a Sleep Hygiene Education Program for Sleep Issues in Breast Cancer Survivors,2020-01-15,2020-07-01,168 days,Withdrawn,Interventional
919PP17,Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin,2019-09-01,2020-05-01,243 days,Completed,Interventional
H-50349,Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer,2023-02-15,2029-09-01,2390 days,Not yet recruiting,Interventional
NIS12501,"A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib",2022-07-08,2023-02-01,208 days,Recruiting,Observational
B002-101,B002 in Patients With HER2-positive Breast Cancer,2019-05-28,2022-04-26,1064 days,Completed,Interventional
MCC-21378,Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer,2022-05-31,2026-05-01,1431 days,Recruiting,Interventional
"2016-051-000001, 2563",Investigating Barriers for Decision Making in a Danish Breast Cancer Screening Context,2022-06-22,2022-11-01,132 days,Recruiting,Interventional
010006,Integrin Î±6-targeted SPECT Imaging of Breast Cancer,2018-03-08,2019-06-30,479 days,Completed,Interventional
20210504,MRI-based Approaches for Multi-parametric Model to Early Predict Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer,2019-01-01,2023-06-30,1641 days,Recruiting,Observational
2021-0358,A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC),2021-11-16,2024-12-29,1139 days,Recruiting,Interventional
LACUDY,Evaluate Efficacy and Safety of LACUDY for Improving Vaginal Environment in Breast Cancer Patient,2022-12-20,2023-02-28,70 days,Not yet recruiting,Interventional
18-2444.cc,Facial Skin Health Tracking Feasibility in Breast Cancer Patients,2020-01-24,2024-08-01,1651 days,Recruiting,Observational
CSPC-DMS-BC-17,Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer,2019-10-01,2021-01-01,458 days,Unknown status,Interventional
UC-0105/1815,"Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis",2019-10-21,2025-03-30,1987 days,"Active, not recruiting",Interventional
NCC3340,A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer,2022-02-01,2024-06-01,851 days,Recruiting,Interventional
YOMA,Effects of Yoga on the Quality of Life of Breast Cancer Patients,2022-05-09,2024-12-01,937 days,Recruiting,Interventional
2022-7735,Life After Breast Cancer - Impact of a Life Coach,2021-09-15,2023-09-01,716 days,Not yet recruiting,Interventional
IRB00130428,The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer,2019-02-20,2023-11-26,1740 days,"Active, not recruiting",Interventional
HR BLTN 014,Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer,2020-04-01,2023-05-01,1125 days,"Active, not recruiting",Interventional
C4891023,TACTIVE-U: A Study to Learn About the Study Medicine (Called ARV-471) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B),2023-03-01,2027-10-06,1680 days,Recruiting,Interventional
SYSU-2022-02,"Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.",2023-02-01,2024-08-01,547 days,Recruiting,Interventional
GO40987,"A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer",2019-07-26,2021-05-25,669 days,Completed,Interventional
HR-BLTN-008,"Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer",2019-11-06,2023-03-31,1241 days,Recruiting,Interventional
OkanU2,Influence of Multidisciplinary Breast Tumor Board on Physician Decision,2018-08-13,2019-11-13,457 days,Unknown status,Observational
HNCH-MBC08-BM02,Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases,2022-04-29,2024-05-01,733 days,Recruiting,Interventional
TRICIA,TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence,2019-12-05,2023-06-01,1274 days,Recruiting,Observational
19-003532,Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers in Patients Undergoing Regional Nodal Irradiation for Breast Cancer,2019-10-01,2023-10-01,1461 days,Recruiting,Observational
SNF4,Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer,2023-02-01,2027-06-01,1581 days,Recruiting,Interventional
PALBOCOMP,Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programe,2018-09-18,2019-09-01,348 days,Completed,Observational
MA-BC-II-006,Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC),2020-05-20,2024-02-28,1379 days,Recruiting,Interventional
17/013,Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer,2018-08-01,2023-06-01,1765 days,"Active, not recruiting",Interventional
LACOG 0221,"Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil",2021-10-01,2023-03-20,535 days,Recruiting,Observational
SNF3,PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer,2023-02-01,2027-06-01,1581 days,Recruiting,Interventional
1780,Identifying Biomarkers for Chronic Pain After Breast Cancer Treatment.,2022-09-01,2025-06-01,1004 days,Not yet recruiting,Observational
2020 - 176,Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer,2021-01-15,2021-12-15,334 days,Unknown status,Interventional
HR-TNBC-HN100,SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer,2020-01-01,2023-01-01,1096 days,Unknown status,Interventional
2018-68-1461,Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer,2018-08-01,2024-07-01,2161 days,Recruiting,Interventional
YANWQ002,the New Geneswell BCT in Vitro Diagnosis of Breast Cancer Prognosis,2020-02-01,2020-12-31,334 days,Unknown status,Observational
STU00206180,A Web-Based Tool to Improve Breast Cancer Survivorship,2019-05-29,2022-05-01,1068 days,Completed,Interventional
MR-01,Monitoring Response to Neoadjuvant Chemotherapy in Breast Cancer Using Ultrafast DCE-MRI,2022-01-03,2024-07-01,910 days,Recruiting,Observational
2019-09-09,Sentinel Lymph Node Biopsy With Hybrid Technique in Breast Cancer,2019-01-01,2025-01-01,2192 days,Recruiting,Interventional
UBRS20013,Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer,2023-06-01,2026-06-01,1096 days,Not yet recruiting,Interventional
SPI-POZ-101,A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer,2018-07-13,2019-04-17,278 days,Terminated,Interventional
HR-BLTN-014,Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer,2019-08-15,2021-04-15,609 days,Unknown status,Interventional
EC/TMC/108/17,Hypo-Fractionated Radiotherapy in Breast Cancer,2018-01-02,2023-01-03,1827 days,Unknown status,Interventional
SGRT-BC,Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer,2022-04-01,2027-04-01,1826 days,Recruiting,Interventional
CMUH108-REC3-090,A Study to Evaluate the Safety and Clinical Outcome of Using FR-Mask in Breast Cancer Patients With Radiation-irritated Skin After Radiotherapy,2019-09-06,2021-12-01,817 days,Unknown status,Interventional
PALBOSPAIN,Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer,2021-07-31,2022-06-08,312 days,Completed,Observational
RC48-C012,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,2020-09-29,2023-12-30,1187 days,Recruiting,Interventional
261\\2021,Real-time Tele-monitoring Versus Routine Monitoring of Breast Cancer Patients Receiving Adjuvant Systemic Therapy,2022-06-01,2024-05-01,700 days,Not yet recruiting,Interventional
ERIBRAIN-IPC 2017-014,Eribulin in Brain Metastases From HER2-negative Breast Cancer,2019-02-26,2020-04-14,413 days,Withdrawn,Interventional
CYH33-G103,"Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer",2021-04-01,2022-12-01,609 days,Unknown status,Interventional
OTT 18-02,Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT),2019-09-17,2022-04-09,935 days,Completed,Interventional
SYSA1901-002,Study to Evaluate the Efficacy and Safety of SYSA1901 vs. PerjetaÂ® of HER2-Positive Breast Cancer,2023-01-09,2026-02-21,1139 days,Recruiting,Interventional
YBCSG-21-03,Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer,2020-12-15,2023-02-25,802 days,Unknown status,Interventional
EBaran,The Effect of Complex Decongestive Physiotherapy on Sensory Parameters in Breast Cancer Related Lymphedema.,2019-11-28,2021-12-01,734 days,Unknown status,Interventional
99mTc-ADAPT6,99mTc-ADAPT6-based HER2 Imaging in Breast Cancer,2019-06-05,2020-09-05,458 days,Completed,Observational
2019-0088,Proton Accelerated Partial Breast Irradiation,2020-07-01,2021-07-08,372 days,Withdrawn,Interventional
R20-030,Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI,2023-12-31,2027-08-31,1339 days,Recruiting,Interventional
NL77000.029.21,Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients,2022-08-24,2035-03-01,4572 days,Recruiting,Interventional
MUKDEN 07,A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients,2023-03-16,2029-02-28,2176 days,Recruiting,Interventional
OstacoliMIND&BC,Mindful-life: Mindfulness Based Intervention vs Cognitive Behavioral Therapy in Patients With Breast Cancer,2022-01-01,2022-12-31,364 days,Unknown status,Interventional
NCC3286,A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway,2022-04-01,2024-08-01,853 days,Recruiting,Interventional
HR-BLTN-010,A Phase â¡ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer,2019-09-30,2022-08-30,1065 days,Unknown status,Interventional
GS-US-595-6184,Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy,2022-12-12,2031-01-01,2942 days,Recruiting,Interventional
CMUH106-REC3-137,Comparative Effectiveness of Acupuncture and Nonsteroidal Anti-inflammatory Drugs for the Management of Aromatase Inhibitor Induced Arthralgia Among Breast Cancer Survivors,2018-03-28,2021-12-31,1374 days,Completed,Interventional
2010134480,Prospective Comparison of Breast MRI vs Contrast Mammography Prior to Surgery in Breast Cancer Patients,2021-01-19,2023-01-01,712 days,Unknown status,Interventional
DS8201-A-U303,Trastuzumab Deruxtecan (DS-8201a) Versus Investigators Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04],2018-12-27,2023-03-01,1525 days,"Active, not recruiting",Interventional
H18-02581,"Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers",2019-01-07,2023-12-31,1819 days,Not yet recruiting,Interventional
SMX 22-002,Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,2023-03-01,2026-06-01,1188 days,Not yet recruiting,Interventional
18-371,"Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial",2019-01-15,2024-12-01,2147 days,"Active, not recruiting",Interventional
K171005J,"Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility",2018-09-09,2020-03-17,555 days,Completed,Interventional
9745,CESM ABMR Breast Cancer Screening Trial,2018-01-03,2022-12-31,1823 days,Completed,Observational
J1836,"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer",2018-11-13,2023-12-31,1874 days,"Active, not recruiting",Interventional
2019/2452,Impact of a Breast cAncer Survivorship Interprofessional Community Care Model,2021-03-01,2022-07-20,506 days,Completed,Interventional
X-XJTU1AFLSY-93,"Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038",2022-06-01,2024-10-30,882 days,Recruiting,Interventional
20-104,"Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives)",2021-09-10,2022-01-21,133 days,Completed,Interventional
SCHBCC-N030,Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS),2020-05-15,2027-05-15,2556 days,Not yet recruiting,Interventional
D967JC00001,A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer,2020-12-28,2025-12-30,1828 days,Recruiting,Interventional
STUDY00022698,MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals,2022-09-07,2025-08-31,1089 days,Recruiting,Observational
CLEE011AUS64,A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors,2020-04-15,2020-06-15,61 days,Completed,Observational
NCC1888,Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib,2021-08-20,2023-09-01,742 days,Not yet recruiting,Interventional
SCAN-B-rec,Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec),2019-01-21,2030-12-01,4332 days,Recruiting,Observational
LMengmeng,An Online Psychosocial Intervention for Fear of Cancer Recurrence in Breast Cancer Survivors,2022-09-30,2023-12-30,456 days,Recruiting,Interventional
XZP-3287-3002,A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer,2022-02-01,2025-12-01,1399 days,Not yet recruiting,Interventional
R21-072,Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI),2023-06-01,2027-08-02,1523 days,Not yet recruiting,Interventional
HCI131027,Functional Precision Oncology for Metastatic Breast Cancer,2021-02-16,2025-08-01,1627 days,Recruiting,Interventional
SCHBCC-N025,A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS),2019-10-01,2022-09-01,1066 days,"Active, not recruiting",Interventional
ERC/2020/10/11 (26/10/2020),Improving Access to Breast Cancer Screening and Treatment in Nigeria: The Triple Mobile Assessment and Patient Navigation Model,2021-12-08,2023-10-31,692 days,Recruiting,Interventional
19-055,A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients,2019-07-11,2026-12-31,2730 days,Recruiting,Interventional
SLNB-ACP,Sentinel Lymph Node Biopsy After Neoadjuvant Treatment in Breast Cancer Patents,2018-09-21,2027-05-01,3144 days,Enrolling by invitation,Observational
AI-BMRI,Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women,2021-09-01,2025-09-30,1490 days,Recruiting,Observational
2019/1318,Exercise in Breast Cancer Survivors,2020-09-08,2023-03-02,905 days,Completed,Interventional
20F.259,Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation,2020-12-07,2024-04-01,1211 days,Recruiting,Interventional
BC-P29,Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT,2020-07-03,2028-09-01,2982 days,Recruiting,Interventional
Smart,An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy,2022-03-07,2022-12-07,275 days,Not yet recruiting,Interventional
OMICS Mark,Metabolomics Explores Biomarkers for Metastatic Breast Cancer,2019-10-01,2023-02-01,1219 days,Unknown status,Observational
RS-NAT01,Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant Therapy,2019-11-01,2022-12-30,1155 days,Unknown status,Interventional
SMX 20-001,Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,2020-09-29,2023-02-10,864 days,"Active, not recruiting",Interventional
2021/32,The Effect of Self-compassion on Breast Cancer,2022-05-15,2022-11-15,184 days,Not yet recruiting,Interventional
BOMB,Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis,2020-05-09,2026-12-31,2427 days,Recruiting,Interventional
XuzhouMedSch3,Effect of Perioperative Low Dose Ketamine on Postoperative Recovery in Patients Undergoing Breast Cancer Surgery,2018-09-20,2020-02-01,499 days,Unknown status,Interventional
MC220301,Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer,2023-03-09,2027-01-30,1423 days,Recruiting,Interventional
FUSCC-TNBC-BLIS,Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer,2023-05-01,2026-02-28,1034 days,Recruiting,Interventional
TeMP 2021,The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery: a Prospective Double-Blind Randomized Clinical Trial.,2022-03-29,2028-04-01,2195 days,Recruiting,Interventional
SMC 2018-07-014-011,Sleep and Activity Patterns in Pre-menopausal Breast Cancer Patients on Tamoxifen Using a Wrist-worn Internet of Things Device,2018-08-10,2020-12-31,874 days,Unknown status,Observational
D931CC00001,Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer,2022-11-07,2026-12-07,1491 days,Recruiting,Interventional
WuhanU,Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP,2022-01-05,2027-09-20,2084 days,Not yet recruiting,Interventional
2022-017,Characterization and Kinetic of Chemotherapy-induced Cardiovascular Toxicity in Breast Cancer,2023-04-01,2024-01-01,275 days,Recruiting,Observational
Stage 1 Compression Therapy,Adjustable Compression Wrap Versus Compression Bandage Reduce to Breast Cancer-related Lymphedema,2021-07-01,2022-12-31,548 days,Not yet recruiting,Interventional
GEICAM/2018-03,Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer,2021-05-21,2024-07-24,1160 days,Recruiting,Observational
018-745,LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer,2019-09-05,2023-12-01,1548 days,"Active, not recruiting",Interventional
4298,mHealth for Breast Cancer Survivors With Insomnia,2022-04-05,2023-03-01,330 days,Recruiting,Interventional
20-371,Niraparib + Dostarlimab In BRCA Mutated Breast Cancer,2020-12-18,2029-07-17,3133 days,Recruiting,Interventional
HBMUFH-101,A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer,2019-08-01,2021-12-01,853 days,Unknown status,Interventional
2019-KY-051,Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer,2019-07-01,2025-07-01,2192 days,Recruiting,Interventional
GCX-BCT-06,Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy,2019-01-11,2029-01-01,3643 days,Recruiting,Interventional
213355,Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer,2018-04-12,2020-03-31,719 days,Completed,Interventional
2022-0056,A Study for the Adjuvant Treatment of Breast Cancer,2022-07-10,2027-12-20,1989 days,Recruiting,Interventional
20192755,Prevention of Cardiovascular Diseases Caused by Complex Treatment of Patients With Primary Operated Breast Cancer,2019-07-01,2023-02-07,1317 days,Completed,Interventional
K3_K1_2,An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain,2022-01-20,2025-06-30,1257 days,Recruiting,Interventional
MEDOPP437,PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin,2023-07-01,2027-07-01,1461 days,Not yet recruiting,Interventional
BC-P31,Clinical Study of Glycosylated Extracellular Vesicles for Early Diagnosis of Breast Cancer,2022-07-14,2024-06-15,702 days,Recruiting,Observational
EORTC-1550-BCG,Dissecting the Pathways of Therapy Resistance in Early Breast Cancer,2020-07-08,2023-07-31,1118 days,Recruiting,Observational
D9670C00001,"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigators Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer",2020-07-24,2026-06-19,2156 days,Recruiting,Interventional
ACR A4707,Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts,2023-03-01,2027-01-01,1402 days,Not yet recruiting,Interventional
42127,Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity,2021-12-01,2026-12-01,1826 days,Not yet recruiting,Observational
handan1,Circulating Tumor Cells Screen for Breast Cancer,2020-02-20,2023-06-20,1216 days,"Active, not recruiting",Observational
IOM-120465,Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.,2022-05-21,2027-05-01,1806 days,Recruiting,Observational
2-025-19,Is Lipid Mapping an Effective Early Detection Tool for Breast Cancer in High-risk Populations?,2019-06-20,2021-12-31,925 days,Unknown status,Observational
OTT 20-11 (IT-02),INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer,2021-03-25,2023-03-01,706 days,Recruiting,Interventional
PREBCA,Progressive Relaxation Training in Breast Cancer Patients Receiving Aromatatase Inhibitor Therapy,2019-10-25,2020-09-24,335 days,Completed,Interventional
OBU-SC-BB-BC-II-010,"Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer",2020-12-01,2023-12-31,1125 days,Recruiting,Interventional
20-09022641,Combined Immunotherapies in Metastatic ER+ Breast Cancer,2020-11-12,2025-10-31,1814 days,Recruiting,Interventional
D9673R00025,A Study of Patients Receiving T-DXd (Trastuzumab Deruxtecan) for Treatment of HER2+ Unresectable and/or Metastatic Breast Cancer,2023-03-15,2025-12-31,1022 days,Not yet recruiting,Observational
SaglikBilimleriU_DU,Investigation of the Effect of Education on Symptom Management on Symptom Management in Patients With Breast Cancer,2022-07-01,2023-04-01,274 days,Recruiting,Interventional
mTPVB SPPB Ver 2,Subpectoral Plexus Block With Multi-level TPVB for Surgical Anesthesia During Primary Breast Cancer Surgery,2023-06-01,2025-01-31,610 days,Not yet recruiting,Interventional
SYSKY-2023-129-01,Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer,2023-02-16,2025-12-01,1019 days,Recruiting,Interventional
R868/18-IEO 916,Predicting Effective Adaptation to Breast Cancer to Help Women to BOUNCE Back,2018-12-06,2021-12-31,1121 days,Recruiting,Observational
309424,Breast CANcer Risk Assessment in Younger Women: BCAN-RAY,2023-05-31,2025-05-01,701 days,Not yet recruiting,Observational
Melody_001,"Validation of MelodyÂ®, a Tear-based Screening Assay for Breast Cancer",2021-06-01,2025-12-01,1644 days,Enrolling by invitation,Observational
19-1812.cc,"Fertility Changes Due to Cancer: an Investigation of Meaning, Psychological Distress, and Psychologi",2021-01-11,2024-12-01,1420 days,"Active, not recruiting",Observational
UW20035,Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer,2021-05-24,2023-11-01,891 days,Recruiting,Interventional
I3Y-NS-O003,Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients With Symp-tomatic Visceral Metastases or High Tumor Burden,2020-12-22,2024-12-01,1440 days,Recruiting,Observational
ID-TMS-02-20201012,CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population,2021-01-01,2024-06-30,1276 days,"Active, not recruiting",Interventional
CABC012,Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer,2019-02-21,2023-01-26,1435 days,"Active, not recruiting",Interventional
ACE-Breast-07,ARX788 in Breast Cancer With Low Expression of HER2,2021-10-20,2023-06-30,618 days,Recruiting,Interventional
2019-053,Intervention to Promote Breast Cancer Screening Among American Indian Women,2020-10-03,2024-12-31,1550 days,"Active, not recruiting",Interventional
SNB vs PET/MRI 1,Axillary Staging in Node Positive Breast Cancer Patients Receiving PST. SNB vs PET/MRI,2019-11-04,2024-04-01,1610 days,Recruiting,Interventional
AITIC,Artificial Intelligence in Breast Cancer Screening Programs in CÃ³rdoba (AITIC),2021-07-01,2023-06-01,700 days,Recruiting,Interventional
NIHR 128311,Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy,2021-02-26,2030-02-28,3289 days,Recruiting,Interventional
Pro00104868,Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer,2020-09-01,2025-08-01,1795 days,Recruiting,Interventional
RG_16-108,NOSTRA-Feasibility Study: A Study Looking at Ultrasound Guided Biopsies for Breast Cancer,2019-05-22,2025-12-31,2415 days,Recruiting,Observational
STUDY00000023,TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer,2019-04-17,2023-12-31,1719 days,"Active, not recruiting",Interventional
2022/0132,The Effect of Myofascial Chain Release Techniques on Shoulder Joint Range of Motion in Breast Cancer Survivors,2022-08-15,2024-02-15,549 days,Not yet recruiting,Interventional
2021C0128,"Brain Imaging, Nutrition, and Cognition in Breast Cancer Survivors",2022-01-18,2023-06-01,499 days,Recruiting,Observational
GMI-1359-210,A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer,2019-11-21,2021-08-25,643 days,Terminated,Interventional
20_RIPH3_06,Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique,2020-10-28,2025-12-28,1887 days,Recruiting,Observational
SHERO,"Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer",2020-06-01,2030-05-31,3651 days,Not yet recruiting,Interventional
MA-BC-II-023,Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy,2023-03-01,2026-03-25,1120 days,Recruiting,Interventional
0494-22-RMB,A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.,2022-12-25,2027-12-31,1832 days,Recruiting,Interventional
ICO-A-2018-10,Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery,2019-03-19,2022-10-19,1310 days,"Active, not recruiting",Interventional
IRB_00162526,Exercise Timing in Breast Cancer Patients,2023-04-01,2023-08-01,122 days,Not yet recruiting,Interventional
REG-074-2020,Pre-operative Exercise During Neoadjuvant Chemotherapy in Patients With Breast Cancer,2021-06-23,2024-04-30,1042 days,Recruiting,Interventional
Woman health,Whole Body Vibration Training and Breast Cancer Risk Factors,2019-08-01,2020-09-01,397 days,Completed,Interventional
CSIIT-C39,Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer,2022-11-01,2023-12-31,425 days,Recruiting,Interventional
99mTc-ZHER2,Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2.,2021-12-22,2023-03-01,434 days,Completed,Interventional
HCC 22-003,Preoperative Irradiation for Stage I Breast Cancer,2023-02-08,2027-09-01,1666 days,Recruiting,Interventional
FAST-F-PG01,Ultra-hypofractionated Radiotherapy in Breast Cancer Patients,2021-07-21,2026-07-21,1826 days,Recruiting,Observational
20-001670,Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring,2020-11-16,2024-11-15,1460 days,Recruiting,Observational
CSIIT-C03,Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy,2020-10-30,2022-12-01,762 days,Unknown status,Interventional
IBCSG 55-17,To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH),2019-04-16,2023-04-30,1475 days,"Active, not recruiting",Interventional
WO42633,A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy,2021-05-04,2034-10-26,4923 days,Recruiting,Interventional
2022-05093-02,The T-REX Trial: Tailored Regional External Beam Radiotherapy in Clinically Node-negative Breast Cancer Patients With 1-2 Sentinel Node Macrometastases.,2023-03-17,2033-12-31,3942 days,Recruiting,Interventional
NRG-BR007,"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)",2021-06-07,2041-07-01,7329 days,Recruiting,Interventional
NCCH2113,Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study,2022-05-24,2027-09-30,1955 days,Recruiting,Observational
YU-FTR-ST-01,"The Effects of Upper Extremity Lymphedema on Posture, Upper Extremity Functions, and Quality of Life",2022-05-02,2022-10-31,182 days,Completed,Observational
CLP0008,Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients,2020-09-01,2025-12-01,1917 days,Recruiting,Interventional
18-040,Topical Calcipotriene Treatment for Breast Cancer Immunoprevention,2018-11-07,2025-07-31,2458 days,Recruiting,Interventional
UPCC 01121,Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer,2021-06-01,2028-05-01,2526 days,Recruiting,Interventional
Molecular imaging of HER2,Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3,2020-02-10,2021-10-04,602 days,Completed,Interventional
OP-1250-002,A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients,2021-12-10,2023-12-01,721 days,Recruiting,Interventional
GEICAM/2018-06,"Trial to Evaluate Diarrhoea Discontinuations at 3 Cycles in Patients With Early-stage HER2+, HR+ Breast Cancer Treated With Neratinib Plus Loperamide Versus Neratinib Dose Escalation Plus Loperamide Administered as Needed Versus Neratinib Plus Loperamide Plus Colesevelam (DIANER)",2022-08-31,2030-01-01,2680 days,Recruiting,Interventional
26272819.3.0000.0068,Breast Cancer and Intrauterine Contraception,2020-08-06,2022-12-31,877 days,Recruiting,Interventional
SA20I0060,Supervised Resistance TRaining amONG Women at Risk of Breast Cancer Related Lymphedema,2021-12-01,2023-06-01,547 days,Recruiting,Interventional
1094/2020,Simultaneous Integrated Boost Technique in Breast Cancer Radiotherapy,2020-04-16,2025-08-31,1963 days,Withdrawn,Interventional
Soh-Med-23-01-34,EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast,2023-01-01,2023-03-01,59 days,Not yet recruiting,Observational
WO42133,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)",2020-09-04,2021-11-24,446 days,Completed,Interventional
110-163-F,A Study Evaluating Near-infrared Zone II Imaging in Sentinel Lymph Node Mapping in Breast Cancer Patients,2022-04-08,2023-04-07,364 days,Recruiting,Interventional
KN035-TH-HER2,KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer,2019-09-01,2022-01-01,853 days,Unknown status,Interventional
MUKDEN 06,A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients,2022-05-23,2026-12-30,1682 days,Recruiting,Interventional
HNCH-MBC09-BM03,Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE),2022-05-30,2024-05-01,702 days,Recruiting,Observational
COSMOPOLITAN,Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer,2019-10-01,2026-05-01,2404 days,Recruiting,Interventional
21-VIN-0166/SAN-0647,"A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and LynparzaÂ® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With BRCA Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer",2022-04-07,2022-10-20,196 days,Completed,Interventional
E19059,Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer,2019-03-05,2023-12-31,1762 days,Recruiting,Observational
ISB 1302-103,Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer,2020-04-08,2020-07-24,107 days,Terminated,Interventional
0063-17,A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients,2018-07-10,2024-07-31,2213 days,Recruiting,Interventional
M16-735,A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC),2018-01-04,2018-10-05,274 days,Terminated,Interventional
NCT20210157-AI-ROL,Artificial Intelligence in Breast Cancer Screening in Region ÃstergÃ¶tland Linkoping,2021-10-15,2022-02-15,123 days,Completed,Observational
19-524,Effects of Exercise in Patients With Metastatic Breast Cancer,2020-01-08,2027-07-01,2731 days,Recruiting,Interventional
HR-BLTN-002,A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physicians Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer,2019-08-15,2021-12-30,868 days,Unknown status,Interventional
CTO-IUSCC-0684,Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer,2020-04-01,2024-07-01,1552 days,Recruiting,Interventional
Tele-Relax,Relaxation Training by Tele-Rehabilitation in Patients With Breast Cancer,2021-01-20,2022-12-01,680 days,Completed,Interventional
NCC1865,A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer,2018-12-22,2022-06-22,1278 days,Unknown status,Interventional
KCSG BR18-16,Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer,2019-08-01,2022-12-01,1218 days,"Active, not recruiting",Interventional
D9673R00028,PROVIDENCE - Real-world Study in Patients With HER2-positive Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan and Offered PRO-React Onco,2022-10-31,2029-12-31,2618 days,Not yet recruiting,Observational
LY01005/CT-CHN-303,Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEXÂ®,2020-10-15,2022-08-30,684 days,Recruiting,Interventional
IFG-08-2019,Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON),2021-07-11,2023-07-01,720 days,Recruiting,Interventional
BC-Genetics,Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Doxorubicin Among Egyptian Breast Cancer Patients,2020-08-01,2023-04-01,973 days,Recruiting,Observational
XZP-3287-3001,A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer,2021-11-16,2029-11-01,2907 days,Recruiting,Interventional
A5481126,Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy,2021-02-24,2023-03-24,758 days,Completed,Interventional
GEP,Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC),2020-10-08,2022-10-31,753 days,Unknown status,Interventional
2019/2632,An Innovative Care-improvement Smartphone-based Perioperative Solution for Women Undergoing Breast Cancer Surgery,2019-11-19,2021-10-31,712 days,Unknown status,Interventional
UMMCHTNBC,Telemonitoring Hypertension and Breast Cancer,2023-02-01,2023-08-31,211 days,Not yet recruiting,Interventional
BTCRC-BRE18-337,"Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers",2019-04-17,2023-06-01,1506 days,Recruiting,Interventional
J18138,Automated Method for Breast Cancer Detection,2019-03-07,2020-12-15,649 days,Terminated,Interventional
19-09020752,CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer,2020-03-04,2028-12-31,3224 days,Withdrawn,Interventional
RC31/21/0368,Impact of Adjuvant Hormone Therapy on Bone and Cardiovascular Risk,2021-10-06,2022-02-01,118 days,Completed,Interventional
20-503,Feasibility of Fasting & Exercise in Pts With HR+ MBC,2021-01-15,2023-07-31,927 days,"Active, not recruiting",Interventional
PGG-BCA2121 / MK-3475-C99,Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA),2021-11-09,2027-01-15,1893 days,"Active, not recruiting",Interventional
ACTRN1261000928213,A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.,2018-03-20,2022-04-01,1473 days,Recruiting,Interventional
Pro2020002182,Breast Cancer and Resistance Exercise Program,2020-12-01,2025-01-01,1492 days,Recruiting,Interventional
160178,"Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer",2018-08-15,2023-01-13,1612 days,"Active, not recruiting",Interventional
MRG002-004,A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer,2021-06-30,2023-10-01,823 days,Recruiting,Interventional
BC-Pyrotinib-NVB,Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer,2021-01-01,2022-02-06,401 days,Completed,Interventional
SYSUCC-016,GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer,2022-02-08,2024-02-08,730 days,Recruiting,Interventional
19-396,Liquid Biopsies and Imaging in Breast Cancer,2019-01-02,2021-12-01,1064 days,Unknown status,Interventional
Shengjing-LJY07,Prone Positioning CT Scan and Ultrasound Assessing Axillary Lymph Nodes in Patients With Breast Cancer Official Title: Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer,2022-03-01,2027-08-31,2009 days,Recruiting,Interventional
HMPL-012-SPRING-R103,Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer,2023-04-01,2025-08-01,853 days,Not yet recruiting,Interventional
CA209-7FL,"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer",2019-11-20,2024-01-15,1517 days,"Active, not recruiting",Interventional
NCC2021291,A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN),2022-06-21,2028-07-01,2202 days,Recruiting,Interventional
2022-A02271-42,Cost of Using FLUOrescence to Green of Indocyanine for the Detection of Breast Cancer.,2023-02-23,2024-02-01,343 days,Recruiting,Observational
20-2338,Effects of Pinkwashed Alcohol Ads in an Online RCT,2023-01-11,2023-01-19,8 days,Completed,Interventional
CNIL-2033408,Chronic Pain and Minor Breast Cancer Surgery,2019-04-01,2019-12-31,274 days,Completed,Observational
22-5307,Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease,2022-11-01,2025-07-01,973 days,Not yet recruiting,Interventional
CEP0431/2018 arm 2,LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2),2019-09-30,2023-09-01,1432 days,Recruiting,Interventional
MA-BC-II-035,Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer,2022-10-01,2026-12-31,1552 days,Enrolling by invitation,Interventional
F2017000 (UAB 17112),Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer,2019-09-06,2024-12-30,1942 days,Recruiting,Interventional
REG-028-2021,Multimodal Pain Treatment for Breast Cancer Surgery - a Prospective Cohort Study,2021-04-19,2023-04-19,730 days,Recruiting,Observational
22040,Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer,2020-04-07,2025-06-07,1887 days,Recruiting,Interventional
CTMS 17-0037,Imipramine on ER+ve and Triple Negative Breast Cancer,2019-07-05,2023-03-01,1335 days,"Active, not recruiting",Interventional
D0816R00025,Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer,2020-05-30,2022-09-30,853 days,Completed,Interventional
201801559A3,Prospective Cohort Study of Traditional Chinese Medicine for Survival of Patients With Early Breast Cancer,2018-11-12,2020-10-24,712 days,Unknown status,Observational
MedOPP238,POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer,2022-03-16,2022-03-16,0 days,Withdrawn,Interventional
BTCRC-BRE19-409,"Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer",2021-02-12,2025-01-01,1419 days,Recruiting,Interventional
2020-0342,Promoting Genetic Counseling Among African American Women With a Family History of Breast Cancer,2023-04-30,2024-12-31,611 days,Not yet recruiting,Interventional
25IB-0023,Exercise Study for Breast Cancer Survivors,2019-11-25,2020-12-01,372 days,Unknown status,Interventional
919PP18,Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO),2019-10-29,2022-06-28,973 days,Completed,Interventional
18-002,A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy,2018-05-23,2024-05-01,2170 days,"Active, not recruiting",Interventional
CMTNCMB,Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test,2019-05-14,2021-03-01,657 days,Unknown status,Observational
ZYYY-BC-001,Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer,2022-09-01,2024-12-01,822 days,Recruiting,Interventional
CAAE: 82691818.0.0000.5154,Effect of Resistance Training Variable Manipulation in Postmenopausal Breast Cancer Survivors.,2018-05-13,2019-12-20,586 days,Unknown status,Interventional
2022/0226,Risk Factors for Shoulder Joint Motion Restriction,2022-08-15,2024-02-15,549 days,Not yet recruiting,Observational
PMD-026-1-001,Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer,2019-11-14,2024-03-01,1569 days,"Active, not recruiting",Interventional
SYSUCC-011,Relationship Between Gut Microbiome and Adjuvant Chemotherapy in Patients With Early Breast Cancer,2018-10-10,2020-10-30,751 days,Terminated,Observational
18432,Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease,2019-03-04,2023-07-31,1610 days,"Active, not recruiting",Interventional
2020-KY-140,Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer,2020-10-14,2030-12-14,3713 days,Recruiting,Interventional
2020-KY-125,Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer,2020-09-09,2024-09-09,1461 days,Recruiting,Interventional
CAAE 42627521600005274,Surgical Pre-habilitation in Breast Cancer.,2022-01-01,2023-12-30,728 days,Recruiting,Interventional
20-1866.cc,Promoting Informed Choice for Breast Cancer Screening,2020-08-07,2025-08-01,1820 days,Recruiting,Observational
20201101.2,"Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer",2021-04-30,2025-04-30,1461 days,Not yet recruiting,Interventional
SYSUCC-008,Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer,2018-01-01,2018-07-30,210 days,Completed,Interventional
S64752,Exploring the Role of Serum Methylmalonic Acid (MMA) in Breast Cancer,2021-01-22,2022-06-24,518 days,Completed,Observational
SURVIVE,Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer,2022-12-07,2035-12-01,4742 days,Recruiting,Interventional
4352,Evaluating the Impact of Evidence-based Information About Mammography on Breast Cancer Screening Decisions,2019-01-01,2020-12-01,700 days,Unknown status,Interventional
CDR0000643461,Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.,2020-09-01,2021-09-01,365 days,Unknown status,Observational
SPHIC-TR-BCa2022-02,A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction,2023-01-10,2028-09-01,2061 days,Recruiting,Interventional
KCSG BR22-20,"Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer",2023-05-31,2029-06-30,2222 days,Not yet recruiting,Interventional
CRE2018013,Effects of Exercise Training at Different Timeline on Shoulder Dysfunction After Breast Cancer Modified Radical Mastectomy,2018-09-10,2020-05-31,629 days,Completed,Interventional
IRB_00137018,A Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Among Breast Cancer Survivors,2021-03-24,2024-01-01,1013 days,Recruiting,Interventional
2022-0353,Feasibility of Implementing Acupuncture Into Federally Qualified Health Center Among Breast Cancer Survivors,2023-01-12,2025-05-31,870 days,Recruiting,Interventional
MCC-19765,Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases,2019-01-30,2024-01-14,1810 days,"Active, not recruiting",Interventional
OSU-21065,Impact of Dietary Inflammatory Potential on Breast Cancer Risk,2022-03-01,2024-12-31,1036 days,Not yet recruiting,Observational
LCCC 1931,LCCC1931:Post-treatment Intervention in Women With Breast Cancer (70y/o+),2020-03-12,2025-06-15,1921 days,"Active, not recruiting",Interventional
A5481167,Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea,2021-12-20,2023-06-30,557 days,"Active, not recruiting",Observational
4-2018-0264,Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16),2022-04-01,2023-05-01,395 days,Not yet recruiting,Interventional
2018/TMC/133/IRB/31,One Week Versus Three Week in Adjuvant Radiotherapy in Breast Cancer,2019-03-26,2029-03-26,3653 days,Recruiting,Interventional
ENDO-RESIST,Determinants of Acquired Endocrine Resistance in Metastatic Breast Cancer: A Pilot Study,2019-02-04,2022-12-31,1426 days,Recruiting,Observational
BRE 354,A Study of U3-1402 in Subjects With Metastatic Breast Cancer,2021-05-03,2023-11-30,941 days,Recruiting,Interventional
IR-1.1,Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway,2021-02-02,2027-02-02,2191 days,Not yet recruiting,Interventional
SYSUCC-017,Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer,2022-03-21,2024-10-01,925 days,Recruiting,Interventional
IB 2015-01,High Intensity Focused Ultrasound Treatment of Breast Tumors. BRIFU Study,2018-06-07,2021-01-01,939 days,Unknown status,Interventional
20-5215.0,An Impact Assessment of a Culturally Tailored Online Psychosocial Program for Chinese Immigrant Women With Breast Cancer,2020-10-01,2022-12-01,791 days,Recruiting,Interventional
MEN1611-01,MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer,2018-07-19,2022-07-31,1473 days,"Active, not recruiting",Interventional
21-325,Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries),2022-09-21,2023-09-21,365 days,Recruiting,Observational
SGNTUC-028,A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer,2022-03-07,2027-06-30,1941 days,Recruiting,Interventional
EORTC QLQ BR45,Psychometric Properties of the Updated Module on Assessing Quality of Life of Patients With Breast Cancer,2019-06-14,2021-12-17,917 days,Completed,Observational
SYSUCC-020,"Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.",2022-10-03,2025-04-01,911 days,Recruiting,Interventional
BC-RWS,Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer,2022-12-10,2024-01-01,387 days,Not yet recruiting,Interventional
C4891001,A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.,2023-03-03,2028-05-15,1900 days,Recruiting,Interventional
1234,Monitoring of Chronic Conditions in Breast Cancer,2022-06-15,2028-06-15,2192 days,Recruiting,Observational
CCR4884,PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer,2020-08-11,2024-07-01,1420 days,Recruiting,Interventional
BreastctDNA01,Breast Cancer Liquid Biopsy Stratification,2018-10-01,2023-10-01,1826 days,"Active, not recruiting",Observational
2016-0537,Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer,2018-01-29,2026-01-01,2894 days,"Active, not recruiting",Interventional
69HCL21_1085,Evaluation of the Diagnostic Performance of a Bra Prototype to Detect Breast Cancer,2023-03-30,2023-08-30,153 days,Recruiting,Interventional
SGNTUC-025,A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer,2020-12-01,2025-10-31,1795 days,Recruiting,Interventional
AIRC IG-23118,Single Fraction Preoperative Radiotherapy for Early Stage Breast Cancer,2021-07-31,2029-03-01,2770 days,Recruiting,Interventional
3-2021-0026,"Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)",2021-05-01,2027-03-30,2159 days,Not yet recruiting,Interventional
BC-P26,Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer,2019-08-01,2020-01-31,183 days,Completed,Interventional
STU-2022-0385,Real-time Intraoperative Breast Cancer Visualization for Margin Assessment,2020-02-18,2024-01-31,1443 days,Recruiting,Interventional
KOTK/2022/12550,Patient-centered Breast Cancer Teleprehabilitation,2023-01-30,2024-08-31,579 days,Recruiting,Interventional
SCHBCC-N029,Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer,2020-05-01,2025-04-01,1796 days,Recruiting,Interventional
PUMCH-MIRC213,99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer,2022-09-07,2023-12-31,480 days,Recruiting,Interventional
A5481145,"A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer",2021-05-24,2022-02-22,274 days,Completed,Observational
TMS01190510,Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels,2019-09-06,2021-06-30,663 days,Completed,Interventional
Concordance,Concordance Between Liquid and Tissue Biopsy,2020-07-01,2022-12-01,883 days,Recruiting,Observational
1752/20,Local Therapy for ER/PR-positive Oligometastatic Breast Cancer,2021-04-01,2031-04-01,3652 days,Recruiting,Interventional
IMAP-CM,Randomized and Multicenter Study to Evaluate a Customizable Support Breast Cancer Material,2021-05-21,2022-03-13,296 days,Completed,Interventional
SRB_201808_163,Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE),2019-02-25,2029-01-30,3627 days,Recruiting,Interventional
UW16151,Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy,2018-01-29,2023-08-01,2010 days,Recruiting,Observational
SMC 2020-11-051,Effect of Prophylactic Medical Compression Therapy on the Reduction of Breast Cancer-related Lymphedema in Patients With Adjuvant Docetaxel Chemotherapy: a Randomized Controlled Study,2021-03-12,2025-12-30,1754 days,Recruiting,Interventional
6037248,Using a Blood Test to Monitor Metastatic Breast Cancer Treatment,2023-04-01,2026-04-01,1096 days,Not yet recruiting,Observational
2016-A01344-47,Adapted Physical Activity for Breast Cancer HER2 Positive Patient,2018-04-27,2024-08-31,2318 days,Recruiting,Interventional
1807187-2,Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE),2018-09-18,2025-06-01,2448 days,Recruiting,Interventional
Lilly-I3Y-US-I026,Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer,2022-04-21,2023-06-01,406 days,Recruiting,Interventional
D8532C00001,A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease,2021-01-28,2029-02-01,2926 days,Recruiting,Interventional
21-159,ATEMPT 2.0: Adjuvant T-DM1 vs TH,2021-06-16,2028-05-01,2511 days,Recruiting,Interventional
RG1121129,"Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial",2022-01-05,2022-11-10,309 days,Completed,Interventional
TJ-IRB20211128,Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer,2021-12-31,2026-12-31,1826 days,Recruiting,Observational
UC-BCG-2103,Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk,2022-10-12,2034-11-01,4403 days,Recruiting,Interventional
21-123,Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer,2021-10-08,2024-10-08,1096 days,Recruiting,Interventional
Ketogenic Diet,Effects of Ketogenic Diet in Overweight and Obese Women With Breast Cancer,2022-01-30,2025-01-30,1096 days,Not yet recruiting,Interventional
20-172,Taking AIM at Breast Cancer,2021-08-13,2026-06-15,1767 days,Recruiting,Interventional
CMUH108-REC1-113,Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients,2020-05-18,2023-07-31,1169 days,Recruiting,Interventional
ALT-P7,"Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients",2018-01-11,2021-01-15,1100 days,Completed,Interventional
I236,CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer,2018-10-17,2023-12-31,1901 days,"Active, not recruiting",Interventional
2019-7-Non-NSU Health,Assessing the Utility of Tissue Dielectric Constant (TDC) Measurements to Differentiate Breast Cancer From Healthy Breasts,2019-02-08,2021-12-31,1057 days,Completed,Interventional
131916,Financial Toxicity in Breast Cancer Surgery,2022-07-18,2025-02-01,929 days,Recruiting,Observational
GCO 17-1585,Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer,2019-01-30,2020-05-29,485 days,Terminated,Interventional
FNF201830,Health-promoting Lifestyle in a Genetic Counseling Clinic,2019-11-13,2022-03-04,842 days,Completed,Observational
DRLCOLCT001,"Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-",2021-04-19,2022-08-19,487 days,Recruiting,Observational
PRO00028602,Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer,2021-03-17,2024-08-01,1233 days,Recruiting,Interventional
D0816C00018,To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.,2018-01-17,2021-10-08,1360 days,Completed,Interventional
HUB-PSI-CAMAD,Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression,2022-05-10,2022-06-29,50 days,Terminated,Interventional
REP0121,To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer,2022-04-19,2024-07-01,804 days,Withdrawn,Interventional
SBMASTER,The MASTER Study (MAmmary Cancer STatin ER Positive Study),2021-01-04,2035-01-01,5110 days,Recruiting,Interventional
AMCI-001,PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer,2019-05-07,2023-12-01,1669 days,Recruiting,Interventional
Fukui-2019-1,Exercise Post-Diagnosis of Breast Cancer,2019-08-28,2026-09-01,2561 days,Recruiting,Interventional
PRO00028925,"Fulvestrant+Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer",2021-02-25,2026-12-01,2105 days,Recruiting,Interventional
K160913J,Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer,2019-04-01,2027-01-01,2832 days,"Active, not recruiting",Interventional
Genetic study and TDM,Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen,2019-09-01,2020-12-01,457 days,Unknown status,Observational
N-20180090,Analgesic Effect of Resistance Training for Breast Cancer Survivors,2020-08-10,2021-09-23,409 days,Completed,Interventional
FDRT-BC016,Neoadjuvant Radiation in Locally Advanced Breast Cancer,2021-03-01,2025-12-01,1736 days,Recruiting,Interventional
RF-2016-02363686,Tomosynthesis as Primary Test for Breast Cancer Screening,2019-07-15,2026-06-30,2542 days,Recruiting,Interventional
UPCC 10117,"Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (""GLACIER"")",2019-02-26,2019-11-12,259 days,Withdrawn,Interventional
A231901CD,Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions,2021-01-15,2027-01-01,2177 days,Recruiting,Interventional
22/409-3611,Ultra-hypofractioNated Adjuvant Radiotherapy Â± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients,2022-10-25,2030-10-25,2922 days,Recruiting,Interventional
YDPLD191016-I1-SYSU-001,Biomarkers of Liposomal Doxorubicin Induced Hypersensitivity Reaction in Breast Cancer Patients,2021-02-07,2023-06-30,873 days,Recruiting,Observational
BC-CIH-H-RWS,H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AIÂ±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study,2022-01-23,2024-08-23,943 days,Recruiting,Interventional
4-2020-1453,"Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing (MUTATION2)",2021-07-01,2022-12-01,518 days,Not yet recruiting,Interventional
IRB15-1005,Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer,2018-11-01,2019-06-01,212 days,Withdrawn,Interventional
LCCC1820,Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer,2020-06-01,2020-09-07,98 days,Withdrawn,Interventional
GC101-21K177,Study on TIL for the Treatment of Advanced Breast Cancer,2021-11-19,2024-12-20,1127 days,Recruiting,Interventional
2019.046,Lifestyles and Breast Cancer,2020-05-29,2024-12-01,1647 days,Recruiting,Interventional
2020-004696-41,Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy,2022-02-24,2025-02-01,1073 days,Recruiting,Interventional
V3002401,Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer,2021-10-12,2023-07-30,656 days,"Active, not recruiting",Interventional
2021-0768,A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer,2022-04-01,2026-08-20,1602 days,Recruiting,Interventional
FDRT-BC008,Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast Cancer,2018-09-01,2028-10-30,3712 days,Recruiting,Interventional
A5481136,Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region,2021-10-01,2022-08-31,334 days,Recruiting,Observational
TILS001 trial,Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS,2022-07-25,2027-09-30,1893 days,Not yet recruiting,Interventional
SYSEC-KY-KS-2022-056,Study on the Correlation Between the Quantitative Parameters of Mr Mean Cell Size Imaging and the Histopathological Characteristics of Breast Cancer,2022-05-11,2023-07-01,416 days,Not yet recruiting,Interventional
S1709-101-888,Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer,2018-06-29,2022-12-30,1645 days,"Active, not recruiting",Interventional
ARV-471-mBC-102,"ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer",2022-09-08,2024-02-01,511 days,Recruiting,Interventional
BR01/02/21,"Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor",2021-12-27,2025-08-01,1313 days,Recruiting,Interventional
MA-BC-II-020,Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer,2021-05-01,2025-12-01,1675 days,Not yet recruiting,Interventional
69HCL16_0536,Facilitate and Sustain Return to Work After Breast Cancer,2021-05-21,2023-12-01,924 days,Recruiting,Observational
NL68820.091.19,Minimal Invasive Breast Cancer Excision Using Vacuum Assisted Biopsy Under Ultrasound Guidance,2021-08-02,2023-12-01,851 days,Recruiting,Interventional
6010121027,Protection of Cardiovascular Function With Crocin in BrEast Cancer Patients Undergoing Radiotherapy and Chemotherapy,2021-03-29,2023-09-25,910 days,Recruiting,Interventional
FS-1502-III1-01,FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer,2023-03-31,2026-01-31,1037 days,Not yet recruiting,Interventional
IIT-0026,Prognostic Indicators for Radiation-induced Breast Fibrosis,2023-04-01,2026-12-01,1340 days,Not yet recruiting,Observational
LCCC2241,Assessing Functional Status Needs Via PRO Measures for Pts With Metastatic Breast Cancer,2023-03-01,2023-12-08,282 days,Not yet recruiting,Observational
2020-0708,"Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study",2021-07-23,2026-04-01,1713 days,Recruiting,Interventional
NCC2493,Radiotherapy for Extracranial Oligometastatic Breast Cancer,2021-04-06,2026-04-30,1850 days,Recruiting,Interventional
20-347,"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer",2021-01-11,2030-09-01,3520 days,Recruiting,Interventional
2018-A01128-47,EMDR Psychotherapy for Anxious-depressive Symptoms in Breast Cancer Patient,2018-11-05,2026-02-05,2649 days,Recruiting,Interventional
ICO 13-001,Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer,2018-07-05,2023-02-05,1676 days,"Active, not recruiting",Interventional
SCBCG-006,A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients,2018-07-25,2028-12-31,3812 days,Recruiting,Interventional
LRP/PegGCSF/2016/004,Immunogenicity Assessment of Peg-filgrastim vs. NeulastaÂ® as Adjunct to Chemotherapy in Patients With Breast Cancer,2018-03-06,2019-01-09,309 days,Completed,Interventional
GRACE,GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer,2022-10-01,2024-01-01,457 days,"Active, not recruiting",Interventional
21-600,Early Intervention,2023-06-01,2025-06-30,760 days,Not yet recruiting,Interventional
114,The Effect of Reiki on Symptom Control and Quality of Life in Breast Cancer Patients,2023-02-01,2023-08-31,211 days,Not yet recruiting,Interventional
YLiu,Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer,2021-07-01,2022-12-31,548 days,Recruiting,Observational
IIT2018-17-McArthur-TCDRT,"Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer",2022-07-01,2027-07-01,1826 days,Withdrawn,Interventional
20 KHCC 91,SBRT for Breast Cancer Oligometastases,2020-06-01,2026-06-01,2191 days,Recruiting,Interventional
SYSUCC-019,"Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial",2022-08-01,2024-12-01,853 days,Recruiting,Interventional
IIT-CRM2020001,Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature,2022-03-08,2025-11-01,1334 days,Recruiting,Interventional
2018-A02191-54,Needs Assessment After Cancer in Patients Treated for Breast Cancer,2018-12-01,2019-02-01,62 days,Completed,Observational
2020-154,Photobiomodulation Therapy for the Management of Breast Cancer-related Lymphedema,2021-02-22,2028-02-01,2535 days,Recruiting,Interventional
CTO-IUSCC-0715,Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs,2020-02-17,2022-08-09,904 days,Completed,Interventional
CLEE011ABR02,Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer,2021-03-23,2021-10-29,220 days,Completed,Observational
SP0048722,Optimizing Quality of Life in Women Living With Metastatic Breast Cancer,2019-04-24,2021-03-08,684 days,Completed,Interventional
38341220.8.0000.0072,"Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery",2021-03-04,2026-12-31,2128 days,Recruiting,Interventional
Neo-ACT,Physical Exercise During Preoperative Chemotherapy for Breast Cancer,2022-11-09,2027-12-01,1848 days,Recruiting,Interventional
CH-BC-059,A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations ï¼STEPï¼,2018-08-09,2023-10-30,1908 days,Enrolling by invitation,Interventional
07102022_SR,Consciousness-based Ayurveda Lifestyle Program for Improving Quality of Life in Survivors of Breast Cancer,2022-09-01,2023-06-01,273 days,"Active, not recruiting",Interventional
GO42784,"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physicians Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)",2021-08-27,2033-11-21,4469 days,Recruiting,Interventional
145314,Safety and Efficacy of Ga68 ÎvÎ²3 IAC PET/CT for Diagnosis and Clinical Management in Angiogenic Breast Cancer Patients,2022-08-30,2024-08-30,731 days,Not yet recruiting,Interventional
New theory(Tamoxifen&retinoic),"Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.",2021-08-01,2021-12-01,122 days,Not yet recruiting,Interventional
20-505,A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer,2021-04-21,2025-01-01,1351 days,Recruiting,Interventional
RadiaAce001,The Effect of RadiaAce Gel in the Prevention and Treatment of Radiation Dermatitis in Breast Cancer Patients,2021-07-14,2022-10-01,444 days,Recruiting,Interventional
Neo-program 2021.02.23,Resistance vs. Aerobic Training on Breast Cancer Patients Undergoing Neoadjuvant Treatment,2022-12-16,2024-04-30,501 days,Recruiting,Interventional
ARV-471-mBC-101,A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCEÂ®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer,2019-08-05,2024-02-01,1641 days,Recruiting,Interventional
275078,Digitally Distributed Yoga for Women Treated for Breast Cancer,2021-10-01,2028-10-01,2557 days,Recruiting,Interventional
IIT-2017-NeoPACT,Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer,2018-09-04,2024-11-01,2250 days,"Active, not recruiting",Interventional
2021000247,"Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.",2021-12-15,2032-12-01,4004 days,Recruiting,Interventional
REaCT-70,Evaluating Harms and Benefits of Endocrine Therapy in Patients â¥70 Years of Age With Lower Risk Breast Cancer,2021-08-19,2024-09-01,1109 days,Recruiting,Interventional
BTCRC-BRE16-042,"Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients",2018-01-29,2024-09-01,2407 days,Recruiting,Interventional
TVD-101-002B,Study of TTI-101 in Combination for Participants With Metastatic Hormone Receptor (HR)-Positive and Human Epidermal Receptor 2 (HER2)-Negative Breast Cancer,2023-01-09,2025-02-01,754 days,Recruiting,Interventional
20-0140-A,MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN Study,2021-09-01,2022-07-01,303 days,Withdrawn,Interventional
D9673R00004,"Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status",2021-05-28,2022-04-26,333 days,Completed,Observational
CA209-929,"Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients",2018-02-14,2019-05-29,469 days,Terminated,Interventional
SYSEC-KY-KS-2019-099,Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy,2019-01-01,2019-07-01,181 days,Completed,Observational
Glnz87?,The Effect of Guided Imagery Based on the Health Promotion Model on the Quality of Life in Breast Cancer Patients,2022-02-01,2022-11-15,287 days,Completed,Interventional
GIM24-PALBO-BP,Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy,2019-07-16,2023-07-31,1476 days,Recruiting,Interventional
18-115,Physiotherapy Program for Breast Cancer Women Following Surgery: A Pilot Clinical Trial,2018-09-01,2021-02-01,884 days,Completed,Interventional
IBISCO Trial,Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer,2023-01-01,2026-12-31,1460 days,Recruiting,Interventional
NBC Che001,Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy,2021-07-13,2022-11-06,481 days,Completed,Interventional
IC 2021-08,Digital Phenotyping in Women Over 70 Years of Age Treated for Breast Cancer With Any Type of Treatment,2023-02-17,2024-11-13,635 days,Recruiting,Interventional
AI Yoga Study on Facebook - 1,Effect of Sukshma Vyayama Yoga on Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors,2018-09-04,2018-10-19,45 days,Completed,Interventional
6222/22.03.2017,Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer,2018-10-01,2019-10-01,365 days,Unknown status,Interventional
SYSEC-KY-KS-2019-055-001,MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02),2019-05-28,2025-05-30,2194 days,Recruiting,Observational
EUBREAST-01,Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients With rCR and pCR in the Breast After NAST,2021-01-13,2028-12-01,2879 days,Recruiting,Interventional
1216-4-011,Lidocaine Versus Duloxetine for the Prevention of Taxane-Induced Peripheral Neuropathy In Breast Cancer Patients,2021-01-15,2022-07-05,536 days,Completed,Interventional
UPCC 15121,Breast Cancer Outreach Among Primary Care Patients,2021-10-25,2022-04-25,182 days,Completed,Interventional
OMERIC-1904,Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer,2020-09-08,2023-09-01,1088 days,Recruiting,Interventional
21-161,A Study of Attention and Memory Processes in Breast Cancer Survivors,2021-05-06,2024-05-01,1091 days,Recruiting,Observational
18-217,Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job,2018-06-07,2023-06-01,1820 days,Recruiting,Interventional
ACE-Breast-06,ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases,2021-07-14,2023-06-30,716 days,Recruiting,Interventional
ONC-010,EndoPredictÂ® Extended Endocrine Trial (EXET),2019-07-02,2022-03-31,1003 days,Terminated,Observational
CHLOBREASTASP,"Breast Cancer Active Surveillance, Alternative Option, Aspirin Included",2018-06-01,2023-05-31,1825 days,Not yet recruiting,Interventional
CLEE011AFR01,Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France,2022-12-13,2027-06-28,1658 days,Recruiting,Observational
CTO-IUSCCC-0781,Exercise in Metastatic Breast Cancer: EMBody,2023-03-01,2027-12-01,1736 days,Not yet recruiting,Interventional
TT420X2101,Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer,2019-01-08,2021-12-30,1087 days,"Active, not recruiting",Interventional
201808046,Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma,2018-08-30,2026-03-22,2761 days,"Active, not recruiting",Interventional
178-2018,Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy,2019-10-01,2022-09-01,1066 days,Recruiting,Observational
OMC2018/01,Implementing PatientsÂ´ Competence in Oral Breast Cancer Therapy,2020-03-01,2021-12-01,640 days,Unknown status,Observational
HS-10352-102,A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer,2022-01-12,2025-12-31,1449 days,Recruiting,Interventional
VersiÃ³n 4- 20/09/2020,Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors,2020-09-01,2021-12-01,456 days,Completed,Interventional
CSPC-KAL-BC-16,Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer,2019-11-20,2022-09-20,1035 days,Unknown status,Interventional
REaCT-Wellness,A Randomized Trial Evaluating Personalized vs Guideline-based Well Follow-up Strategies for Patients With Early-stage Breast Cancer,2022-08-19,2026-07-01,1412 days,"Active, not recruiting",Interventional
NEXT-BRCA,Implementing Exercise Into Clinical Practice in Breast Cancer Care,2019-10-03,2023-12-31,1550 days,"Active, not recruiting",Interventional
AB PoC 2021 RUS,Retrospective Comparative in Vitro Case-controlled Study of the Liquid Biopsy Test System in Women With Breast Cancer,2021-06-16,2021-12-31,198 days,Recruiting,Observational
MedOPP167,Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients,2019-04-30,2021-03-31,701 days,Terminated,Interventional
LPM-008,The LightPathÂ® and 68Ga-RM2 in Breast Cancer Study,2018-11-30,2023-11-01,1797 days,Not yet recruiting,Interventional
DATOS-20220624-ASJF-Efecto car,Cardioprotective Effect of Acute Exercise in Breast Cancer Patients,2023-01-23,2024-10-01,617 days,Recruiting,Interventional
2019.444,Fibrotic Focus in Breast Cancer,2019-12-01,2023-11-30,1460 days,Not yet recruiting,Observational
NSABP FB-13,Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer,2018-10-22,2021-01-30,831 days,Completed,Interventional
202207198RINB,Can ILR Reduce the Risk of Arm Lymphedema?,2023-02-14,2028-08-01,1995 days,"Active, not recruiting",Interventional
FZPL-â¢-303,A Study of FluzoparibÂ±Apatinib Versus Chemotherapy Treatment of Physicians Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation,2020-07-13,2025-06-30,1813 days,Recruiting,Interventional
SYSUCC 019,Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients,2022-06-15,2025-12-31,1295 days,Recruiting,Interventional
BCSPilot01,A Combined Exercise Training Program for Women Living With Breast Cancer,2023-02-01,2023-08-30,210 days,Not yet recruiting,Interventional
2014CB543202-03,Acupuncture for Breast Cancer Related Lymphedema,2019-11-01,2021-04-01,517 days,Unknown status,Interventional
578-21-FB,Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy,2022-03-02,2031-09-01,3470 days,Recruiting,Interventional
1107210020,Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer,2020-09-17,2022-02-15,516 days,Completed,Observational
107CS-6,Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer,2018-07-25,2022-04-01,1346 days,Unknown status,Interventional
BRE 381,Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer,2023-03-01,2026-07-01,1218 days,Not yet recruiting,Interventional
IRB00048455,Histamine and Bone Pain Association in Participants With Breast Cancer Metastatic in the Bone,2019-01-31,2023-10-01,1704 days,Recruiting,Observational
2022-009,Thero2-01S22 in HER2-positive Breast Cancer,2023-05-15,2027-05-15,1461 days,Not yet recruiting,Interventional
CCR5654,"Biological Characteristics of Older Women (> 70 Years) With ER Positive, HER2 Negative Early Breast Cancer",2022-07-21,2023-08-31,406 days,Enrolling by invitation,Observational
KCT 005,"A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery",2021-06-01,2021-12-31,213 days,Recruiting,Interventional
2022-YXZX-YX-08,Ultrasound Radiomics for Predicting Breast Cancer and Axillary Lymph Node Metastasis,2023-04-01,2025-08-31,883 days,Not yet recruiting,Observational
G1T28-212,"Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer",2021-11-19,2023-03-13,479 days,Completed,Interventional
SCHBCC-NO28,Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer,2020-04-21,2030-04-30,3661 days,Recruiting,Interventional
PI-2021-3,Design and Evaluation of the Effects of a Physical Therapy Program With Digital Support in Patients With Breast Cancer,2021-08-02,2024-05-01,1003 days,Recruiting,Interventional
ID-RCB 2022-A01488-35,Diagnostic Performance of Breast Cancer Screening Second Reading Process Assisted by AI,2023-05-01,2027-05-01,1461 days,Not yet recruiting,Interventional
MA-BC-â¡-021,Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer,2021-03-25,2022-12-31,646 days,Recruiting,Interventional
2021-KY-124-001,Aesthetic Outcomes of Oncoplastic Breast Surgery for Breast Cancer in the Upper Inner Quadrant,2022-01-18,2022-11-01,287 days,Recruiting,Interventional
NCKUH SLNB,The Validation of Sentinel Lymph Node Biopsy After Neo-adjuvant Chemotherapy in Breast Cancer Patients,2021-05-20,2022-12-01,560 days,"Active, not recruiting",Observational
DFP22-0020,Resistance-type Exercise Training in Postmenopausal Women Survivors of Breast Cancer,2023-03-01,2024-08-01,519 days,Not yet recruiting,Interventional
CCM 1505,Coronary Artery Calcium and Cardiovascular Risk Factors Analysis After RT or Breast Cancer,2022-03-24,2024-06-01,800 days,Recruiting,Interventional
PER.CIN.BN.95.III,Comparing Efficacy and Safety Between PertuzumabÂ® and PerjetaÂ® in Neoadjuvant Treatment of HER2+ Breast Cancer,2018-08-11,2020-05-27,655 days,Completed,Interventional
21-5021,Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN),2021-09-22,2024-12-01,1166 days,Recruiting,Interventional
C4891006,TACTIVE-U: A Study to Learn About the Study Medicine (Called ARV-471) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A),2023-02-23,2027-06-12,1570 days,Recruiting,Interventional
2021-0840,Acupuncture for Psychoneurological Symptoms Among Breast Cancer Survivors,2021-11-01,2025-05-31,1307 days,"Active, not recruiting",Interventional
OV-121,Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP,2018-06-20,2023-05-01,1776 days,"Active, not recruiting",Interventional
042110,CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage,2022-04-06,2027-11-28,2062 days,"Active, not recruiting",Interventional
BC-09638,GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.,2022-03-21,2027-03-01,1806 days,Recruiting,Interventional
LB1802,Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast Cancer,2019-07-22,2024-03-01,1684 days,Recruiting,Observational
2018-0601,Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women,2019-07-15,2023-03-31,1355 days,Recruiting,Interventional
D967JC00002,A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer,2020-12-17,2023-08-10,966 days,"Active, not recruiting",Interventional
UKM14_0016,Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D Mammography,2018-07-05,2025-03-31,2461 days,"Active, not recruiting",Interventional
RJBC-HFRNI,Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment,2019-02-21,2027-12-01,3205 days,Recruiting,Interventional
m-VCAP1,Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer,2022-01-01,2023-06-01,516 days,Recruiting,Interventional
19-133,An Online Research Study: BrainHealth in Breast Cancer Survivors,2022-06-01,2024-06-01,731 days,Recruiting,Interventional
CLEE011A2206,"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.",2018-08-29,2024-12-11,2296 days,"Active, not recruiting",Interventional
CASE3118,Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer,2019-01-14,2023-09-01,1691 days,"Active, not recruiting",Interventional
2020(55),Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer,2021-03-01,2030-10-30,3530 days,Recruiting,Interventional
WO40324,"A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer",2018-06-14,2023-11-16,1981 days,"Active, not recruiting",Interventional
Geneplus2020BC01,ctDNA Monitoring in Early Breast Cancer,2019-11-29,2024-06-01,1646 days,Recruiting,Observational
ML39208,A Study to Assess the Feasibility of an E-Health System (ZEMY) Designed to Manage Symptoms in Participants With Breast Cancer Under Anti-Cancer Treatment,2018-06-12,2019-04-19,311 days,Completed,Interventional
18/028,"Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer",2019-09-25,2024-12-01,1894 days,Recruiting,Interventional
19-005860,Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer Survivors,2021-04-01,2023-12-30,1003 days,"Active, not recruiting",Observational
A231701CD,Increasing Patients Engagement in Breast Cancer Surgery Decision-Making,2019-03-01,2023-12-15,1750 days,"Active, not recruiting",Interventional
FDRT-BC017,Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer,2021-09-20,2027-08-01,2141 days,Recruiting,Interventional
AC699-001,Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer,2022-12-29,2024-12-31,733 days,Recruiting,Interventional
2020-495,Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer,2020-09-20,2027-09-20,2556 days,Recruiting,Interventional
CTRIAL-IE 17-13,Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer,2019-11-12,2020-11-02,356 days,Terminated,Interventional
00005038,Family History and Breast Cancer Education Trial,2021-04-01,2022-09-30,547 days,Completed,Interventional
H-43432,Sitravatinib in Metastatic Breast Cancer,2021-09-22,2023-01-03,468 days,Terminated,Interventional
2020-010,Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer,2021-12-15,2029-12-15,2922 days,Recruiting,Observational
Contralateral Screening,Screening Contralateral Breast Cancers in Patients With Newly Diagnosed Breast Cancer,2022-05-01,2026-01-31,1371 days,Recruiting,Observational
HCRN BRE18-334,"Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer",2021-08-24,2034-01-31,4543 days,Recruiting,Interventional
ACT16105,Phase 2 Study of Amcenestrant (SAR439859) Versus Physicians Choice in Locally Advanced or Metastatic ER-positive Breast Cancer,2019-10-22,2023-09-29,1438 days,"Active, not recruiting",Interventional
OSU-22013,Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer,2022-06-13,2025-10-31,1236 days,Recruiting,Interventional
I-3364822,Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Breast Cancer,2023-05-01,2029-02-28,2130 days,Not yet recruiting,Interventional
ICO-N-2019-04,[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers,2020-06-11,2021-07-21,405 days,Completed,Interventional
2007-206-1145,"Diffusion-Weighted MRI for Diagnosis of Multifocal, Multicentric Breast Cancer",2022-05-01,2026-01-31,1371 days,Not yet recruiting,Observational
20140299,Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases,2018-03-19,2021-12-03,1355 days,Completed,Interventional
2019.629,Artificial Intelligence in Mammography-Based Breast Cancer Screening,2020-07-01,2024-06-30,1460 days,Recruiting,Observational
CS003-BC,Safety and Efficacy Evaluation of the P2Et Extract in Patients With Breast Cancer,2022-03-01,2023-06-30,486 days,Recruiting,Interventional
2020-005722-28,Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer,2021-05-11,2026-06-11,1857 days,Recruiting,Interventional
EORTC-1617-QLG-BCG,Follow-up in Early and Locally Advanced Breast Cancer Patients,2020-10-14,2023-04-01,899 days,"Active, not recruiting",Observational
MD-127-2019,Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study),2020-03-01,2022-04-30,790 days,Unknown status,Interventional
2020-07-064-002,Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors,2020-10-26,2021-12-31,431 days,Completed,Interventional
UC-BCG-2204,Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer,2023-05-01,2026-05-01,1096 days,Not yet recruiting,Interventional
PYHOPE-BC-104,Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer,2021-06-03,2024-05-31,1093 days,Recruiting,Interventional
TMZ-TNBC,Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC),2023-04-01,2027-12-01,1705 days,Not yet recruiting,Interventional
STUDY-20-01174,Increasing Breast Cancer Screening in Chinese Immigrants,2021-07-01,2022-12-13,530 days,Completed,Interventional
SIM-1907-02-SERD-101,"Phase I Study to Evaluate SCR-6852 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer",2022-05-18,2025-09-08,1209 days,Recruiting,Interventional
20-151,Refining Local-Regional Therapy for IBC,2021-06-02,2027-12-01,2373 days,Recruiting,Interventional
RJBC-SHF RNI,Adjuvant Regional Nodal Radiation Therapy for One Week in Breast Cancer,2020-12-01,2026-12-30,2220 days,Recruiting,Interventional
YOUNGBC-17,Real-world Study of UTD1 in Chinese Advanced Breast Cancer,2022-04-01,2023-05-01,395 days,Recruiting,Observational
HREBA.CC-21-0429,Exercise Rehabilitation Via a Mobile Application for Individuals With Breast Cancer Undergoing Chemotherapy,2022-10-20,2023-06-30,253 days,Recruiting,Interventional
Metastatic Breast Cancer,"Î¤reatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer",2019-01-31,2024-01-31,1826 days,Recruiting,Observational
UW17107,ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer,2018-11-13,2021-02-13,823 days,Terminated,Interventional
NL63209 041 18,MRI-guided Single Dose Preoperative Radiotherapy in Low-risk Breast Cancer,2019-03-04,2031-11-01,4625 days,Withdrawn,Interventional
KCSG BR19-15,T-DM1 in HER2-positive Metastatic/Relapsed Breast Cancer,2019-12-19,2020-07-31,225 days,Unknown status,Observational
2020-AHL-001,"Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer",2023-05-01,2025-09-01,854 days,Not yet recruiting,Interventional
SAMuhammad,Outcome of Neo-adjuvant Chemotherapy Followed by Breast Conservative Surgery in Breast Cancer in Upper Egypt,2018-12-01,2020-12-01,731 days,Unknown status,Interventional
202201100,A Low AGE (Advanced Glycation End-product) Dietary Intervention for Breast Cancer Survivors,2022-10-14,2023-12-10,422 days,"Active, not recruiting",Interventional
2019-A02195-52,Immunomonitoring of Breast Cancer Patients During Systemic Treatment,2020-05-26,2024-05-26,1461 days,Recruiting,Interventional
ShantouCH02,Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index,2021-08-01,2024-12-30,1247 days,Recruiting,Interventional
PekingUPH10B003,Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients,2021-03-28,2026-12-31,2104 days,Recruiting,Interventional
GE-280-401,Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients,2023-01-05,2025-10-02,1001 days,Recruiting,Observational
CTMS# 19-0028,Effects of Creatine Supplementation in Breast Cancer Survivors,2020-09-30,2024-09-01,1432 days,Recruiting,Interventional
NEO-01,OA for Breast Cancer NAC Response,2021-03-30,2023-01-04,645 days,Completed,Interventional
NL58040.091.16,Minimal Invasive Breast Cancer Excision Using the Breast Lesion Excision System Under Ultrasound Guidance,2018-02-19,2019-07-31,527 days,Terminated,Interventional
LQ006,Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer,2019-04-19,2021-12-31,987 days,Unknown status,Interventional
MCC-19-15740,Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters),2021-03-01,2025-01-31,1432 days,Recruiting,Interventional
K180603J,Advanced MR Techniques for Breast Cancer Detection,2019-07-01,2024-07-01,1827 days,Withdrawn,Interventional
ABLE02,A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer,2020-06-24,2024-06-01,1438 days,Recruiting,Interventional
MCC-21-BRE-54,"Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer",2022-02-18,2036-10-01,5339 days,Recruiting,Interventional
CLEE011A3201C,Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer,2019-02-25,2023-05-15,1540 days,"Active, not recruiting",Interventional
2/108/7,What Factors Affect Breast Cancer Neoadjuvant Chemotherapy Efficacy?,2018-05-02,2019-06-01,395 days,Unknown status,Interventional
EOC202A1101,Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer,2018-10-16,2021-12-25,1166 days,Completed,Interventional
HUM00140468,Acupressure for Pain and Opioid Use Among Breast Cancer Patients,2018-09-17,2019-10-17,395 days,Terminated,Interventional
18-2562.cc,Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey,2019-10-30,2024-06-01,1676 days,Recruiting,Interventional
19-586,Prolonged Nightly Fasting in Breast Cancer Survivors,2020-07-24,2022-07-05,711 days,Completed,Interventional
2014CB543202-02,Warm Acupuncture for Breast Cancer Related Lymphedema,2018-01-18,2020-12-26,1073 days,Completed,Interventional
CER2021,"Prevalence of Lymphedema in Valle Del Cauca, Colombia.",2018-01-18,2021-12-31,1443 days,"Active, not recruiting",Observational
IB 2017-05,Brief Intervention for Tobacco and Alcohol Risk Reduction for Couple During Breast Cancer Treatment.,2019-08-01,2022-08-01,1096 days,Unknown status,Interventional
On4Rehab Pilot Trial,Physical Exercise for Breast Cancer Survivors: Face-to-face Versus Home-based,2021-05-01,2021-09-30,152 days,Completed,Interventional
IIT-0005,Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting,2019-08-28,2021-09-01,735 days,Unknown status,Interventional
PROTECT,Prospective Surveillance for Breast Cancer-Related Lymphedema,2021-01-04,2024-12-01,1427 days,Recruiting,Interventional
MD 134/2022,Inflammatory Blood Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy,2022-09-01,2023-12-01,456 days,Not yet recruiting,Observational
NCC2129,Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer,2019-12-28,2023-01-30,1129 days,Unknown status,Interventional
001,Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer,2022-02-20,2024-12-20,1034 days,Not yet recruiting,Interventional
SYSU-CSCO-2020,Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab,2020-02-01,2025-02-01,1827 days,Not yet recruiting,Interventional
IRB18-0970,A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer,2019-02-18,2025-12-01,2478 days,Recruiting,Interventional
2019-09-023,Omitting Biopsy of SEntinel Lymph Node With Radiation After Neoadjuvant Chemotherapy in Breast Cancer (OBSERB) Trial,2020-07-01,2025-06-30,1825 days,Not yet recruiting,Interventional
Shengjing-LCG004,Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT,2021-07-19,2026-11-30,1960 days,Recruiting,Interventional
A5481093,A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib),2024-03-01,2024-04-30,60 days,Not yet recruiting,Observational
MedOPP168,"Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer",2019-04-30,2022-03-02,1037 days,Terminated,Interventional
LUN_DBT_121,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",2022-03-22,2023-02-28,343 days,Recruiting,Observational
I239,CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer,2019-12-19,2022-12-31,1108 days,"Active, not recruiting",Interventional
IRB00158622,Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings,2018-11-11,2020-12-30,780 days,Completed,Interventional
RFTMBCPW,Fulvestrant in Metastatic Breast Cancer,2018-08-01,2021-10-01,1157 days,Unknown status,Interventional
s63338,The Added Value of a Third Supervised Training Session to a Standard 12-week Rehabilitation Program After Breast Cancer: Pilot Study,2021-06-05,2022-01-31,240 days,Completed,Interventional
2017-0071,"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer",2018-08-20,2024-12-31,2325 days,"Active, not recruiting",Interventional
2019/00283,A Pilot Tele-rehabilitation Trial for Breast Cancer Survivors,2020-11-01,2022-12-31,790 days,Recruiting,Observational
20200628GD,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,2020-07-08,2022-07-31,753 days,Unknown status,Interventional
ANLO-BC,Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer,2022-03-22,2024-10-01,924 days,Recruiting,Interventional
SHR-A1811-III-306,SHR-A1811 Versus Investigators Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial,2023-05-30,2026-06-30,1127 days,Not yet recruiting,Interventional
REO 028,A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study,2020-06-10,2024-07-01,1482 days,"Active, not recruiting",Interventional
LQ007,Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer,2019-04-19,2021-12-31,987 days,Unknown status,Interventional
2019-KY-049,Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positiveï¼HR-Positive Metastatic Breast Cancer,2019-07-17,2022-07-06,1085 days,Unknown status,Interventional
D9268C00001,"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigators Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)",2021-10-18,2025-08-15,1397 days,"Active, not recruiting",Interventional
ET17-203 DISCO,Efficacy of Exercise Using Connected Activity Trackers and Therapeutic Education in Localized Breast Cancer,2018-05-18,2022-09-23,1589 days,Completed,Interventional
GO 22/41,Reliability and Validity of The 6 Minute Pegboard and Ring Test in Patients With Breast Cancer,2022-03-01,2022-11-30,274 days,Completed,Observational
YOUNGBC-16,MammaPrint Value for Pre-menopausal Breast Cancer Patients,2022-07-15,2024-07-15,731 days,Recruiting,Observational
07068-02,Oxygen Partial Pressure After Breast Cancer Surgery,2023-02-23,2024-06-01,464 days,Recruiting,Observational
EC/2017/0200,Intra-operative PET-CT: a Novel Approach to Determine Excision Margins in Lumpectomy Breast Cancer.,2018-01-01,2023-12-31,2190 days,Recruiting,Interventional
99mTc-DARPinG3 breast cancer,99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast Cancer With Metastatic Lymph Nodes Before Targeted Therapy,2022-12-20,2023-12-01,346 days,Enrolling by invitation,Observational
200277,Focused Ultrasound and Gemcitabine in Breast Cancer,2022-01-27,2025-01-01,1070 days,Recruiting,Interventional
CFT / sp123,A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer,2023-12-01,2025-05-31,547 days,Not yet recruiting,Interventional
2021-1201,3D Printed Breast Models in the Surgical Management of Breast Cancer,2023-07-31,2027-02-28,1308 days,Not yet recruiting,Interventional
FDRT-BC012,Single Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast Cancer,2021-01-01,2026-12-31,2190 days,Recruiting,Interventional
99mTc- RM26,Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26,2021-02-01,2023-06-01,850 days,Enrolling by invitation,Interventional
2103254164,Pioglitazone Therapy Targeting Fatigue in Breast Cancer,2021-12-23,2023-04-01,464 days,Recruiting,Interventional
MA-BC-II-026,Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC),2022-07-10,2026-12-31,1635 days,Not yet recruiting,Interventional
OBU-BC-II-079,Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer,2023-01-01,2024-07-01,547 days,Not yet recruiting,Interventional
BCD-178-2,Clinical Study of the Efficacy and Safety of BCD-178 and PerjetaÂ® as Neoadjuvant Therapy of HER2-Positive Breast Cancer,2023-01-30,2026-01-31,1097 days,Recruiting,Interventional
YOUNGBC-24,Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer,2021-11-01,2024-07-01,973 days,"Active, not recruiting",Observational
AAAT4412,Breast Elasticity Imaging During Neoadjuvant Chemotherapy,2021-06-14,2024-01-01,931 days,Recruiting,Interventional
SHR6390-Ib/II-201,A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,2018-03-22,2022-06-30,1561 days,"Active, not recruiting",Interventional
N19MIM,Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial,2021-03-23,2030-05-01,3326 days,"Active, not recruiting",Interventional
CA209-7A8,A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer,2019-10-18,2021-07-27,648 days,Completed,Interventional
CFT/sp123,"A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer",2019-09-01,2021-02-28,546 days,Withdrawn,Interventional
EVER-132-002,Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC),2020-11-23,2024-03-01,1194 days,"Active, not recruiting",Interventional
KY20192081-F-1,Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer,2019-08-21,2022-08-21,1096 days,Unknown status,Interventional
AC682-001,A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer,2021-11-12,2023-09-01,658 days,Recruiting,Interventional
ATOS-Z-201,(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer,2023-02-14,2025-07-01,868 days,Recruiting,Interventional
UC-0140/1711 - UCBG3-06,Study on Androgen Receptor and Triple Negative Breast Cancer,2018-03-14,2022-07-20,1589 days,Completed,Interventional
2018-05-0155,Improving Brain Function After Breast Cancer Study,2018-09-28,2020-01-30,489 days,Completed,Interventional
SBU-PCWRT-BREAST,Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer,2022-07-15,2029-08-01,2574 days,Recruiting,Interventional
2021.240,Effectiveness of Mobile Messenger-initiated Reminder on Biannual Mammography Adherence in Breast Cancer Screening,2022-06-01,2024-05-31,730 days,Not yet recruiting,Interventional
YOUNGBC-6,Real World Study of Lapatinib Among Metastatic Breast Cancer Patients,2019-01-10,2020-05-20,496 days,Completed,Observational
HNCH-BC008,Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer,2021-09-28,2028-09-01,2530 days,Recruiting,Interventional
PLATO study,PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate,2019-11-08,2028-12-31,3341 days,Recruiting,Interventional
PI20/596,"Long-term Outcomes After Breast Cancer Liver Metastasis Surgery: an European, Retrospective, Snapshot Study",2021-03-15,2021-07-31,138 days,Unknown status,Observational
SCBCG-022,A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Postmenopausal Breast Cancer Patients,2018-06-15,2023-06-15,1826 days,Not yet recruiting,Observational
RSRB00066846,"A Whole-food, Plant-Based Nutrition Intervention in Women With Metastatic Breast Cancer",2018-07-05,2022-07-01,1457 days,Completed,Interventional
HERMIONE-10,Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer,2021-03-22,2023-03-01,709 days,Recruiting,Observational
KC19EESI0325,Real-time Interactive Digital Healthcare System in Post Operation Patients With Breast Cancer; Pilot Study,2019-10-21,2020-04-27,189 days,Completed,Interventional
16-007764,Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography,2018-09-01,2019-04-30,241 days,Withdrawn,Interventional
18-621,Tucatinib + Abemaciclib + Herceptin for HER2+ MBC,2020-06-28,2020-09-22,86 days,Withdrawn,Interventional
STOP-BC Trial,Sulindac and Breast Density in Women at Risk of Developing Breast Cancer,2020-11-20,2027-02-01,2264 days,Recruiting,Interventional
IRB-59141,Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer,2023-02-23,2024-03-01,372 days,Recruiting,Interventional
SYSU005,Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation,2021-06-16,2025-06-01,1446 days,Recruiting,Interventional
ZN-c5-002,A Study of ZN-c5 in Participants With Breast Cancer,2020-01-03,2021-05-25,508 days,Completed,Interventional
Fudan University,NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy,2018-07-03,2021-09-01,1156 days,Unknown status,Interventional
18-8214-BO,Effectiveness of Ear Acupuncture to Improve Insomnia in Women With Breast Cancer,2019-06-12,2020-02-19,252 days,Completed,Interventional
B00157,A Pilot Study of Ultrasound-guided Vacuum-assisted Excision of Breast Cancers,2018-06-25,2021-05-31,1071 days,Completed,Observational
1711-048-898,Unnecessary Mastectomy Due to False Size Prediction by Preoperative Imaging Studies in Breast Cancer,2018-03-23,2022-12-31,1744 days,Recruiting,Interventional
2021-A03091-40,Evaluation of the Interest of a Postural and Functional Analysis for the Follow-up of the Adapted Motor Activity of Patients Treated for Breast Cancer,2023-02-01,2026-06-01,1216 days,Not yet recruiting,Interventional
HR-BLTN-001,Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC,2019-03-01,2020-12-01,641 days,Unknown status,Interventional
A5481166,Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan,2022-04-20,2024-06-30,802 days,"Active, not recruiting",Observational
D081CC00012,LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS),2023-03-07,2026-12-14,1378 days,Recruiting,Observational
Luminal A sirt1,Role of SIRT1 in Regulation of Epithelial-to-mesenchymal Transition in Breast Cancer Lymph Nodes Metastasis,2019-01-01,2020-12-30,729 days,Unknown status,Observational
DokuzEU.Com.Garments,COMPRESSION GARMENTS in BREAST CANCER-RELATED LYMPHEDEMA,2019-03-30,2019-08-29,152 days,Completed,Observational
P.T.REC/012/002968,RESISTANCE VERSUS AEROBIC EXERCISES ON Breast Cancer Patients,2020-12-12,2021-04-01,110 days,Unknown status,Interventional
IIT-2021-ASSET,Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer,2022-03-28,2024-06-01,796 days,Recruiting,Interventional
MC200302,"Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer, the ENHANCE Study",2021-06-09,2025-05-15,1436 days,Recruiting,Observational
4-2020-1131,Talazoparib Maintenance Therapy in Triple-negative Breast Cancer,2021-03-01,2024-03-01,1096 days,Not yet recruiting,Interventional
145358,"A Phase I/II Multicenter, Open-Label Study of Lu-177-Î±vÎ²3-IAC, for the Treatment of Angiogenic Breast Cancer Patients.",2023-01-30,2024-08-30,578 days,Not yet recruiting,Interventional
UMCC 2018.016,The ConnectedCancerCare Pilot Study (CCC),2018-08-08,2019-08-30,387 days,Completed,Interventional
TP.102.17.22.PAR,Pilot Clinical Evaluation of a Microwave Imaging System for Breast Cancer Detection,2023-03-09,2024-11-30,632 days,Recruiting,Interventional
EFC15935,Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer,2020-10-14,2023-12-29,1171 days,"Active, not recruiting",Interventional
BC-NEO-IIT-SHR6390,SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.,2021-08-02,2023-03-31,606 days,Completed,Interventional
GDWCH-001,Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer,2021-11-01,2024-12-30,1155 days,Not yet recruiting,Interventional
S2010,"Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study",2023-03-29,2028-05-01,1860 days,Recruiting,Interventional
SMC-2018-10-062,Feasibility of a Modular mHealth for Tailored Rehabilitation of Breast Cancer,2019-04-22,2021-03-30,708 days,Completed,Interventional
SMX 18001,Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,2019-09-20,2024-02-01,1595 days,"Active, not recruiting",Interventional
A5481154,Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole,2021-02-03,2025-11-30,1761 days,"Active, not recruiting",Observational
TEBICA002,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,2019-08-01,2022-02-01,915 days,Completed,Interventional
CWCD118B12201,Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer,2023-09-15,2029-07-18,2133 days,Not yet recruiting,Interventional
22-002857,"Assessment of the Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Systemic Therapy and Surgery, UTMOST Trial",2023-06-01,2024-10-01,488 days,Not yet recruiting,Observational
CALORIE,Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy,2019-02-01,2021-02-01,731 days,Unknown status,Interventional
IFOM-CPO007/2019/PO006,A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer,2020-07-16,2026-12-01,2329 days,Recruiting,Observational
S-detect 2019,Application of Deep-learning and Ultrasound Elastography in Opportunistic Screening of Breast Cancer,2019-01-01,2021-01-01,731 days,Completed,Observational
AABCSR,Stress Reactivity Among African American Breast Cancer Survivors,2018-10-19,2021-07-20,1005 days,Completed,Observational
NRG-BR008,Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer,2023-03-13,2037-02-01,5074 days,Recruiting,Interventional
FMSU2017-002B,Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer - A Pivotal Study,2018-04-06,2018-08-31,147 days,Completed,Observational
2019-A01592-55,Transcutaneous Breast Cancer Diagnosis by Canine Odorology,2020-02-03,2024-03-30,1517 days,Suspended,Interventional
ABY-025-MI301,A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer,2018-08-22,2025-11-01,2628 days,Recruiting,Interventional
202202045MIPA,Olaparib Maintenance Therapy in Metastatic Breast Cancer,2022-12-12,2025-12-31,1115 days,Recruiting,Interventional
22-07025006,Diabetes Care for Breast Cancer Patients,2023-02-21,2026-12-01,1379 days,Recruiting,Interventional
2019/044,Evaluation of the Effect of Mediterranean Diet on Breast Cancer Patients,2019-10-22,2021-01-20,456 days,Completed,Interventional
B2017-11,Neoadjuvant Goserelin for Triple Negative Breast Cancer,2018-03-01,2023-03-01,1826 days,Unknown status,Interventional
2022-0651,The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts,2022-12-05,2027-12-31,1852 days,Recruiting,Observational
Pro00088926,Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer,2019-05-07,2023-02-27,1392 days,Completed,Interventional
Tmab-TK006-102b,Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases,2018-05-01,2019-05-01,365 days,Unknown status,Interventional
YOUNGBC-10,Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients,2018-05-15,2021-05-15,1096 days,Completed,Observational
Ahead-BC-20170323,Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer,2018-03-15,2020-03-15,731 days,Unknown status,Interventional
21090645,Omega-3 and Vitamin D Supplementation in Breast Cancer Women,2022-04-20,2022-12-30,254 days,Recruiting,Interventional
18-0234,The REACH Study: A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors,2019-04-01,2020-08-31,518 days,Completed,Interventional
20-1434.cc,Cancer Patient Perspectives During COVID-19,2020-08-24,2023-06-01,1011 days,"Active, not recruiting",Observational
P20CA217199-9492018,A Community Dance Intervention Engaging Breast Cancer Survivors in a Middle-income Country,2019-03-01,2020-08-31,549 days,Completed,Interventional
Pro00107216,The Effect of Intermittent Fasting on Body Composition in Women With Breast Cancer,2021-12-02,2023-08-01,607 days,Withdrawn,Interventional
HREBA.CC 19-0363,Rise Up After Breast Cancer,2020-01-01,2020-08-31,243 days,Completed,Interventional
AHQU-2021004,Acupuncture for Stiffness of Joint Related to Aromatase Inhibitors in Patients With Early-Stage Breast Cancer,2021-10-20,2023-06-01,589 days,Recruiting,Interventional
H20-03123,Breast Cancer Endocrine Therapy FITness (BE-FIT) Trial.,2021-03-15,2023-12-31,1021 days,Recruiting,Interventional
CSPC-KAL-AE-01,Real-world Study for the Safety of Albumin-Bound Paclitaxel in Recurrent or Metastatic Breast Cancer,2019-09-01,2022-02-01,884 days,Unknown status,Observational
SYS-C-201801-5010,Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer,2018-05-01,2030-05-01,4383 days,Recruiting,Interventional
SCBCG-021,A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Premenopausal Breast Cancer Patients,2018-06-15,2023-06-15,1826 days,Not yet recruiting,Observational
15-017,Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer,2018-09-10,2022-07-01,1390 days,Unknown status,Interventional
ZN-c5-003,A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer,2020-11-12,2022-10-24,711 days,Completed,Interventional
114421,Understanding and Addressing Patient and Provider Preferences Around Discussions of Cost of Breast Cancer Care,2018-11-05,2020-11-16,742 days,Completed,Interventional
M14ABC,"A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients",2018-05-15,2022-07-01,1508 days,Terminated,Interventional
CLIN-52014-452,Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment,2022-06-09,2024-07-30,782 days,Recruiting,Observational
18-004803,Evaluation of Magseed as Localization Device for Biopsy Proven Metastatic Axillary Lymph Nodes,2018-10-30,2019-12-01,397 days,Terminated,Interventional
34615/4/21,The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer,2021-06-10,2022-11-05,513 days,Completed,Interventional
CLAG525B2101,"A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer",2018-07-02,2021-11-24,1241 days,Completed,Interventional
MINERVA,Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management,2022-04-27,2026-04-01,1435 days,Recruiting,Interventional
LACOG 0419,Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer,2021-01-12,2029-08-23,3145 days,Recruiting,Interventional
CHB18.04,Quality of Life and Sexuality of Patients Over 65 Years Undergoing Adjuvant Treatment for Breast Cancer,2018-10-16,2022-01-14,1186 days,Completed,Interventional
CSIIT-C21,A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer,2022-07-10,2024-07-10,731 days,Not yet recruiting,Interventional
BOOG 2018-01,Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study,2019-02-27,2032-05-01,4812 days,"Active, not recruiting",Interventional
AMC2020-17,Upper Limb Function After Breast Cancer Surgery: the Role of Post-operative Physical Therapy Intervention,2018-07-01,2019-09-01,427 days,Completed,Interventional
KY20222062-C-1,"Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer",2022-11-01,2023-12-31,425 days,Not yet recruiting,Interventional
RCVDBCIIR005,Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer,2023-03-01,2024-08-31,549 days,Not yet recruiting,Interventional
20201540,Prospective Evaluation of Targeted Axillary Dissection (TAD),2022-03-01,2025-03-01,1096 days,Recruiting,Interventional
STUDY00003282,Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer,2021-09-22,2025-05-01,1317 days,"Active, not recruiting",Interventional
IRB-2022-348,Transversus Thoracic Muscle Plane Combined With Pectoral Nerves Block for Breast Cancer Surgery,2022-07-15,2023-09-10,422 days,Not yet recruiting,Interventional
LCCC 1639,"Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC",2018-11-28,2019-10-11,317 days,Terminated,Interventional
SCHBCC-N034,Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D),2021-07-01,2026-06-30,1825 days,Not yet recruiting,Interventional
2022-0431,A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC),2023-06-30,2024-03-29,273 days,Not yet recruiting,Interventional
CBYL719C1201,Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer,2020-11-20,2027-10-02,2507 days,Recruiting,Interventional
SYSA1802-CSP-006,A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC),2021-10-01,2023-10-01,730 days,Recruiting,Interventional
201805027RSA,East Asian Breast Cancer Genome Atlas and Recurrence Risk Prediction,2018-10-18,2028-07-01,3544 days,Recruiting,Observational
KY2022-097-B,CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer,2023-04-01,2028-12-30,2100 days,Not yet recruiting,Observational
KY2019-023,Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer,2019-06-18,2026-11-01,2693 days,"Active, not recruiting",Interventional
GE-226-004,Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer,2023-12-01,2024-12-01,366 days,Not yet recruiting,Interventional
MEDOPP447,Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer,2022-05-15,2024-10-01,870 days,Withdrawn,Interventional
2021P002871,Optimizing Functional Recovery of Breast Cancer Survivors,2019-08-28,2023-03-31,1311 days,"Active, not recruiting",Interventional
CABC - Kreftfor project - SEB,Coping After Breast Cancer - a Randomized Clinical Trial With Two Digital Interventions,2021-01-15,2035-12-31,5463 days,Recruiting,Interventional
201708076,Mindful Movement in Women Receiving Adjuvant or Neoadjuvant Therapy for Breast Cancer,2018-01-10,2019-06-26,532 days,Completed,Interventional
TWT-203,"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer",2022-05-27,2025-08-01,1162 days,Recruiting,Interventional
Radiodermatitistalita60,The Use of Photobiomodulation in the Management of Radiodermatitis in Breast Cancer Patients,2022-11-01,2024-08-01,639 days,Not yet recruiting,Observational
CO41101,A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.,2019-11-25,2023-02-28,1191 days,Completed,Interventional
EA1183,"Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study",2020-04-02,2027-08-31,2707 days,Recruiting,Interventional
WO42312,"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physicians Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)",2020-11-27,2023-11-27,1095 days,"Active, not recruiting",Interventional
MEDOPP367,Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status,2022-02-22,2024-02-28,736 days,Recruiting,Observational
YXH2022ZX02167,Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancerï¼an Observational Single Center Study of Clinical Efficacy in Adjuvant Chemotherapy,2022-11-04,2025-06-16,955 days,Recruiting,Observational
NHP,Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer,2021-03-01,2023-02-28,729 days,Unknown status,Interventional
JU 2020/1732-51,Digi-Do - a Digital Information Tool to Help Patients Diagnosed With Breast Cancer,2020-09-01,2023-12-31,1216 days,"Active, not recruiting",Interventional
NL69081.041.19,The Effect of Hyperbaric OxygeN Therapy on brEast Cancer Patients With Late Radiation toxicitY - UMBRELLA HONEY Trial,2019-08-28,2023-09-01,1465 days,Recruiting,Interventional
NCCH1607,"PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY",2018-02-09,2025-04-01,2608 days,"Active, not recruiting",Interventional
AAAS2359,Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition,2020-01-25,2021-01-25,366 days,Unknown status,Interventional
21-06023682,"De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You",2022-01-12,2028-12-31,2545 days,Recruiting,Observational
HSEARS20210816002,The Effects of a Nurse-led mHealth Program for Symptom Self-management of Breast Cancer Patients Undergoing Chemotherapy,2022-06-07,2023-02-28,266 days,Recruiting,Interventional
GALAXY,Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancerï¼GALAXYï¼,2023-03-14,2026-10-10,1306 days,"Active, not recruiting",Interventional
D926XC00001,A Study of Dato-DXd With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03),2022-11-28,2030-03-27,2676 days,Recruiting,Interventional
PUMCH-BC500,Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Breast Cancer,2019-04-25,2025-03-01,2137 days,Recruiting,Observational
HRS-8080-I-101,A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults,2022-02-17,2025-07-31,1260 days,Enrolling by invitation,Interventional
S2020-300-01,Sonazoid Contrast-enhanced Ultrasound in Assessing Effectiveness of Neoadjuvant Chemotherapy in Breast Cancer Patients.,2020-08-01,2021-12-01,487 days,Unknown status,Observational
99mTc-DARPinG3,99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy,2022-05-01,2023-01-31,275 days,Completed,Observational
ONA-XR-103,Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer,2022-12-02,2026-04-30,1245 days,"Active, not recruiting",Interventional
EMERGENCE GSO/2020/JF-001,Evaluation of Changes in the Immunological Microenvironment Surrounding Subcutaneous Breast Cancer Metastases After Liquid Nitrogen Cryotherapy,2022-02-16,2023-12-01,653 days,Recruiting,Interventional
Soh-Med-22-05-24,Dosimetric Comparison of Three Radiation Techniques for Hypofractionated Whole Breast Radiotherapy in Early Breast Cancer,2022-07-20,2025-08-01,1108 days,Not yet recruiting,Observational
2022-0315,Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer,2023-02-09,2032-12-31,3613 days,Recruiting,Interventional
KCSG BR19-13,High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx),2020-02-11,2025-02-01,1817 days,Recruiting,Interventional
STU00216520,Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia,2023-01-19,2026-11-30,1411 days,Recruiting,Interventional
SYSEC-KY-KS-2019-054-001,Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01),2019-05-28,2025-01-01,2045 days,Recruiting,Observational
ICO-2020-25,Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients,2021-09-21,2024-06-01,984 days,Recruiting,Interventional
20805,BATs in Patients With Breast Cancer and Leptomeningeal Metastases,2019-02-26,2021-12-14,1022 days,Terminated,Interventional
HRS-1358-I-101,A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer,2023-02-07,2025-06-30,874 days,Enrolling by invitation,Interventional
IRFMN-BRC-7103,Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer,2018-03-05,2023-07-25,1968 days,"Active, not recruiting",Interventional
BL-M02D1-101,A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors,2022-05-20,2024-05-01,712 days,Recruiting,Interventional
RJBC1901,Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer,2019-09-09,2020-04-30,234 days,Terminated,Interventional
PELICAN-IPC 2015-016,Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer,2018-07-24,2025-04-30,2472 days,Recruiting,Interventional
YO41137,"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer",2020-02-05,2025-11-11,2106 days,"Active, not recruiting",Interventional
BC2,A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer,2019-02-20,2025-12-20,2495 days,Not yet recruiting,Interventional
CO40016,"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer",2018-01-06,2023-01-04,1824 days,Completed,Interventional
ADIGYN,Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer,2021-01-20,2030-09-01,3511 days,Recruiting,Interventional
NICSO-GINSENG,American Ginseng for the Prevention of Moderate-severe Fatigue in Breast Cancer Patients,2018-11-29,2020-08-01,611 days,Unknown status,Interventional
ATADEK-2018 / 9,KÄ°NECTÂ® - Video Games Based Physiotherapy Programme in Patients With Breast Cancer Surgery,2018-09-03,2019-08-05,336 days,Completed,Interventional
UW22095,Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer,2022-11-16,2025-11-01,1081 days,Recruiting,Interventional
HREBA.CC-18-0657,Diet Restriction and Exercise-induced Adaptations in Metastatic Breast Cancer,2019-04-23,2023-12-31,1713 days,Enrolling by invitation,Interventional
NSABP FB-12,Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling,2018-05-14,2023-10-30,1995 days,Recruiting,Interventional
4469,PIK3CA in HER2+ BC and pCR Trial,2022-05-02,2023-09-01,487 days,"Active, not recruiting",Interventional
RTM 2015,Microwave Radiometry for the Diagnosis and Monitoring of Breast Cancer,2019-09-01,2020-02-01,153 days,Withdrawn,Observational
Breast-Chi-2022,Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor,2019-07-10,2022-08-01,1118 days,Recruiting,Observational
STUDY00018504,"Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer",2018-12-12,2026-12-31,2941 days,Recruiting,Interventional
38RC19.362,Feasibility Study on the Characterization of the Immune Profile of Young Patients After Treatment for Breast Cancer,2020-06-15,2021-11-01,504 days,Unknown status,Observational
YOUNGBC-19,Chidamide in Combination With Abemaciclib and Fulvestrant in Breast Cancer Patients Previously Treated With Palbociclib,2022-07-01,2023-05-01,304 days,Recruiting,Interventional
CTFSp161,Personalised Disease Monitoring in Metastatic Breast Cancer,2019-05-08,2030-01-31,3921 days,Recruiting,Observational
CCR5316,A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer,2022-03-30,2030-09-01,3077 days,Recruiting,Interventional
STUDY00000675,Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer,2021-07-16,2024-12-31,1264 days,Recruiting,Interventional
FILBLAU1022,Effectiveness and Safety Study of FilgrastineÂ® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy,2023-05-01,2024-12-01,580 days,Not yet recruiting,Interventional
CBYL719C2303,"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.",2021-11-29,2026-09-23,1759 days,Recruiting,Interventional
US-MAM,The Diagnosis and Prognosis of Nonpalpable Breast Cancer Detected by the US vs Mammography: a Clinical Noninferiority Trial.,2020-04-01,2023-03-31,1094 days,Recruiting,Observational
BC-IIT-SHR6390-FMTN,A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.,2021-05-26,2023-09-30,857 days,"Active, not recruiting",Interventional
LV,"Breast Cancer, Omics, and Precision Medicine",2022-01-01,2023-12-01,699 days,Not yet recruiting,Interventional
CAPRICE-IPC 2020-053,A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr,2023-03-01,2027-12-01,1736 days,Not yet recruiting,Interventional
P0268,Prospective Validation of 3D Dose Metrics as Selection Criteria for Adaptive Radiotherapy in Breast Cancer Patients,2018-01-01,2018-08-20,231 days,Completed,Observational
HMPL-012-SPRING-R101,An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer,2022-07-01,2025-07-01,1096 days,Recruiting,Interventional
2107239-9,Reverse Triple Negative Immune Resistant Breast Cancer,2022-06-30,2023-03-01,244 days,Recruiting,Interventional
Breast PTC,Postoperative Identification of Tumor Cells at the Lumpectomy Site of Patients With Early Breast Cancer,2021-08-17,2026-08-30,1839 days,Suspended,Interventional
201900115B0,Evaluation of the Effects of the Couple-based Family Nursing for Women With Breast Cancer,2019-03-14,2020-01-07,299 days,Completed,Interventional
2021-A02664-37,Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.,2022-05-27,2024-10-01,858 days,Recruiting,Interventional
EF 160,Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Breast Cancer,2020-10-30,2025-06-30,1704 days,Recruiting,Interventional
D20148,Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI),2021-08-13,2024-09-01,1115 days,Recruiting,Interventional
CBYL719C2202,"Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant",2022-04-06,2023-05-10,399 days,"Active, not recruiting",Interventional
PUMCH-BC503,Evaluation of Prognostic Monitoring for Young Breast Cancer Patients,2019-04-25,2025-03-01,2137 days,Recruiting,Observational
TRIO036,"Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer",2020-08-25,2022-07-04,678 days,Completed,Interventional
EG017,To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer.,2023-02-28,2026-06-29,1217 days,Not yet recruiting,Interventional
TIPN in China,Taxane Induced Peripheral Neuropathy in Chinese Patients With Breast Cancer,2019-08-23,2020-12-01,466 days,Unknown status,Observational
2019000486,"Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer",2020-12-30,2025-06-01,1614 days,"Active, not recruiting",Interventional
Alpha-Lipoic Acid,Alpha-Lipoic Acid in Breast Cancer Patients,2019-03-01,2020-10-30,609 days,Completed,Interventional
VICC BREP 1898,Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer,2019-07-18,2024-07-01,1810 days,"Active, not recruiting",Interventional
MD.22.07.674,Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients,2022-03-01,2023-12-15,654 days,Recruiting,Interventional
07-2021/EK OUSA,Impact of Novel Thoracic Wall Blocks With Dexmetomidine on Inflammatory Markers Following Breast Cancer Surgery,2021-11-01,2023-12-01,760 days,Not yet recruiting,Interventional
I241,Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer,2023-01-27,2028-06-01,1952 days,Recruiting,Interventional
853.4,"Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women With Breast Cancer",2019-02-18,2019-12-31,316 days,Unknown status,Interventional
ShandongCHI-08,Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients,2018-09-20,2019-09-20,365 days,Unknown status,Observational
173-18-CA,Perioperative Mindfulness Proposal,2019-07-31,2023-12-31,1614 days,Recruiting,Interventional
1400,Tahini and Dermatitis in Breast Cancer,2021-05-08,2021-07-15,68 days,Not yet recruiting,Interventional
NCC2167,Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine,2020-04-01,2023-12-31,1369 days,Recruiting,Interventional
UW 18-526,The Effect of Acupuncture for Insomnia in Breast Cancer Patients Undergoing Chemotherapy,2019-03-26,2020-10-31,585 days,Completed,Interventional
H-1905-141-1035,Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer,2020-02-18,2025-12-31,2143 days,Recruiting,Interventional
EUBREAST-2 INDAX,Individualized Locoregional Treatment of Initially Biopsy-proven Node-positive Breast Cancer After Primary Systemic Therapy,2021-01-01,2029-12-31,3286 days,Withdrawn,Interventional
HRHB-CB001,"Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer",2020-03-01,2024-03-01,1461 days,Not yet recruiting,Interventional
NSABP FB-14,Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer,2019-05-03,2024-06-30,1885 days,"Active, not recruiting",Interventional
ADG106-T6002,"A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer",2022-05-19,2030-02-01,2815 days,Recruiting,Interventional
1812850942,Telephone Support for Metastatic Breast Cancer Patients,2019-06-20,2023-09-19,1552 days,"Active, not recruiting",Interventional
RJBC1801,Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer,2019-04-01,2022-10-01,1279 days,Recruiting,Interventional
UTAR- 8068/000,A Systemic Approach to Study the Traditional Chinese Medicine as an Adjuvant Treatment in Breast Cancer Patients,2022-04-22,2024-04-01,710 days,Recruiting,Interventional
SH APBI RISE,Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr,2022-03-01,2027-03-31,1856 days,Recruiting,Interventional
TOL2506A,Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer,2021-07-01,2025-04-30,1399 days,Recruiting,Interventional
852000,FES BPET-DBT in Newly Diagnosed Breast Cancer,2023-04-01,2026-01-01,1006 days,Not yet recruiting,Interventional
2019-A02500-57,Management of Cognitive Difficulties After Cancer Treatments in Women Treated for Breast Cancer: Feasibility Study (Step 1 of the Cog-Stim Protocol),2020-01-24,2022-02-11,749 days,Completed,Interventional
JCOG1919E,A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer,2021-01-21,2025-06-30,1621 days,Recruiting,Interventional
AI-BMRI-S,Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening and Diagnosis of Breast Cancer,2022-02-28,2025-09-30,1310 days,Recruiting,Observational
Prix Ruban Rose/2020/FF-03,Multidisciplinary Care Pathway With Electronic Patient Reported Outcomes (ePRO) Post-operative Follow-up of Breast Cancer Surgery Complications to Optimize Patient Quality of Life,2022-07-25,2024-07-01,707 days,Recruiting,Interventional
SBU-SBRT-BREAST-NO-SX,Stereotactic Body Radiation Therapy (SBRT) for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery,2020-08-19,2027-08-31,2568 days,"Active, not recruiting",Interventional
IUSCC-0680,Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors,2019-10-02,2023-09-01,1430 days,Recruiting,Interventional
E7389-M065-401,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",2018-03-28,2019-06-28,457 days,Completed,Interventional
UPCC 04119,BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy,2020-12-07,2024-08-01,1333 days,Recruiting,Interventional
HCRN BRE20-468,"Ribociclib And Endocrine Treatment of Physicians Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer",2022-09-13,2027-12-01,1905 days,Recruiting,Interventional
2021-04,Smart Bra for Diagnosing Breast Cancer,2022-04-19,2022-11-19,214 days,Not yet recruiting,Interventional
18-000718,"Team Based Psychosocial Care to Promote, Maintain and Restore Wellness of Breast Cancer Patients",2018-11-28,2024-11-01,2165 days,"Active, not recruiting",Interventional
MOST Pain,Optimizing Psychological Treatment for Pain After Breast Cancer,2022-09-01,2024-10-01,761 days,Recruiting,Interventional
AQUAFIT-2018,Water-based Versus Land-based Exercise for Breast Cancer Survivors,2020-09-01,2023-04-30,971 days,Recruiting,Interventional
Moderate Dose Omega-3,Study of Moderate Dose Omega 3 Fatty Acid Supplement in Premenopausal Women at High Risk for Breast Cancer,2018-02-05,2021-03-01,1120 days,Unknown status,Interventional
Pro00104863,"Exercise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Breast Conservation Therapy for Women With Early Stage Breast Cancer",2021-09-01,2022-09-01,365 days,Withdrawn,Interventional
MA40,Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor,2020-12-01,2026-12-31,2221 days,Recruiting,Interventional
HR-BLTN-003,Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer,2019-06-26,2023-12-31,1649 days,"Active, not recruiting",Interventional
Velocity,Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer,2022-03-01,2023-08-28,545 days,Recruiting,Interventional
KN026-201,Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer,2019-12-31,2025-12-31,2192 days,"Active, not recruiting",Interventional
GBG105,"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer",2023-01-02,2027-01-01,1460 days,Recruiting,Interventional
KN026-208,Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer,2021-08-09,2023-02-15,555 days,Recruiting,Interventional
27600,Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer,2022-11-01,2027-02-01,1553 days,Recruiting,Interventional
RnaDx-BRV-BC- 01,RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy,2018-04-26,2025-10-26,2740 days,Recruiting,Interventional
ZN-c5-001,A Study of ZN-c5 in Subjects With Breast Cancer,2018-12-08,2022-12-22,1475 days,Completed,Interventional
2020-A00398-31,Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer,2021-11-19,2026-05-31,1654 days,Recruiting,Interventional
CSIIT-C10,Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors,2022-02-07,2022-12-30,326 days,Not yet recruiting,Interventional
ICON CA209-9FN,Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer,2018-01-21,2027-05-11,3397 days,"Active, not recruiting",Interventional
31052019,Implementation of a CDSS in Oncology Patients During COVID-19,2020-03-11,2021-04-15,400 days,Completed,Interventional
iOM-110393,Self-efficacy Coaching for Women With Breast Cancer,2018-03-16,2018-11-22,251 days,Completed,Interventional
201711073,"MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer",2018-09-30,2021-02-28,882 days,Withdrawn,Interventional
L21-076,Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers,2024-01-01,2027-06-01,1247 days,Not yet recruiting,Interventional
2020-007,Characterization of Neuromuscular Function and Fatigue After Breast Cancer Treated With Adjuvant Chemotherapy (PROTECT-04),2020-09-29,2021-09-06,342 days,Completed,Interventional
19-300,Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer,2019-08-30,2024-08-30,1827 days,Recruiting,Interventional
RAD1901-308,Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer,2019-05-10,2024-08-01,1910 days,"Active, not recruiting",Interventional
LAE205INT3101,Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer,2022-02-18,2024-12-30,1046 days,Recruiting,Interventional
201900180,89Zr-atezolizumab PET Scan and Lobular Breast Cancer,2019-12-18,2022-05-01,865 days,Terminated,Interventional
201911047,Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer,2020-09-14,2021-03-03,170 days,Terminated,Interventional
CAAP CA,Light Emitting Diode for theTreatment of Genitourinary Syndrome of Menopause Associated With Breast Cancer Treatment,2019-01-30,2021-02-01,733 days,Unknown status,Interventional
JTU-6H-20211230001,Effect of the Axillary Lymphatic /Vein Reflux Ratio on Postoperative Upper Limb Edema and Dysfunction in Breast Cancer,2021-12-01,2024-03-01,821 days,Recruiting,Observational
BCT 2102,Tucatinib Together With Pembrolizumab and Trastuzumab,2023-03-07,2025-09-01,909 days,Recruiting,Interventional
OCOG-2019-RHEAL,Hypofractionated LocoRegional Radiotherapy in Breast Cancer,2021-02-10,2027-12-31,2515 days,Recruiting,Interventional
KY20223267-1,PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer,2020-01-01,2023-12-31,1460 days,Recruiting,Interventional
SGNTUC-016,A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer,2019-10-02,2024-04-30,1672 days,Recruiting,Interventional
SHEPHERD-2021-2,Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis,2022-08-01,2026-07-01,1430 days,Recruiting,Observational
GUMPTION,Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer,2021-02-01,2023-01-01,699 days,Recruiting,Interventional
MA-BC-II-018,"Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial",2021-04-20,2028-12-31,2812 days,Recruiting,Interventional
A5481168,Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC,2022-06-02,2022-11-30,181 days,Recruiting,Observational
1401,Grape Juice and Dermatitis in Breast Cancer,2021-05-08,2021-07-15,68 days,Not yet recruiting,Interventional
SCHBCC-N041,SNF Platform Study of HR+/ HER2-advanced Breast Cancer,2022-12-30,2026-12-01,1432 days,Recruiting,Interventional
IBIO-301,A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer,2018-03-18,2023-09-22,2014 days,"Active, not recruiting",Interventional
FUSCC-T-sunflower,Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower),2022-11-01,2026-03-01,1216 days,Not yet recruiting,Interventional
05022020,FALSE POSITIVE FINDINGS IN BREAST CANCER TOMOSYNTHESIS,2019-01-01,2020-01-01,365 days,Completed,Observational
BTP-66732,"A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer",2022-06-01,2025-07-31,1156 days,Not yet recruiting,Interventional
CSIIT-C18,Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer,2021-08-18,2023-09-18,761 days,Recruiting,Interventional
2021C0102,"Remote Assessment of Cognition, Insulin Resistance and Omega-3 Fatty Acid Biomarkers in Breast Cancer Survivors",2022-01-18,2023-04-01,438 days,Recruiting,Observational
CTO-IUSCCC-0758,Breast Cancer BRCA1 Carriers: a Pilot Study,2021-11-01,2024-12-31,1156 days,Withdrawn,Observational
CLOVER,Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer,2018-07-03,2025-11-01,2678 days,Recruiting,Interventional
LOXO-PIK-21001,A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors,2022-05-11,2025-05-01,1086 days,Recruiting,Interventional
SPI-GCF-104,"Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer",2020-03-11,2025-06-30,1937 days,Recruiting,Interventional
HNCH-BC006,Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2 Positive Operable Breast Cancer,2020-09-18,2023-12-31,1199 days,Recruiting,Interventional
2019-0550,Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer,2019-08-09,2026-09-27,2606 days,"Active, not recruiting",Interventional
NL74126.091.20,Adherence Improving Self-Management Strategy (AIMS) in Breast Cancer Patients Using Adjuvant Endocrine Treatment (AET),2020-12-13,2022-12-31,748 days,Unknown status,Interventional
ALTERBC008,A Phase â¡ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer,2021-08-01,2023-07-31,729 days,Recruiting,Interventional
IOM-050371,Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line,2018-05-24,2022-11-30,1651 days,Completed,Interventional
IRB-2021-04,Evaluate Impact of Exercise Program on Fatigue in Breast Cancer During Chemotherapy,2022-12-22,2026-06-01,1257 days,Recruiting,Interventional
DPMBC301,Compare the Efficacy and the Safety of Doxorubicin and Cyclophosphamide Followed by Taxotere Versus Doxorubicin and Cyclophosphamide Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer,2022-02-01,2024-12-01,1034 days,Not yet recruiting,Interventional
SYHX2011-001,A Pharmacokinetic Comparison Study of SYHX2011 and AbraxaneÂ® in Patients With Advanced Breast Cancer,2022-03-31,2022-10-30,213 days,Not yet recruiting,Interventional
21-225,A Study of Multiparametric MRI and pHLIPÂ® ICG in Breast Cancer Imaging During Surgery,2021-11-19,2025-11-01,1443 days,Recruiting,Interventional
KCSG-BR18-13/TR-03,Phase II Study of HerzumaÂ® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer,2019-12-03,2021-12-01,729 days,Unknown status,Interventional
SELEBREC,Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.,2022-05-19,2025-11-19,1280 days,Recruiting,Observational
ICPS002/20,Radiofrequency Ablation (RFA) in Breast Tumors,2020-05-01,2024-12-15,1689 days,Recruiting,Interventional
21-698,Alcohol and Breast Cancer (ABC) Trial,2022-08-09,2024-08-31,753 days,Recruiting,Interventional
RJBC2001,"Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer",2020-05-30,2027-12-30,2770 days,"Active, not recruiting",Interventional
H-2009-079-1157,Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency,2021-05-25,2025-05-10,1446 days,Recruiting,Interventional
20P.020,"Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer",2020-12-21,2024-01-01,1106 days,Withdrawn,Interventional
GB491-005,A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer,2021-06-02,2024-02-01,974 days,Recruiting,Interventional
012342QM,Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer,2019-05-01,2025-04-01,2162 days,Not yet recruiting,Interventional
GDWCH002(TNBC),ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer,2021-10-01,2024-05-01,943 days,Not yet recruiting,Interventional
HR-BLTN 015,A Multi-cohort Phase II Study of HER2-positive and Triple-negative Breast Cancer Brain Metastases.,2020-03-30,2022-01-30,671 days,Unknown status,Interventional
HER2BRAIN,TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN),2021-10-01,2025-09-30,1460 days,Not yet recruiting,Interventional
HNCH-MBC10,A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer,2022-06-28,2024-06-28,731 days,Not yet recruiting,Interventional
NOGGO B3,Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer,2018-07-17,2032-10-01,5190 days,"Active, not recruiting",Observational
IC 2020-20,Digital Phenotyping in Young Breast Cancer Patients Treated With Neoadjuvant Chemotherapy,2021-09-20,2024-09-01,1077 days,Recruiting,Interventional
2017-004909-41,Prevention of Cardiac Dysfunction During Breast Cancer Therapy,2019-01-14,2025-09-14,2435 days,"Active, not recruiting",Interventional
2022JC-55,Acupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.,2022-08-01,2027-07-31,1825 days,Not yet recruiting,Interventional
AI-Breast-US,"Using Deep Learning Methods to Analyze Automated Breast Ultrasound and Hand-held Ultrasound Images, to Establish a Diagnosis, Therapy Assessment and Prognosis Prediction Model of Breast Cancer.",2020-02-01,2024-09-01,1674 days,Recruiting,Observational
2021-0974,Time Restricted Eating During Chemotherapy for Breast Cancer,2022-08-01,2026-03-01,1308 days,Recruiting,Interventional
ICO-2020-28,Detection and Metabolic Characterization in DOPA PET/CT of Brain Metastases,2021-12-03,2024-02-01,790 days,Recruiting,Interventional
HNCH-MBC12,Study of SHR-A1811 in HER2-positive Advanced Breast Cancer With Brain Metastases,2023-03-31,2026-04-30,1126 days,Recruiting,Interventional
Twisted Pink Foundation,Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer,2021-09-02,2031-07-01,3589 days,Recruiting,Interventional
HORMONOVILLE,Evaluation of the Impact of a Pharmaceutical Interview on the Adherence to Hormonotherapy in Women With Breast Cancer,2019-06-25,2021-08-27,794 days,Unknown status,Interventional
ET17-093 BreastImmune03,Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease,2019-07-02,2023-12-01,1613 days,"Active, not recruiting",Interventional
1910208-9,Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer,2019-12-25,2022-06-01,889 days,Recruiting,Interventional
CSPC-KAL-BC-11,Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer,2019-11-20,2021-06-20,578 days,Unknown status,Interventional
1503144-7,"Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)",2019-03-01,2021-05-30,821 days,Unknown status,Interventional
IRB00022667,Developing and Evaluating Culturally Relevant Interventions to Improve Breast Cancer Screening,2023-05-01,2025-12-01,945 days,Not yet recruiting,Interventional
TOL2506A-EXT,"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study",2022-12-28,2028-06-01,1982 days,Enrolling by invitation,Interventional
IKP275 / GBG91,Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients,2019-09-10,2021-05-03,601 days,Completed,Interventional
BELIEVE@BC,Effect of the App Bone@BC Version 4.0 Under the Follow-up for Patients With Early Breast Cancer,2022-05-01,2025-10-01,1249 days,Not yet recruiting,Interventional
GCC 1926,GammaPod Dose Escalation Radiation for Early Stage Breast Cancer,2021-09-15,2028-12-01,2634 days,Recruiting,Interventional
HIFU202207,To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer,2022-09-01,2024-12-30,851 days,Not yet recruiting,Interventional
18-195,Screening For BCRL In Targeted Therapy For Breast Cancer,2018-12-13,2026-09-30,2848 days,Recruiting,Observational
BO40747,A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer,2019-01-11,2023-08-24,1686 days,"Active, not recruiting",Interventional
KA22053,The 24 Hour Effects of Remedial Exercises With and Without Compression Therapy on Breast Cancer-related Lymphedema,2022-05-16,2022-12-10,208 days,Completed,Interventional
BOOG-2017-01,"Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.",2019-06-15,2027-08-01,2969 days,"Active, not recruiting",Interventional
GO39869,"Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer",2018-04-17,2021-07-16,1186 days,Completed,Interventional
2021-0532,Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy,2021-08-31,2025-07-31,1430 days,Recruiting,Observational
P2100-SUR-S11,"Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer",2021-09-10,2026-06-01,1725 days,Recruiting,Interventional
BC-IIT-FMTN-SHR6390-ET,"Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer",2021-12-08,2026-01-30,1514 days,Recruiting,Interventional
2022JC-55-1,Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.,2022-12-01,2027-12-01,1826 days,Not yet recruiting,Interventional
XJTU1AF-CRF-2020-006,Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer,2021-01-01,2024-02-28,1153 days,Recruiting,Interventional
2018-062,Reducing Metabolic Syndrome Among Breast Cancer Survivors,2018-11-06,2020-09-13,677 days,Completed,Interventional
SPY LNM 01,A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer,2019-01-04,2020-09-28,633 days,Completed,Interventional
QUILT-3.067,QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.,2018-03-16,2023-01-01,1752 days,"Active, not recruiting",Interventional
1808189-7,Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer,2018-11-26,2020-02-01,432 days,Unknown status,Interventional
Version 1.0_16.08.2021,TAD in Primary Breast Cancer With Initially â¥ 3 Suspicious Lymph Nodes,2022-03-07,2032-03-01,3647 days,Recruiting,Observational
17041,A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer,2018-11-28,2023-09-20,1757 days,"Active, not recruiting",Interventional
TSL-CM-TSL1502-â¡,A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations,2022-08-01,2026-06-30,1429 days,Not yet recruiting,Interventional
82071993,Assessment of Brain Cognitive Impairment in Breast Cancer,2022-05-31,2027-05-30,1825 days,Recruiting,Observational
QL1701-002,"A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus HerceptinÂ® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer",2020-04-29,2023-10-01,1250 days,"Active, not recruiting",Interventional
FAVOR,"Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer",2020-07-01,2026-04-30,2129 days,Not yet recruiting,Interventional
60905722.0.0000.0072,Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiation vs Nodal Moderate Hypofractionated Radiotherapy,2022-10-18,2030-12-31,2996 days,Recruiting,Interventional
197520,Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer,2021-03-11,2029-03-01,2912 days,Recruiting,Interventional
17249,A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body,2019-08-02,2020-05-14,286 days,Completed,Interventional
Onkologikoa,PFMT Educational Intervention for Patients With Advancer Breast Cancer,2021-09-02,2023-04-10,585 days,Recruiting,Interventional
ET17-057,Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer,2018-08-06,2024-04-01,2065 days,Recruiting,Interventional
2019-A02397-50,Comparison of Changes in the Quality of Life of Patients Operated on Breast Cancer at the DrÃ´me ArdÃ¨che Breast Institute According to Access to Supportive Oncological Care (IDSein),2021-02-22,2023-08-22,911 days,Recruiting,Observational
21-018,A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer,2022-01-31,2024-01-01,700 days,Recruiting,Interventional
ShandongCHI-20,Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer,2021-08-01,2024-07-31,1095 days,Not yet recruiting,Interventional
YBCSG-22-08,Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions,2021-01-01,2022-06-01,516 days,Completed,Observational
AL-2001,Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.,2021-03-01,2025-11-01,1706 days,Recruiting,Interventional
kazuma,"To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study",2021-07-01,2025-09-01,1523 days,Recruiting,Interventional
308-2017,Use of Quantitative Ultrasound to Guide Adaptive Chemotherapy Among Women With Breast Cancer,2018-06-13,2028-06-01,3641 days,Recruiting,Interventional
Pro00107615,TOPS for African American Breast Cancer Survivors,2021-06-11,2022-08-30,445 days,Completed,Interventional
RSINETE,RWS of Inetetamab HER2 Positive Advanced Breast Cancer,2021-07-01,2021-12-01,153 days,Not yet recruiting,Observational
AC682-002,A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer,2022-10-01,2024-12-01,792 days,Recruiting,Interventional
PRO00037175,Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer,2020-03-05,2025-01-01,1763 days,Recruiting,Interventional
55516,Effectiveness of Aerobic Exercises and Laughter Yoga Compared With Yoga in Anxiety/Depression Levels in Breast Cancer,2022-01-05,2022-07-29,205 days,Completed,Interventional
MA-BC-II-007,Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer,2021-01-01,2025-06-01,1612 days,Not yet recruiting,Interventional
SIESTA_01,Pilot Study to Evaluate Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer,2020-09-24,2025-12-31,1924 days,Recruiting,Observational
48347821.8.0000.5249,The Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer Patients,2022-06-02,2023-12-02,548 days,Not yet recruiting,Interventional
OBU-BC-II-086,"Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy",2023-05-01,2025-12-01,945 days,Not yet recruiting,Interventional
200218,Mobile Apps to Reduce Distress in Breast Cancer Survivors Using an Adaptive Design,2021-09-27,2024-09-01,1070 days,Recruiting,Interventional
2017 0105,Health Benefits of HIT for Breast Cancer Patients,2019-05-01,2019-12-31,244 days,Withdrawn,Interventional
MYBC,Multidisciplinary Shared Decision Making of Fertility Preservation in Young Women With Breast Cancer,2021-12-01,2028-12-01,2557 days,Not yet recruiting,Interventional
D-FR-01070-003,Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer,2018-10-22,2019-02-06,107 days,Terminated,Interventional
MUKDEN01,"Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial",2020-07-27,2026-12-30,2347 days,"Active, not recruiting",Interventional
R174-A11507-17-S52,Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression,2021-03-01,2022-12-01,640 days,Withdrawn,Interventional
000001,Reliability and Reproducibility of Bandaging in Breast Cancer,2020-01-01,2021-12-30,729 days,Completed,Interventional
18-240,"Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer",2018-07-13,2023-07-01,1814 days,Recruiting,Observational
BG01-2102,Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer,2023-01-15,2025-12-31,1081 days,Not yet recruiting,Interventional
19-004343,"Comprehensive Genetic Assessment, Risk and Education in a Mammography Pilot",2019-08-20,2022-05-31,1015 days,Enrolling by invitation,Interventional
Shandong CHI-11,Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer,2020-01-01,2024-12-01,1796 days,Not yet recruiting,Interventional
NCC2225,Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer,2020-09-23,2023-07-11,1021 days,Recruiting,Interventional
NCC-006461,Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer,2020-06-01,2023-12-31,1308 days,Recruiting,Interventional
OZM-103,A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer,2020-02-01,2020-06-09,129 days,Withdrawn,Interventional
SCHBCC-NO27,Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients,2020-06-09,2021-08-31,448 days,Unknown status,Interventional
2022/0035983,The Unmet Needs and the Workplace Reintegration of Breast Cancer Patients: the NEW-BreCa Project,2022-05-09,2024-05-01,723 days,Recruiting,Observational
2020/482,"Supervised Exercise, Sleep in Patients With Non Metastatic Breast Cancer",2021-04-08,2023-08-01,845 days,Recruiting,Interventional
TUXEDO-1,Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases,2020-07-28,2023-07-28,1095 days,"Active, not recruiting",Interventional
CIBI375Y008,"A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations",2022-09-08,2025-09-08,1096 days,Recruiting,Interventional
NL76658.029.21,Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer,2021-10-11,2023-10-01,720 days,Recruiting,Interventional
SCHBCC-N032,"Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer",2021-10-15,2024-10-15,1096 days,Recruiting,Interventional
OE861801,A Phase I Study of LX-039 Tablets,2020-01-07,2023-07-19,1289 days,Enrolling by invitation,Interventional
1808189-8,Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer,2018-11-19,2019-07-30,253 days,Unknown status,Interventional
4-2018-0765,"Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients",2019-06-10,2023-10-30,1603 days,Recruiting,Interventional
38406,Exercise and Cognitive (Brain) Function in Breast Cancer Patients Getting Chemotherapy After Breast Surgery,2019-12-12,2023-04-30,1235 days,Recruiting,Observational
2020/134,Analgesic Efficacy of Erector Spinae Plane Block After Breast Cancer Surgery,2018-09-01,2021-03-03,914 days,Completed,Observational
LB,Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer,2018-12-18,2021-10-01,1018 days,Unknown status,Interventional
CSIIT-C34,Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer,2023-02-07,2025-12-01,1028 days,Recruiting,Interventional
19-886,RCT of CBD for Anxiety in Advanced Breast Cancer,2022-01-19,2024-02-18,760 days,Recruiting,Interventional
IEO 0834/,CDH1 Germline Mutations in Lobular Breast Cancer,2018-12-01,2023-06-30,1672 days,"Active, not recruiting",Observational
FACILE,FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer,2018-12-27,2025-11-27,2527 days,Recruiting,Interventional
RP6530-2101,"Efficacy and Safety of Tenalisib (RP6530), a PI3K Î´/Î³ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer",2021-10-13,2022-12-01,414 days,"Active, not recruiting",Interventional
GEICAM/2021-08,Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab,2023-07-01,2029-03-01,2070 days,Not yet recruiting,Interventional
SYHX2011-002,A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound),2023-05-01,2024-09-01,489 days,Not yet recruiting,Interventional
ZDWY.XBZL.002,Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer,2022-03-01,2024-09-01,915 days,Not yet recruiting,Interventional
D8664R00002,ZoladexÂ® 10.8 BC RWS,2022-01-06,2024-02-28,783 days,Recruiting,Observational
BO41843,"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)",2020-10-09,2027-03-18,2351 days,"Active, not recruiting",Interventional
HSEARS20180509004,Acupuncture for Joint Symptoms in Patients With Breast Cancer,2019-03-01,2022-01-31,1067 days,Terminated,Interventional
Shandong CHI-10,Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer,2019-10-25,2024-12-31,1894 days,Not yet recruiting,Interventional
erector-spinae,Postoperative Analgesia in Breast Cancer Surgery: Safety and Efficiency of Ultrasound Guided Erector Spinae Plane Block,2018-12-17,2019-06-30,195 days,Completed,Interventional
CHD049-17,Pilot Study Describing the Early Evolution of the Sexual Function of Patients Receiving Adjuvant Hormone Therapy for Breast Cancer,2018-02-20,2020-05-15,815 days,Unknown status,Observational
OnkoFit I,Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Adjuvant Radiotherapy of Breast Cancer,2020-08-01,2025-08-01,1826 days,Recruiting,Interventional
103089,"A ""Window Trial"" on Curcumin for Invasive Breast Cancer Primary Tumors",2020-01-29,2023-08-31,1310 days,"Active, not recruiting",Interventional
SHR6390-III-301,A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,2019-06-13,2022-12-30,1296 days,Unknown status,Interventional
17575,A Study of LY3484356 in Women With Breast Cancer Before Having Surgery,2021-04-21,2022-11-11,569 days,Completed,Interventional
IMMU-132-09,Study of Sacituzumab Govitecan-hziy Versus Treatment of Physicians Choice in Participants With HR+/HER2- Metastatic Breast Cancer,2019-05-08,2024-10-01,1973 days,"Active, not recruiting",Interventional
2017-IIT-HER2-Aspire,Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer,2018-10-15,2025-10-15,2557 days,"Active, not recruiting",Interventional
QL1209-301,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.,2020-11-01,2022-12-01,760 days,Unknown status,Interventional
17395,"A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer",2019-09-16,2023-03-23,1284 days,Withdrawn,Interventional
2019-A01323-54,Health-Related Quality of Life Coupled With Therapeutic Information on Compliance to Endocrine Therapy in Breast Cancer,2021-05-14,2025-10-01,1601 days,Recruiting,Interventional
D967RC00001,"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer",2021-10-25,2026-06-26,1705 days,Recruiting,Interventional
UPCC 10119,ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer,2021-11-01,2028-12-01,2587 days,Recruiting,Interventional
WO41554,"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer",2020-01-29,2025-09-19,2060 days,Recruiting,Interventional
2020-0198,Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test,2022-08-18,2028-12-31,2327 days,Recruiting,Interventional
UC-0109/1805,My Personalized Breast Screening,2019-07-18,2025-12-31,2358 days,Recruiting,Interventional
SHR-1210-III-318,"A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.",2020-07-14,2024-01-01,1266 days,Recruiting,Interventional
H21089,Breathing Exercise for Chronic Pain Management in Breast Cancer Survivors,2023-01-01,2023-12-31,364 days,Not yet recruiting,Interventional
CSPC-DMS-BC-11,Phase â¡ Study of Pegylated Liposomal Doxorubicinï¼PLDï¼Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer,2019-03-11,2022-05-01,1147 days,Unknown status,Interventional
270-2018,Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer,2018-08-30,2024-08-30,2192 days,"Active, not recruiting",Observational
0379520202023,Pain Neuroscience Education and Graded Exposure to Movement in Breast Cancer Survivors,2021-04-01,2023-06-30,820 days,Recruiting,Interventional
S63893,Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity,2021-02-01,2025-01-31,1460 days,Withdrawn,Interventional
KM10B,Efficacy and Safety of Trastuzumab Biosimilar (HerzumaÂ®) Plus Treatment of Physicians Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer,2018-12-15,2022-06-30,1293 days,Unknown status,Interventional
TriMix-Breast,Intratumoral TriMix Injections in Early Breast Cancer Patients,2018-11-12,2024-12-30,2240 days,Recruiting,Interventional
19-486,A Study of the Bodys Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer,2020-03-04,2024-03-01,1458 days,Recruiting,Interventional
UC-GMP-2206,Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib,2023-06-01,2030-06-01,2557 days,Not yet recruiting,Interventional
SYSUCC-003,Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer,2021-04-20,2025-02-01,1383 days,Recruiting,Interventional
soh-Med-21-10-17,Adjuvant Whole Breast Irradiation in Five Fractions Versus Fifteen Fractions in Early Breast Cancer,2021-06-01,2023-10-01,852 days,Recruiting,Observational
2021-005,Consequences of Eccentric Cycling on Exercise-related Neuromuscular Responses and Biomarkers in Breast Cancer Patients,2021-11-22,2022-04-28,157 days,Completed,Interventional
MRG002-009,A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients,2022-03-23,2023-10-01,557 days,Recruiting,Interventional
CBYL719G12301,Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation,2020-07-16,2024-04-02,1356 days,Recruiting,Interventional
TCF20-BRE-01,Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376,2020-12-23,2025-11-01,1774 days,"Active, not recruiting",Interventional
GS-US-586-6144,Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer,2021-12-14,2025-01-01,1114 days,Recruiting,Interventional
PMC_TTAC-0001_05,TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer,2019-01-03,2022-10-26,1392 days,"Active, not recruiting",Interventional
EOC103A3101,"Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer",2018-05-15,2023-03-01,1751 days,"Active, not recruiting",Interventional
CO41012,A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer,2019-11-15,2023-09-30,1415 days,"Active, not recruiting",Interventional
SYM013,Alopecia Prevention Scalp Cooling in Chinese Breast Cancer Patients,2021-01-08,2025-12-31,1818 days,"Active, not recruiting",Interventional
SHR6390-III-302,A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,2019-07-19,2023-12-30,1625 days,"Active, not recruiting",Interventional
HR-BLTN-016,Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer,2020-02-28,2023-11-15,1356 days,Recruiting,Observational
Pro2021000838,"Aim 3, Adapting and Implementing Evidence-based Breast Cancer Follow-up in Primary Care",2023-12-01,2025-12-01,731 days,Not yet recruiting,Interventional
CSPC-DMS-BC-K07,Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer,2021-12-20,2028-01-31,2233 days,Recruiting,Interventional
SGNLVA-002,Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer,2018-02-27,2024-12-31,2499 days,Recruiting,Interventional
WO43919,"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy",2023-05-31,2029-03-30,2130 days,Recruiting,Interventional
KSVGH20-CT7-26,Influence of Co-Vid 19 Pandemic on Screening Mammography Single Institution,2020-07-03,2021-06-01,333 days,Unknown status,Observational
EMBRAVE-001,Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients,2021-06-01,2024-06-01,1096 days,Not yet recruiting,Interventional
I 72218,A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity,2019-01-16,2021-02-05,751 days,Completed,Interventional
FCN-437c-III201,"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole Â± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.",2022-03-02,2025-03-02,1096 days,Recruiting,Interventional
MCC-20899,Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases,2021-11-30,2024-12-31,1127 days,Recruiting,Interventional
2021-TNBC-01,Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer,2021-09-20,2024-11-01,1138 days,Recruiting,Interventional
FCN-437c-III202,"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant Â± Goseraline Versus Placebo Combined With Fulvestrant Â± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.",2022-01-18,2024-05-18,851 days,Recruiting,Interventional
breast-202204,Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer,2022-01-01,2023-06-30,545 days,Recruiting,Interventional
20150288,Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors,2019-01-01,2024-01-01,1826 days,Withdrawn,Interventional
D9673R00005,Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer,2021-05-14,2022-10-31,535 days,Completed,Observational
P170927J,Evaluation of Innovative Therapeutic Approaches of Vaginal and Sexual Dysfunction After Breast Cancer Treatment,2021-02-01,2024-02-01,1095 days,Not yet recruiting,Interventional
HBBL-01,Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study,2019-04-30,2022-04-30,1096 days,Unknown status,Interventional
PCZCTP-220702-001,"Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer",2023-02-01,2024-06-01,486 days,Not yet recruiting,Interventional
FDRT-BC015,The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients,2021-01-01,2026-12-31,2190 days,Recruiting,Observational
ERC-260,Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer,2018-11-06,2019-12-05,394 days,Withdrawn,Interventional
POL6326-009,"Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer",2019-06-14,2022-03-01,991 days,Unknown status,Interventional
911,"Effects of Green Coffee Extract Supplementation on Leptin, Ghrelin, Adiponectin,Anthropometric Measurements, Lipid Profile in Breast Cancer Survivors",2018-03-12,2019-08-12,518 days,Unknown status,Interventional
EAGER-001,Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer,2021-03-01,2022-12-01,640 days,Recruiting,Interventional
206010,Vaccination of Triple Negative Breast Cancer Patients,2019-01-25,2023-01-09,1445 days,Completed,Interventional
IRB#18853,Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening,2019-09-19,2023-06-01,1351 days,Recruiting,Interventional
UKFC-PU-2019-01-08,Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients,2021-09-07,2023-12-30,844 days,Not yet recruiting,Interventional
2018-001705-91,Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer,2019-04-30,2021-01-31,642 days,Completed,Interventional
KA-20007,"The Effect of Oral Cryotherapy on Anticipatory, Acute and Late Nausea and Vomiting in Breast Cancer Patients",2020-07-21,2021-05-17,300 days,Completed,Interventional
Arise-FJ-B02,Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer,2021-10-01,2023-12-31,821 days,Not yet recruiting,Interventional
SYSU-2021,Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer,2021-06-25,2025-07-01,1467 days,Recruiting,Interventional
SHR-A1811-II-202,A Phase Ib/II Study of SHR-A1811 Injection in HER2 Positive Breast Cancer,2022-05-23,2025-12-31,1318 days,Recruiting,Interventional
IL-2.001,Efficacy of Interleukin-2 in Triple Negative Breast Cancer,2023-04-01,2025-04-01,731 days,Not yet recruiting,Interventional
REaCT-Algorithm,Evaluating Whether Integration of Prognostic and Predictive Algorithms Into Routine Clinical Practice Effect Whether Oncologists Order Multigene Assays in Patients With Early Stage Breast Cancer,2020-03-06,2022-05-18,803 days,Completed,Observational
2019-A03112-55,Use of Cognitive Stimulation Software for Patients Over the Age of 70 Followed for Breast Cancer: COG-TAB-AGE Feasibility Study,2020-06-05,2022-12-01,909 days,"Active, not recruiting",Interventional
017-396,Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer,2018-02-08,2020-12-31,1057 days,Completed,Interventional
G1T28-213,Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer,2021-11-22,2024-07-01,952 days,"Active, not recruiting",Interventional
Shengjing-LCG012,A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer,2021-10-20,2023-07-01,619 days,Recruiting,Interventional
NK/7784/Study/249,Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Breast Cancer With Brain Oligometastasis,2021-08-31,2026-08-31,1826 days,Recruiting,Interventional
A5481159,Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone,2021-02-17,2021-12-09,295 days,Completed,Observational
CL0006,Intraoperative Detection of Residual Cancer in Breast Cancer,2018-02-06,2020-04-10,794 days,Completed,Interventional
ZEN003694-004,A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer,2019-06-26,2024-05-01,1771 days,Recruiting,Interventional
GS-US-569-6172,Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors or Triple-negative Breast Cancer,2021-10-20,2025-06-01,1320 days,"Active, not recruiting",Interventional
TED15954,Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer,2019-03-25,2023-05-31,1528 days,"Active, not recruiting",Interventional
s2192648,"""Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients""",2021-10-03,2023-04-01,545 days,Recruiting,Interventional
UC-0140/1812,"Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.",2019-08-26,2027-08-01,2897 days,Recruiting,Interventional
MAMA_MOVE_Gaia After Treatment,Effects of a Physical Exercise Program in Quality of Life of Breast Cancer Survivors,2018-07-01,2022-01-01,1280 days,Completed,Interventional
SunYatsenU2H-LQ5,Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer,2021-05-01,2023-09-01,853 days,Not yet recruiting,Observational
HNCH-BC011,Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer,2022-12-20,2029-12-31,2568 days,Recruiting,Interventional
NCC3397,Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer,2022-03-24,2027-03-24,1826 days,Recruiting,Interventional
IC 2020-10,Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer,2021-03-23,2025-06-01,1531 days,Recruiting,Interventional
CTMX-2009-002,Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer,2020-12-29,2023-04-30,852 days,"Active, not recruiting",Interventional
2021-SR-592,Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer,2022-04-15,2025-09-01,1235 days,Not yet recruiting,Observational
PR351/20,TAD After Chemotherapy in Locally Advanced Breast Cancer,2021-02-01,2024-02-01,1095 days,Recruiting,Observational
2020-006106-23,Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva),2021-12-06,2025-06-01,1273 days,Suspended,Interventional
HR-NeoBC-HN003,Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.,2019-06-01,2020-12-30,578 days,Unknown status,Interventional
IEO 1730,LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients,2022-05-16,2027-05-16,1826 days,Recruiting,Observational
GIM23-POSTER,Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients,2019-10-24,2032-07-31,4664 days,"Active, not recruiting",Observational
17320,"A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer",2019-08-14,2020-08-11,363 days,Terminated,Interventional
15.03.2023,Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.,2022-04-01,2022-12-01,244 days,Completed,Observational
PALBOBIN,Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer,2020-11-18,2023-08-01,986 days,"Active, not recruiting",Interventional
2018.451,"FES (16Î±-[18F]-Fluoro-17Î²-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET",2018-11-13,2023-01-29,1538 days,"Active, not recruiting",Interventional
202103030005,Evaluation and Re-evaluation of Post-mastectomy Pain Syndrome by Breast Cancer EDGE Task Force Outcomes,2021-03-03,2022-04-04,397 days,Completed,Interventional
D8530C00002,A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer,2020-04-22,2023-05-31,1134 days,"Active, not recruiting",Interventional
MA-BC-II-033,The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis,2022-06-01,2027-12-01,2009 days,Not yet recruiting,Interventional
NL81896.078.22,Tamoxifen Prediction Study in Patients With ER+ Breast Cancer,2022-09-01,2023-07-01,303 days,Not yet recruiting,Interventional
SDX-0103,Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Breast Cancer,2022-08-26,2026-09-01,1467 days,Recruiting,Interventional
17-428,Olaparib In Metastatic Breast Cancer,2018-04-01,2022-12-30,1734 days,Recruiting,Interventional
CO42177,"A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer",2020-09-28,2023-03-08,891 days,Completed,Interventional
MO39874,A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer,2019-12-17,2024-12-15,1825 days,"Active, not recruiting",Interventional
202007016,Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer,2020-11-19,2026-05-31,2019 days,"Active, not recruiting",Interventional
B003-101,B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer,2019-04-01,2023-07-31,1582 days,"Active, not recruiting",Interventional
DOUBLE,Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer,2022-06-10,2025-03-09,1003 days,Not yet recruiting,Interventional
0000012,"Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient",2020-12-01,2021-02-01,62 days,Unknown status,Observational
REaCT-5G,"A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy",2021-06-09,2023-12-01,905 days,"Active, not recruiting",Interventional
STUDY00019489,177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer,2022-09-01,2023-12-20,475 days,Not yet recruiting,Interventional
CO40151,A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer,2018-02-13,2022-03-15,1491 days,Completed,Interventional
TQB2450-Ib-07,A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC),2019-05-09,2020-12-30,601 days,Unknown status,Interventional
R19-149,Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging,2024-03-01,2028-06-30,1582 days,Recruiting,Interventional
2021/609,Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast Cancer,2021-12-01,2024-03-01,821 days,Not yet recruiting,Interventional
BOOG-2017-02,Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer,2018-02-01,2023-06-01,1946 days,Withdrawn,Interventional
2017-A03413-50,Metastatic Breast Carcinoma and Women Sexual Quality of Life,2018-03-12,2018-04-04,23 days,Completed,Observational
AK117-203,A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer,2022-03-23,2023-10-30,586 days,Recruiting,Interventional
HR-NeoBC-HN002,Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.,2018-11-20,2020-10-20,700 days,Completed,Interventional
2021-0491,Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen,2021-10-01,2023-10-31,760 days,Recruiting,Observational
2021-A02007-34,"Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients With HER2+ Breast Cancer",2021-12-14,2024-07-01,930 days,"Active, not recruiting",Observational
GIM26-TRASTHER,Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy,2021-07-27,2025-05-02,1375 days,Recruiting,Observational
AND019-MN-101,A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer,2022-10-05,2025-05-01,939 days,Recruiting,Interventional
SKB264-â¢-03,"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer",2022-06-10,2024-12-31,935 days,Not yet recruiting,Interventional
NCR191600,Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer,2022-09-01,2023-08-01,334 days,Withdrawn,Observational
495573096,Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer,2019-03-01,2021-02-28,730 days,Unknown status,Interventional
ESPB in breast cancer surgery,Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery,2020-08-01,2022-04-01,608 days,"Active, not recruiting",Interventional
SI 475/2019,Analgesic Effect of Adding Thoracic Paravertebral Nerve Blocks to Modified PEC Block in Breast Cancer Surgery,2019-08-01,2022-03-01,943 days,Recruiting,Interventional
JS001-026-III-TNBC,Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment,2018-12-21,2024-12-31,2202 days,"Active, not recruiting",Interventional
CBYL719CIN01,"Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment",2022-08-10,2024-11-15,828 days,Recruiting,Interventional
SPORT-DS,Single Pre-Operative Radiation Therapy - With Delayed Surgery for Low Risk Breast Cancer,2018-04-01,2022-12-31,1735 days,"Active, not recruiting",Interventional
WO43571,"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)",2022-07-04,2032-09-30,3741 days,Recruiting,Interventional
2020-0232,Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC),2020-07-09,2026-07-01,2183 days,Recruiting,Interventional
TQB2450-III-06,A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC),2020-06-01,2022-07-01,760 days,Unknown status,Interventional
CASE5119,Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer,2021-08-12,2023-06-01,658 days,Recruiting,Interventional
EVER-132-001,Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments,2020-10-23,2023-05-01,920 days,"Active, not recruiting",Interventional
AH150201,"Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c",2019-02-14,2022-06-30,1232 days,Unknown status,Interventional
99mTc-ADAPT6 in breast cancer,99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes,2022-05-01,2022-12-31,244 days,Completed,Interventional
MOST Pain Pilot,Optimizing Psychological Treatment for Pain After Breast Cancer: A Pilot Study,2021-03-01,2021-08-01,153 days,Completed,Interventional
214-2018,Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI,2018-10-01,2021-01-01,823 days,Completed,Observational
TBDBreast50,Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer,2018-05-01,2018-05-01,0 days,Withdrawn,Interventional
BAC,Satisfaction Survey for the Outpatient Unit Dedicated to Post-cancer Treatment,2022-07-18,2023-03-06,231 days,Completed,Observational
I237,CFI-400945 in Patients With Advanced/Metastatic Breast Cancer,2018-12-21,2023-06-30,1652 days,"Active, not recruiting",Interventional
KarolinskaUD,"OptiBra Study, Optimal Postoperative Bra After Breastcancer Surgery",2019-05-20,2020-05-30,376 days,Unknown status,Interventional
QUILT-3.058,A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies,2021-09-27,2023-01-04,464 days,Terminated,Interventional
20200225,Effect of Esketamine on Postoperative DepressionãGut MicrobiotaãBispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI),2021-10-08,2023-12-30,813 days,Recruiting,Interventional
SCCC-03121; STU-2021-0657,"CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer",2022-04-20,2026-04-01,1442 days,Recruiting,Interventional
BC-Fluzoparib,Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer,2021-02-08,2024-12-31,1422 days,Recruiting,Interventional
NCC1969,Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer,2019-04-11,2022-12-31,1360 days,Recruiting,Interventional
HX008-Ib/II-TNBC-01,A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer,2019-07-15,2021-12-01,870 days,Unknown status,Interventional
STUDY00004350,A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy,2023-03-21,2025-03-30,740 days,Recruiting,Interventional
14/2021,Efficacy of Expressive Writing on Quality of Life Among Breast Cancer Survivors in Oman: A Double Blind Randomized Controlled Trial,2022-01-01,2024-12-30,1094 days,Not yet recruiting,Interventional
HNCH-MBC07,Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure,2022-05-13,2025-11-01,1268 days,Recruiting,Interventional
HR-BLTN-III-NeoBC,Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer,2018-07-24,2022-06-01,1408 days,"Active, not recruiting",Interventional
A5481123,RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.,2019-01-04,2019-06-24,171 days,Completed,Observational
SYSU-2022-UCAN,Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer,2022-06-21,2027-06-01,1806 days,Recruiting,Interventional
19-113,Exercise Treatment With Standard Therapy for Metastatic Breast Cancer,2019-06-12,2023-08-01,1511 days,Recruiting,Interventional
B013-301,Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer,2022-12-06,2026-12-31,1486 days,Recruiting,Interventional
4CAST,Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer,2021-11-01,2024-12-01,1126 days,Not yet recruiting,Interventional
811,"Effects of Green Coffee Extract Supplementation on Adropin, Irisin, Vaspine,Systemic Inflammation and Oxidative Stress in Breast Cancer Survivors",2018-02-11,2019-10-11,607 days,Unknown status,Interventional
SHR1210-III-322,A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC),2020-12-09,2024-01-30,1147 days,Recruiting,Interventional
BC- T-DM1,Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy,2022-09-30,2025-08-23,1058 days,Not yet recruiting,Interventional
HERMIONE-7,"Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)",2020-01-07,2023-12-01,1424 days,"Active, not recruiting",Interventional
RG1006427,Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer Survivors,2020-02-21,2021-10-28,615 days,Completed,Interventional
CO41863,A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer,2020-09-23,2021-02-04,134 days,Terminated,Interventional
21030,Portable Scalp Cooling System for the Improvement of Chemotherapy-Induced Hair Loss in Patients With Metastatic Breast Cancer,2022-12-14,2023-11-14,335 days,Withdrawn,Interventional
BAT-8001-002-CR,The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer,2018-07-01,2021-12-31,1279 days,Unknown status,Interventional
CBYL719A0US03T,"Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer",2021-08-25,2023-07-01,675 days,Recruiting,Interventional
EH20-251,Advanced Diffusion Tensor MRI for Breast Cancer,2021-02-03,2024-02-01,1093 days,Recruiting,Observational
MedOPP190,"Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)",2020-06-15,2022-12-31,929 days,Terminated,Interventional
Combined CTH and HT in MBC,"Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study",2018-08-30,2021-02-01,886 days,Unknown status,Interventional
KN046-203,A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer,2019-05-30,2023-09-15,1569 days,"Active, not recruiting",Interventional
A5481095,TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.,2018-03-01,2018-07-01,122 days,Completed,Observational
DZ2019HE001,"DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer",2020-09-21,2024-05-01,1318 days,"Active, not recruiting",Interventional
S62794,"Preventing Taxane-related Peripheral Neuropathy, Pain and Nail Toxicity: A Prospective Self-controlled Trial Comparing Hilotherapy With Frozen Gloves in Early Breast Cancer",2019-06-20,2020-11-20,519 days,Completed,Interventional
SHR6390-SHR1020-I-101-BC,A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer,2021-10-25,2023-10-31,736 days,Recruiting,Interventional
IIT2022-07-YUAN-IB-TNBC,Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer,2023-04-01,2026-10-01,1279 days,Not yet recruiting,Interventional
MA-BC-II-047,Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase â b Study,2022-11-01,2025-11-30,1125 days,Not yet recruiting,Interventional
FUSCC,Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA),2022-02-01,2026-08-01,1642 days,Not yet recruiting,Interventional
222.20,SBRT in Early Breast Cancer in Elderly Women,2021-01-01,2023-11-01,1034 days,Recruiting,Interventional
Bioscore in breast cancer,Prognostic Significance of Bioscore in Nonmetastatic Breast Cancer,2018-01-01,2020-10-16,1019 days,Completed,Observational
NCC201711008,Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,2018-02-20,2019-06-25,490 days,Unknown status,Interventional
ShandongCHI-06,Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy,2018-10-01,2025-12-01,2618 days,Not yet recruiting,Interventional
2019-0634,Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women,2021-11-22,2022-12-31,404 days,Recruiting,Interventional
275142,An EORTC Study Updating the QLQ-BR23 to BR45,2020-11-02,2022-12-31,789 days,Recruiting,Observational
NCC2474,Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer,2020-09-01,2022-12-01,821 days,Unknown status,Interventional
MK 3475-318,Effect of Pembrolizumab (KeytrudaÂ®) on Biomarkers in Early Breast Cancer.,2018-01-18,2020-03-31,803 days,Completed,Interventional
Medical Research Institute,"US Guided Erector Spinae Plane Block in Breast Cancer Surgery: Analgesia, Spread and Immunomodulation",2020-11-25,2022-01-21,422 days,Completed,Interventional
MCLA-128-CL02,MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer,2018-01-15,2024-02-15,2222 days,"Active, not recruiting",Interventional
HNCH-HER2-MBC001,Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.,2021-04-23,2022-10-30,555 days,Recruiting,Interventional
P170929J,PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers,2022-05-01,2030-05-01,2922 days,Not yet recruiting,Interventional
GB491-004,GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer,2021-09-10,2024-01-31,873 days,Recruiting,Interventional
MORE-T trial,Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients,2021-10-21,2028-12-31,2628 days,Recruiting,Interventional
2022-A01192-41,SexoMBC2 Non Interventional Study,2022-12-05,2023-06-01,178 days,Recruiting,Observational
IJB-LOB-2019,Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE),2021-01-14,2024-07-01,1264 days,Recruiting,Interventional
Cardiotoxicity study,Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients,2021-01-08,2021-12-30,356 days,Unknown status,Observational
MS200647_0020,Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer,2020-10-12,2022-07-08,634 days,Terminated,Interventional
262840,CIPN in Early Stage Breast Cancer Patients,2022-05-26,2024-01-01,585 days,Recruiting,Interventional
2023-YBSF-480,A Predictive Model for Breast Cancer,2023-04-01,2024-12-01,610 days,Not yet recruiting,Observational
U025,Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer,2018-06-06,2022-05-04,1428 days,Completed,Interventional
KN026-205,Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer,2022-05-25,2024-12-30,950 days,Recruiting,Observational
Soh-Med-21_10_18,One Week Adjuvant Radiotherapy for Breast Cancer,2021-10-01,2023-10-01,730 days,Recruiting,Interventional
SPH4336-301,Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer,2023-04-30,2024-12-16,596 days,Not yet recruiting,Interventional
HCB/2019/0786,Sexual and Vaginal Health in Breast Cancer Women Receiving Aromatase Inhibitors Before and After CO2 Laser Therapy,2020-10-30,2022-08-30,669 days,"Active, not recruiting",Interventional
2019-185-AGH,Evaluation of Mepitel FilmÂ® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer,2020-01-15,2023-12-01,1416 days,Recruiting,Interventional
EC2019/0127,Hyperventilation and Oxygenation to Prolong Breath Hold in Breast Cancer Irradiation Treatment,2019-03-15,2021-02-22,710 days,Completed,Interventional
REaCT-OGF,Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy,2023-04-17,2025-10-01,898 days,Recruiting,Interventional
2021P002943,Evaluating Scaleup of an Adapted Breast Cancer Early Diagnosis Program in Rwanda,2022-09-15,2023-12-31,472 days,Not yet recruiting,Observational
NCI-2021-08921,Metformin and Nightly Fasting in Women With Early Breast Cancer,2023-01-30,2024-11-30,670 days,Not yet recruiting,Interventional
AIs with chemotherapy in MBC,Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer,2023-08-30,2025-05-31,640 days,Not yet recruiting,Interventional
CTRIAL-IE 22-01,Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study),2023-03-30,2028-03-30,1827 days,Not yet recruiting,Interventional
SIBP-01-3,A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer,2019-06-30,2021-07-30,761 days,Unknown status,Interventional
20-068,MARGetuximab Or Trastuzumab (MARGOT),2020-07-13,2027-07-01,2544 days,Recruiting,Interventional
19-002448,Interactive Care Plan for the Monitoring of Symptoms and Recovery in Patients With Stage 0-III Breast Cancer,2020-08-20,2023-11-25,1192 days,"Active, not recruiting",Interventional
2022-09/2057,The Effect of Premedication on Postoperative Pain and Anxiety in Breast Cancer Surgery,2022-10-16,2023-01-30,106 days,Recruiting,Observational
TEMPLATE,Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancerï¼A Prospective Multiple-center Phase II Study,2021-05-27,2023-06-01,735 days,Not yet recruiting,Interventional
UC Laser,Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors,2018-03-20,2022-06-01,1534 days,Recruiting,Interventional
CO42867,A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer,2021-06-20,2026-10-31,1959 days,Recruiting,Interventional
GBG 93,"A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).",2018-03-01,2023-03-31,1856 days,Recruiting,Interventional
2022-0500,Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors or Chemotherapy in Luminal B/HER2-negative Breast Cancer (DAPATH),2022-10-01,2025-10-31,1126 days,Recruiting,Interventional
IJB-LBC-NEOCHECKRAY-2018,"Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:",2019-11-06,2026-01-15,2262 days,Recruiting,Interventional
HR-MBC-HN001,A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer,2018-11-20,2022-12-30,1501 days,"Active, not recruiting",Interventional
MCC-19803,Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer,2019-04-26,2021-01-06,621 days,Terminated,Interventional
20-130,Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer,2020-10-08,2025-07-01,1727 days,Recruiting,Interventional
BG01-2001,PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer,2020-10-15,2021-02-19,127 days,Completed,Interventional
CBYL719CIN02,Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world,2021-10-27,2025-09-30,1434 days,Recruiting,Observational
ROGABREAST,"Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.",2020-11-25,2023-04-04,860 days,Completed,Interventional
SYSU-2021-UCAN,Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer,2022-03-01,2030-03-01,2922 days,Not yet recruiting,Interventional
18040334,Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer,2018-01-15,2019-09-05,598 days,Completed,Interventional
Labra-001,Photobiomodulation Therapy for the Prevention of Acute Radiodermatitis in Breast Cancer Patients Undergoing Radiotherapy,2020-07-01,2021-06-01,335 days,Completed,Interventional
M19-992,"A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy",2020-05-21,2020-10-08,140 days,Terminated,Interventional
2021-1122,"AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer",2022-05-01,2024-12-30,974 days,Recruiting,Interventional
SYSKY-2022-105-01,Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer,2022-08-01,2024-12-01,853 days,Recruiting,Interventional
CS2-19004,Chemotherapy - Induced Peripheral Neuropathy,2019-10-01,2020-10-15,380 days,Completed,Interventional
CBYL719C2404,"A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting",2023-04-28,2025-12-19,966 days,Recruiting,Observational
I2I1,Connecting Breast Cancer Survivors for Exercise,2021-05-10,2022-01-30,265 days,Completed,Interventional
2019-01-064,TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery,2019-05-27,2022-10-31,1253 days,Unknown status,Interventional
ZhejiangCH-0709,RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer,2021-07-01,2025-11-01,1584 days,Not yet recruiting,Observational
SHR-A1811-206,A Phase â b/â¡ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.,2023-04-01,2025-02-27,698 days,Not yet recruiting,Interventional
FOENIX-MBC2 TAS-120-201,A Study of TAS-120 in Patients With Metastatic Breast Cancer,2019-08-30,2023-06-30,1400 days,"Active, not recruiting",Interventional
IRB18-1178,Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer,2019-11-25,2024-04-10,1598 days,Recruiting,Interventional
ML43171,"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physicians Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)",2022-08-03,2026-03-31,1336 days,Recruiting,Interventional
UC-BCG-2011,Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer,2021-12-17,2025-06-30,1291 days,Recruiting,Interventional
CSIIT-C41,Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy,2023-05-01,2024-11-01,550 days,Not yet recruiting,Interventional
MO43110,A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer,2022-07-05,2025-09-25,1178 days,Recruiting,Interventional
EUBREAST 3,AXillary Surgery After NeoAdjuvant Treatment,2020-04-28,2030-04-01,3625 days,Recruiting,Observational
SHR-1210-III-327,A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer,2021-11-30,2023-04-30,516 days,Not yet recruiting,Interventional
EOC202A2102,"HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy",2022-04-01,2025-05-01,1126 days,Not yet recruiting,Interventional
IEO 675,Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer,2020-07-01,2021-12-01,518 days,Unknown status,Interventional
MP-05-2021-2605,Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer,2021-03-30,2023-02-01,673 days,Recruiting,Interventional
7339-009,Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009),2019-12-19,2026-01-26,2230 days,"Active, not recruiting",Interventional
MC1831,"Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer",2019-08-28,2024-04-30,1707 days,Recruiting,Interventional
OSU-20380,Development of a Genetic Counseling Patient Preference Intervention for Women at Elevated Risk for Breast Cancer,2020-12-09,2022-10-30,690 days,Completed,Observational
D933LC00001,A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer,2018-12-21,2023-06-30,1652 days,"Active, not recruiting",Interventional
MA-BC-II-042,Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer,2022-11-23,2026-12-31,1499 days,Recruiting,Interventional
2020-1190,Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer,2021-05-21,2023-11-30,923 days,Recruiting,Interventional
HRS8807-I-101,"A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer",2021-10-26,2024-12-31,1162 days,Recruiting,Interventional
2019-00673; sp19Kurzeder,Digoxin Induced Dissolution of CTC Clusters,2020-07-08,2022-06-01,693 days,Recruiting,Interventional
BreCLIM-2018-116-31M,BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases,2020-01-01,2029-12-31,3652 days,Recruiting,Interventional
TQ-B3525-I-02,"A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer",2020-07-01,2021-09-01,427 days,Unknown status,Interventional
HKUCTR-2709,Use of Superparamagnetic Iron Oxide (SPIO) in Sentinel Lymph Node Detection for Breast Cancer,2018-07-24,2024-06-30,2168 days,Recruiting,Interventional
MUKDEN5,Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer,2022-02-25,2025-01-31,1071 days,Not yet recruiting,Interventional
Prevention of neuropathy,Photobiomodulation for Prevention of Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer,2023-01-10,2024-12-30,720 days,Not yet recruiting,Interventional
TQB3616-II-01,A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer,2021-02-04,2023-01-31,726 days,Unknown status,Interventional
s61033,A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer,2018-12-11,2023-12-01,1816 days,"Active, not recruiting",Observational
s17-00995,MBSR During AI Therapy for Breast Cancer,2018-04-23,2020-09-08,869 days,Completed,Interventional
SHR9549-I-101,SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer,2018-07-25,2019-10-14,446 days,Terminated,Interventional
18/0059,Health Status of Women With Breast Cancer,2019-03-14,2019-11-30,261 days,Unknown status,Observational
3-2019-0140,Effects of Mediterranean Diet Based Intervention in Breast Cancer Patients,2019-08-01,2021-08-01,731 days,Unknown status,Interventional
IRB00109957,THRIVE Breast Cancer App Study,2018-11-15,2022-06-30,1323 days,Completed,Interventional
IRB18-00912,Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery,2020-02-04,2024-04-30,1547 days,Recruiting,Interventional
Shengjing-LJY03,CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer,2019-11-01,2024-08-31,1765 days,Recruiting,Observational
0392-18-HMO,CO2 Laser Therapy for the Treatment of GSM in Patients With Breast Cancer,2019-02-01,2023-08-01,1642 days,"Active, not recruiting",Interventional
UW19046,FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer,2020-10-20,2023-12-01,1137 days,Recruiting,Interventional
I 73718,Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer,2019-12-06,2024-02-27,1544 days,"Active, not recruiting",Interventional
21/079,Prediction of Individual Radiosensitivity During Radiotherapy for Breast Cancer Patients,2022-05-09,2024-12-31,967 days,Recruiting,Observational
2018-1133,Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer,2019-08-23,2024-01-31,1622 days,"Active, not recruiting",Observational
HCB/2020/0971,Evaluation of the Impact of a Multidimensional ICT Intervention on the Quality of Life of Breast Cancer Survivors,2020-12-01,2023-06-30,941 days,Recruiting,Interventional
FJD-LCO2-19-01,A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients.,2022-12-01,2026-01-01,1127 days,Not yet recruiting,Interventional
MC01/05/20; IST-325 (KPT),Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START),2021-03-01,2025-11-01,1706 days,Recruiting,Interventional
KROG 21-07,Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients,2022-04-01,2032-12-31,3927 days,Not yet recruiting,Interventional
22012020,Bubble: A New VR-AI Way of Treatment for Hot Flashes in Women With Breast Cancer,2018-02-01,2019-02-28,392 days,Completed,Interventional
2020-1267,Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion,2021-03-19,2024-12-31,1383 days,"Active, not recruiting",Interventional
HER2BAT,A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone,2020-05-10,2024-03-31,1421 days,Recruiting,Interventional
18291,A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer,2022-10-09,2025-01-30,844 days,Recruiting,Interventional
ARIANNA (SOLTI-1502),Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC,2020-06-01,2022-10-10,861 days,Terminated,Interventional
PROICM 2019-05 MAC,Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery,2021-05-18,2024-07-01,1140 days,Recruiting,Interventional
BLI-1401-2-01,"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.",2023-09-01,2025-02-28,546 days,Not yet recruiting,Interventional
R018-SABI-00193,Genetic Markers of Circulating Tumor DNA for Monitoring Breast Cancer Patients in Costa Rica,2019-01-07,2020-11-30,693 days,Unknown status,Observational
20221120,A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause,2023-06-01,2026-06-01,1096 days,Not yet recruiting,Interventional
Geriatric-CDK4/6,Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?,2021-10-01,2021-12-15,75 days,Not yet recruiting,Observational
CLEAR,Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer,2018-08-01,2025-07-31,2556 days,Recruiting,Interventional
Regina Elena,Endometrial Changes in Breast Cancer Women.,2023-01-26,2024-01-26,365 days,"Active, not recruiting",Observational
2.777.676,Photobiomodulation for Breast Cancer Radiodermatitis,2018-09-26,2021-07-20,1028 days,Completed,Interventional
IC 2017-06,Study to Assess the Impact of Personalized Coaching on the Time Period and Quality of Return to Work After Breast Cancer,2020-10-05,2024-04-05,1278 days,Recruiting,Interventional
Pro00087654,Family History in a Singapore Oncology Population,2019-01-07,2019-08-31,236 days,Completed,Observational
IRMA,Impact of Recurrence Score on Adjuvant Treatment Decisions in Breast Cancer Patients,2019-03-01,2023-06-30,1582 days,Recruiting,Observational
CO40115,A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer,2018-04-02,2024-05-03,2223 days,"Active, not recruiting",Interventional
111-009-F,A Study for Optimization of 6% Hydroxyethyl Starch Based Indocyanine Green Near-infrared Fluorescence Navigated Sentinel Lymph Node Biopsy for Breast Cancer Patients,2022-04-08,2023-04-07,364 days,Recruiting,Interventional
2020-2-4023,Deep Inspiration Breath-hold Radiotherapy for Left-sided Breast Cancer,2021-09-01,2023-06-30,667 days,Recruiting,Observational
21129002,Topical Menthol Application in Chemotherapy-Related Peripheral Neuropathy in Patients With Breast Cancer,2022-07-01,2023-04-01,274 days,Completed,Interventional
MCC-20915,"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab",2021-10-28,2025-10-01,1434 days,Recruiting,Interventional
PMCT-IMSLNB-MIT,Internal Mammary Sentinel Lymph Node Biopsy With Modified Injection Technique,2018-07-01,2020-12-31,914 days,Unknown status,Interventional
V2000701,Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer,2022-04-11,2024-01-30,659 days,Recruiting,Interventional
University Brunswick,Physical Activity Levels and Functional Improvement in Breast Cancer Survivors,2018-09-11,2021-04-01,933 days,Unknown status,Interventional
1605576856,Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients,2021-05-03,2023-05-01,728 days,Recruiting,Interventional
3475-B49,Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49),2021-06-18,2028-07-21,2590 days,Recruiting,Interventional
2018-0287,"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study",2019-05-31,2024-04-26,1792 days,Recruiting,Interventional
SABO 21-01,Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer,2022-09-19,2027-12-31,1929 days,Recruiting,Interventional
UW20037,Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study),2021-10-05,2025-03-01,1243 days,Recruiting,Interventional
20201101,Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study),2021-04-30,2025-04-30,1461 days,Not yet recruiting,Interventional
ZJCH-CK19B,A Prospective Validation Cohort Study of a Prediction System on nSLN Metastasis in Early Breast Cancer,2018-10-15,2020-06-01,595 days,Unknown status,Interventional
69HCL21_0145,Immediate Breast Reconstructions Increasing,2021-01-01,2021-06-01,151 days,Unknown status,Observational
IPI-549-03,Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3),2019-12-17,2022-08-01,958 days,"Active, not recruiting",Interventional
2017-0500,M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer,2018-05-30,2022-09-21,1575 days,Terminated,Interventional
APG2575XU103,"A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer",2021-08-13,2023-10-01,779 days,Recruiting,Interventional
BLTN-NeoBC1115,Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer,2019-11-01,2021-04-01,517 days,Unknown status,Interventional
22-259,A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer,2022-09-06,2025-09-06,1096 days,Recruiting,Interventional
UW18099,Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer,2022-05-16,2031-01-01,3152 days,Recruiting,Interventional
17384,A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer,2021-05-10,2024-02-09,1005 days,"Active, not recruiting",Interventional
BL-B01D1-104,A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors,2022-08-11,2024-08-01,721 days,Recruiting,Interventional
M21CSM,COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study,2023-04-17,2040-04-01,6194 days,Recruiting,Interventional
4-2022-0600,Robot-assisted vs. Open Nipple-sparing Mastectomy With Immediate Breast Reconstruction,2022-10-01,2030-06-01,2800 days,Not yet recruiting,Interventional
RS1637/21,Single-cell RNAseq Breast Cancer,2021-12-14,2024-12-31,1113 days,Recruiting,Observational
22239,Treatment of Frailty With Fisetin (TROFFi) in Breast Cancer Survivors,2023-03-27,2025-05-15,780 days,Recruiting,Interventional
202107015,"Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTumÂ® Serum Thymidine Kinase 1 (TK1) Activity Testing",2022-03-07,2027-03-31,1850 days,Recruiting,Interventional
20171,Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer,2021-07-27,2023-12-12,868 days,Recruiting,Interventional
UPCC 17119,Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Ancillary Study,2020-08-01,2024-12-01,1583 days,Enrolling by invitation,Observational
HS-10352-101,Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer,2020-09-08,2023-08-31,1087 days,Recruiting,Interventional
NNG17.2,Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients,2018-02-02,2021-02-19,1113 days,Completed,Interventional
XJTU1AF-CRF-2018-001,Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients,2019-04-01,2024-12-31,2101 days,Recruiting,Observational
I 571719,Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors,2020-07-03,2025-07-03,1826 days,Recruiting,Observational
2019-40016-06,Vitamin D Can Increase Pathological Response of the Breast Cancer Patients Treated With Neoadjuvant Therapy,2019-05-10,2020-12-10,580 days,Unknown status,Interventional
IRB-52869,Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer,2023-03-20,2026-12-01,1352 days,Recruiting,Interventional
D9266C00001,"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)",2022-07-11,2024-06-23,713 days,Recruiting,Interventional
1B-21-6,Breast Cancer Survivorship Biorepository,2022-04-11,2028-04-11,2192 days,Recruiting,Observational
2017/78,"Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)",2023-03-01,2032-03-01,3288 days,Not yet recruiting,Interventional
ICRG0201,"Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.",2022-12-20,2026-06-01,1259 days,Recruiting,Interventional
SHR-A1811-III-301,"A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane",2022-07-29,2024-12-31,886 days,Recruiting,Interventional
IRB-63041,Study Assessing QBS72S For Treating Brain Metastases of Breast Cancer,2022-08-16,2026-08-01,1446 days,Recruiting,Interventional
U21-02-4401,Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition,2021-08-08,2025-07-01,1423 days,Recruiting,Interventional
AssiutU AAHelmy,Multimodal Ultrasonographic Assessment of Ipsilateral Axillary Lymph Nodes in Patients With Breast Cancer: A STARD Study,2022-05-15,2023-06-15,396 days,Not yet recruiting,Observational
Pro00100408,Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer,2019-06-19,2024-01-01,1657 days,Recruiting,Observational
Polarhis,Assessment of Lumpectomy Margins With the Histolog Scanner in Comparison With Intraoperative Imaging Techniques,2020-10-01,2022-05-31,607 days,Completed,Observational
GS-US-592-6173,"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physicians Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",2022-07-25,2027-02-01,1652 days,Recruiting,Interventional
SCO-120-19-22,A Study in Patients With Advanced Breast Cancer,2022-05-20,2024-01-01,591 days,Recruiting,Interventional
GS-US-592-6238,Study of Sacituzumab Govitecan-hziy Versus Treatment of Physicians Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer,2022-07-20,2027-05-01,1746 days,Recruiting,Interventional
CBYL719C2201,Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer,2021-01-20,2025-07-31,1653 days,Recruiting,Interventional
TQB3616-III-01,TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail,2022-03-18,2023-12-01,623 days,Recruiting,Interventional
19/218,Increasing Access to Breast Cancer Screening Among Immigrants,2021-04-15,2030-12-31,3547 days,"Active, not recruiting",Interventional
CHANGEABLE,Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer,2020-09-14,2022-12-28,835 days,Recruiting,Interventional
19-3032.cc,Combined Modality Exercise and Appetite in Breast Cancer Survivors,2020-06-05,2021-09-20,472 days,Terminated,Interventional
SCT200IITNBC,Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer,2018-07-20,2019-12-31,529 days,Unknown status,Interventional
651,Breast Cancer: Axillary Conservation After Neoadjuvant Chemotherapy in Micro Metastatic Sentinel Lymph Nodes.,2019-06-21,2027-06-21,2922 days,Recruiting,Interventional
H3B-6545-J081-103,"Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer",2020-09-30,2023-11-30,1156 days,"Active, not recruiting",Interventional
2019-00174 Neoadj Breast Pilot,"Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer",2019-10-01,2020-12-31,457 days,Withdrawn,Interventional
MO40628,A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer,2018-12-19,2022-10-12,1393 days,Completed,Interventional
NNG17.1,Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.,2019-05-27,2021-02-19,634 days,Completed,Interventional
STUDY00004618,A Patient Reminder and Self-Referral Via Online Patient Portals and Text Messaging to Improve Adherence to Breast Cancer Screening,2022-09-05,2023-03-31,207 days,"Active, not recruiting",Interventional
19959,Effects of Computer-Assisted Cognitive Rehabilitation Programs With Breast Cancer Survivors,2018-02-26,2020-02-26,730 days,Unknown status,Interventional
AIPAC-003,Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy,2023-03-20,2027-07-31,1594 days,Recruiting,Interventional
18-1068,Clinician Communication About Sexual Health,2020-02-07,2020-10-12,248 days,Completed,Interventional
SuleymanDU-SALMAN-F-001,The Effect of Mobile Application-based Information About Before and After Surgery,2021-04-01,2021-08-30,151 days,Completed,Interventional
IIBSP-SIL-2017-70,Evaluation of a New Technique to Fill the Defect Generated After Conservative Surgery in Breast Cancer,2019-09-18,2022-03-01,895 days,Completed,Interventional
Shoulder exercise cancer,Limited Versus No-limited Shoulder Movement in Breast Cancer Surgery,2019-02-01,2019-12-20,322 days,Completed,Interventional
NCI-2022-00004,Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body,2022-03-25,2026-06-30,1558 days,Recruiting,Interventional
GC-627-05,Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,2018-04-12,2020-03-05,693 days,Completed,Interventional
LCCC 2104,Comparison of Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN),2022-05-17,2025-05-17,1096 days,Recruiting,Interventional
2021SQGH00743,The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer,2021-09-01,2026-08-31,1825 days,Recruiting,Interventional
rosuva2020,Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients,2020-09-15,2023-09-15,1095 days,Recruiting,Interventional
N21CPB-IRBd22-103,Communication in Breast Cancer Care,2022-06-05,2022-12-31,209 days,Recruiting,Interventional
UPNA-CUMACA-B2022,Web-based Intervention for Long-term Breast Cancer Survivors,2023-01-01,2024-06-01,517 days,Not yet recruiting,Interventional
213831,Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease,2021-06-28,2029-08-28,2983 days,Recruiting,Interventional
Pro00109917,Noninvasive Assessment of Lymphedema Among Breast Cancer Survivors,2022-05-26,2023-08-01,432 days,Recruiting,Interventional
GCO 17-2320,Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer,2018-05-17,2020-02-10,634 days,Completed,Interventional
32158620.0.0000.0072,Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia,2020-08-05,2022-02-28,572 days,"Active, not recruiting",Observational
MA-BC-II-025,Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer,2021-07-02,2027-12-31,2373 days,Recruiting,Interventional
CPO-NBP-2002,NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy,2023-06-30,2025-01-30,580 days,Not yet recruiting,Interventional
INT/2020/VOICE,"Implementation, Effectiveness and Impact of a Value Based Intervention for Patients With Breast or Lung Cancer",2019-01-01,2023-06-30,1641 days,"Active, not recruiting",Interventional
N assisted,A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment With Trastuzumab Combined With Parezumab,2023-02-16,2028-11-01,2085 days,Recruiting,Interventional
PROSOM-K,Study of the Functioning of Prospective Memory in Breast Cancer and the Influence of Sleep,2018-01-05,2020-03-06,791 days,Completed,Interventional
SYSKY-2022-024-01,Construction and Effect Evaluation of Malignant Fungating Wounds Care Regimen for Breast Cancer Patients,2022-06-24,2024-07-30,767 days,Recruiting,Interventional
NL62441.068.17,PET-MRI for Axillary Staging in Node Negative Breast Cancer Patients,2018-02-22,2023-12-01,2108 days,Recruiting,Interventional
EP0062-101,Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer,2022-12-01,2025-03-01,821 days,Not yet recruiting,Interventional
LightCT-PKUPH,Light-CT in the Diagnosis of Breast Tumor and Lymph Node,2018-04-01,2023-12-31,2100 days,Recruiting,Observational
KY2022-044-B,"CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial",2022-09-14,2029-06-01,2452 days,Recruiting,Interventional
SUGBG-2021001,Sentinel Node Localization and Staging With Low Dose Superparamagnetic Iron Oxide,2021-11-01,2024-04-30,911 days,"Active, not recruiting",Interventional
PI2018_843_0061,Feasibility of Total Mastectomy in Ambulatory Care,2021-01-01,2024-03-01,1155 days,Recruiting,Interventional
2110244-11,Comparison of Dexamethasone Alone vs in Combination With Pericardium 6 (P6) Electrical Stimulation or Granisetron in the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Breast Cancer Surgery,2021-11-01,2023-05-02,547 days,Recruiting,Interventional
2018-09-20 Version 1.2,Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer,2019-03-01,2023-09-30,1674 days,Recruiting,Observational
HSM/VGH-2019-12-009CC,Web-based Oncofertility Support Tool for Reproductive-age Women With Breast Cancer,2020-01-01,2021-08-05,582 days,Completed,Interventional
2021-A01550-41,Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast Cancer,2022-09-27,2025-09-01,1070 days,Recruiting,Interventional
2449PT,Effect of Exercise Mode in Breast Cancer-Related Lymphedema,2019-01-15,2020-05-05,476 days,Completed,Interventional
20220430GD,Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation,2022-05-06,2028-12-31,2431 days,Recruiting,Interventional
StrataXRT,A Study of StrataXRT in the Prevention of Radiation Dermatitis in Breast Cancer Patients,2022-10-13,2023-06-30,260 days,Recruiting,Interventional
TQB3909-Ib/II-01,A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer,2023-03-02,2023-12-01,274 days,Recruiting,Interventional
events in breast cancer,Skeletal Events of Hormonal Treatment and Radiotherapy in Patient With Breast Cacer,2021-12-01,2021-12-01,0 days,Unknown status,Observational
"S-20200021, 19-16321",An Individualised Treatment vs. a Minimal Program in Women With Late-term Shoulder Impairments After Breast Cancer.,2022-04-04,2022-10-10,189 days,Completed,Interventional
Exo-LCR-1807,Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.,2019-07-01,2023-10-01,1553 days,Withdrawn,Interventional
ILLUMINE,Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer,2020-01-01,2024-03-31,1551 days,Recruiting,Observational
AGO/2019/003,Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer,2020-11-24,2021-05-01,158 days,Withdrawn,Interventional
C4891016,A Study to Learn About the ARV-471 (PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC),2022-08-16,2023-04-19,246 days,"Active, not recruiting",Interventional
MCC-19220,PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient,2020-12-01,2022-12-01,730 days,Withdrawn,Interventional
2020-A01916-33,Adapted Fencing in Breast Cancer: a Pilot Study,2021-11-10,2022-11-01,356 days,Recruiting,Interventional
MC220902,Evaluation of Endocrine Therapy-Induced Alopecia Among Postmenopausal and Premenopausal Female Patients With Breast Cancer,2022-12-12,2024-08-01,598 days,Recruiting,Observational
BR-003,Confirmatory Clinical Evaluation of NovilaseÂ® Laser Therapy for Focal Destruction of Malignant Breast Tumors,2023-04-30,2025-03-31,701 days,Not yet recruiting,Interventional
2021/156064(REK),Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients,2023-03-16,2035-09-30,4581 days,Recruiting,Interventional
MedOPP199,"Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -",2019-05-07,2019-12-31,238 days,Completed,Interventional
RECHMPL21_0680,Impact of Video Information Support on Preoperative Anxiety in Breast Cancer Surgery,2022-06-22,2025-04-01,1014 days,Recruiting,Interventional
ShengjingH 3,"Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy",2021-07-19,2026-12-31,1991 days,Recruiting,Observational
18459,A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer,2022-10-04,2032-03-15,3450 days,Recruiting,Interventional
PRO00030295,Avanzando Juntas: Adapting an Evidence Based Weight Loss Program for Hispanic Breast Cancer Survivors,2019-11-01,2022-07-30,1002 days,Completed,Interventional
DBCG RT SDM,Shared Decision Making With Breast Cancer Patients,2020-03-04,2023-07-31,1244 days,"Active, not recruiting",Interventional
NBK 171/1/2021,"Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a ""Window of Opportunity"" Study",2022-01-01,2026-12-06,1800 days,Not yet recruiting,Interventional
NCC1787,Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer,2018-12-01,2021-12-31,1126 days,Unknown status,Interventional
UCI 19-145 [HS# 1459],"Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer",2022-08-31,2028-12-31,2314 days,Recruiting,Interventional
20923,"Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand",2020-05-18,2022-05-24,736 days,Terminated,Observational
SUN-2252,Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients,2021-07-21,2023-12-01,863 days,Recruiting,Observational
18496,"Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer",2019-03-04,2023-12-21,1753 days,"Active, not recruiting",Interventional
INT214/22,Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial,2023-03-01,2025-03-01,731 days,Not yet recruiting,Interventional
201906,Psychological Interventions to Prevent Late Effects in Breast Cancer,2020-10-01,2025-01-01,1553 days,Recruiting,Interventional
BL-M07D1-101,A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors,2022-08-09,2024-08-01,723 days,Recruiting,Interventional
22-250,TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients,2023-03-20,2027-02-01,1414 days,Recruiting,Interventional
2021-0669,Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer,2022-12-31,2023-12-31,365 days,Not yet recruiting,Observational
HCI130492,Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics,2021-05-03,2025-08-01,1551 days,Recruiting,Interventional
E7090-J081-102,A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer,2020-10-09,2024-04-30,1299 days,"Active, not recruiting",Interventional
Folio No.03-2022,Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae,2022-09-05,2023-01-09,126 days,Completed,Interventional
S63330,FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.,2020-09-01,2024-10-31,1521 days,Recruiting,Interventional
CA209-8H3,"Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients",2019-04-03,2025-04-01,2190 days,Recruiting,Interventional
A171601,"Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer",2018-08-15,2024-08-01,2178 days,"Active, not recruiting",Interventional
OP-1250-001,"A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer",2020-08-13,2023-12-01,1205 days,Recruiting,Interventional
A5481122,Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy,2019-01-25,2022-12-01,1406 days,"Active, not recruiting",Observational
21-091,A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer,2021-12-15,2023-12-15,730 days,Recruiting,Interventional
1890-1-2019,Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy,2019-01-14,2019-08-13,211 days,Completed,Observational
CARDIEJERCAN,Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients,2021-09-13,2022-09-20,372 days,Not yet recruiting,Interventional
RIBBS 2019/37,Risk-Based Breast Screening in Young Women,2020-01-20,2026-01-31,2203 days,"Active, not recruiting",Interventional
CCR5234,Digital Delivery of Information About Genetic Testing for Breast Cancer,2021-07-05,2022-12-01,514 days,"Active, not recruiting",Interventional
2574,Prospective Thinking in Hormone-Responsive Breast Cancer,2018-08-01,2019-09-20,415 days,Completed,Interventional
IFG-06-2019,Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer,2021-03-11,2023-09-15,918 days,Recruiting,Interventional
439-21,High-intensity Exercise After Treatment,2022-03-28,2023-07-30,489 days,"Active, not recruiting",Interventional
VHIO20002,A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020,2022-05-11,2025-04-11,1066 days,Recruiting,Interventional
H-45698,Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ),2023-04-01,2027-01-01,1371 days,Recruiting,Interventional
FDRT-BC010,Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases,2020-01-02,2023-08-12,1318 days,"Active, not recruiting",Interventional
D8666C00004,To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.,2020-03-31,2021-11-04,583 days,Withdrawn,Interventional
17-0310,Narrative Visualization for Breast Cancer Survivors Physical Activity,2018-09-01,2022-03-31,1307 days,Completed,Interventional
OTT 17-02,Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients,2018-02-28,2019-04-02,398 days,Completed,Interventional
MC1835-ACCRU-BR-1701,"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery",2020-02-20,2025-01-15,1791 days,Recruiting,Interventional
CCR4772,PRELUDE Study of Lymphatic Surgery to Treat Breast Cancer Related Lymphoedema,2021-10-13,2024-04-01,901 days,Recruiting,Interventional
UC-BCG-2205,Treatment for Breast Cancer Patients With Meninges Invaded by Tumor Cells,2023-09-01,2027-03-01,1277 days,Not yet recruiting,Interventional
IEO 0837/,Patients Preferences for Adjuvant Endocrine Therapy in Early Breast Cancer,2018-06-05,2021-12-31,1305 days,Unknown status,Observational
PHDW-006,Psychological Factors and Oncological Outcomes of Triple-negative Breast Cancer,2020-12-01,2021-12-01,365 days,Unknown status,Observational
AnhuiPH,A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2,2019-04-10,2020-10-10,549 days,Unknown status,Observational
21094,CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer,2021-10-18,2023-12-01,774 days,Recruiting,Interventional
PECP,The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer,2018-12-01,2020-11-30,730 days,Unknown status,Interventional
UPCC 11121,"Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer",2021-10-21,2039-10-01,6554 days,Recruiting,Observational
CBYL719A03201,Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant,2022-03-08,2022-09-19,195 days,Terminated,Interventional
11066,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,2021-07-17,2025-01-01,1264 days,Recruiting,Interventional
S-64813,"Clinical, Histological and In-depth Molecular Characterization as Well as Experimental Models of Liver Metastasis From Patients With Breast Cancer in Order to Identify New Potential Treatment Avenues.",2023-03-01,2025-03-01,731 days,Not yet recruiting,Observational
2020-0831,Comparing the Performance of Automated Breast Ultrasonography to Hand-Held Whole Breast Ultrasonography in Breast Cancer Treatment Response Assessment,2021-11-29,2021-11-29,0 days,Withdrawn,Observational
SDO-006-20-01,To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer,2020-04-27,2021-01-28,276 days,Withdrawn,Interventional
ASSOCIHER,Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy,2022-05-01,2022-10-01,153 days,Completed,Observational
VICC BRE 20104,Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment,2021-08-09,2024-12-01,1210 days,Recruiting,Observational
22-655,STOP-HER2: Stopping Trastuzumab in HER2+ MBC,2023-04-19,2036-02-01,4671 days,Recruiting,Interventional
CL0007,Investigation of Novel Surgical Imaging for Tumor Excision,2019-11-04,2022-05-04,912 days,Completed,Interventional
EPTTCSM (239BRC18.0129),Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer,2019-01-22,2019-07-22,181 days,Unknown status,Observational
MO39193,A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer,2018-01-11,2024-01-31,2211 days,Recruiting,Interventional
HSR210410,Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer,2022-05-01,2026-10-01,1614 days,Not yet recruiting,Interventional
ALTER-BC-003,AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer,2022-07-01,2024-03-01,609 days,Not yet recruiting,Interventional
"CD133, Breast Cancer",CD133 Expression in Mammary Invasive Ductal Carcinoma,2021-05-01,2021-12-01,214 days,Recruiting,Observational
2021-40-2343,RWE About QOL and Compliance of Patients With OFS in China,2021-11-01,2024-04-01,882 days,Not yet recruiting,Observational
NL67422.041.18,Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer,2021-03-01,2022-11-01,610 days,Unknown status,Interventional
AL-TNBC-01,A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer,2020-08-14,2023-12-01,1204 days,"Active, not recruiting",Interventional
300007016,"Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations",2021-09-01,2023-12-01,821 days,Recruiting,Interventional
QUILT-3.057,QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine,2018-09-01,2021-12-01,1187 days,Withdrawn,Interventional
2021-0261,Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer,2021-04-23,2022-05-09,381 days,Completed,Interventional
69HCL19_0593,"PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study",2020-12-01,2023-06-01,912 days,Not yet recruiting,Observational
H3B-6545-G000-102,A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer,2020-04-01,2024-03-31,1460 days,"Active, not recruiting",Interventional
NCI-2018-01581,"Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer",2018-12-14,2024-12-31,2209 days,Recruiting,Interventional
CAR202,A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC,2021-11-05,2024-08-09,1008 days,Recruiting,Interventional
SIB16134,Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer,2018-05-22,2019-08-01,436 days,Withdrawn,Interventional
2020-11/15,"The Effect of Art Therapy on Pain, Emesis, Anxiety and Quality of Life, Breast Cancer",2021-09-01,2022-10-07,401 days,Completed,Interventional
20D.876,SABR-CaRe in Early Stage Breast Cancer,2021-08-23,2026-01-01,1592 days,Recruiting,Interventional
41494,Feasibility of a Remotely-Delivered Yoga Intervention on Cognitive Function in Breast Cancer Survivors,2021-12-13,2022-07-27,226 days,Completed,Interventional
19D.799,A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer,2022-11-18,2023-04-01,134 days,Recruiting,Interventional
21-110,Anti-anxiety Biotics for Breast Cancer Survivors,2021-07-20,2022-05-01,285 days,Completed,Interventional
GM1-CIPN-202,"A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer",2023-04-20,2025-12-31,986 days,Not yet recruiting,Interventional
HSaleem,Kinesiology Taping Technique in Post-mastectomy Breast Cancer Related Lymphedema,2021-04-04,2022-02-28,330 days,Recruiting,Interventional
220493,Lymphatic Function in Patients Who Have Undergone Breast Cancer Treatment,2018-09-01,2019-08-01,334 days,Unknown status,Interventional
2020-q12,Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer,2021-06-22,2025-07-31,1500 days,Recruiting,Interventional
1280-0022,The XENERAâ¢ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread,2018-11-28,2022-05-11,1260 days,Completed,Interventional
0124-18-TLV,Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor,2019-01-01,2021-06-01,882 days,Unknown status,Interventional
112626,Three Fraction Radiation to Induce Immuno-Oncologic Response,2020-09-02,2025-05-01,1702 days,Recruiting,Interventional
BL2014084,"This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment",2018-09-01,2019-12-31,486 days,Unknown status,Interventional
20160504,Impact of Intensive Follow-up for Bone Metastasis on Characteristics and Prognosis of Chinese Breast Cancer Patients,2018-03-01,2019-03-31,395 days,Completed,Observational
RLY-2608-101,"First-in-Human Study of Mutant-selective PI3KÎ± Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer",2021-12-08,2025-08-31,1362 days,Recruiting,Interventional
CLEE011A2207,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",2019-06-11,2025-12-30,2394 days,"Active, not recruiting",Interventional
21050,An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis,2022-12-21,2025-02-25,797 days,Recruiting,Interventional
55054,Inspiratory Muscle Training in Obese Breast Cancer Survivors,2023-07-01,2029-06-30,2191 days,Not yet recruiting,Interventional
PILOT 171548,RISE - Reduce Sitting Time Among Breast Cancer Survivors,2022-03-29,2023-02-07,315 days,"Active, not recruiting",Interventional
Pro00109777,Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib,2023-03-23,2025-04-01,740 days,Recruiting,Interventional
22-225,ETHAN - ET for Male BC,2023-02-01,2036-04-01,4808 days,Not yet recruiting,Interventional
ShandongCHI-04,The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy,2018-02-08,2020-02-08,730 days,Unknown status,Interventional
1710018694,Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients,2018-11-15,2026-12-30,2967 days,Recruiting,Interventional
MC1733,A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer,2020-09-23,2024-08-15,1422 days,Recruiting,Interventional
294-2018,Efficacy Study of Mepitel Film the Prophylaxis of Radiation-Induced Skin Reactions in Breast Cancer Patients,2019-03-14,2020-09-08,544 days,Completed,Interventional
29747,T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer,2018-12-06,2022-12-22,1477 days,Completed,Interventional
IFG-NIB-01,Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC,2018-03-23,2021-01-22,1036 days,Completed,Interventional
PRESSODOU-1809,Mechanical Stimulation on Pain Level and Functional Discomfort After Breast Cancer Surgery,2020-05-27,2023-11-01,1253 days,Recruiting,Interventional
2022/005-OST,Exploratory Evaluation of the Functional/Emotional Life Characteristics During the First Year of Ongoing Endocrine Adjuvant Treatment With Aromatase Inhibitors in Breast Cancer Patients With Reduced Bone Mineral Density,2023-01-09,2024-06-30,538 days,Recruiting,Observational
WSG-AM08,"Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC",2019-07-02,2027-07-31,2951 days,Recruiting,Interventional
MRG002-005,A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC),2021-05-13,2023-02-01,629 days,Recruiting,Interventional
HLX10-013-TNBCneo,to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC),2020-04-17,2027-04-09,2548 days,Not yet recruiting,Interventional
INT 192/19,Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer,2020-05-05,2024-05-01,1457 days,"Active, not recruiting",Interventional
YWBC-001,"A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast Cancer",2020-04-01,2025-03-31,1825 days,Recruiting,Observational
IRB-53650,"Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer",2020-10-13,2021-10-22,374 days,Terminated,Interventional
VICC BRE 17107,Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer,2018-07-10,2020-12-10,884 days,Terminated,Interventional
2017-004938-28,Satisfaction Assessment of Patients With Local Breast Cancer When Using Cosmetics During Chemotherapy and Post-treatment Thermal Cure,2018-08-03,2020-11-30,850 days,Completed,Interventional
Pro00103625,Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer,2020-09-14,2023-12-30,1202 days,"Active, not recruiting",Interventional
2017/01,Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients,2018-01-10,2022-04-30,1571 days,Completed,Interventional
NCI-2018-01519,Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer,2018-09-12,2027-06-01,3184 days,Recruiting,Interventional
G0F9119N,CoMoon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy,2020-12-01,2022-12-31,760 days,Completed,Interventional
OP_1413,Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer,2021-10-01,2025-09-01,1431 days,Recruiting,Interventional
2020-001,"Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer",2022-04-30,2025-04-01,1067 days,Not yet recruiting,Interventional
NCI-2022-07265,"Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer, A ComboMATCH Treatment Trial",2023-03-06,2026-11-01,1336 days,Recruiting,Interventional
AURORA US,Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer,2019-09-16,2023-11-15,1521 days,Recruiting,Observational
G1T28-208,"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)",2021-04-15,2024-10-25,1289 days,"Active, not recruiting",Interventional
ZZBGCART-016,EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer,2022-05-01,2025-05-01,1096 days,Recruiting,Interventional
18HH4880,D4 Choline Breast PET/CT,2022-02-24,2024-11-03,983 days,Recruiting,Observational
21-038,Fulvestrant + Neratinib In Breast Cancer,2021-12-01,2024-12-01,1096 days,Not yet recruiting,Interventional
STUDY00004257,"Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer",2022-09-02,2025-04-15,956 days,Recruiting,Interventional
IC 2020-15,Study Evaluating Hot Flashes in Hormone Sensitive Breast Cancer,2021-03-23,2022-04-11,384 days,Completed,Observational
09.2019.865,Responsiveness of Outcome Scales in Breast Cancer Related Lymphedema,2019-10-19,2020-05-30,224 days,Unknown status,Interventional
I-3010822,"Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer",2023-05-01,2027-04-01,1431 days,Not yet recruiting,Interventional
PALBO01/2021,Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period,2021-12-15,2023-11-15,700 days,Recruiting,Observational
UMCC 2021.056,An Attention-Restorative Therapy (ART)-Based Virtual Reality Intervention to Address Cancer-Related Cognitive Impairments Among Breast Cancer Survivors,2021-10-26,2022-05-16,202 days,Completed,Interventional
BOOG 2019-01,"TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer",2020-09-25,2024-07-01,1375 days,Recruiting,Interventional
AZV2022,The Effectiveness of Psychological Interventions in Psycho-neuroendocrine-immune Network in Breast Cancer Survivors,2022-06-06,2025-06-01,1091 days,Recruiting,Interventional
RF-2016-02362383,Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer,2019-06-18,2023-09-01,1536 days,Recruiting,Interventional
HYPART,HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART).,2021-03-30,2028-08-20,2700 days,Recruiting,Interventional
CLEE011AUS65,Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors,2020-05-08,2020-07-31,84 days,Completed,Observational
UTD-1-BM-II,"The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer.",2022-07-20,2025-07-20,1096 days,Recruiting,Interventional
IUSCC-0647,Effects of Aromatase Inhibitor Therapy on Muscle Function,2018-07-26,2020-02-07,561 days,Completed,Observational
SL-2020076,Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude,2021-10-01,2024-12-01,1157 days,Not yet recruiting,Observational
2022-A00171-42,Support and Post-therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment,2022-06-27,2026-11-30,1617 days,Recruiting,Observational
2018/14-01,A New Mindfulness Intervention Called Mindfulness Based Swinging Technique (MBST) for Women With Breast Cancer,2018-11-29,2022-10-20,1421 days,Completed,Interventional
UC-0140/1814,"Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients",2019-10-23,2027-10-23,2922 days,Recruiting,Interventional
20221297,Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer,2023-07-31,2029-07-31,2192 days,Not yet recruiting,Interventional
NBG-19-01; SWEBCG 19-01,"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC",2019-12-20,2035-06-30,5671 days,Recruiting,Interventional
bakircaymzeren07,Does Inclusion of Diaphragmatic Breathing Exercises in Complete Decongestive Therapy Provide Further Benefits in Patients With Breast Cancer Related Lymphedema,2023-03-20,2023-09-01,165 days,Recruiting,Interventional
2021SCR,Cone Beam Breast CT for Breast Cancer Screening,2021-10-30,2023-10-30,730 days,"Active, not recruiting",Interventional
Lymphedema Rehabilitation,New Therapeutic Approach in Upper Limb Lymphedema Secondary to Breast Cancer: Activity-oriented Proprioceptive Antiedema Therapy (TAPA),2019-03-01,2021-09-01,915 days,Unknown status,Interventional
VMA-253-18,Fish Oil and EPO in Breast Cancer,2019-02-20,2024-06-20,1947 days,Recruiting,Interventional
IRB-30000320,"Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors",2020-01-17,2025-08-31,2053 days,Recruiting,Interventional
9764,"Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",2018-09-01,2025-03-14,2386 days,Withdrawn,Interventional
EA1211,"Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial",2023-05-11,2025-03-31,690 days,Not yet recruiting,Interventional
11B1920N_BCS-PAIN,The Effect of Pain Neuroscience Education and Behavioural Graded Activity on Chronic Pain in Breast Cancer Survivors,2020-10-12,2024-04-01,1267 days,Recruiting,Interventional
ShandongCHI-13,Comparison Study of Different Tumor Biopsy Method for Sentinel Lymph Node Biopsy in Breast Cancer,2020-11-01,2021-06-01,212 days,Unknown status,Interventional
MIMIR-mTNBC,Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer,2023-03-01,2027-05-20,1541 days,Not yet recruiting,Observational
LCCC1934,Reverse Axillary Mapping in Breast Radiation Treatment Planning,2021-05-01,2027-01-01,2071 days,Withdrawn,Observational
3-2020-0448,Repeat Sentinel Lymph Node Biopsy in Ipsilateral Breast Tumor Recurrence,2020-03-01,2029-01-31,3258 days,Recruiting,Interventional
17502,A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer,2019-12-10,2024-12-31,1848 days,"Active, not recruiting",Interventional
Pro2020001306,Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer,2021-05-18,2024-01-31,988 days,Recruiting,Interventional
2861/20,Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer,2021-03-01,2028-04-30,2617 days,Recruiting,Interventional
WO40181,"A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy",2018-09-06,2021-05-06,973 days,Terminated,Interventional
GY202201,Efficacy of Acupuncture Treatment for Breast Cancer-associated Insomnia,2022-10-20,2025-06-01,955 days,Recruiting,Interventional
BMTN,Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer,2018-07-01,2021-02-15,960 days,Completed,Interventional
2020-12518,Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer,2020-07-16,2027-07-01,2541 days,Recruiting,Observational
20190304-01H,"Breaststroke Swimming After Breast Cancer Treatment/Surgery as a Means of Treatment for Seroma, Lymphedema, and Chronic Arm and Chest Pain",2023-01-01,2025-12-31,1095 days,Recruiting,Interventional
UKT HT03_1,Prospective Assessment of Quality of Life in Patients With Locally Recurrent Breast Cancer and Hyperthermic Radiotherapy,2020-08-01,2026-12-31,2343 days,Recruiting,Observational
30388,"Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors",2019-04-19,2024-11-30,2052 days,"Active, not recruiting",Interventional
STUDY00146320,Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens,2021-12-14,2026-01-31,1509 days,Recruiting,Interventional
SM-88-001,Study of SM-88 in Advanced Cancers,2022-10-01,2023-10-01,365 days,Withdrawn,Interventional
2022-A00437-36,Impact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer,2022-10-01,2027-06-01,1704 days,Not yet recruiting,Interventional
2018-01-054,Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy,2018-03-01,2023-08-31,2009 days,"Active, not recruiting",Observational
2.073.549,Pilates and Dance to Breast Cancer Patients Undergoing Treatment,2018-01-01,2020-12-30,1094 days,Completed,Interventional
NCI-2020-02319,Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer,2020-08-10,2023-12-31,1238 days,Recruiting,Interventional
2-114-18,Is Dietary Nitrate Effective in Reducing Aerobic Glycolysis in Breast Cancer?,2019-05-13,2020-06-30,414 days,Unknown status,Interventional
P170407J,Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer,2019-11-28,2022-08-30,1006 days,Completed,Interventional
QF-SC10914-203,A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients,2020-08-12,2022-08-30,748 days,Unknown status,Interventional
BRAVE,QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting: Comparison Between Public and Private Institutions.,2021-07-14,2022-07-30,381 days,Enrolling by invitation,Observational
D926PC00001,"A Study of Dato-DXd Versus Investigators Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)",2022-05-16,2025-12-03,1297 days,Recruiting,Interventional
NL76792.091.21,DLSCT for Breast Cancer Detection in Women With Dense Breasts,2022-01-01,2023-01-01,365 days,Recruiting,Observational
IRB00376235,The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer,2023-11-01,2028-12-31,1887 days,Not yet recruiting,Interventional
HCRN BRE18-360,Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physicians Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases,2022-03-09,2026-09-01,1637 days,Recruiting,Interventional
19-1974.cc,Appetite and Exercise in Breast Cancer Survivors,2020-02-07,2022-02-05,729 days,Completed,Interventional
H19-02480,BREast Cancer And Sexuality Treatment,2020-01-06,2023-12-01,1425 days,"Active, not recruiting",Interventional
190025,Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies,2022-01-04,2023-12-29,724 days,Enrolling by invitation,Observational
HS-10342-201,A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer,2021-09-30,2023-12-31,822 days,Not yet recruiting,Interventional
2020-01-mp-BUS,Multi-parametric Breast Ultrasound Imaging as a Potential Biomarker for Breast Cancer,2020-11-15,2021-12-13,393 days,Completed,Interventional
IRB202000746,"A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)",2020-09-26,2029-09-26,3287 days,"Active, not recruiting",Interventional
108818,Early Detection of Cardiac Damage With CMR in Women With Breast Cancer,2020-03-01,2021-03-31,395 days,Unknown status,Observational
CBCSG041,Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction,2022-09-01,2027-10-01,1856 days,Not yet recruiting,Interventional
WEBAPPAC,Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer,2020-09-03,2025-03-03,1642 days,Recruiting,Interventional
PILHLE-001,"Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial",2021-05-19,2028-05-19,2557 days,Recruiting,Interventional
21-579,Low-field MRI for Breast Cancer Screening,2022-09-01,2024-09-01,731 days,Not yet recruiting,Interventional
A011801,"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial",2021-01-06,2035-05-01,5228 days,Recruiting,Interventional
Maple Tree Exercise,Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients,2019-08-23,2021-12-01,831 days,Unknown status,Interventional
ERC/2019/10/05,Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria,2019-10-05,2023-06-30,1364 days,Recruiting,Interventional
A5481151,Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor,2021-09-01,2021-09-01,0 days,Completed,Observational
22145,Effects a Honey Based Syrup on Blood Parameters in Patients With Breast Cancer,2020-06-15,2020-10-05,112 days,Completed,Interventional
ICS Maugeri - CE 2202,Standard Silicone-based vs. B-LiteÂ® Light Weight Breast Implant After Total Mastectomy and Radiotherapy for Breast Cancer,2018-06-01,2021-06-30,1125 days,Completed,Interventional
TCHP,Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer,2019-08-01,2021-07-31,730 days,Unknown status,Interventional
19-001881,Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors,2021-09-29,2024-11-01,1129 days,Recruiting,Interventional
STU-2020-1043,Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib,2021-04-15,2024-12-22,1347 days,Recruiting,Interventional
D0819C00005,Lynparza Breast Cancer Clinical Experience Investigation,2018-08-14,2022-03-24,1318 days,Completed,Observational
041-2018,Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer,2018-07-18,2023-03-31,1717 days,Completed,Interventional
RESCREEN,Optimized Rehabilitation Following Primary Breast Cancer Surgery,2018-11-15,2025-11-01,2543 days,Recruiting,Interventional
NCI-2019-00048,"A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer",2019-02-13,2022-02-19,1102 days,Withdrawn,Interventional
IRB-57111,Mental Health Disparities in Spanish Speaking Latina Breast Cancer Patients,2021-03-15,2026-10-31,2056 days,"Active, not recruiting",Interventional
2022-0959,Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery,2023-08-31,2028-12-31,1949 days,Not yet recruiting,Interventional
I 60517,Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice,2019-02-06,2022-08-30,1301 days,Completed,Interventional
OSU-21185,Health Coaching-Based Navigation at the Conclusion of Treatment for the Support of Black Breast Cancer Survivors,2022-11-14,2023-12-31,412 days,Recruiting,Interventional
A221803,Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy,2022-06-15,2025-12-31,1295 days,Recruiting,Interventional
STUDY00003100,Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts,2021-05-20,2024-07-01,1138 days,Recruiting,Interventional
IndonesiaU2022,The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer,2022-08-19,2025-02-01,897 days,Recruiting,Interventional
FM-17-B01,Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer,2018-09-07,2027-06-15,3203 days,"Active, not recruiting",Interventional
MC220303,Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women,2023-03-14,2033-01-15,3595 days,Recruiting,Observational
STUDY00007842,Music as a Perioperative Therapy in Breast Cancer Patients,2019-07-10,2021-10-27,840 days,Withdrawn,Interventional
STUDY00001007,Peer Support For Young Adult Women With High Breast Cancer Risk,2020-07-15,2025-06-01,1782 days,Recruiting,Interventional
20-009279,Evaluating the Association Between Changes in the Gut Microbiome and Chemotherapy-Induced Nausea in Women Receiving Chemotherapy for Stage I-III Breast Cancer,2021-04-14,2024-04-15,1097 days,Recruiting,Observational
H19094,Effects of a Traditional Chinese Exercise Program on Symptom Cluster in Breast Cancer Patients,2020-05-04,2021-04-06,337 days,Completed,Interventional
20-133,A Study of PRP Treatment for Hair Loss After Cancer Therapy in Women With Breast Cancer,2020-06-23,2024-06-01,1439 days,"Active, not recruiting",Interventional
KKKR-Neulasta OS-01,An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (NeulastaÂ®),2018-01-18,2021-06-30,1259 days,Completed,Observational
16-185671,Integrative Approaches to Cancer Survivorship: Project 3,2018-04-17,2020-01-30,653 days,Completed,Interventional
M18BEL,Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO,2019-10-04,2027-01-07,2652 days,Recruiting,Interventional
"UPCC# 15122, IRB # 852205",CAR T Cells in Mesothelin-Expressing Breast Cancer,2023-02-06,2038-02-01,5474 days,Recruiting,Interventional
HCC 20-243,Apollo Device for Metastatic Breast Cancer (MBC),2021-02-01,2026-03-01,1854 days,Recruiting,Interventional
Alaa_Negm_MSc_2023,"Effect of Kinesiotaping Augmented By Resistive Exercise on Fatigue, Physical Strength, Quality of Life in Breast Cancer Survivors",2023-02-20,2023-06-20,120 days,Not yet recruiting,Interventional
SunYatsenU2H-LQ3,"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC",2020-08-03,2032-08-01,4381 days,Recruiting,Interventional
LCCC1745,"ARFI, VisR and DDAI Ultrasound for Improving Discrimination of Malignant and Unresponsive Breast Cancer",2018-05-10,2021-07-15,1162 days,Completed,Observational
BYEC20211201,Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC,2022-01-14,2024-06-01,869 days,Recruiting,Interventional
18-140,Sexual Health and Rehabilitation After Ovarian Suppression Treatment,2018-12-01,2019-12-01,365 days,Completed,Interventional
2022-0378,Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care,2023-01-18,2028-09-01,2053 days,Recruiting,Interventional
20-221,Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity,2021-08-12,2026-06-15,1768 days,Recruiting,Interventional
IRB-58571,Analysis of Patient Understanding of Radiation Therapy Among Patients With Breast Cancer,2021-01-20,2021-10-12,265 days,Completed,Interventional
BPI-1178-2019-001,A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer,2020-06-15,2024-03-15,1369 days,Recruiting,Interventional
Organoids Breast,Developing Breast (Cancer) Organoids,2022-09-01,2028-05-01,2069 days,Recruiting,Observational
PUMCH-2020-EBC,A Prospective Cohort Study Comparing Disparity in Surgical Procedure (Wide Local Excision Only vs Any Other Surgery Procedures) Among the Elderly Breast Cancer Patients,2020-06-01,2027-06-01,2556 days,Not yet recruiting,Observational
E-HHC-2016-0245,Adaptive Symptom Care Using Fish-Based Nutritional Directives Post Breast Cancer,2018-04-11,2022-03-25,1444 days,Suspended,Interventional
21656,"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer",2022-10-14,2024-12-07,785 days,Recruiting,Interventional
UC-0140/1901,Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer,2020-06-11,2028-06-01,2912 days,Recruiting,Interventional
HE072-CSP-002,Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance,2021-04-01,2024-04-01,1096 days,Not yet recruiting,Interventional
ACCRU-BR-1801,T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer,2020-11-11,2022-02-16,462 days,Withdrawn,Interventional
17-00890,Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC),2019-05-02,2023-05-01,1460 days,"Active, not recruiting",Interventional
2020-01,Exercise Therapy During Radiotherapy,2020-10-10,2021-04-10,182 days,Unknown status,Interventional
TransRosaLEE-IPC 2021-075,"Trans-RosaLEE Study: a Biomarker-directed, Translational Study",2023-01-01,2027-10-01,1734 days,Not yet recruiting,Interventional
UMCC 2021.109,Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer,2022-03-28,2023-10-01,552 days,Recruiting,Interventional
TROIKA,"A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to HerceptinÂ® in HER2+ Early Breast Cancer Patients",2018-02-19,2022-01-13,1424 days,Completed,Interventional
2000024495,Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer,2019-07-22,2023-08-30,1500 days,"Active, not recruiting",Interventional
HMCC-BR22-001,Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC),2023-01-12,2028-12-02,2151 days,Recruiting,Interventional
I 1680021,Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer,2023-05-07,2025-05-07,731 days,Not yet recruiting,Interventional
NCC1692,Anlotinib in Metastatic HER2 Negative Breast Cancer,2018-07-12,2020-03-15,612 days,Completed,Interventional
0201263,Hypofractionation And Ultra-Hypofractionation In Adjuvant Radiotherapy For Breast Cancer,2019-06-28,2021-06-28,731 days,Unknown status,Interventional
19/002,"Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer",2021-03-01,2025-09-30,1674 days,Recruiting,Interventional
CIH-TZS-20190912,Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China,2019-09-13,2023-05-31,1356 days,Recruiting,Observational
NCI-2019-06461,"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer",2019-12-06,2023-06-30,1302 days,Recruiting,Interventional
HNCH-BC001,The TP Regimen in the Treatment of Early Triple Negative Breast Cancer,2018-11-23,2022-11-26,1464 days,Completed,Interventional
S-169,Complementary and Alternative Medicine on Mental Health in Breast Cancer Patients,2020-07-01,2021-10-30,486 days,Unknown status,Interventional
ExtremeHypofractionationBreast,Postoperative Radiation of Patients With Breast Cancer in Extreme Hypofractionation.,2022-08-01,2035-07-30,4746 days,Not yet recruiting,Observational
HCI103657,Merestinib on Bone Metastases in Subjects With Breast Cancer,2018-01-11,2019-06-24,529 days,Terminated,Interventional
HS627-III,Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel,2020-06-30,2021-11-20,508 days,Unknown status,Interventional
17782,A Study of Abemaciclib in Indian Women With Advanced Breast Cancer,2021-02-22,2023-03-03,739 days,Recruiting,Interventional
LQ004,Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer,2018-11-01,2020-06-01,578 days,Unknown status,Interventional
KutahyaMSUcancer,Clinical Classification of Pain in Breast Cancer Survivors,2023-07-01,2023-10-01,92 days,Recruiting,Observational
2021-A03166-35,Functional Evaluation After Breast Reconstruction With a Minimally Invasive Latissimus Dorsi Flap Following Radical Surgery for Breast Cancer.,2022-07-01,2025-01-01,915 days,Not yet recruiting,Interventional
AAAS9859,Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI),2022-01-19,2025-05-01,1198 days,Recruiting,Interventional
249571,Mini-AFTERc Intervention for Fear of Cancer Recurrence,2019-06-13,2020-09-01,446 days,Unknown status,Interventional
2022/050,Telerehabilitation in Survival Breast Cancer Patients,2022-10-20,2023-12-30,436 days,Recruiting,Interventional
BR01/01/22,Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer,2022-12-31,2026-12-31,1461 days,Not yet recruiting,Interventional
POLAR-01,Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer,2018-08-01,2021-06-01,1035 days,"Active, not recruiting",Observational
UMCC 2020.122,"Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer",2021-03-04,2023-07-01,849 days,Recruiting,Interventional
CA048-001,A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread,2020-09-22,2022-08-15,692 days,Completed,Interventional
NCI-2022-10810,"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer",2023-03-02,2027-02-23,1454 days,Recruiting,Interventional
RG1004302,Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer,2020-04-08,2025-02-01,1760 days,Recruiting,Interventional
Pro00100093,A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer,2019-03-01,2024-12-01,2102 days,Recruiting,Interventional
0201-21,Implantation of CEST and CESL MRI Methods for Detection of Breast Tumors,2022-05-01,2025-05-31,1126 days,Not yet recruiting,Interventional
CORE,Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity,2018-04-01,2018-05-01,30 days,Terminated,Interventional
ENZENO-C-101,ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study),2021-07-26,2024-01-31,919 days,Recruiting,Interventional
19206,Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.,2020-03-25,2023-12-15,1360 days,Recruiting,Interventional
NEO-R-IPC 2019-041,Real Time Molecular Analysis of Breast Cancer Receiving Neo-adjuvant Chemotherapy,2022-11-03,2030-01-01,2616 days,Recruiting,Observational
S00748-NIM,Ice Plant Intensive Cream for the Prevention of Hand-Foot Syndrome in Breast Cancer: Pilot Randomized Controlled Trial,2023-03-01,2024-02-28,364 days,Not yet recruiting,Interventional
ATENTO19,Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO),2021-09-30,2023-09-30,730 days,Recruiting,Interventional
STUDY00002373,Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy,2022-12-01,2025-07-31,973 days,Not yet recruiting,Interventional
SCHBCC-N048,Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.,2023-03-17,2027-01-01,1386 days,Recruiting,Interventional
3-2020-0343,Primary Surgical Prevention of Breast Cancer-related Lymphedema,2021-01-01,2027-12-31,2555 days,Not yet recruiting,Interventional
KSF2-1707,Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer,2018-03-23,2028-01-01,3571 days,"Active, not recruiting",Interventional
UW 19-045,Acupuncture for Insomnia in Breast Cancer Patients Undergoing Chemotherapy,2019-11-18,2022-04-01,865 days,Unknown status,Interventional
22-074,A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer,2022-10-03,2027-10-01,1824 days,Recruiting,Interventional
09.2018.,Diagnostic Accuracy of Dermal Thickness in Lymphedema,2018-09-28,2018-12-19,82 days,Completed,Observational
lithium and breast cancer,Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients,2020-08-01,2022-06-01,669 days,Completed,Interventional
18549,Remotivation Process for Improving Adherence to Lymphedema Treatment Programs in Patients With Breast Cancer-Related Lymphedema,2019-04-19,2024-03-31,1808 days,"Active, not recruiting",Interventional
EGC002,Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer,2018-10-16,2022-01-20,1192 days,Completed,Interventional
Multimodal Project,Multimodal Project,2023-01-01,2023-09-01,243 days,Not yet recruiting,Interventional
201710109,Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy,2019-08-08,2023-08-23,1476 days,"Active, not recruiting",Interventional
2016-003518-28,Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer,2018-12-01,2021-12-01,1096 days,Unknown status,Interventional
BR01/02/19,Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA),2019-08-14,2024-10-01,1875 days,Recruiting,Interventional
ZLiu,Radiomics of Mp-MRI Assessing NAC Outcome in Breast Cancer,2018-07-18,2022-06-01,1414 days,Unknown status,Observational
XJLL-KY20212136,RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer,2021-11-26,2025-09-30,1404 days,Not yet recruiting,Interventional
2017-073,The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer,2018-03-09,2023-05-31,1909 days,"Active, not recruiting",Interventional
CMUH107-REC3-102,Yoga for Aromatase Inhibitor-related Knee Pain Relief in Breast Cancer Patients,2019-03-10,2019-09-05,179 days,Completed,Interventional
THALIA-01,Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study,2019-08-01,2022-12-01,1218 days,Recruiting,Observational
C-MOT,Copenhagen Master Observational Trial,2021-08-01,2023-12-31,882 days,Recruiting,Observational
BC-P32,Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer,2023-03-06,2025-03-06,731 days,Not yet recruiting,Observational
HBO001,Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy,2019-07-01,2024-05-01,1766 days,"Active, not recruiting",Interventional
RG1718047,"Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer",2019-04-01,2022-10-30,1308 days,Withdrawn,Interventional
19-0448,XoftÂ® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer,2019-09-10,2027-09-10,2922 days,Recruiting,Observational
2020-006,Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients,2020-09-16,2021-05-20,246 days,Completed,Interventional
TX05-03,"Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With HerceptinÂ® in HER2+ Early Breast Cancer",2018-06-28,2021-02-04,952 days,Completed,Interventional
2016/65,Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer,2018-10-25,2025-10-24,2556 days,"Active, not recruiting",Interventional
22-490,VS-6766+Abema+Fulv in Met HR+/HER- BC,2023-02-23,2028-12-31,2138 days,Recruiting,Interventional
HCRN BRE19-433,"A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer",2021-04-01,2024-07-01,1187 days,"Active, not recruiting",Interventional
19P.117,Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences,2019-05-20,2023-10-01,1595 days,"Active, not recruiting",Interventional
S2020-09,Comparison of Microwave Ablation With Breast Conserving Surgery for Breast Tumor,2020-09-18,2023-05-30,984 days,Recruiting,Interventional
SYSKY-2022-445-01,"Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study",2023-04-01,2023-12-30,273 days,Not yet recruiting,Observational
CGAprediting,The Value of Geriatric Assessments in Older Patients With Breast Cancer,2018-04-01,2025-05-01,2587 days,Recruiting,Observational
J17118,Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC,2018-07-20,2024-07-01,2173 days,Recruiting,Interventional
EQ132-201,A Study of Lerociclib in Participants With Advanced Breast Cancer,2021-12-21,2026-05-01,1592 days,Recruiting,Interventional
UW21062,Remote Electronic Assessment of Survivors With Feedback Communication and Directed Referrals,2021-08-24,2022-07-28,338 days,Completed,Interventional
ACT16106,"Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer",2020-02-04,2021-05-28,479 days,Terminated,Interventional
2018/8361/I,MUltimodal Targeted Axillary Surgery,2019-10-23,2022-11-15,1119 days,Recruiting,Interventional
427 BC SDM,Enhancing Shared Decision-Making in Breast Cancer,2018-12-11,2022-12-31,1481 days,Completed,Interventional
20210901-jiangchunling,A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases,2022-03-01,2024-09-30,944 days,Recruiting,Interventional
CH-BC-086,Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC,2021-09-01,2022-09-01,365 days,Recruiting,Observational
2023-3181,Thoracic Paravertebral Block Anesthesia for Breast Cancer Surgery,2022-11-04,2023-12-01,392 days,Recruiting,Interventional
IRB00154162,Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection,2022-03-01,2024-02-02,703 days,Recruiting,Observational
2020KT151,Trastuzumab(HenliusÂ®) Combined With Pertuzumab(PerjetaÂ®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab,2021-05-10,2023-12-10,944 days,Recruiting,Observational
01,Self-applied Acupressure for Arthralgia-fatigue-sleep Disturbance in Breast Cancer,2021-06-05,2022-03-29,297 days,Recruiting,Interventional
CHUV-DO-0009-CyberImmunoBreast,CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC),2021-04-08,2025-12-01,1698 days,Recruiting,Interventional
NCC3222,Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC,2021-12-01,2024-06-01,913 days,Recruiting,Observational
PEMBRACA,Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA),2018-12-12,2023-01-30,1510 days,Completed,Interventional
170115,T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery,2018-04-18,2023-06-30,1899 days,"Active, not recruiting",Interventional
IJB-EBC-Decrescendo-2020,De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade,2022-01-17,2029-03-01,2600 days,Recruiting,Interventional
ANG1005-CLN-07,ANG1005 in Leptomeningeal Disease From Breast Cancer,2023-12-01,2024-12-01,366 days,Not yet recruiting,Interventional
FASCINATE-N,Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy,2022-11-01,2025-09-01,1035 days,Recruiting,Interventional
Manual Therapy BCS,Effects of Manual Therapy on Chronic Pain and Functionality of Breast Cancer Survivors,2019-11-01,2020-02-27,118 days,Terminated,Interventional
KUH5101090,"The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients",2018-03-21,2018-03-21,0 days,Withdrawn,Interventional
17471,Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer,2018-06-14,2023-12-29,2024 days,"Active, not recruiting",Interventional
BAIBU-FTR-ED-001,Effect of Different Bandage Interface Pressures on Breast Cancer Related Lymphedema,2019-06-01,2022-05-18,1082 days,Completed,Interventional
STUDY00018239,Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer,2018-05-03,2020-11-18,930 days,Completed,Interventional
NCO-21001,Comparison of [68Ga]GaFAPI-46 PET/CT and [18F]FDG PET/CT Findings in Breast Carcinoma,2021-02-04,2022-12-01,665 days,Recruiting,Interventional
16-015,Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib,2018-04-24,2021-10-28,1283 days,"Active, not recruiting",Interventional
2170-29-02/1-2,The Immune Response of Breast Cancer Patients Treated With Levobupivacaine Using Paravertebral or Superficial Chest Blocks,2023-04-01,2025-12-01,975 days,Not yet recruiting,Interventional
22-10590-BO,Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients,2022-04-01,2023-12-01,609 days,Not yet recruiting,Observational
GBG 97,Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer,2018-03-15,2022-07-31,1599 days,"Active, not recruiting",Interventional
DOT-1871-KIE-0120-I,Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW,2021-06-01,2023-03-01,638 days,Withdrawn,Interventional
IIT-2017-MM-BRST-Her2noRT,Omission of Radiation in Patients With Her-2 Positive Breast Cancer,2018-02-23,2026-12-31,3233 days,Recruiting,Interventional
KaratayUHaticeTEZ,The Effect of Training Given by Mobile Application to Women Undergoing Breast Surgery,2022-06-01,2022-12-01,183 days,Completed,Interventional
YBCSG-21-01,Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab,2021-09-15,2024-10-31,1142 days,Recruiting,Interventional
4-2017-1108,"Cosmetic Outcome, Patient-reported Outcomes, and Reconstruction-related Complications in Breast Cancer Women Treated With or Without Post-mastectomy Radiation Therapy",2018-02-01,2024-02-01,2191 days,Recruiting,Observational
UniUrb_21/10.07.2019,Movement and Health Beyond Care (MoviS),2020-01-07,2025-11-30,2154 days,Recruiting,Interventional
Shengjing-LJY02,DFS and QOL After Modified Radical Mastectomy vs. Expanded Mckissock Surgery for EIC of the Breast,2019-10-01,2026-09-01,2527 days,Recruiting,Interventional
2016-6346,Comparison of Healthy Diets on Breast Cancer Markers,2018-06-22,2020-08-25,795 days,Completed,Interventional
N19TON,Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients,2020-02-21,2026-12-15,2489 days,Recruiting,Interventional
Soh-Med-23-02-16,Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients,2023-04-01,2025-08-01,853 days,Not yet recruiting,Interventional
SIMR_onc19_IIS_DAndre_Ashwaga,Ashwagandha for Cognitive Dysfunction,2020-01-01,2022-11-01,1035 days,Unknown status,Interventional
PROICM 2018-02 SKY,Feasibility Study: Yoga Educational Project,2018-08-31,2019-07-30,333 days,Completed,Interventional
GRASPA-TNBC-2018-02,Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2),2019-06-13,2022-03-31,1022 days,Terminated,Interventional
NCI-2016-01293,Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer,2018-03-16,2023-06-03,1905 days,"Active, not recruiting",Interventional
BOOG 2021-01 SEQUEL-Breast,SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast),2022-06-02,2028-03-01,2099 days,Recruiting,Interventional
2020-1138,A Study on the Effectiveness of WeChat-based Online Education to Reduce Perioperative Anxiety in Breast Cancer Patients,2021-02-01,2022-03-31,423 days,Completed,Interventional
432-17,Facilitating Oncology Patient-Clinician Communication Via E-health Innovations,2018-01-31,2019-12-20,688 days,Completed,Interventional
20170770,"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer",2020-02-26,2027-01-14,2514 days,Recruiting,Interventional
GATTUM -1,Gated Radiotherapy in Left Sided Breast Cancer Patients,2018-05-01,2019-12-01,579 days,Unknown status,Observational
YX2021-070(F1),Effect of Intravenous S-ketamine on Opioid Consumption,2021-10-07,2023-07-07,638 days,Recruiting,Interventional
RI-002,Parallel Comparison of 18 Gene Classifiers and Oncotype DX (Nanostring),2018-06-01,2018-11-01,153 days,Completed,Observational
LCI-BRE-MTN-NIR-001,LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer,2021-04-01,2026-01-01,1736 days,Withdrawn,Interventional
7119-001,A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001),2021-04-08,2028-12-06,2799 days,"Active, not recruiting",Interventional
1B-16-11,Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer,2019-07-29,2025-07-29,2192 days,Withdrawn,Interventional
PRO2,Evaluation of the Mediduxâ¢ Digital Health Application in Patients With HER2-positive Breast Cancer During Chemotherapy in Combination With HER2-targeted Therapy or Antibody-drug Conjugate Therapy.,2022-08-29,2024-03-29,578 days,Recruiting,Interventional
KTI-21-01,Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC),2023-07-01,2024-12-31,549 days,Not yet recruiting,Interventional
CDX-ONC-101,"A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer",2023-01-15,2025-01-30,746 days,Not yet recruiting,Interventional
ICL-2022-1,Personalized Preventive Support for Cognitive Impairment in Non-Metastatic Breast Cancer (EFACog),2023-07-01,2025-09-01,793 days,Not yet recruiting,Interventional
1070741-1,Subclinical Lymphedema Treatment Study,2018-04-01,2025-12-01,2801 days,"Active, not recruiting",Interventional
MO42319,A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC),2021-06-07,2029-12-31,3129 days,"Active, not recruiting",Interventional
2021-1031,"A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer",2022-10-28,2025-01-01,796 days,Recruiting,Interventional
MCC-19337,HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer,2018-06-06,2024-08-01,2248 days,"Active, not recruiting",Interventional
18175,"A Study of Imlunestrant, Investigators Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer",2021-10-04,2027-08-31,2157 days,Recruiting,Interventional
4090,Study Evaluating Flexitouch Plus With Connectivity on Compliance in 30 Patients With Breast Cancer-Related Lymphedema.,2020-08-13,2021-11-19,463 days,Completed,Interventional
2021332GD,Contrast-enhanced Ultrasonography Combined With Blue Dye as Dual-tracer for Sentinel Lymph Node Biopsy,2021-06-15,2023-08-15,791 days,Not yet recruiting,Interventional
18238,Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer,2022-03-11,2026-02-16,1438 days,Recruiting,Interventional
21152,Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer,2022-06-21,2023-09-07,443 days,Recruiting,Interventional
BLTN-Ig,Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer,2020-07-07,2023-12-30,1271 days,"Active, not recruiting",Interventional
I 62218,Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer,2019-01-09,2023-06-02,1605 days,"Active, not recruiting",Interventional
Pro00080769,Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA),2018-10-04,2022-06-30,1365 days,Completed,Interventional
E2019316,A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer,2020-05-01,2022-06-01,761 days,Unknown status,Interventional
22-364,Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer,2023-01-30,2028-01-30,1826 days,Recruiting,Interventional
ISK-N103,"Safety and Efficacy of IV Nerofeâ¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer",2018-09-06,2020-04-21,593 days,Withdrawn,Interventional
NCI-2019-02752,Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer,2019-10-21,2023-11-01,1472 days,Recruiting,Interventional
STao-003,Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer,2019-06-24,2023-06-26,1463 days,Not yet recruiting,Interventional
RECHMPL20_0130,Contraception and Cervical and Breast Cancer Screening in Obese Versus Non-obese Women,2020-06-01,2021-09-01,457 days,Completed,Observational
OSU-17122,Exercise and Diet Counseling Program in Improving Quality of Life in Stage I-III Breast Cancer Survivors,2019-03-06,2023-12-31,1761 days,Recruiting,Interventional
SKB264-â¡-07,SKB264 +/- KL-A167 in Recurrent or Metastatic Triple-negative Breast Cancer,2022-07-01,2024-07-01,731 days,Not yet recruiting,Interventional
LonghuaH,Clinical Study on Auricular Points Sticking Plus Chinese Medication for Hot Flashes in Breast Cancer Women,2019-01-04,2019-12-01,331 days,Unknown status,Interventional
OTT 18-01,Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL),2018-10-31,2023-12-01,1857 days,"Active, not recruiting",Interventional
ZL-1302-002,A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC,2020-01-13,2021-09-01,597 days,Unknown status,Interventional
PTC-breastNAT,PTC Guiding Neoadjuvant Treatment in Breast Cancer,2021-11-01,2023-12-31,790 days,Not yet recruiting,Interventional
MCC-21-18633,Entertainment Media to Deliver Educational Messages About Mammography in Saudi Arabia,2022-02-10,2022-03-14,32 days,Completed,Interventional
Fudan-P1-201701,PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients,2019-05-15,2022-12-30,1325 days,"Active, not recruiting",Interventional
CBYL719C2005,Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib,2022-02-28,2023-06-30,487 days,Recruiting,Observational
2018-0473,Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer,2019-07-31,2024-02-28,1673 days,Recruiting,Interventional
BCIG,Clinical Study of Imaging Genomics Based on Machine Learning for BCIG,2020-12-01,2023-12-30,1124 days,Not yet recruiting,Observational
2019-0638,Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer,2020-12-03,2023-12-31,1123 days,Recruiting,Interventional
ZG-2021-002,ZetaFuseâ¢ Bone Graft in the Repair of Bone Defects From Metastatic Breast Cancer in the Spinal Vertebral Body,2022-09-01,2023-09-01,365 days,Recruiting,Interventional
NCC1786,Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer,2019-01-01,2025-03-01,2251 days,Recruiting,Interventional
NU 19B07,"SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer",2022-11-10,2022-11-10,0 days,Withdrawn,Interventional
LUT-RD-02-01,LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients,2021-01-30,2022-07-15,531 days,Completed,Interventional
Neo-RT,Neo-RT: A Study Investigating Whether Changing the Sequence of Treatments (Starting Radiotherapy Followed by Hormone Therapy Before Surgery) is Feasible,2018-03-26,2022-12-31,1741 days,Recruiting,Observational
MEDOPP445,Preventive stRategy for IMMU132-relatED AEs in TNBC - PRIMED,2023-02-07,2025-12-14,1041 days,Recruiting,Interventional
OSU-18174,A QoL Intervention for Young African American Breast Cancer Survivors,2022-08-01,2023-09-30,425 days,Recruiting,Interventional
ICR-CTSU/2017/10065,PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer,2019-10-15,2025-12-01,2239 days,Recruiting,Interventional
VICC BRE 18108,A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer,2019-07-08,2025-05-01,2124 days,Recruiting,Interventional
RIGAIN,RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer,2019-08-20,2030-12-31,4151 days,Recruiting,Interventional
Survey_App,Anonymous Survey of Breast Cancer Patients Concerning Their Use of Medical Apps,2022-09-01,2023-08-01,334 days,Recruiting,Interventional
DR210090_SILENCE,Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea,2022-06-01,2024-05-01,700 days,Not yet recruiting,Interventional
69HCL21_0552,NEOZOL_Follow-up Study,2021-05-01,2021-12-31,244 days,Not yet recruiting,Observational
OSU-21035,Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors,2021-06-28,2025-08-31,1525 days,Recruiting,Interventional
19-031,ADVANCE (A Pilot Trial),2019-03-21,2023-03-21,1461 days,"Active, not recruiting",Interventional
20-166,Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC,2020-07-20,2027-04-01,2446 days,Recruiting,Interventional
INCMNSZ REF 1239,Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients,2018-02-01,2021-11-01,1369 days,Unknown status,Interventional
OSU-20101,A Quality of Life Intervention (Y-AMBIENT) for Young African American With Stage I-III Breast Cancer,2022-06-01,2024-12-31,944 days,Recruiting,Interventional
UW18063,Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS,2019-01-03,2024-12-31,2189 days,Recruiting,Interventional
N201912134,A Patient-centered Continuous and Interdisciplinary Shared Decision Making Approach for Breast Cancer Rehabilitation,2020-05-05,2021-05-05,365 days,Unknown status,Interventional
SAHZhejiangU---Breast,Application of Radiomics in Breast Cancer,2018-01-01,2028-12-01,3987 days,Recruiting,Observational
IRST174.21,"Yoga on QOL Physiological Distress&Fatigue, on Patients Affected by Breast Cancer in Adjuvant Radiotherapy",2019-08-02,2022-04-04,976 days,Unknown status,Interventional
PEAR-TNBC_ Protocol_v2.0,Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment,2022-06-06,2024-12-31,939 days,Recruiting,Observational
ML42876,The Efficacy and Safety of Neoadjuvant Trastuzumab Plus Taxane With and Without Pertuzumab Therapy,2021-04-29,2021-11-15,200 days,Recruiting,Observational
OSU-18201,Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With Lymph-Node Positive Breast Cancer,2019-01-09,2023-12-31,1817 days,"Active, not recruiting",Interventional
H-1912-010-086,To Assess the Efficacy of the LYMPHA in the Prevention of Lymphedema Following Axillary Dissection for Breast Cancer,2020-03-05,2022-02-28,725 days,Unknown status,Interventional
MHICC-2018-003,"Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia",2021-12-02,2026-01-01,1491 days,Recruiting,Observational
DAN-22220205,A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer,2022-02-02,2024-04-30,818 days,Recruiting,Interventional
UPCC 21118,"HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer",2020-10-15,2024-04-01,1264 days,Recruiting,Interventional
IRB00049171,Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer,2018-06-21,2020-03-05,623 days,Completed,Observational
MA-BC-II-002,Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer,2020-05-22,2023-12-01,1288 days,Recruiting,Interventional
I 2612022,Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer,2023-05-01,2027-05-01,1461 days,Not yet recruiting,Interventional
M21CAR,DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy,2022-07-01,2037-05-01,5418 days,Not yet recruiting,Interventional
IFOM-CPT008/2022/PO007,Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel,2022-12-15,2025-11-01,1052 days,Recruiting,Interventional
RG1122380,STEMVAC in Patients With Early Stage Triple Negative Breast Cancer,2022-11-17,2024-04-30,530 days,Recruiting,Interventional
4070,A Study Evaluating FT-SW in Unilateral Breast Cancer-Related Lymphedema Patients,2020-01-23,2020-02-08,16 days,Terminated,Interventional
RG1003977,Acute Exercise Intervention in Reducing Breast Cancer Risk in Healthy Participants,2019-03-25,2022-06-30,1193 days,Completed,Interventional
2022-0239,Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen,2022-05-01,2032-10-01,3806 days,Recruiting,Observational
20190812,Succinylated Gelatin for Prevention of Fluid Retention in Patients With Breast Cancer Receiving Docetaxel Chemotherapy,2019-09-01,2020-09-30,395 days,Completed,Interventional
BabesBolyaiOncovox,A Guided Online Intervention to Improve Quality of Life in Breast Cancer Patients - a Randomised Clinical Trial,2021-11-15,2022-05-01,167 days,Recruiting,Interventional
CADPT01A12101C,Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).,2019-01-31,2023-02-06,1467 days,Terminated,Interventional
V2011801,P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .,2021-12-30,2023-06-30,547 days,Withdrawn,Interventional
R.18.02.33,Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy,2019-08-01,2026-08-01,2557 days,Recruiting,Interventional
Exactis-05,RWD Study in HER2+ mBC Patients in Third-Line Therapy,2020-10-01,2021-05-30,241 days,Completed,Observational
R21052,Factors Influencing Breast Cancer Resection Volumes And Their Impact on Treatment Outcome (FIBRATIO),2022-05-28,2025-04-01,1039 days,Recruiting,Observational
MCC-19-14621,Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx,2019-05-10,2022-04-18,1074 days,Completed,Interventional
I-19-04120,Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer,2022-04-07,2025-04-15,1104 days,Recruiting,Interventional
042001,"INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study",2020-07-13,2023-09-30,1174 days,Recruiting,Interventional
767/29-09-2017,Vaginal Laser Therapy in Breast Cancer Survivors,2018-12-01,2020-08-01,609 days,Unknown status,Interventional
WSG-AM12,NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer,2023-08-01,2028-06-01,1766 days,Not yet recruiting,Interventional
CSIIT-C37,Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer,2023-05-01,2024-09-01,489 days,Not yet recruiting,Interventional
STUDY00002985,Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer,2021-10-22,2024-12-31,1166 days,Recruiting,Interventional
i 67518,Exercise and Nutrition Education in Improving Physical Function and Quality of Life in Older Breast Cancer Survivors,2019-03-25,2021-05-21,788 days,Terminated,Interventional
HCI153239,"Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC",2023-01-06,2027-09-30,1728 days,Suspended,Interventional
268-2017,Assessment of Left-sided Cardiac Sparing Through the Use of 3-dimensional Surface Matching-based Deep Inspiration Breath Hold and Active Breathing Control,2018-05-19,2022-01-30,1352 days,Completed,Interventional
16-304,Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma,2018-04-01,2030-04-01,4383 days,"Active, not recruiting",Interventional
2019-A02374-53,"Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer",2020-06-17,2023-03-01,987 days,Unknown status,Interventional
2022-191,Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients,2023-04-01,2027-07-01,1552 days,Not yet recruiting,Interventional
NCI-2017-02320,"Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer",2018-08-07,2018-08-07,0 days,Withdrawn,Interventional
GIM25-CAPT,Atezolizumab Plus CArboplatin Plus Nab-paclitaxel,2020-07-03,2024-07-03,1461 days,Recruiting,Interventional
ERC/2018/06/01,Case Control Study to Identify Modifiable Risk Factors for Colorectal and Breast Cancer in Nigeria,2021-04-12,2024-04-01,1085 days,Recruiting,Observational
ELA-0121,Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer,2022-08-31,2025-12-01,1188 days,Recruiting,Interventional
844978,Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts,2021-09-23,2025-07-13,1389 days,Recruiting,Observational
APPI2-PT-2020-AIMSS,Targeted Physiotherapeutic Treatment for Aromatase Inhibitor-associated Musculoskeletal Pain in Breast Cancer Survivors,2020-10-14,2023-11-30,1142 days,Recruiting,Interventional
EDP1503-101,"A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors",2018-12-19,2021-10-31,1047 days,Completed,Interventional
S2020-300,Prospective Multicenter Study on Clinical Application of Sonazoid in Breast Tumor,2020-08-15,2021-10-01,412 days,Recruiting,Observational
187519,"Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer",2019-07-08,2023-07-30,1483 days,Recruiting,Interventional
OnerCengiz,The Effect of Mindfulness Program on Spiritual Well-BeingBreast Cancer Patients,2021-09-29,2022-06-30,274 days,Completed,Interventional
PH-CP026,PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy,2018-03-01,2021-08-27,1275 days,Completed,Interventional
B1432020000025,"Pain, Nutrition and Glycemic Response in Chronic Low Back Pain and Breast Cancer Survivors",2020-09-21,2022-12-19,819 days,Completed,Interventional
IFG-05-2019,Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO,2022-07-30,2026-02-01,1282 days,Recruiting,Interventional
CTP-BRST-01,Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases,2019-11-28,2027-10-01,2864 days,Recruiting,Interventional
A221801,"Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial",2022-09-01,2027-05-01,1703 days,Not yet recruiting,Interventional
50619,Patient Outcomes From Second Film-readers and Test Threshold Relaxation in Breast Screening,2018-10-01,2023-12-30,1916 days,Enrolling by invitation,Observational
2016-0538,Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer,2019-06-07,2023-12-31,1668 days,Recruiting,Interventional
2018/455,Stochastic Modulated Vibrations on Autonomic Nervous System of Breast Cancer Patients During Radiotherapy,2019-07-04,2020-10-31,485 days,Unknown status,Interventional
MC2031,"Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer",2020-01-23,2021-11-17,664 days,Withdrawn,Interventional
2019-1237,Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy,2022-08-15,2026-12-31,1599 days,Recruiting,Observational
9988,Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors,2018-04-18,2019-07-15,453 days,Completed,Interventional
TN.32.1.17.SATF,Pilot Clinical Study on a Low-power Electromagnetic Wave Breast Imaging Device for Cancer Screening Purposes.,2018-10-10,2020-05-07,575 days,Completed,Interventional
ACT-MBC,ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC),2022-12-12,2024-12-31,750 days,Recruiting,Observational
KN026-US-I-001,KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer,2019-06-18,2022-12-31,1292 days,"Active, not recruiting",Interventional
MC1931,Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer,2020-04-28,2024-06-01,1495 days,Recruiting,Interventional
CBTMMUH,Effect of Perioperative CBT on Chronic Persistent Postsurgical Pain Among Breast Cancer Patients,2021-05-31,2023-03-02,640 days,Completed,Interventional
20180259-01H,Mid-point Transverse Process to Pleura Block for Breast Cancer Surgery: A Randomized Controlled Trial,2020-01-01,2023-12-31,1460 days,Recruiting,Interventional
2017-0502,M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer,2018-08-03,2024-12-31,2342 days,"Active, not recruiting",Interventional
PHRI.SCHOLAR-2,Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction,2021-07-01,2025-12-01,1614 days,Recruiting,Interventional
OSU-18317,Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer,2020-12-11,2024-01-02,1117 days,Recruiting,Interventional
e-OTCAT20,Telehealth Program to Prevent Cancer and Chemotherapy-related Cognitive Impairment.,2020-10-31,2023-10-30,1094 days,Enrolling by invitation,Interventional
23-050,A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction,2023-04-01,2028-04-01,1827 days,Not yet recruiting,Interventional
19447,Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors,2022-06-15,2023-06-15,365 days,Withdrawn,Interventional
20G.093,"Tai Chi for Relieving Aromatase Inhibitor-Induced Arthralgia in Patients With Stage I-III Breast Cancer, the TaiChi4Joint Trial",2020-03-11,2021-12-23,652 days,Completed,Interventional
ANI251_BCS-PI,PI-targeted PNE+MI Compared to BIOMEDICAL Education in BCS,2021-04-01,2024-04-01,1096 days,Recruiting,Interventional
NCI-2019-05187,"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer",2019-11-20,2023-11-20,1461 days,Recruiting,Interventional
OUMK59829,Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer,2022-10-01,2027-09-30,1825 days,Not yet recruiting,Interventional
STUDY00000057,"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor",2019-04-01,2023-12-01,1705 days,"Active, not recruiting",Interventional
LACOG 0122,Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study,2023-05-01,2024-07-01,427 days,Not yet recruiting,Observational
239531,Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors,2021-06-07,2024-06-01,1090 days,Recruiting,Interventional
Castle06(BC),Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy,2022-05-01,2024-04-01,701 days,Recruiting,Interventional
STUDY02000934_1,A Single Arm Pilot Study to Refine a Novel Approach to Exercise Promotion Based on Affect-regulation,2021-08-10,2022-06-13,307 days,Completed,Interventional
IFG-01-2022,"Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients",2022-10-12,2026-10-01,1450 days,Recruiting,Interventional
PI-0171-2020,Pain Treatment in a Breast Cancer Population. PaiNEd Study.,2022-04-04,2023-09-01,515 days,Recruiting,Interventional
STU-2019-0529,Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM),2020-01-22,2022-06-15,875 days,Terminated,Interventional
NBC Sur001,Targeted Biopsy of Carbon Nanoparticles Labelled Axillary Node for cN+ Breast Cancer,2020-09-24,2024-04-30,1314 days,Recruiting,Interventional
RG1718049,Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy,2018-10-25,2020-09-22,698 days,Terminated,Interventional
55457122.3.0000.5330,Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System,2022-11-09,2023-12-31,417 days,Recruiting,Observational
2020-A02045-34,The E-consult Application for Patients With Breast Cancer: Interest in Empathy and Empowerment of Patients.,2020-12-24,2022-11-16,692 days,Completed,Observational
ESPvsPECS/AOP,Comparison of Erector Spinae Plane Block With PECS II Block in Patients Undergoing Breast Cancer Surgery,2022-01-01,2023-01-01,365 days,Withdrawn,Interventional
MP-12-2021-2565,Single Pre-Operative Radiation Therapy - With Delayed or No Surgery (SPORT-DNS),2021-10-08,2028-12-31,2641 days,Recruiting,Interventional
S1703,S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer,2018-07-16,2038-01-01,7109 days,Recruiting,Interventional
OSU-19152,EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer,2020-10-07,2021-12-31,450 days,Recruiting,Interventional
2018-11-128,Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer,2019-07-19,2023-07-18,1460 days,Recruiting,Interventional
OSU-20340,Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer,2023-03-01,2024-12-31,671 days,Recruiting,Interventional
PAXMAN,Cooling Cap Trial to Prevent Permanent Chemotherapy-induced Alopecia in Breast Cancer Patients,2020-12-23,2022-08-30,615 days,Completed,Interventional
MC210303,Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast Cancer,2023-04-07,2027-03-01,1424 days,Recruiting,Interventional
2020-01097,Effect of Heavy-load Resistance Training During Chemotherapy on Muscle Cellular Outcomes,2018-12-05,2023-01-01,1488 days,"Active, not recruiting",Interventional
NL80749.058.22 DIRECT 2,"Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer",2023-05-01,2032-05-01,3288 days,Recruiting,Interventional
NCI-2022-04956,"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer",2022-09-30,2025-09-30,1096 days,Recruiting,Interventional
IRB-2022-329,Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency,2022-09-01,2025-06-30,1033 days,Not yet recruiting,Interventional
N20ESP,Ultrasound-guided Erector Spinae Plane Block Versus Paravertebral Block in Breast Cancer Patients Undergoing Mastectomy With Immediate Reconstruction - a Non-inferiority Trial,2021-06-01,2022-12-31,578 days,Recruiting,Interventional
SMC2018-09-029-003,The Effects of Anesthetics on Persistent Pain Following Breast Cancer Surgery,2018-12-31,2019-12-30,364 days,Completed,Observational
UZBRU_VHH1_3,Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients,2019-04-01,2024-12-01,2071 days,Recruiting,Interventional
17753,T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer,2020-02-05,2024-04-30,1546 days,Recruiting,Interventional
35945/10/22,Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients,2022-10-28,2024-10-28,731 days,Enrolling by invitation,Interventional
2019-5382,Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk,2019-10-24,2024-04-01,1621 days,Recruiting,Interventional
IRB00105944,"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis",2019-02-08,2023-08-10,1644 days,"Active, not recruiting",Interventional
IRB202201483,Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors,2022-11-08,2023-05-31,204 days,Recruiting,Interventional
MC18C3,Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer,2020-09-18,2024-12-01,1535 days,Recruiting,Interventional
2022-376,Digital Cognitive Behavioral Therapy for Insomnia for Chronic Insomnia in Breast Cancer Survivors,2023-04-01,2025-08-01,853 days,Not yet recruiting,Interventional
2019-1042,Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer,2021-05-03,2029-12-09,3142 days,Recruiting,Observational
20-002712,Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer,2020-09-23,2024-12-31,1560 days,Recruiting,Interventional
Gabapentin RCT,Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy,2018-07-02,2020-06-30,729 days,Unknown status,Interventional
FS-CY1502-Ph1-01,Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.,2019-10-11,2025-06-01,2060 days,Recruiting,Interventional
167514,Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib,2018-10-09,2022-10-31,1483 days,Completed,Interventional
G1T48-01,"G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer",2018-05-09,2022-09-29,1604 days,Completed,Interventional
PH-CP032,PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients,2022-06-15,2022-12-01,169 days,Recruiting,Interventional
2018-0062,Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer,2020-07-28,2025-03-31,1707 days,Recruiting,Interventional
URomLS-2019a,The Recovery of Reaching Movement in Breast Cancer Survivors: Two Different Rehabilitative Protocols in Comparison,2018-01-08,2019-07-19,557 days,Completed,Interventional
ODO-TE-B201,"Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC",2019-02-05,2021-06-11,857 days,Terminated,Interventional
ReMig,Rehabilitation on Equal Terms - The ReMig Study,2023-01-10,2025-05-15,856 days,Recruiting,Observational
MAMMoutreach,Opt-in vs. Opt-out for Breast Cancer Screening,2022-04-18,2022-08-31,135 days,Not yet recruiting,Interventional
EVE-CWM-01,Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study,2021-05-01,2021-08-30,121 days,Completed,Observational
SAFE-FORWARD,Safety of Ultra-hypofractionated Whole Breast Irradiation After Breast-conserving Surgery,2021-11-30,2022-12-01,366 days,Recruiting,Observational
20-222,Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy,2021-07-14,2023-06-15,701 days,Recruiting,Interventional
20-001275,"Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer",2020-10-09,2025-09-30,1817 days,Recruiting,Interventional
2018-8984,Low Energy Dissection Vs. Electrocautery in Lumpectomy Shaved Surgical Margins,2019-03-15,2020-06-15,458 days,Unknown status,Observational
OSU-22083,Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer,2022-12-14,2024-12-31,748 days,Recruiting,Interventional
CF22200A,Effects of an Exercise Intervention on Taxane-induced Peripheral Neuropathy in Breast Cancer Survivors,2022-12-01,2023-12-31,395 days,Not yet recruiting,Interventional
2018-0550,Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy,2019-01-14,2023-12-31,1812 days,"Active, not recruiting",Interventional
3543,Effectiveness of Ultrasound Guided PECS Block on Opioid Consumption and Patient Satisfaction Through Adequate Pain Control Following Breast Cancer Surgery.,2022-01-01,2023-08-30,606 days,Recruiting,Interventional
EstroTEP COMPARE,Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES,2020-01-01,2021-02-01,397 days,Unknown status,Interventional
230/HÄÄÄ-ÄHYD,2D Speckle-tracking Echocardiography in Chemotherapy-induced Cardiomyopathy With Cardiovascular Risk Factors,2020-09-15,2023-06-30,1018 days,Recruiting,Observational
2020-0715,Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer,2022-03-11,2028-12-31,2487 days,Recruiting,Interventional
NCI-2019-06088,Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones,2019-12-27,2023-06-30,1281 days,Recruiting,Interventional
MA-BC-II-037,Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02),2022-05-20,2026-01-01,1322 days,Recruiting,Interventional
A5481152,First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.,2020-10-13,2028-04-03,2729 days,Recruiting,Observational
S2007,Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases,2020-12-15,2026-12-01,2177 days,Recruiting,Interventional
LCZ696ABM001.001,Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM),2023-02-01,2028-02-01,1826 days,Not yet recruiting,Interventional
2018-0127,Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer,2018-08-14,2020-12-31,870 days,Unknown status,Interventional
19-004024,RBX7455 Before Surgery for the Treatment of Operable Breast Cancer,2020-08-31,2025-12-17,1934 days,"Active, not recruiting",Interventional
ANG-002,Harvest of CTCs From MBC Patients Using the Parsortixâ¢ PC1 System,2018-03-29,2019-12-31,642 days,Completed,Observational
115300-20-52703,Early Rehabilitation for Breast Cancer - A Randomized Control Trial,2021-04-01,2022-12-31,639 days,Unknown status,Interventional
MC1635,Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery,2018-02-07,2023-06-30,1969 days,"Active, not recruiting",Interventional
IIT2019-21-Basho-TOPAZ,TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases,2022-06-01,2024-06-01,731 days,Withdrawn,Interventional
81603703,Effects of Infrared Laser Moxibustion on Cancer-related Fatigue in Breast Cancer Patients,2018-06-20,2021-07-27,1133 days,Completed,Interventional
38RC20.120,"Complications After Lumpectomy, Sentinel Node and Radiotherapy in Breast Cancer Patients and Physiotherapy Care",2021-06-01,2022-01-28,241 days,Completed,Observational
BTCRC BRE15-024,Ribociclib and Bicalutamide in AR+ TNBC,2018-05-07,2024-09-01,2309 days,Recruiting,Interventional
2021-375,Efficacy of Metformin as Preventive Treatment in Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients,2022-04-12,2022-10-30,201 days,Completed,Interventional
3474028/2019,Effects of the Anchor System in the Postural Stability,2020-03-01,2024-03-01,1461 days,Recruiting,Interventional
2020-0245,"Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial",2021-03-07,2022-02-16,346 days,Withdrawn,Interventional
18-000427,"Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted",2019-07-10,2024-07-01,1818 days,"Active, not recruiting",Interventional
CASE11119,Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program,2021-01-06,2023-12-01,1059 days,Recruiting,Interventional
ZLYNXM202014,Identification and Preservation of Arm Lymphatics,2020-06-20,2025-09-30,1928 days,Recruiting,Interventional
19.07,ImmunoBreast - A Phase Ib Study,2020-04-21,2023-05-21,1125 days,Recruiting,Interventional
REaCT-Low Risk HER-2,A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer,2019-05-01,2022-05-11,1106 days,Completed,Interventional
D19160,Lumpectomy Specimen Margin Evaluation With Tomography and Structured Light Imaging,2020-02-06,2022-03-16,769 days,Completed,Observational
PRO00035701,"Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer",2021-10-21,2028-01-01,2263 days,Withdrawn,Interventional
REaCT-CHRONO,Evaluating the Dose Timing (Morning vs Evening) of Endocrine Therapy and Its Effects on Tolerability and Compliance,2021-06-30,2023-08-01,762 days,"Active, not recruiting",Interventional
Acu-CIPN,Acupuncture in Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer,2020-09-01,2023-12-01,1186 days,Recruiting,Interventional
202104085,Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma,2021-08-12,2029-06-30,2879 days,Recruiting,Interventional
ZL-MG-BC-001,A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC,2020-08-25,2021-04-27,245 days,Completed,Interventional
P170104J,"A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer",2018-06-27,2022-06-01,1435 days,Unknown status,Interventional
Pro00104214,Well-Being After Breast Cancer Surgery,2021-06-08,2025-04-30,1422 days,Recruiting,Interventional
CLEE011AIT01,"Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant",2018-02-02,2024-07-01,2341 days,"Active, not recruiting",Interventional
MedOPP150,"First Line Atezolizumab, Paclitaxel, and Bevacizumab (AvastinÂ®) in mTNBC",2020-10-05,2023-12-01,1152 days,Recruiting,Interventional
ODO-TE-B202,Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC,2019-07-09,2021-06-23,715 days,Terminated,Interventional
IO Panel,Tumor Immune Mechanism of Axillary Lymph Node Metastasis in Early Luminal Type A Breast Cancer,2020-05-01,2021-12-31,609 days,Unknown status,Observational
Study00146761,Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers,2021-12-02,2023-12-31,759 days,Recruiting,Interventional
17-546,Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC,2018-05-21,2025-12-01,2751 days,"Active, not recruiting",Interventional
DRACARYS,Dragonboat Activity for Breast Cancer,2021-05-15,2021-09-30,138 days,Completed,Interventional
PA18-1077,"Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery",2019-05-21,2023-03-31,1410 days,Recruiting,Observational
RIPH2_BREYSSE_ETAPH,"Therapeutic Education and Nursing Support Program for Supportive Care, in Patients Treated With Hormone Therapy for Non-metastatic Breast Cancer",2021-08-09,2024-08-01,1088 days,Recruiting,Interventional
I 60217,Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects,2018-10-18,2023-06-18,1704 days,Recruiting,Interventional
21-001819,"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer",2022-04-07,2025-04-01,1090 days,Recruiting,Interventional
ARC-2 (AB928CSP0002),A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies,2018-10-15,2021-07-02,991 days,Completed,Interventional
IRB00076577,Oral Aromatase Inhibitors Modify the Gut Microbiome,2022-03-29,2023-09-01,521 days,Recruiting,Observational
RJ-101-RCT-001,Study to Investigate the Effect of AB-101 in Breast Cancer Survivors,2018-07-09,2019-10-12,460 days,Completed,Interventional
KEK 2021-D0051,HER2-directed Biosimilar in Breast Cancer: Real World ePRO,2021-12-14,2023-06-30,563 days,Recruiting,Observational
SCHBCC-N046,FUSCC Refractory TNBC Platform Study (FUTURE2.0),2023-03-01,2026-06-01,1188 days,Not yet recruiting,Interventional
2021-1151-002,OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk,2023-02-06,2033-01-01,3617 days,Recruiting,Interventional
Aqua POLO-IPC 2019-028,Feasibility Study of an Adapted and Supported Water Polo Program to Reduce Fatigue Related to Cancer and Improve Psychological and Social Recovery in Patients With Breast Cancer Remission,2021-03-15,2021-12-31,291 days,Unknown status,Interventional
OSU-20408,An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors,2021-11-01,2024-12-31,1156 days,Recruiting,Interventional
21D.625,Intermittent Fasting for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery,2022-07-28,2024-05-01,643 days,Suspended,Interventional
TNBC-NEO,Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC,2019-05-10,2026-05-01,2548 days,Withdrawn,Interventional
RD19/125787,Guide for Prioritisation of Patients for Referral to Breast Clinics,2020-02-12,2023-02-11,1095 days,Suspended,Observational
13/21,Continuous Pectoral Nerve Block in Breast Cancer Surgery,2019-07-30,2019-11-15,108 days,Completed,Interventional
NCI-2017-01960,Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer,2018-06-15,2022-03-25,1379 days,Completed,Interventional
USB_22 Trial,Serratus Anterior Plane Block to Prevent Chronic Postoperative Pain in Breast Cancer,2022-08-01,2023-07-31,364 days,Recruiting,Interventional
YOUNGBC-12,Eribulin in mTNBC Patients,2019-12-15,2020-12-20,371 days,Completed,Observational
CSIIT-C25,Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC,2022-05-23,2024-05-23,731 days,Recruiting,Interventional
SAKK 95/17,Activity Program During Aromatase Inhibitor Therapy,2019-03-28,2025-12-01,2440 days,"Active, not recruiting",Interventional
2018-A01019-46,Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer,2018-09-13,2022-03-23,1287 days,Completed,Interventional
Fisioterapia en Linfedema,Effects of Physiotherapy in the Treatment of Lymphedema After Breast Cancer,2022-03-01,2022-10-27,240 days,Completed,Interventional
2019-0752,Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations,2020-02-05,2023-12-31,1425 days,"Active, not recruiting",Interventional
STUDY00003705,Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer,2022-10-19,2023-03-31,163 days,Recruiting,Interventional
CL 2775,Use of Topical Olive Oil Cream for Prophylaxis Against Acute Radiodermatitis in Breast Cancer Patients,2021-11-04,2023-06-01,574 days,Recruiting,Interventional
STUDY00003782,RAGE Inhibition to Decrease Therapy Cardiotoxicity in Women With Early Breast Cancer,2023-05-01,2024-11-01,550 days,Recruiting,Interventional
X9001194,UK Ibrance Patient Program (IPP) Study,2019-03-01,2021-03-04,734 days,Completed,Observational
MUST-02-001,Safety and Performance of the Multi-Modal UltraSound Tomography (MUST) Device in Breast Cancer Screening,2020-01-14,2021-11-01,657 days,Unknown status,Interventional
UEM QuirÃ³n,Effects of a Physical Exercise Intervention During Neoadjuvant Chemotherapy in Women With Breast Cancer,2019-11-01,2022-01-01,792 days,Unknown status,Interventional
IB2022-04,Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer.,2023-02-01,2024-12-01,669 days,Recruiting,Interventional
D5336C00001,To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.,2018-03-07,2023-09-29,2032 days,"Active, not recruiting",Interventional
CE 193/17,"Oxidative Stress, Anxiety and Depression in Breast Cancer Patients: Impact of Music Therapy",2018-02-01,2019-12-31,698 days,Completed,Interventional
IRAS 314460,CLI and FAR for Intraoperative Margin Assessment,2022-10-30,2024-12-31,793 days,Not yet recruiting,Interventional
UPCC12118,Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab,2019-08-09,2024-12-31,1971 days,"Active, not recruiting",Interventional
LCCC 1716,PET/MR in Surgical Planning for Breast CA Treated With Neoadj Chemo,2018-12-05,2020-02-17,439 days,Terminated,Interventional
YL202-INT-101-01,A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer,2022-12-20,2025-12-01,1077 days,Recruiting,Interventional
227/KEPK/IX/2022,The Effectiveness of Lymphatic Bypass Supermicrosurgery,2022-10-06,2024-07-01,634 days,Recruiting,Interventional
OFA,Opioid Free Anesthesia in Breast Cancer Surgery,2020-07-01,2022-03-15,622 days,Completed,Interventional
STUDY00021243,Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer,2021-06-07,2024-06-30,1119 days,Recruiting,Interventional
HNCH-2022KY59,UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases,2022-08-01,2025-07-01,1065 days,Recruiting,Interventional
Prevention of radiodermatitis,Photobiomodulation for Prevention of Radiodermatitis in Women With Breast Cancer Undergoing Adjuvant Radiotherapy,2023-02-06,2025-02-06,731 days,Not yet recruiting,Interventional
EXERT-BC,"EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Breast CA",2022-10-01,2023-08-01,304 days,Recruiting,Observational
D3614C00001,Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC,2019-06-25,2023-10-06,1564 days,Recruiting,Interventional
AH150202-1,"Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin",2020-06-30,2023-06-30,1095 days,Recruiting,Interventional
yifeng,Prevalence and Risk Factors for Pain and Related Adverse Reactions Among Breast Cancer Survivors on Aromatase Inhibitors,2022-12-30,2023-04-20,111 days,Recruiting,Observational
MEC-2021-0829,An Integrated Optimization of Surgery and Radiotherapy Techniques to Improve Cosmetic Outcome and Quality of Life in Breast Conserving Therapy for Breast Cancer Patients (STARLINGS Study),2022-04-11,2025-09-01,1239 days,Recruiting,Observational
YOUNGBC-23,The Rechallenge of ADCs in MBC Patients,2022-09-01,2024-09-01,731 days,"Active, not recruiting",Observational
D8530C00007,AZD9833 China PK Study,2021-11-12,2023-11-13,731 days,Recruiting,Interventional
NEODOC-2021668610-165,Evaluation of NeoNaviaÂ® Biopsy System in Axillary Lymph Nodes,2019-02-14,2021-06-30,867 days,Unknown status,Observational
21-194,"A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer",2021-09-09,2023-09-09,730 days,Recruiting,Interventional
Exactis-03,Combination of Olaparib and Navitoclax in Women With HGSC and TNBC,2022-11-09,2025-04-28,901 days,Recruiting,Interventional
MedOPP100,A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent,2018-04-17,2021-12-31,1354 days,Terminated,Interventional
SYSU003-2020,Nail Changes Associated With Chemotherapy and Prevention of Nail Pigmentation by Ice Water Immersion,2020-02-01,2022-12-01,1034 days,Unknown status,Interventional
MS201922_0010,Study of M4344 in Combination With Niraparib,2020-12-01,2023-09-01,1004 days,Withdrawn,Interventional
HR-BLTN-III-MBC-C,A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer,2019-04-22,2024-07-30,1926 days,"Active, not recruiting",Interventional
ZWI-ZW25-202,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,2020-06-10,2023-06-30,1115 days,"Active, not recruiting",Interventional
MC1892,Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy,2018-09-10,2021-09-10,1096 days,Withdrawn,Interventional
MC1734,"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer",2020-01-10,2023-07-31,1298 days,Recruiting,Interventional
UW20058,Intraoperative Evaluation of Axillary Lymphatics,2022-05-05,2023-06-01,392 days,Recruiting,Interventional
DokuzEUBanuNihan,Diagnostic Contribution of Ultrasonography in Breast Cancer-Related Lymphedema,2020-01-02,2020-01-31,29 days,Completed,Interventional
202207200MIPB,"A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC",2022-09-16,2026-09-30,1475 days,Recruiting,Interventional
2019COIMBRA001,Combining Interventions of Fertility Preservation to Mitigate Fertility Loss After Breast Cancer,2020-11-01,2021-12-31,425 days,Unknown status,Interventional
TADANAC,Targeted Axillary Dissection After Neo-adjuvant Chemotherapy,2021-04-21,2024-06-01,1137 days,Recruiting,Observational
00055029,Investigation of a Digital Healthy Habits Program for Individuals With Breast Cancer,2021-07-05,2021-08-12,38 days,Completed,Observational
C4391002,A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors,2022-03-14,2027-12-30,2117 days,Recruiting,Interventional
CPH-2022-10-MHS-2,Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine,2022-12-08,2023-11-01,328 days,Recruiting,Interventional
HCRN BRE17-141,Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers,2022-07-21,2024-02-01,560 days,Recruiting,Interventional
YOUNGBC-11,First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients,2020-08-25,2023-10-15,1146 days,Recruiting,Interventional
C4891018,A Study to Learn About the Study Medicine (Called ARV-471) in People With ER+/HER2- Advanced BC in China,2023-02-20,2024-12-03,652 days,Recruiting,Interventional
P-2020-246,Stick Together - Pilot Intervention Study,2023-02-01,2024-05-31,485 days,Enrolling by invitation,Interventional
YOUNGBC-18,Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC,2022-06-15,2025-03-15,1004 days,Recruiting,Interventional
SHR-1210-APTN-IIT-TNBC,A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC,2018-01-10,2020-09-30,994 days,Completed,Interventional
PF008,Treatment Patterns of Neratinib in HER2+ EBC in China,2022-09-30,2026-06-30,1369 days,Not yet recruiting,Observational
FMUUH-BC-2201,PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients,2023-01-27,2024-05-31,490 days,Not yet recruiting,Interventional
20-153,Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC,2020-09-23,2027-06-01,2442 days,Recruiting,Interventional
OBU-BC-II-024,Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer,2020-07-01,2026-12-01,2344 days,Recruiting,Interventional
328717,Effects of a Physical Exercise and Health Education Program for Women With Breast Cancer Undergoing Chemotherapy,2019-03-01,2023-01-31,1432 days,Unknown status,Interventional
2066383,Metacognitive Strategy Training in Cancer-related Cognitive Impairment,2022-08-09,2024-06-01,662 days,Recruiting,Interventional
2021-5644,App for Adverse Events to Oral Chemotherapy - Pilot Study,2023-01-16,2023-12-31,349 days,Recruiting,Interventional
MC1935,Assessing the Rate of Complications in X-Ray Therapy Versus Proton Beam Radiation Therapy After Breast Conserving Surgery or Mastectomy in Treating Patients With Breast Cancer,2020-06-01,2024-06-01,1461 days,Recruiting,Interventional
19F.265,A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer,2018-11-07,2024-05-31,2032 days,Recruiting,Interventional
201901698B0,Music Therapy in Patients With Breast Cancer- a Randomized Controlled Trial,2020-09-01,2020-12-31,121 days,Unknown status,Interventional
2,A Feasibility Study of the Bone@BC App Version 3.0,2022-12-01,2024-10-30,699 days,Not yet recruiting,Interventional
2018-0477,Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer,2019-04-01,2023-08-01,1583 days,Recruiting,Observational
MedOPP253,Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer,2020-10-08,2024-01-31,1210 days,"Active, not recruiting",Interventional
S-20180117,Treatment of Breast Cancer-related Lymphedema With Stem Cells and Fat Grafting,2018-12-18,2021-06-01,896 days,Completed,Interventional
BZ01/17,Effect of Quilting Sutures on Post-operative Drainage After Mastectomy and/or Axillary Lymph Node Dissection,2019-02-19,2020-10-01,590 days,Terminated,Interventional
712,Effects of Interpectoral-Pectoserratus Plane Block After Breast Cancer Surgery,2022-10-06,2023-04-06,182 days,Not yet recruiting,Observational
RC48-C006,A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases,2018-04-24,2023-12-31,2077 days,Recruiting,Interventional
KGYY-001,Plasmodium Immunotherapy for Breast and Liver Cancers,2018-08-10,2021-12-31,1239 days,Unknown status,Interventional
1808852902,"Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets",2018-12-19,2021-04-26,859 days,Completed,Interventional
UHaiArtBC,The Role of Emotional Processing in Improving the Quality of Life of Breast Cancer Patients,2019-06-11,2022-06-10,1095 days,Completed,Interventional
16381,Responsiveness to Acute Changes in Exercise and Relaxation (RACER) Trial,2018-10-15,2019-02-28,136 days,Completed,Interventional
NL67059.068.18,Microsurgical Treatment of Breast Cancer-related Lymphedema by Lymphaticovenous Anastomosis,2019-01-01,2022-08-01,1308 days,Recruiting,Interventional
WHUH-BC-001,Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received â¦ 1 Line of Chemotherapy,2021-10-01,2024-10-01,1096 days,Not yet recruiting,Interventional
ALRN-6924-1-05,A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer,2023-01-09,2023-02-22,44 days,Terminated,Interventional
202301160RINA,Novel MRI Techniques on Evaluation of Lymphedema,2023-04-10,2026-12-01,1331 days,Recruiting,Observational
IRB00223131,Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study,2021-02-08,2023-12-31,1056 days,"Active, not recruiting",Interventional
202111198,Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM),2023-04-30,2029-10-31,2376 days,Not yet recruiting,Interventional
Shengjing-LCG003,Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy,2021-07-19,2026-05-31,1777 days,Not yet recruiting,Interventional
AHQU-2022002,Personalized Electroacupuncture Treatment for Chemotherapy-induced Nausea and Vomiting in Breast Cancer (PET),2022-03-15,2024-12-31,1022 days,Recruiting,Interventional
IC 2019-04,MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery,2020-08-04,2022-01-28,542 days,Completed,Interventional
STU00201961B,A Research Study for Latina Women With Breast Cancer,2021-04-01,2023-04-25,754 days,"Active, not recruiting",Interventional
2-107-05-079,Use of a Remifentanil-propofol Mixture in Patients Undergoing Breast Cancer Surgery,2018-08-03,2018-12-27,146 days,Completed,Interventional
2001272738,Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women,2022-08-30,2025-08-30,1096 days,Withdrawn,Observational
2018/781,Pre-operative Hypnosis to Prevent Side Effects After Surgery,2018-05-01,2020-12-31,975 days,Completed,Interventional
2012-090-1182,Shared Decision Making in Surveillance for Distant Metastasis in Breast Cancer,2021-07-06,2024-01-31,939 days,Enrolling by invitation,Interventional
IRB00054587,Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases,2019-03-13,2023-08-01,1602 days,Recruiting,Interventional
VSN-18-199,The Effects of Light Therapy to Treat Cancer-related Side Effects,2020-06-08,2024-07-01,1484 days,Recruiting,Interventional
2022YF035-01,Dalpiciclib Plus Letrozole and Capecitabine,2022-08-10,2024-08-01,722 days,Not yet recruiting,Interventional
22-544,TRUDI: TDXD+Durva in HER2+/Low IBC,2023-06-01,2032-12-01,3471 days,Not yet recruiting,Interventional
2019-06-027,Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation,2019-10-17,2021-12-31,806 days,Unknown status,Observational
MRI in response assesment,Functional MRI in Predicting Response to Chemotherapy,2019-06-15,2023-12-30,1659 days,Recruiting,Observational
021-013772,Marker Technique Comparison in Targeted Axillary Dissection,2023-07-01,2025-01-01,550 days,Not yet recruiting,Interventional
GCO 15-1783,Systematic Light Exposure for Fatigue in Breast Cancer Patients,2018-01-25,2022-04-30,1556 days,Recruiting,Interventional
1191/2018,"Exercise, Cancer and Cognition: The ECCO-Study",2019-12-01,2025-12-01,2192 days,Recruiting,Interventional
NCI-2017-01119,Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer,2019-03-12,2024-04-30,1876 days,"Active, not recruiting",Interventional
UAB 1794,"Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD",2019-02-20,2024-07-22,1979 days,"Active, not recruiting",Interventional
19-5080,Cardio-Oncology Rehabilitation Exercise,2022-03-14,2023-12-01,627 days,Recruiting,Observational
METIS,ACH-TH vs EC-TH as Neoadjuvant Therapy for HER2-positive EBC,2019-01-10,2022-01-01,1087 days,Unknown status,Interventional
IUSCC-0616 (1709077419),Investigating the Preventative Ability of Massage Therapy on Paclitaxel Induced Peripheral Neuropathy,2018-02-08,2018-10-15,249 days,Terminated,Interventional
IRB00092014,IORT-Breast at Medical Center Navicent Health,2019-03-19,2029-12-31,3940 days,Recruiting,Observational
APA-PG1,Adapted Physical Activity (APA) in a Breast Cancer Population.,2019-01-01,2022-12-31,1460 days,"Active, not recruiting",Interventional
26778919.3.0000.0072,Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer,2020-01-30,2022-02-28,760 days,Unknown status,Interventional
HSM/VGH-2017-01-011AC,Effects of Naturalistic Decision-Making Model-based Oncofertility Care Education,2018-05-01,2020-08-30,852 days,Completed,Interventional
H2207-207-1346,Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor,2022-12-31,2025-12-31,1096 days,Not yet recruiting,Interventional
CRM-BRE-002,The Malaysian Soy and Mammographic Density Study,2018-11-19,2020-06-01,560 days,Unknown status,Interventional
BC-TATOO-2020,Application of Preoperative Axillary Lymph Node Marking With Nano-Carbon in Breast Cancer Patients Before Neoadjuvant Chemotherapy,2020-03-01,2023-03-31,1125 days,Recruiting,Interventional
ICO-N-2018-03,Sentinel Lymph Node After Neoadjuvant Chemotherapy in Breast Carcinoma,2019-01-08,2023-10-01,1727 days,Recruiting,Interventional
20190511,Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy,2019-12-01,2021-06-01,548 days,Completed,Interventional
RG1121659,Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer,2022-01-23,2023-09-30,615 days,Recruiting,Interventional
17-AKD-186,Erector Spinae Block in Segmental Mastectomy.,2018-04-03,2019-05-01,393 days,Unknown status,Interventional
Immuno2020-01,A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC,2020-03-25,2023-08-31,1254 days,"Active, not recruiting",Interventional
BGB-A317-ZW25-101,Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab,2020-03-26,2026-12-31,2471 days,"Active, not recruiting",Interventional
STUDY00011444,Nurse AMIE: Addressing Metastatic Individuals Everyday,2019-03-01,2020-09-01,550 days,Completed,Interventional
TQB3616-â¢-02,"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Flulvesant Versus Placebo in Combination With Flulvesant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer",2022-06-01,2026-06-01,1461 days,Not yet recruiting,Interventional
ATOX-2018,Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer,2019-01-15,2027-01-31,2938 days,Recruiting,Interventional
A5481150,Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC,2021-07-15,2025-04-30,1385 days,Recruiting,Observational
SHAW001,Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients,2023-01-01,2026-12-31,1460 days,Not yet recruiting,Interventional
71306642-5/24,Serratus Plane Plus Pectoral I Block Versus Serratus Plane Block for Perioperative Analgesia in Breast Cancer Surgery,2019-04-06,2019-09-20,167 days,Completed,Interventional
CETC 002,Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell Phenotype in Relation to Patient Age.,2021-07-01,2026-12-31,2009 days,Recruiting,Observational
2021-0077,Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer,2021-11-04,2025-12-31,1518 days,Recruiting,Interventional
SYSA1501-CSP-005,"DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer",2022-05-01,2023-12-31,609 days,Not yet recruiting,Interventional
00031569,Photoacoustic Lymph Node Imaging,2019-11-01,2025-12-31,2252 days,Suspended,Observational
1028595,Chemotherapy-Induced Peripheral Neuropathy-Essential Oil Intervention,2018-06-25,2019-12-30,553 days,Completed,Interventional
QoLMa,Quality of Life Improvement During Chemotherapy,2021-07-31,2024-12-30,1248 days,Recruiting,Interventional
CTPR-0015,"An Efficacy Study of the XoftÂ® AxxentÂ® eBxÂ® IORT SystemÂ® ""Lite""",2022-06-30,2034-06-30,4383 days,Withdrawn,Interventional
FZPL-Ib-105,A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC,2019-06-04,2021-02-09,616 days,Completed,Interventional
TDM of TAM,Therapeutic Dose Monitoring (TDM) of Tamoxifen,2022-04-04,2023-03-01,331 days,"Active, not recruiting",Interventional
STUDY20110029,Screening Contrast-Enhanced Mammography as an Alternative to MRI,2021-02-15,2024-01-31,1080 days,"Active, not recruiting",Interventional
ECP 250 - 15/16,Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer,2018-10-01,2020-09-30,730 days,Unknown status,Interventional
CTR20220630,Mindfulness Yoga and Sexual Functioning,2022-08-01,2024-08-01,731 days,Not yet recruiting,Interventional
2022-001,Deformable Image Registration for Breast Adaptive Tomotherapy,2022-06-27,2023-04-04,281 days,Completed,Observational
REC 22/WA/0164,Acceptance and Usability of an App Promoting Healthy Behaviours Amongst Young Women at Increased Risk of Breast Cancer,2022-11-03,2023-03-10,127 days,Completed,Interventional
2019DEPO-TRIGGER001,DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation,2020-11-01,2021-12-31,425 days,Unknown status,Interventional
OSU-16288,Nipple Aspirate Fluid in Detecting Breast Cancer,2019-07-25,2023-12-31,1620 days,Recruiting,Interventional
20.478.486,Is Breast Massage Necessary to Find Sentinel Lymph Node?,2021-12-06,2023-08-01,603 days,Recruiting,Interventional
829400,Abbreviated Breast MRI After Cancer Treatment,2018-09-07,2024-09-30,2215 days,"Active, not recruiting",Observational
J16146,Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins,2018-01-26,2023-07-01,1982 days,Recruiting,Interventional
2022-A02337-36,4D CT Scan With Respiratory Gating Versus 3D CT Scan Concerning Cardiac Dosimetry Assesment for Left Sided Breast Cancers Radiotherapy.,2023-02-01,2023-06-01,120 days,Not yet recruiting,Interventional
STUDY00001721,Evaluation of Hydroxychloroquine to Prevent CIPN,2023-06-01,2024-12-01,549 days,Not yet recruiting,Interventional
H19017,Somatic Acupressure for Symptom Cluster Management in Breast Cancer Patients,2021-03-15,2022-07-20,492 days,Completed,Interventional
1100903,Effect of Acupuncture vs Chinese Medicine vs Combined Therapy on Aromatase Inhibitor-related Arthralgia Among Women With Early-Stage Breast Cancer,2022-05-05,2023-03-03,302 days,Recruiting,Interventional
LAAVA2,Laser Therapy for Vulvovaginal Symptoms in Breast Cancer Patients,2018-07-24,2021-10-01,1165 days,Unknown status,Interventional
BXu-1839,The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency,2019-02-22,2024-12-01,2109 days,Recruiting,Interventional
NABP201801,A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC,2018-12-21,2020-07-30,587 days,Suspended,Interventional
RG1121642,Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer,2022-06-09,2024-11-01,876 days,Recruiting,Interventional
C-plus-Pairs,"A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.",2023-03-01,2023-09-01,184 days,Recruiting,Interventional
46.20 PAR ComEt CBM,Breast Stereotactic Radiotherapy to Primary Tumors in Metastatic Patients,2020-07-10,2023-04-10,1004 days,Recruiting,Interventional
URomLS_4,Metabolomic Evaluation of Psycho-surgical Synergy on Body Image Restoration After Breast Cancer,2022-10-26,2024-01-30,461 days,Recruiting,Interventional
012418QM,Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC,2018-12-19,2026-01-30,2599 days,"Active, not recruiting",Interventional
R_ReLoCC,Registry of Local Recurrences After Breast-conserving Surgery,2023-01-01,2026-06-01,1247 days,Not yet recruiting,Observational
2020466,PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC,2021-03-01,2024-03-01,1096 days,Not yet recruiting,Interventional
SYM011,AKY15-HK-301_NEPA Study,2018-02-27,2025-12-31,2864 days,Recruiting,Interventional
2021-0031,"An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer",2021-04-08,2024-03-01,1058 days,Recruiting,Interventional
16-0040-02,Pink Warrior 2: Teleconference-based Gaming Support,2020-05-11,2022-03-29,687 days,Completed,Interventional
X4P-001-201,"A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC",2021-07-21,2023-05-21,669 days,Enrolling by invitation,Interventional
2022-008,Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C),2022-12-15,2030-12-15,2922 days,Not yet recruiting,Interventional
2017-0479,Comprehensive Lifestyle Change To Prevent Breast Cancer,2019-04-04,2022-09-01,1246 days,Recruiting,Interventional
SYSU-2022-01,Mechanism Exploration of Anti-HER-2 Small-molecule Tyrosine Kinase Inhibitor-related Diarrhea and Establishment of Prevention and Treatment Model(Measure),2023-04-12,2024-08-01,477 days,Recruiting,Interventional
SAKK 21/18,Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC,2019-06-25,2021-04-15,660 days,Terminated,Interventional
HelouEl,Factor Influencing Breast Surgery Type Decision-Making,2022-06-15,2022-08-19,65 days,Completed,Observational
2018/827,Aspects of Breast-conserving Surgery,2019-01-01,2022-06-30,1276 days,Completed,Observational
RWS-PEGCSF,Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer,2019-01-20,2021-12-31,1076 days,Unknown status,Observational
736-19,The Patterns of Activity and Cognition During Treatment (PACT) Study,2021-01-15,2022-10-31,654 days,"Active, not recruiting",Interventional
198411013011,The Effect of Walking Exercise Based on TOUS on Peripheral Neuropathy and Arthralgia-Myalgia in Women With Breast Cancer,2022-07-20,2023-10-06,443 days,Recruiting,Interventional
AP1907-50101,Perioperative Analgesic Modalities for Breast Cancer Surgeries,2020-01-28,2020-07-01,155 days,Completed,Interventional
YOUNGBC-13,18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response,2018-09-01,2020-07-24,692 days,Completed,Observational
2021-19,The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC,2021-09-15,2025-12-31,1568 days,Recruiting,Interventional
A5481170,European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies,2022-02-08,2023-03-30,415 days,Recruiting,Observational
RLY-5836-101,First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors,2023-03-29,2026-01-13,1021 days,Recruiting,Interventional
BRI-ROL-001,Combination Study of SV-BR-1-GM With Retifanlimab,2018-03-16,2023-06-30,1932 days,Recruiting,Interventional
RP-PG-1214-20016,What Are the Benefits and Harms of Risk Stratified Screening in the NHS Breast Screening Programme: Study Protocol,2019-08-01,2022-06-30,1064 days,Completed,Interventional
220287,The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies,2023-04-01,2025-03-15,714 days,Not yet recruiting,Interventional
PI17/01687,Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity,2018-08-01,2022-03-01,1308 days,"Active, not recruiting",Interventional
BCP-25,Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study),2019-03-07,2023-12-31,1760 days,Recruiting,Interventional
20210312/2,Neoadjuvant Chemotherapy in Breast Cancer,2021-03-12,2024-03-30,1114 days,Recruiting,Interventional
2018-1518,"Pain, Psychological, and Endocannabinoid Responses to Yoga in Breast Cancer Survivors With Chemotherapy-induced Neuropathic Pain",2019-07-31,2020-02-03,187 days,Completed,Interventional
EUBREAST-4,MEthods for LOcalization of Different Types of Breast Lesions,2023-01-01,2026-12-01,1430 days,Recruiting,Observational
UCI 18-79 [HS# 2020-5660],Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer,2020-07-23,2022-02-16,573 days,Terminated,Interventional
ePOST,Efficacy of Point Of Service Testing in MBC,2019-06-11,2024-08-01,1878 days,Recruiting,Interventional
URCC16070,Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer,2018-04-19,2025-06-30,2629 days,Recruiting,Interventional
Shengjing-LJY06,Axillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant Chemotherapy,2021-11-01,2028-10-31,2556 days,Recruiting,Interventional
Pro00105104,Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477),2020-11-13,2021-05-05,173 days,Terminated,Interventional
202210064DIPD,"LLLT for BCRL: a Randomized, Placebo-controlled Study",2023-02-15,2024-10-31,624 days,Not yet recruiting,Interventional
PERT.21.001,"A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)",2022-09-17,2024-12-31,836 days,Not yet recruiting,Interventional
HCI140278,[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial,2021-03-31,2025-04-30,1491 days,Recruiting,Interventional
MedOPP068,PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA),2019-04-05,2022-11-30,1335 days,Completed,Interventional
69HCL17_0480,Collaborative Self-Management Support in Chronic Conditions - Qualitative Study,2018-04-14,2019-06-27,439 days,Completed,Observational
KCT003,A Multi-center Randomized Control Cross-over Study to Evaluate the Safety and Effectiveness of the Dayspring Active Wearable Compression Device vs. an Advanced Pneumatic Compression Device for Treating Breast Cancer Related Lymphedema,2021-06-01,2021-12-31,213 days,Recruiting,Interventional
SILMET_0107665,SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET),2023-01-02,2027-01-01,1460 days,Recruiting,Interventional
S-20180134,Prevention of Breast Cancer-related Lymphedma With Tacrolimus,2020-02-26,2022-09-01,918 days,"Active, not recruiting",Interventional
241379,Carbon Dye Tattooing of Biopsied Axillary Node in Breast Cancer,2018-04-27,2019-07-31,460 days,Completed,Interventional
A5481158,Swedish Ibrance Registries Insights (SIRI),2020-12-15,2022-12-31,746 days,Recruiting,Observational
2021/270,Effect of Nurse-led Supportive Care on Quality of Life,2022-01-03,2022-06-10,158 days,Completed,Interventional
EUBREAST-11R,International Prospective REgistry on Pre-pectorAl Breast REconstruction,2023-05-10,2027-05-10,1461 days,Not yet recruiting,Observational
202109031MIPD,"Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC",2023-01-17,2025-12-31,1079 days,Recruiting,Interventional
00048814,Mobile Behavior Change Program for Weight Loss in Breast Cancer Survivors,2021-03-24,2021-10-01,191 days,Completed,Interventional
JD-LK-2022-136-01,"Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)",2022-10-30,2024-10-17,718 days,Not yet recruiting,Interventional
2017/12-SBO-GHMG,Autohypnosis and Cancerology,2018-05-23,2022-07-01,1500 days,Completed,Interventional
WSG-NIS04 / PROOFS,PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS,2022-12-07,2035-06-01,4559 days,Recruiting,Observational
LYT-100-2020-01,LYT-100 in Healthy Volunteers and BCRL,2020-03-01,2022-09-09,922 days,Completed,Interventional
SCHBCC-N023,Patient Report Outcome-Reconstruction and Oncoplastic Cohort,2019-07-01,2024-12-30,2009 days,Recruiting,Observational
2017-0328,Development of Exercise Promotion Program Using a Mobile Community,2018-01-30,2018-12-31,335 days,Completed,Interventional
2179 CE,Music Listening in Radiotherapy Treatment,2018-03-05,2020-09-30,940 days,Completed,Interventional
Pro00117242,Moving Forward Together 4,2022-11-01,2025-01-01,792 days,Recruiting,Interventional
MC1937,Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer,2020-07-27,2028-07-27,2922 days,Recruiting,Observational
2018-A03054-51,Loreline Study: Characterization of Long Responders Under Eribuline,2019-08-23,2021-02-28,555 days,Completed,Observational
US-003,Magseed Enabled Long-Term Localization of Axillary Lymph Nodes,2019-06-13,2024-04-01,1754 days,Recruiting,Interventional
7119-002,Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002),2022-06-29,2025-12-29,1279 days,"Active, not recruiting",Interventional
21-169,Scalp Cooling in MBC,2021-10-07,2026-06-01,1698 days,Recruiting,Interventional
2018-002,Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast,2019-06-21,2023-04-15,1394 days,Unknown status,Interventional
12345,The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer,2021-01-28,2024-01-28,1095 days,"Active, not recruiting",Interventional
GLSI-21-01,Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects,2022-08-11,2026-12-01,1573 days,Recruiting,Interventional
A221702,Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection,2019-05-31,2024-01-01,1676 days,Recruiting,Interventional
22-006606,3D Ultrasound for the Imaging of Axillary Lymph Nodes in Patients With Breast Cancer,2023-02-14,2025-04-01,777 days,Recruiting,Interventional
CAPRICE,Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study,2019-05-01,2023-01-31,1371 days,Terminated,Interventional
CT/2019/CANFLAX,Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study?,2020-10-21,2022-12-31,801 days,Unknown status,Interventional
20-754,Axillary Lymph Node Tattoo Marking Study,2021-12-29,2025-06-30,1279 days,Recruiting,Interventional
URomLS-2019,The Sequelae of Mastectomy and Quadrantectomy Respect to the Reaching Movement in Breast Cancer Survivors,2018-04-23,2019-04-15,357 days,Completed,Interventional
2021-01-075,PALbociclib Endocrine Therapy Followed by Talazo vs. Talazoz-Atezo Study,2021-09-01,2027-12-31,2312 days,Not yet recruiting,Interventional
mavis20023,Application-Enabled Shared Decision-Making,2019-08-01,2020-07-31,365 days,Completed,Interventional
HiFi-APBI,High Five (HiFi) Accelerated Partial Breast Irradiation Study,2021-10-01,2025-12-31,1552 days,Recruiting,Interventional
Self-compassion FCR,Fear-focused Self-Compassion Therapy for Young Breast Cancer Patients Fear of Cancer Recurrence,2021-09-15,2023-12-01,807 days,Recruiting,Interventional
20-010751,3D Ultrasound Breast Imaging,2021-11-19,2025-12-31,1503 days,Recruiting,Interventional
IJB-BC-TDM1BM-2016,Kadcyla In pAtients With bRAin Metastasis,2018-02-23,2018-08-27,185 days,Withdrawn,Interventional
1B-15-6,Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors,2019-03-08,2019-07-31,145 days,Withdrawn,Interventional
P018,"A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel",2023-06-01,2026-02-01,976 days,Withdrawn,Interventional
QUILT 2021-1,The QUILT Study: Quilting Sutures in Patients Undergoing Breast Cancer Surgery,2022-08-01,2023-07-01,334 days,Not yet recruiting,Interventional
2020-10/850,Correlation of Preoperative Anxiety With Early Postoperative Cognitive Dysfunction in Breast Cancer Patients,2020-10-21,2021-07-13,265 days,Completed,Observational
IEO 0758/,Histology VABB-Histology Post Surgery Pilot Project (BETTY Trial),2018-06-01,2021-12-31,1309 days,"Active, not recruiting",Observational
MC18C1,Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer,2019-05-24,2023-06-01,1469 days,"Active, not recruiting",Interventional
GN19ON381,Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy,2021-03-15,2022-11-25,620 days,Recruiting,Observational
CBYL719H12301,Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss,2020-06-08,2024-06-19,1472 days,"Active, not recruiting",Interventional
2021/03,A Deep Learning Method to Evaluate QT on Ribociclib,2022-12-01,2024-12-01,731 days,Not yet recruiting,Observational
WSG-AM11,"Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC",2020-09-02,2027-12-01,2646 days,Recruiting,Interventional
2018-0528,An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction,2019-05-24,2024-04-30,1803 days,Recruiting,Interventional
1024489,Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2),2019-04-29,2023-12-31,1707 days,Recruiting,Interventional
OBI-822-011,Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC,2018-12-05,2027-12-30,3312 days,Recruiting,Interventional
CCR 5006,Exploring the Link Between Cancer Genetics and PPSP,2019-07-01,2019-12-01,153 days,Unknown status,Observational
ICO-N-2018-12,Intravenous Chemotherapy and Plant-based Dietary Supplements,2019-04-02,2020-05-13,407 days,Completed,Observational
20180349,Health Economy Register,2019-07-05,2020-12-31,545 days,Completed,Observational
MSCW2019,Mindfulness and Self-compassion Focussed Walking,2019-08-08,2022-12-31,1241 days,Recruiting,Interventional
H-18016600,Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer,2018-12-17,2026-11-01,2876 days,Recruiting,Observational
2020-12-044-012,Pilot Study to Evaluate the Prevention and Safety of Doxorubicin-induced Cardiomyopathy Using Extracorporeal Shock Waves,2020-10-01,2023-06-01,973 days,Recruiting,Interventional
IJB-PRINTEMPS-2022,Multidisciplinary Approach to Fatigue,2022-08-19,2027-09-01,1839 days,Recruiting,Interventional
NIS07075,Real-life Pan-HER-blockade With Neratinib,2020-07-02,2025-01-01,1644 days,Recruiting,Observational
HNCH-BC009,"Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer",2022-01-01,2024-06-01,882 days,Recruiting,Interventional
c5ZTCN100,A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS,2021-05-31,2022-06-23,388 days,Completed,Interventional
CRO-2019-26,Does Type of Anesthesia Influence Inflammation Change After Breast Surgery?,2019-10-31,2021-11-01,732 days,Unknown status,Interventional
YM111146EF,Effects of Kombucha Intervention on Emotional Distress and Sleep Quality in Breast Cancer Survivors,2022-12-12,2025-12-12,1096 days,Recruiting,Interventional
AP2205-5015,Erector Spinae Plane Block Versus General Anesthesia in Breast Cancer Surgeries,2022-06-27,2023-04-10,287 days,Recruiting,Interventional
LCCC1921,Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer,2019-09-25,2022-04-04,922 days,Completed,Interventional
182113,Improving Cognition After Cancer,2019-09-09,2024-02-01,1606 days,Recruiting,Interventional
EC /2018/0996,Pre- or Postoperative Accelerated Radiotherapy,2018-09-17,2021-11-19,1159 days,Completed,Interventional
ICO_UCC_202001,SMS Messaging as a Tool to Improve Cancer Screening Programs,2020-09-15,2022-12-31,837 days,Unknown status,Interventional
19-008929,Cryotherapy for the Prevention of Taxane-Induced Sensory Neuropathy of the Hands and Feet in Breast Cancer Patients,2020-01-23,2024-12-31,1804 days,"Active, not recruiting",Interventional
2018-172,The Effects of Wheat Sprouts Supplements on the Key Health Indicators of the Patients With Breast Cancer After Chemotherapy,2019-04-22,2020-10-01,528 days,Completed,Observational
19-578,Sacituzumab Govitecan In TNBC,2020-07-07,2026-10-01,2277 days,"Active, not recruiting",Interventional
Ref. 070/2018,Comparative Analysis of Three Locoregional Anesthesia Methods in Breast Tumour Pathology Surgery,2018-06-01,2020-06-30,760 days,Completed,Interventional
2021-04031,Supporting Women With Breast Cancer to Practice DIBH at Home Before Radiation Therapy,2023-09-01,2029-03-30,2037 days,Not yet recruiting,Interventional
A211601,Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502,2018-08-01,2022-07-18,1447 days,Terminated,Observational
PSCI 21-045,Trial Assessing Light Intensity Exercise on the Health of Older Breast Cancer Survivors,2021-11-22,2023-11-01,709 days,Recruiting,Interventional
22-4004,African Cancer Genome: GMD,2022-11-28,2024-07-01,581 days,Recruiting,Observational
AC-TMSQ-2018,Effect of Therapeutic Massage on Sleep Quality and Stress Levels in Women With Breast Cancer,2018-04-01,2019-01-09,283 days,Completed,Interventional
STU-2019-0769,PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer,2019-07-23,2021-06-15,693 days,Completed,Interventional
R-2021-3203-005,Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.,2021-04-26,2026-06-30,1891 days,Recruiting,Interventional
CD07_TNBC,Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC,2019-04-22,2022-09-16,1243 days,"Active, not recruiting",Interventional
F16J16000620002,Innovation in Mammography: Tomosynthesis Pathways,2018-09-03,2021-09-01,1094 days,Unknown status,Interventional
NUR20-0124CRYO,The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer,2020-08-04,2021-02-03,183 days,Terminated,Interventional
32551/09/2018,Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy,2018-09-10,2019-12-10,456 days,Completed,Interventional
AAAS3402,Glucose Monitoring During Chemotherapy,2019-10-31,2023-12-01,1492 days,"Active, not recruiting",Observational
2017-1535,OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease,2018-05-21,2022-12-01,1655 days,"Active, not recruiting",Interventional
HUM00208684,Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging,2022-07-25,2026-07-01,1437 days,Recruiting,Observational
12341234,Brass Mesh Bolus in Rotational Post-Mastectomy Radiation Therapy,2022-10-01,2023-10-01,365 days,Not yet recruiting,Interventional
Mepitel RCT,Randomized Phase III Trial With Mepitel Film for the Prophylaxis of Radiation Dermatitis in Breast Cancer Patients,2020-01-30,2024-12-01,1767 days,"Active, not recruiting",Interventional
ShandongCHI-07,Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy,2018-11-01,2025-11-01,2557 days,Not yet recruiting,Interventional
D8532C00005,"A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833",2022-05-10,2022-06-20,41 days,Completed,Interventional
CADEX-0001,Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer,2019-03-01,2023-10-01,1675 days,Suspended,Observational
ELIPSE (SOLTI-1905),"Elacestrant in Preoperative Setting, a Window of Opportunity Study",2021-02-09,2022-02-25,381 days,Completed,Interventional
VI-ISRP-026,A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment Outcomes,2018-08-01,2020-03-01,578 days,Suspended,Interventional
5652-18-SMC,Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients,2019-03-25,2020-05-03,405 days,Completed,Interventional
Ä°boelif22,"The Relationships Between Physical Activity Level, Quality of Life and Cognitive Level in Breast Cancer Patients",2022-01-05,2022-09-05,243 days,Recruiting,Observational
FEMAL,Comparison of the Efficacy and Tolerability of Femal Versus Placebo,2019-05-10,2022-04-01,1057 days,Completed,Interventional
20-30638,Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP),2022-02-01,2023-09-01,577 days,Recruiting,Interventional
R.20.11.1099,Ultrasonographic Axillary Localization,2020-12-15,2022-04-01,472 days,Unknown status,Interventional
IRB00074154,Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients,2021-10-22,2024-07-01,983 days,Recruiting,Interventional
SMC 2021-05-045,SMC Radiation Oncology Breast Cancer Cohort Study,2021-01-01,2030-12-31,3651 days,Recruiting,Observational
CI-01022,Online Psychological Care Program for Women Who Attend a Breast Clinic.,2023-05-01,2024-08-01,458 days,Not yet recruiting,Interventional
SamsunU,Combination of Serratus Anterior and Pectoral Nerve Blocks (PECS II) as Main Anesthetic Method in Breast Cancer Surgery,2022-07-07,2023-07-20,378 days,Recruiting,Observational
ShandongCHI-18,Patient Report Outcome and Oncological Safety -Oncoplastic and Conventional BCS Cohort,2021-10-01,2024-12-30,1186 days,Not yet recruiting,Observational
JWCI OBCS WITH IORT,Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.,2021-12-16,2026-02-01,1508 days,Recruiting,Interventional
AAAT8915,Vaginal Dilator Therapy Among Women With Gynecologic and Breast Cancers Experiencing Dyspareunia,2022-08-03,2024-02-29,575 days,Recruiting,Interventional
20-513,Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer,2020-11-24,2024-11-01,1438 days,Recruiting,Interventional
IRB00313835,Evaluating the Use of Patient Navigation to Promote Timely Diagnostic Evaluation During the COVID-19 Pandemic,2022-07-18,2024-06-01,684 days,Recruiting,Interventional
HE-202012,Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer,2021-06-18,2028-07-28,2597 days,Recruiting,Interventional
NCC201804007,Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model,2019-01-01,2020-07-01,547 days,Unknown status,Interventional
110.01-2016-GES-0001,Automated Breast Ultrasound Case Collection Registry,2018-07-12,2019-01-25,197 days,Terminated,Observational
PREVENT,"Swiss Multi-centre, Randomized, Placebo Controlled Trial of Pregabalin for Prevention of Persistent Pain in High Risk Patients Undergoing Breast Cancer Surgery",2018-01-09,2024-01-01,2183 days,Recruiting,Interventional
QL-KPTB-150,Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer,2018-12-10,2019-01-26,47 days,Completed,Interventional
REaCT-Hot Flashes Pilot,Utilizing MyChart to Assess the Effectiveness of Interventions for Vasomotor Symptoms: A Feasibility Study,2022-02-25,2022-09-22,209 days,Completed,Interventional
IRB00081356,Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer,2019-12-17,2041-01-01,7686 days,Recruiting,Observational
VIL-HEQ-17-014,Health and QoL in Oncological Patients: Management of Bone Pathology in Italian Citbl Population,2018-07-26,2021-10-26,1188 days,Unknown status,Observational
COMPLEMENT,Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients,2022-06-01,2025-03-01,1004 days,Not yet recruiting,Interventional
DHLI-BC/OC-BE-001,Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (LipodoxÂ®) in Chinese Patients,2021-07-28,2022-04-30,276 days,Recruiting,Interventional
GS18/107321,ePainQ - Feasibility Study,2018-08-06,2020-03-30,602 days,Unknown status,Interventional
2019-003825-56,"Study Comparing LymphoseekÂ® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer",2020-03-01,2021-08-01,518 days,Unknown status,Interventional
80252,Breast Reconstruction and Neoadjuvant Radiotherapy,2022-05-01,2024-03-01,670 days,Not yet recruiting,Interventional
Exo-LCR,Feasibility of Exosome Analysis in Cerebrospinal Fluid During the Diagnostic Workup of Metastatic Meningitis (Exo-LCR),2023-01-04,2026-12-01,1427 days,Recruiting,Interventional
MCC-19117,Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer,2018-02-19,2026-12-01,3207 days,"Active, not recruiting",Interventional
EA1181,CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy,2020-02-11,2038-12-31,6898 days,Recruiting,Interventional
PAL-ZJCC-02,Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients,2021-04-22,2023-06-30,799 days,Recruiting,Interventional
GCO 18-1832,Leflunomide in Previously Treated Metastatic Triple Negative Cancers,2019-04-16,2025-10-01,2360 days,Recruiting,Interventional
DS_v01,A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations,2020-04-28,2023-09-01,1221 days,Recruiting,Observational
T06/024/21,Exercise and Tumor Blood Flow in Lymphoma And Breast Cancer Patients (EXETUMOR 3),2021-08-10,2022-12-31,508 days,Recruiting,Interventional
ES,Effect of Low-dose Esketamine on Postoperative Depression in Patients With Breast Cancer,2021-02-10,2022-05-10,454 days,Completed,Interventional
Study00145121,Pilot Study of Effects of DuaveeÂ® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms,2020-06-01,2021-07-31,425 days,Terminated,Interventional
STU 042018-083,Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod,2019-04-22,2030-06-28,4085 days,"Active, not recruiting",Interventional
AcuBreast 2020,Fatigue as a Late Effect in Breast Cancer Survivors - is Acupuncture a Treatment Option?,2021-09-01,2023-07-01,668 days,Recruiting,Interventional
4-2020-1093,Radiotherapy for Thoracic and Breast Cancer and the Related Cardiotoxicity Following Treatment (RACCOON),2020-12-22,2022-12-01,709 days,Unknown status,Observational
A012103,Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab,2023-05-10,2033-05-31,3674 days,Not yet recruiting,Interventional
HREBA.CC-22-0128,Impact of Metabolic Health Patterns And Breast Cancer Over Time in Women,2023-06-05,2027-06-01,1457 days,Not yet recruiting,Interventional
A191901,Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy,2021-02-15,2025-10-01,1689 days,Suspended,Interventional
VICCBRE2257,Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy,2023-04-30,2028-05-01,1828 days,Not yet recruiting,Interventional
HCI69515,Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment,2018-01-31,2026-01-01,2892 days,Recruiting,Interventional
TX05-03E,Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03,2019-08-20,2022-03-08,931 days,Completed,Interventional
2019/639,Effect of Nurse-led Supportive Care on Caregiver Burden and Well-being,2022-04-18,2023-01-13,270 days,Completed,Interventional
GBG 107,Long-term Safety and Efficacy of GBG Study Participants,2022-10-12,2030-05-19,2776 days,Recruiting,Observational
CE-MRI&CESM in breast lesions,CE-MRI&CESM in Solid Breast Lesions,2021-04-01,2023-05-01,760 days,Not yet recruiting,Observational
PBCST,Precision Breast Conserving Surgery With Guidance.,2021-08-01,2023-01-01,518 days,Completed,Interventional
NEODOC- 2021668610-221,Comparison Trial of Open-tip Pulsed Needle Biopsy and Conventional Core Biopsy in Axillary Lymph Nodes,2020-07-13,2021-12-31,536 days,Unknown status,Interventional
9785-CL-0018,A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer,2020-01-27,2020-12-27,335 days,Completed,Interventional
2021-03165,Validation of Scales in Reconstructive Breast Surgery,2021-06-21,2027-12-21,2374 days,Recruiting,Observational
IRB202202679,Exercise to ReGain Stamina and Energy (The EXERGISE Study),2023-03-01,2024-03-01,366 days,Not yet recruiting,Interventional
Arise-FJ-B102,Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer,2019-11-01,2023-11-01,1461 days,Not yet recruiting,Interventional
453190,Study of the Effects of Cyclodynon on Reducing the Cumulative Risk of Breast Cancer Development in a Female Aged 40-52,2020-07-22,2022-05-01,648 days,Unknown status,Interventional
RenJiH-2018-038,"CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial",2018-08-24,2019-06-30,310 days,Completed,Interventional
202110124,Utilizing Social Contacts to Facilitate Mammogram Screening Among African American Women,2022-03-18,2022-06-30,104 days,Completed,Interventional
MCC-21262,A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV),2023-03-28,2026-03-01,1069 days,Recruiting,Interventional
18-003544,Comparison of Three Methods for Early Detection of Breast Cancer,2019-10-15,2021-10-05,721 days,Completed,Interventional
CKRC2021-CCV,Feasibility of Providing a Purpose Renewal Intervention for Cancer Survivors Via Virtual Groups,2021-03-01,2024-02-17,1083 days,Enrolling by invitation,Interventional
BEXMET,The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC,2020-10-01,2023-06-30,1002 days,Recruiting,Interventional
PICC One Day 01 (ET15-123),Iterative PICC Placement Versus Long Term Device,2018-01-10,2018-01-10,0 days,Withdrawn,Interventional
IRB00049061,Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer,2018-08-03,2021-02-21,933 days,Completed,Interventional
CP-13-001,MarginProbe 2.0 Data Collection Protocol,2021-12-15,2023-12-31,746 days,Recruiting,Observational
SOLTI-1710,Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy,2019-11-21,2022-02-24,826 days,Completed,Interventional
IJB-SYNERGY-012017,Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC,2018-12-28,2023-10-01,1738 days,"Active, not recruiting",Interventional
IRB00046759,Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer,2018-03-26,2018-11-01,220 days,Completed,Interventional
18947,Sentinel Lymph Node Mapping With Near Infrared Fluorescent Markers,2018-07-20,2022-05-25,1405 days,Completed,Interventional
2021-A03027-34,Shared Decision Making on Care Pathways and CAMs: A Pilot Study,2022-09-01,2023-08-01,334 days,Not yet recruiting,Interventional
IRB-44367,Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy,2018-08-01,2022-12-01,1583 days,Recruiting,Interventional
NEPA-17-05,A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer,2018-03-16,2018-09-19,187 days,Completed,Interventional
SHR6390-III-303,"Phase III Study ï¼SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative",2021-04-30,2031-10-31,3836 days,Enrolling by invitation,Interventional
I3Y-MC-B009,A Prospective Post-Marketing Observational Safety Study of VerzeniosÂ® (Abemaciclib) Among Breast Cancer Patients in China VerzeniosÂ® (Abemaciclib) Among Breast,2022-03-01,2026-05-01,1522 days,Not yet recruiting,Observational
17/222,Under- and Overdiagnosis in BreastScreen Norway,2018-07-01,2020-06-08,708 days,Completed,Observational
JCL2020,A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast,2020-07-14,2026-10-01,2270 days,Recruiting,Interventional
2022-761,Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality,2023-02-01,2024-07-01,516 days,Not yet recruiting,Interventional
19-302,"Study of iBreast, a Handheld Device to Detect Breast Abnormalities During Screening Visits for Breast Cancer",2021-01-29,2024-01-01,1067 days,"Active, not recruiting",Interventional
BFH-BC,ESM Versus OM ï¼A Randomized Controlled Trial,2020-12-01,2022-12-31,760 days,Unknown status,Interventional
RT 1901,Hypofractionated Versus Conventional Fractionation Radiotherapy,2019-07-01,2020-12-01,519 days,Unknown status,Interventional
MC1732,Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery,2018-11-20,2023-11-20,1826 days,"Active, not recruiting",Interventional
ET19-084 - CICA-RT,Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients,2020-06-06,2022-10-09,855 days,Unknown status,Interventional
A5481160,"Demographics, Characteristics, Treatment Patterns and Clinical Outcomes of Palbociclib Treated Patients in Israel",2020-12-06,2021-10-06,304 days,Completed,Observational
21623,Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer,2022-07-03,2023-01-26,207 days,Withdrawn,Interventional
CASE10116,Breast Reconstruction Following Breast Cancer in Very High Risk Patients,2019-05-31,2022-07-01,1127 days,Withdrawn,Interventional
2021/271,Effect of Laughter Therapy on Perceived Stress and Quality of Life,2022-02-17,2022-06-12,115 days,Completed,Interventional
CASE5Y21,A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose,2022-10-19,2025-06-30,985 days,Recruiting,Interventional
University in Zielona Gora,Inertial Rehabilitation in Women After Mastectomy,2019-04-02,2019-07-24,113 days,Completed,Interventional
T148/2020,Exercise and Tumor Blood Flow in Breast Cancer Patients,2020-09-07,2024-12-31,1576 days,Recruiting,Interventional
ICO-2019-16,Satisfaction and QUality of Life After Breast REconstruction,2019-09-03,2019-11-25,83 days,Completed,Observational
ISI dV SP - NSM-01,Robotic vs. Open NSM for Early Stage Breast Cancer,2023-04-01,2026-12-01,1340 days,Not yet recruiting,Interventional
ATOPE18,Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program,2019-09-01,2022-12-31,1217 days,Recruiting,Interventional
ChungnamNU.J1,VR-based Intervention for Cognitive Restoration,2019-12-10,2024-12-31,1848 days,Recruiting,Interventional
EC/2017/1261,Effect of Non-estrogenic Pollen Extract PCC-100 on Hot Flushes,2018-10-15,2023-12-31,1903 days,Recruiting,Interventional
M21REO,"Association of Silicone Breast Implant Reconstruction and -Enlargement With Overall Wellbeing, Lymphoma and Auto-immune Disease",2022-07-01,2025-06-01,1066 days,Not yet recruiting,Observational
EORTC-2129-BCG,TREAT ctDNA Elacestrant,2023-05-01,2030-05-01,2557 days,Not yet recruiting,Interventional
22-001501,Characterization of TRPC6 to Predict and Prevent Chemotherapy Related Cardiac Toxicity and Heart Failure in Patients With Breast Cancer,2022-08-18,2027-09-01,1840 days,Recruiting,Observational
NCI-2021-11793,Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer,2022-03-15,2024-03-14,730 days,Recruiting,Interventional
ET19-283,Prospective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma,2020-10-01,2030-10-01,3652 days,Not yet recruiting,Observational
2019-4433,Angiomammography and Neoadjuvant Chemotherapy,2018-01-03,2024-06-30,2370 days,Recruiting,Interventional
THERMOEDEME,Spa Therapy for Upper Limb Lymphoedema,2019-06-20,2022-12-01,1260 days,Unknown status,Interventional
C3621001,Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC,2018-11-27,2021-09-27,1035 days,Terminated,Interventional
LSB-12345,Intraoperative Use of ClearEdge Device in Breast Conserving Surgery,2022-10-10,2024-12-31,813 days,Recruiting,Interventional
108511,Breathwork App for Cancer Survivors,2021-11-17,2023-05-31,560 days,Recruiting,Interventional
202101421A0,Pilot Study of Single-port Robot-assisted Nipple-sparing Mastectomy,2022-07-30,2023-08-01,367 days,"Active, not recruiting",Interventional
960-CSP-USA_DenseBreasts_USS1,A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts,2018-04-15,2019-04-30,380 days,Terminated,Interventional
PROICM 2018-09 BSA,Clinical Database of Safe Personalized Adjuvant Breast Radiotherapy Based on Individual Radiosensitivity,2019-05-23,2024-06-01,1836 days,Recruiting,Observational
211521,nCCR for Chemotherapy Related Cognitive Impairment Randomized Study,2022-08-01,2025-03-01,943 days,Recruiting,Interventional
BC-P30(FZQ),Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy,2022-06-10,2026-11-01,1605 days,Recruiting,Interventional
2017-0672,"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas",2018-04-27,2024-06-30,2256 days,Recruiting,Interventional
2019-4432,Screening Contrast-enhanced Mammography,2018-12-12,2024-12-01,2181 days,Recruiting,Observational
22-508,Implantable Microdevice for TNBC - Pilot Study,2023-05-01,2028-09-01,1950 days,Not yet recruiting,Interventional
NCC2021-0335,Local and Regional Radiotherapy for Nipple Sparing Mastectomy With Implant,2021-11-15,2028-12-31,2603 days,Enrolling by invitation,Observational
LET,Lymphedema Treatment Registry,2021-10-01,2023-01-01,457 days,Not yet recruiting,Observational
Pectoral nerve block in breast,Pectoral Nerve Block During Mastectomy,2023-04-01,2024-12-30,639 days,Not yet recruiting,Interventional
TNBC,Epidemiology of TNBC in Asyut Clinical Oncology Department,2022-11-01,2023-12-01,395 days,Not yet recruiting,Observational
NU 18B05,Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast,2020-02-17,2024-06-25,1590 days,Recruiting,Interventional
20476,Immune Effects in Patients Treated With Whole Breast Irradiation,2018-10-01,2020-03-01,517 days,Unknown status,Interventional
ICRCTSU/2019/10068,PreOperative Endocrine Therapy for Individualised Care With Abemaciclib,2020-12-23,2032-03-31,4116 days,Recruiting,Interventional
EU001,Magseed Pro(R)/ Sentimag(R) Gen3,2023-03-02,2024-12-31,670 days,Not yet recruiting,Interventional
2018-63,Does Chemotherapy Train the Mutation of the Pig-A Gene? (PIGA),2019-01-10,2021-01-10,731 days,Unknown status,Interventional
2020-06245,Effects of Expectations and Body Image in Breast Reconstruction,2021-02-01,2024-12-31,1429 days,Recruiting,Observational
18-168,"Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue",2018-09-17,2024-08-31,2175 days,"Active, not recruiting",Interventional
2021-A01407-34,Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration,2022-04-15,2023-04-15,365 days,Not yet recruiting,Interventional
soh-Med-21-02-05,Modified Pectoral Nerve Block Versus Serratus Plane Block,2021-05-20,2023-08-20,822 days,Not yet recruiting,Interventional
CIMPAX BREAST,Continuous Serrates Plane Block in Axillary Dissection,2018-06-13,2020-06-13,731 days,Unknown status,Interventional
YOUNGBC-20,Detection and Analysis of MBC With Heterogeneous ER Expression,2022-01-15,2022-12-15,334 days,Completed,Observational
18D.003,"Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence",2019-07-31,2023-10-31,1553 days,Recruiting,Interventional
20-002505,Mayo Designed Soft Tissue Ultrasound-Detectable Marker,2020-11-02,2022-04-07,521 days,Completed,Interventional
XianganHXiamenU,NIR Fluorescent Molecular Probe for the Identification of Breast Tissue,2023-02-17,2024-01-29,346 days,Recruiting,Interventional
YOUNGBC-21,Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab,2022-10-01,2023-05-01,212 days,"Active, not recruiting",Observational
201900572,The SONImage Study,2019-12-05,2025-07-01,2035 days,Recruiting,Interventional
MEDOPP459,Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67â¥10%,2023-05-01,2024-10-01,519 days,Not yet recruiting,Interventional
MedOPP485,A PoC Study to Evaluate Treatments Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population,2023-09-30,2028-03-30,1643 days,Not yet recruiting,Interventional
09.2019.866,Ultrasonographic Evaluation of Changes After Complex Decongestive Therapy,2019-10-20,2020-03-30,162 days,Unknown status,Interventional
A5481128,Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.,2019-10-19,2022-04-01,895 days,Completed,Observational
YOUNGBC-3,500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI,2018-05-14,2019-05-15,366 days,Completed,Observational
020-008,Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC,2020-10-15,2023-12-01,1142 days,Recruiting,Interventional
YOUNGBC-14,Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine,2020-01-15,2021-06-15,517 days,Completed,Observational
LQiao,HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC,2020-01-01,2023-01-01,1096 days,Recruiting,Interventional
2021157,Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer,2022-09-01,2024-09-01,731 days,Not yet recruiting,Interventional
2020-KY-051,Type I Interferon Alfa-2a in Postmastectomy Breast Reconstruction,2020-08-06,2021-07-14,342 days,Completed,Interventional
YOUNGBC-25,Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor,2022-12-01,2023-05-01,151 days,Recruiting,Observational
Shengjing-LCG011,"Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC",2022-02-10,2027-12-31,2150 days,Recruiting,Interventional
BC-09374,LymphoVenous Anastomosis to Prevent Breast Cancer Related Lymphedema,2021-06-30,2025-12-27,1641 days,Recruiting,Interventional
2021-02902,PACED-digitized Support During Adjuvant Endocrine Therapy,2021-10-25,2024-12-01,1133 days,Recruiting,Interventional
GCO 19-0477,"Vaccination With Flt3L, Radiation, and Poly-ICLC",2019-04-05,2025-03-01,2157 days,Recruiting,Interventional
202100318,Testosterone & Tamoxifen Trial,2022-11-10,2024-01-03,419 days,Recruiting,Interventional
19-458,A Study of the Use of Text Message Reminders to Take Palbociclib,2019-12-27,2023-12-27,1461 days,"Active, not recruiting",Interventional
S1904,Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE),2020-09-01,2028-06-01,2830 days,Recruiting,Interventional
Seno_Ex_MAC 003,Comparison of Conventional With Sonography Assisted Breast Surgery After Neoadjuvant Chemotherapy,2018-10-01,2023-04-01,1643 days,Recruiting,Interventional
E2018210,Effect of Radiation and Its Timing on Breast Reconstruction in Chinese Patients,2019-01-01,2023-04-01,1551 days,Unknown status,Observational
CL(3204),Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms,2022-02-10,2023-12-01,659 days,Recruiting,Interventional
211-2018,MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients With Triple Negative or HER2+ MBC,2018-11-08,2021-06-01,936 days,Unknown status,Interventional
J17120,"Cancer, Obesity/Overweight and Insomnia Study",2018-06-12,2020-11-30,902 days,Completed,Interventional
AAAO1760,CBPR - BRCA Genetic Testing Among Orthodox Jews,2018-03-13,2019-01-29,322 days,Completed,Interventional
1712078374,"Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome",2018-02-28,2022-06-15,1568 days,Completed,Interventional
D17168,The Prone to Supine Breast MRI Trial,2018-07-12,2020-07-31,750 days,Completed,Interventional
ShandongCHI-14,Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC,2021-01-01,2022-06-01,516 days,Unknown status,Observational
2020-KY-007,The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome,2022-01-01,2030-12-31,3286 days,Not yet recruiting,Interventional
DELFINO trial,"Density Lowering Effect of ""OFS Add on to TMX""(DELFINO Trial)",2018-09-03,2023-10-02,1855 days,Recruiting,Interventional
PRISMA,Primary Hormone-sensitive Breast Cancer: Need-driven Health Care Improvement by Patient-centred Digital Application,2022-11-01,2025-06-01,943 days,Not yet recruiting,Interventional
3125001,Safety and Pharmacokinetics of ODM-209,2019-04-17,2023-10-01,1628 days,"Active, not recruiting",Interventional
ShandongCHI-16,"Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis",2021-01-01,2022-03-01,424 days,Unknown status,Interventional
ERAS-ABR,ERAS in Autologous Breast Reconstruction: A Pilot RCT,2019-11-05,2020-06-30,238 days,Completed,Interventional
ProFertil,Use of GnRHa During Chemotherapy for Fertility Protection,2023-03-31,2032-01-31,3228 days,Not yet recruiting,Interventional
MEDOPP240,Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients,2020-10-23,2024-07-31,1377 days,"Active, not recruiting",Interventional
TQB3616-I-0001,A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics,2019-03-01,2021-09-30,944 days,Unknown status,Interventional
7964,Clinical Validation of an Artificial Intelligence Algorithm to Help Interpret Mammograms,2021-04-20,2022-12-31,620 days,Recruiting,Observational
BreastIls-1605,Endogenous Mechanisms of Inactivation of the Endothelium Tumor,2018-01-31,2019-10-01,608 days,Unknown status,Observational
18-00309,Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy,2019-12-13,2024-04-01,1571 days,Recruiting,Interventional
2005P002282,Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions,2020-09-29,2021-06-24,268 days,Completed,Observational
2023-9333,The MARVIN Chatbots to Provide Information for Different Health Conditions,2023-05-01,2034-12-31,4262 days,Not yet recruiting,Interventional
STUDY00020501,"Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study",2022-03-18,2024-09-30,927 days,Recruiting,Interventional
[2016]124,Serratus Plane Block in Preventing Postoperative Pain of Mastectomy,2018-08-01,2019-12-01,487 days,Completed,Interventional
IIT2018-04-MCARTHUR-NEOHP,Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab,2019-01-25,2025-07-01,2349 days,Recruiting,Interventional
MCP Study,Prevention of Obesity-related Cancers: Setting up of a Multi-Cancer Education and Prevention Program in Hong Kong,2018-08-06,2023-12-31,1973 days,Recruiting,Interventional
STUDY00000194,"Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases",2020-06-12,2021-09-13,458 days,Withdrawn,Interventional
mastectomy coverage formula 20,New Formula to Predict the Need for Reconstructive Coverage Following Mastectomy,2020-08-15,2020-11-15,92 days,Completed,Observational
SIB2232,SMART-ER: Symptom Monitoring With Patient-reported Outcomes,2022-10-03,2023-06-09,249 days,Recruiting,Interventional
KC19EEDT0031,Omitting vs. Doing Intraoperative Frozen Section Biopsy for Margin Status in Breast Conserving Surgery,2020-09-24,2026-06-01,2076 days,Recruiting,Interventional
22-008,Onvansertib + Paclitaxel In TNBC,2022-09-30,2029-02-15,2330 days,Recruiting,Interventional
1807188-16,FUSCC Refractory TNBC Umbrella (FUTURE),2018-10-18,2022-12-01,1505 days,Recruiting,Interventional
OSU-20429,Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel,2021-10-07,2024-12-31,1181 days,Recruiting,Interventional
2020/295,"The PreQ-20 TRIAL, a Prospective Cohort Study of Patients Undergoing Prepectoral Breast Reconstruction",2020-06-22,2026-12-01,2353 days,Recruiting,Interventional
SunYatsenU2H-LQ4,"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC",2021-04-01,2033-09-01,4536 days,Recruiting,Interventional
Phaon1,Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy,2021-03-01,2026-01-01,1767 days,"Active, not recruiting",Interventional
SUGBG-2021002,Premarking of Axillary Nodes Before Start of Neoadjuvant Chemotherapy Using Magnetic Approach,2021-10-01,2023-07-01,638 days,Recruiting,Interventional
S2018-2450-0001,Distress Reduction by Activity Tracking and Activity Enhancement by Mobile Support Group in Oncology,2019-01-07,2020-11-16,679 days,Completed,Interventional
IIT-0016,Exercise and Compression for Lymphedema,2022-05-27,2024-05-31,735 days,Recruiting,Interventional
N.sativavsRID BreastCancerpt.,Evaluation of the Effect of Nigella Sativa for the Prophylaxis to Radiation Induced Dermatitis in Breast Cancer Patients,2023-01-24,2024-04-01,433 days,Recruiting,Interventional
00130272,PhysioTouch for Treatment of Radiation Fibrosis,2018-12-01,2020-04-01,487 days,Withdrawn,Interventional
URCC-18007,Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors,2019-06-28,2024-03-24,1731 days,Recruiting,Interventional
jcl2020-2 breast cancer,3D Printed Bolus in Post-mastectomy Radiotherapy,2020-03-01,2021-04-20,415 days,Unknown status,Interventional
OP-1250-003,Phase 1b Combo w/ Ribociclib and Alpelisib,2022-08-31,2024-08-31,731 days,Recruiting,Interventional
17-001546,Evaluating Mepitel in Post-mastectomy Patients and the Role of the Skin Microbiome in Radiation Dermatitis,2018-04-11,2019-11-25,593 days,Completed,Observational
38285020.8.0000.0072,"Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer",2020-12-17,2022-01-17,396 days,Completed,Interventional
TMP-0315-2018,Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel),2020-04-09,2023-06-01,1148 days,Recruiting,Interventional
21-3117.cc,Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC,2022-01-04,2022-12-01,331 days,Withdrawn,Interventional
IRB00103558,Resistance Training to Improve Fatigue and Physical Function in Postmenopausal Breast Cancer Survivors,2018-12-10,2020-03-12,458 days,Completed,Interventional
ICOnnectat-BC,"Online Psychosocial Cancer Screening, Monitoring and Stepped Treatment in Cancer Survivors",2021-01-01,2022-06-30,545 days,Unknown status,Interventional
C3441038,Korea Post Marketing Surveillance (PMS) Study of TalzennaÂ®,2024-05-01,2026-11-30,943 days,Not yet recruiting,Observational
20-028,Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA),2020-07-02,2025-12-30,2007 days,Recruiting,Interventional
ICO-2021-36,Pain and Functional Recovery After Mastectomy and IBR by Implant: Prepectoral Versus Subpectoral Technique,2022-09-01,2023-09-01,365 days,Not yet recruiting,Observational
STU-2022-0091,Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy,2022-03-08,2024-02-01,695 days,Recruiting,Interventional
2021-0048-B,Erector Spinae Block vs. Placebo Block Study,2023-09-01,2024-12-01,457 days,Not yet recruiting,Interventional
Breastblock,Regional Anesthesia for Breast Surgery,2019-05-29,2022-06-01,1099 days,Unknown status,Interventional
OMS-I141 (KEYNOTE-890),Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC,2018-10-11,2024-08-01,2121 days,Recruiting,Interventional
L424,Cancer Surveillance and Support,2021-03-22,2023-09-01,893 days,Recruiting,Observational
BHP0111,Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza),2019-08-01,2021-09-20,781 days,Completed,Interventional
18-001926,Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors,2019-10-07,2024-06-01,1699 days,Recruiting,Interventional
20CX6399,Histolog Comparison to Standard Histology,2021-06-04,2023-12-01,910 days,"Active, not recruiting",Observational
REDHEMOPACH,Hemopatch Versus Axillary Drainage After Axillary Lymphadenectomy,2020-03-01,2023-02-14,1080 days,Completed,Interventional
PMC_TTAC-0001_06 / KEYNOTE-C14,Olinvacimab With Pembrolizumab in Patients With mTNBC,2021-09-30,2026-08-30,1795 days,Recruiting,Interventional
INSPIRE-001,Intercostobrachial Nerve Sparing to Reduce Post-Surgical Pain,2019-10-15,2020-12-01,413 days,Unknown status,Interventional
STUDY00149312,Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC,2022-12-05,2025-12-01,1092 days,Recruiting,Interventional
IIT2021-10-Giuliano-OmitRT,Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response,2022-05-01,2028-05-01,2192 days,Not yet recruiting,Interventional
VICCBRE2256,Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort,2023-05-30,2037-05-30,5114 days,Recruiting,Interventional
Patient reported outcome,Patient Reported Outcomes After Oncoplastic Breast Conserving Surgery,2023-03-01,2024-09-01,550 days,Not yet recruiting,Observational
EAZ171,Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer,2019-06-27,2023-09-01,1527 days,"Active, not recruiting",Interventional
2017/62,Effects of Slow-Stroke Back Massage on CRF,2018-06-18,2019-04-15,301 days,Completed,Interventional
17-001864,SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer,2019-04-07,2021-12-06,974 days,Completed,Interventional
SCHBCC-N031,An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.,2020-05-15,2023-11-15,1279 days,Recruiting,Interventional
20429001,Central Obesity and Cancer Prevention for Chinese American Women,2019-10-16,2020-12-01,412 days,Unknown status,Interventional
2000020335,"Lifestyle, Exercise, and Nutrition Study Early After Diagnosis",2018-01-02,2023-12-31,2189 days,"Active, not recruiting",Interventional
KN026-CHN-001,Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer,2018-09-17,2023-08-30,1808 days,"Active, not recruiting",Interventional
Pro00103527,mHealth Behavioral Cancer Pain Intervention for Medically Undeserved Patients,2021-10-20,2025-01-31,1199 days,Recruiting,Interventional
21-374,A Study of Tumor Imaging With Multispectral Optoacoustic Tomography,2022-07-27,2023-07-27,365 days,Recruiting,Observational
CBCRP 23AB-1400,Reducing Breast Cancer Risk in Korean American Women,2019-03-16,2019-12-31,290 days,Completed,Interventional
MC02/04/19,"A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)",2020-07-13,2023-07-01,1083 days,Recruiting,Interventional
EJERDIETLINF,Reduction of Lymphedema Secondary to Breast Cancer,2021-05-17,2024-05-17,1096 days,"Active, not recruiting",Interventional
22-5074,Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE),2023-06-01,2027-12-01,1644 days,Not yet recruiting,Interventional
STUDY00018789,StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients,2022-12-01,2024-03-01,456 days,Not yet recruiting,Interventional
SCHBCC-SOAPET,Sentinel Node Biopsy Vs Observation After Axillary PET,2019-09-04,2027-09-01,2919 days,Recruiting,Interventional
3212,"A Survey to Assess Knowledge, Attitudes & Practices in Surgeons With Regards to Breast Conservation Surgery & Mastectomy",2019-04-02,2019-10-31,212 days,Completed,Observational
ATADEK-2022/08/20,The Effect of Manual Lymph Drainage in the Treatment of Breast Edema,2022-05-30,2024-01-15,595 days,Recruiting,Interventional
2018-06,Early Detection of Imaging-derived Subclinical Cardiac Injuries,2019-01-24,2024-09-02,2048 days,Recruiting,Observational
OBU-BC-â¡-077,"Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer",2022-10-20,2024-10-20,731 days,Not yet recruiting,Interventional
RG1005296,"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer",2022-04-20,2027-06-30,1897 days,Recruiting,Interventional
B7391012,A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer,2023-05-31,2025-08-16,808 days,Not yet recruiting,Observational
ONCO-FIRE,ONCOlogy-targeted NLP-powered Federated Hyper-archItecture and Data Sharing Framework for Health Data Reusability,2023-06-01,2025-12-01,914 days,Not yet recruiting,Observational
2021-01534,Effect of Breast Implants om Mammography Screening,2021-05-12,2023-12-31,963 days,"Active, not recruiting",Observational
RD19/123502,Plant Sterol INtervention for Cancer Prevention (PINC),2020-02-10,2021-12-31,690 days,Recruiting,Interventional
091-19,Study on Physical Activitys Relationship With Cancer and Cognition,2019-09-30,2021-07-15,654 days,Completed,Interventional
PR139/21,Axillary Reverse Mapping in Breast Cancer,2021-06-01,2023-12-01,913 days,Recruiting,Interventional
2021.341,Project Breast47: Effect of an Educational Intervention,2022-01-15,2022-06-26,162 days,Completed,Interventional
17-361,BEFORE Decision Aid Implementation Study,2018-09-01,2019-12-31,486 days,Unknown status,Interventional
PPMP_INO,Persistant Post-mastectomy Pain in Breast Cancer : Incidence and Risk Factors,2018-12-10,2021-03-07,818 days,Completed,Observational
Overcome project,"Overcome, a Program of Therapeutic Exercise and Functional Recovery to Improve the Functional Capacity of Women With Breast Cancer and Bone Metastases",2022-02-07,2024-02-01,724 days,Recruiting,Interventional
DS8201-A-A103,DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein,2018-04-02,2022-09-28,1640 days,Completed,Interventional
Xiangan Hospital of XMU,Artificial Intelligence Analysis of Fluorescence Image to Intraoperatively Detect Metastatic Sentinel Lymph Node.,2021-11-01,2024-12-01,1126 days,Recruiting,Observational
OBU-BJ-BB-BC-II-007,Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy,2021-11-20,2024-12-31,1137 days,Recruiting,Interventional
NU 21B01,"Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study",2022-11-28,2024-07-01,581 days,Recruiting,Interventional
COOL-CLIN-2022-01,Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss,2022-08-15,2024-03-15,578 days,Not yet recruiting,Interventional
110.01-2018-GES-0001,Automated Breast Ultrasound as an Adjunct to Screening Digital Breast Tomosynthesis,2018-08-01,2021-08-01,1096 days,Withdrawn,Observational
NURS-IIR-IUSCCC-0748,Biobehavioral Correlates of Cancer-related Cognitive Dysfunction and Its Co-occurring Symptoms,2020-11-16,2021-07-27,253 days,Completed,Observational
2020-1243,Music and Surgery Associated With Relationship and Satisfaction,2020-09-21,2021-12-31,466 days,Unknown status,Interventional
OSU-19085,Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer,2020-11-01,2021-12-31,425 days,Withdrawn,Interventional
SYSUCC-012,GM1 Prophylaxis for WBRT Related Cognitive Dysfunction,2020-05-15,2024-12-31,1691 days,Recruiting,Interventional
IMPACTT,Impact of a Patient Decision Aid Intervention,2022-11-15,2024-06-01,564 days,Recruiting,Interventional
UUBreast01,Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ,2020-03-01,2027-12-30,2860 days,Recruiting,Interventional
1/2020,Impact of Oncotype DXÂ® on Treatment Recommendation and Its Economic Evaluation Under the Brazilian Society Perspective,2018-08-08,2019-02-04,180 days,Completed,Observational
CBBCT2018CIH,The Technical Operations And Standard Clinical Application Protocol of CBBCT in Diagnostic Process of Breast Cancer,2018-01-01,2020-12-31,1095 days,Completed,Interventional
30-225 ex 17/18,Laser vs Hyaluronic Acid for GSM in Breast Cancer,2019-01-24,2023-12-31,1802 days,Recruiting,Interventional
ITSligo SG,Using an Adjustable Compression Garment for Secondary Upper Limb Lymphoedema,2020-10-30,2022-01-31,458 days,Unknown status,Interventional
STUDY00003067,Lung and Breast Cancer Prevention by an Integrated Intervention of Maternal Smoking Cessation and Breastfeeding,2021-01-01,2023-06-30,910 days,"Active, not recruiting",Interventional
850366,"The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients",2023-03-01,2025-02-01,703 days,Recruiting,Interventional
PROICM 2019-02 PRA,"Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic "" Patient Reported Outcome "") on Breast-related Quality of Life",2020-09-28,2025-06-30,1736 days,Recruiting,Interventional
060021-HMO-CTIL,"Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap",2021-09-26,2023-07-01,643 days,Recruiting,Observational
2018/13,Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer,2018-11-12,2022-12-31,1510 days,Completed,Interventional
A095053,Breast Screening - Risk Adaptive Imaging for Density,2019-05-28,2026-10-31,2713 days,Recruiting,Interventional
202302077,Prehabilitation to Revolutionize Oncology: Telehealth Exercise for Cognitive Triumphs (The PROTECT Trial),2023-04-30,2024-10-31,550 days,Not yet recruiting,Interventional
MC210301,"Long Term Followup of Patients Enrolled in MC1137, BEAUTY Study",2023-01-27,2033-12-31,3991 days,Recruiting,Observational
Yunwei Wei 2019-09-12,Study on Skin Microbiome of HFS,2019-09-10,2020-10-15,401 days,Unknown status,Observational
2.510.081,PILATES METHOD ON THE UPPER LIMBS FUNCTIONALITY,2018-05-01,2019-01-30,274 days,Completed,Interventional
K170702J,Follow-up of Elderly Patients in Ambulatory Surgery,2018-01-01,2019-03-01,424 days,Unknown status,Observational
GX-I7-CA-006,Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899),2019-03-27,2024-04-01,1832 days,"Active, not recruiting",Interventional
R17137,Thermal Suit With Forced-air Warming in Breast Cancer Surgery,2018-02-20,2018-07-06,136 days,Completed,Interventional
2021-395,Efficacy of Cilostazol in Prevention of Peripheral Neuropathy,2022-03-28,2022-12-30,277 days,Completed,Interventional
IC 2018-09,Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR),2021-02-02,2023-08-02,911 days,Recruiting,Interventional
NeoCAT,A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs,2022-12-01,2025-09-01,1005 days,Recruiting,Interventional
AAAR9515,The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL,2019-04-25,2023-04-01,1437 days,"Active, not recruiting",Interventional
2019-01395CE3508,Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients,2020-09-15,2024-12-31,1568 days,Recruiting,Observational
RG1007463,"Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer",2021-07-19,2022-08-16,393 days,Terminated,Interventional
PA191001001,Pectoral Nerve Block II and Erector Spine Plane Block in Breast Cancer Surgery,2019-07-01,2020-09-01,428 days,Completed,Interventional
18070604,A Study of Serum Folate Levels in Patients Treated With Olaparib,2020-07-21,2024-06-01,1411 days,"Active, not recruiting",Interventional
1613494-3,Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island,2020-08-28,2022-09-01,734 days,Unknown status,Observational
2021198-1,Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer,2022-03-31,2025-12-31,1371 days,Recruiting,Interventional
PROTOCOL-M7-037,Micrima MARIA Data Collection for Machine Learning Study,2022-01-27,2023-03-31,428 days,Recruiting,Interventional
201801105,RANKL Inhibition and Breast Tissue Biomarkers,2018-06-01,2018-12-03,185 days,Completed,Interventional
202004120MINB,The Effect of Intraoperative Dexmedetomidine on Postoperative Morphine Requirements After Breast Cancer Surgery,2021-04-20,2025-07-01,1533 days,Recruiting,Interventional
CHIR-05-IMTAD,Ideal Marker for Targeted Axillary Dissection,2021-01-01,2023-05-30,879 days,Recruiting,Observational
EAQ201,COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation,2021-12-02,2024-10-30,1063 days,"Active, not recruiting",Observational
STUDY00001356,IIT2020-20-SHIRAZIP-WALK: Nature Walks,2021-06-21,2023-12-01,893 days,Recruiting,Interventional
PANTHERA,Evaluation of the Subjectively Perceived Pelvic Floor Function in Patients With Gynecological Tumors and Breast Cancer Under Systemic Tumor Therapy Using a Validated Questionnaire,2018-04-01,2023-12-31,2100 days,Recruiting,Observational
IC 2020-04,ER-One: A Double-blind Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery,2021-06-28,2023-08-01,764 days,Recruiting,Interventional
Remimazolam_recovery,Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol,2022-08-02,2022-12-21,141 days,Completed,Interventional
BIOC-046,A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide,2022-09-07,2025-01-01,847 days,Recruiting,Observational
RECHMPL21_0525,Tridimensional Geometric Modeling of the Breast,2022-03-31,2023-12-01,610 days,"Active, not recruiting",Interventional
2022037,Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage â¡-â¢ HR-positive/HER2-negative Breast Cancer,2022-09-10,2024-08-10,700 days,Not yet recruiting,Interventional
Q122-2001,Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor,2018-10-24,2020-09-09,686 days,Completed,Interventional
S64410,UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research,2020-11-30,2035-09-01,5388 days,Recruiting,Interventional
MC1689,"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer",2018-03-27,2023-05-01,1861 days,Suspended,Interventional
2017C0165,Cancer Activity and Lifestyle Measurement Study,2019-01-04,2024-11-01,2128 days,"Active, not recruiting",Observational
2017-0301,Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers,2019-01-01,2026-02-01,2588 days,Withdrawn,Interventional
S59396,Cancer Related Cognitive Impairment After Chemotherapy: Evaluation of Potential Therapeutic Interventions,2018-10-01,2021-09-30,1095 days,Unknown status,Interventional
1105/18,The Immersive Experience of Virtual Reality During Chemotherapy in Patients With Early Breast and Gynecological Cancers: the Patients Dream Study,2019-04-01,2021-04-01,731 days,Completed,Interventional
RFID,Breast Localization: RFID Tags vs Wire Localization,2021-05-15,2023-11-15,914 days,Recruiting,Observational
SP11631,Trial to Compare the Efficacy and Safety of F-627 and GRANÂ®,2018-04-12,2019-06-19,433 days,Completed,Interventional
EKNZ 2015-026,Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus,2020-03-01,2021-09-01,549 days,Withdrawn,Interventional
5505,PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEALTHY OVARIES,2023-03-20,2026-05-02,1139 days,Not yet recruiting,Observational
H-37314,Translating Research Into Practice,2018-08-06,2023-06-01,1760 days,"Active, not recruiting",Interventional
852666,Improving Utilization of Supplemental Breast MRI Screening for Women With Extremely Dense Breasts,2023-04-10,2024-04-01,357 days,Enrolling by invitation,Interventional
Three birds with one stone,Three Birds With One Stone,2021-09-01,2023-12-01,821 days,"Active, not recruiting",Interventional
XZP-3287-1001,A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors,2018-05-22,2022-12-30,1683 days,Unknown status,Interventional
I 56617,"Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer, Sarcoma, Skin Cancer, or Soft Tissue Malignancy and Healthy Volunteers",2018-06-28,2023-03-15,1721 days,Terminated,Interventional
TAK-676-1003,A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers,2021-09-09,2024-02-18,892 days,Recruiting,Interventional
STUDY00022229,ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer,2023-07-30,2025-07-31,732 days,Not yet recruiting,Interventional
CR108557,"A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults",2018-12-06,2019-03-12,96 days,Completed,Interventional
FMP-2020-01-TIP,TIP in Patients Affected by Metastatic TNBC,2022-09-16,2025-09-16,1096 days,Recruiting,Observational
UPCC 25920,Pilot Study of an NTproBNP Guided Strategy of Cardioprotection,2021-03-18,2025-06-01,1536 days,Recruiting,Interventional
MEDOPP243,"DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease",2020-05-25,2023-04-04,1044 days,Completed,Interventional
4901,An Enhanced Artificial Intelligence Breast MRI Interpretation System,2019-04-01,2020-07-01,457 days,Unknown status,Interventional
22-269,Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial),2022-09-08,2025-02-28,904 days,Recruiting,Interventional
2016-051-000001- 1731,The Role of Circadian Rhythms in Cancer-Related Symptoms,2020-06-01,2022-06-01,730 days,Unknown status,Observational
Yvonne Wengstrom,Sensorimotor Training Using Whole Body Vibration Exercise to Reduce Chemotherapy-induced Peripheral Neuropathy,2022-10-17,2024-04-25,556 days,Recruiting,Interventional
4-2019-0795,Improvement of Patient Experience and Healthcare Providers Productivity Using Virtual Reality in the Field of Radiation Therapy,2020-03-13,2021-10-01,567 days,Unknown status,Interventional
None yet,An Observational Prospective Cohort Study Using an Actigraphy Device.,2018-05-15,2018-08-31,108 days,Completed,Observational
REaCT-Hold BMA,Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer,2020-10-09,2024-11-01,1484 days,Recruiting,Interventional
20180569-01H,Evaluation of a Novel Axillary Lymph Node Ink Localization Technique: A Feasibility Study,2020-01-02,2023-08-01,1307 days,Recruiting,Interventional
2020-0761,Evaluation of Mailers Promoting Mammogram Screening,2020-10-02,2021-10-05,368 days,Completed,Interventional
202005217,Implementing BREASTChoice Into Practice,2020-11-04,2023-04-30,907 days,"Active, not recruiting",Interventional
Abbreviated Breast MRI,Abbreviated Breast MRI in Cancer Detection,2019-04-01,2022-03-01,1065 days,Unknown status,Observational
SBI-CIP 20-002,Fluorescence Imaging of Carcinoma During Breast Conserving Surgery,2021-04-27,2023-12-01,948 days,Recruiting,Interventional
DS8201-A-U106,DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer,2020-02-10,2024-03-01,1481 days,Recruiting,Interventional
A2018-002,Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations,2018-02-26,2021-12-01,1374 days,Unknown status,Interventional
STUDY00016221,Nurse AMIE for Echo Show: Randomized Control Trial,2021-02-02,2022-02-28,391 days,Completed,Interventional
2669,Prospective Observational Study for Breast Microcalcifications Classification With Artificial Intelligence Techniques,2022-07-22,2025-07-25,1099 days,Recruiting,Observational
PR275/20,Impact of Systematic Shaving on Margins,2020-10-07,2023-10-16,1104 days,Recruiting,Interventional
X-PACT 101,"X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma",2021-12-08,2025-02-01,1151 days,Recruiting,Interventional
SHF-WBI,Super Hypofractionated Irradiation For Whole Breast Treatment,2021-01-23,2026-12-10,2147 days,Recruiting,Interventional
MCC-20257,Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk,2020-01-30,2023-01-19,1085 days,"Active, not recruiting",Observational
19-07020531,Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study,2020-06-30,2027-12-31,2740 days,Recruiting,Interventional
DS8201-A-U105,Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer,2018-06-20,2022-07-01,1472 days,"Active, not recruiting",Interventional
NAUTILUS study,No Axillary sUrgical Treatment In Clinically Lymph Node Negative Patients After UltraSonography,2020-09-15,2027-12-31,2663 days,"Active, not recruiting",Interventional
BrUOG 387,TAS-116 Plus Palbociclib in Breast and Rb-null Cancer,2023-05-01,2025-04-01,701 days,Not yet recruiting,Interventional
Instituto Nacional do CÃ¢ncer,Effectiveness of Compressive Bandage Use in Seroma Prevention,2021-11-08,2023-03-30,507 days,Not yet recruiting,Interventional
HP-LY-CL-2063,Clinical Study With LymfactinÂ® in the Treatment of Patients With Secondary Lymphedema (AdeLE),2018-06-07,2024-12-01,2369 days,"Active, not recruiting",Interventional
2008222-12,Accuracy of VABB Elite 10G Versus BARD 14G CNB,2020-11-01,2022-06-30,606 days,"Active, not recruiting",Interventional
2019-0837-002,Capsular Contracture After PMRT Using Prepectoral Versus Subpectoral Implant-based Breast Reconstruction: PREPER Trial,2020-06-01,2025-06-30,1855 days,Not yet recruiting,Interventional
9785,Non-contrast DWI for Supplemental Screening,2018-07-16,2028-07-01,3638 days,Enrolling by invitation,Observational
BCP24,To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph Nodes,2018-10-20,2022-06-30,1349 days,Recruiting,Interventional
IRB00083573,Cardiac Outcomes With Near-Complete Estrogen Deprivation,2022-09-02,2027-12-01,1916 days,Recruiting,Interventional
CCR5199,ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab,2022-03-02,2026-03-16,1475 days,Recruiting,Interventional
HVST-HEMO-20,The Effectiveness of HemopatchÂ® in the Reduction of Post-surgical Serous Drainage,2021-11-08,2022-11-01,358 days,Recruiting,Interventional
1708018471,Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome,2018-01-22,2021-07-31,1286 days,Completed,Observational
APBI Registry,Registry for Accelerated Partial Breast Irradiation With (SBRT) or (IMRT),2021-06-01,2024-12-01,1279 days,Withdrawn,Observational
STUDY00019979,Women In Steady Exercise Research - Window of Opportunity for Exercise and Tumor Biology,2022-07-29,2024-12-01,856 days,Recruiting,Interventional
109489,Time Restricted Eating on Cancer Risk,2022-05-04,2024-05-01,728 days,Recruiting,Interventional
IIT2019-14-SHIRAZIP-SWEAT,Streaming Web-based Exercise At Home: A Pilot Study,2020-07-07,2023-03-30,996 days,Completed,Interventional
SGNTUC-019,Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations,2021-01-11,2025-05-31,1601 days,"Active, not recruiting",Interventional
EORTC-1984-BCG,Chemo-free BRCA-targeted Neoadjuvant Strategy,2022-09-01,2030-02-18,2727 days,Not yet recruiting,Interventional
H-43277,Wrist Cooling for Hot Flashes Clinical Trial,2023-03-05,2024-01-01,302 days,Recruiting,Interventional
Oncolact2020,Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact,2022-05-11,2024-05-05,725 days,Recruiting,Interventional
OE20/2020,Effectiveness of Cohesive Bandage on Axillary Web Syndrome After,2019-01-10,2021-12-01,1056 days,Unknown status,Interventional
GNC-035-101ï¼V1.1ï¼,"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors",2021-09-15,2023-06-01,624 days,Withdrawn,Interventional
2022-0880,Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation,2023-04-05,2028-11-01,2037 days,Recruiting,Interventional
ABCB1 in Paclitaxel Neuropathy,ABCB1 SNPs as Predictors of PIPN,2018-03-01,2020-01-31,701 days,Completed,Observational
ACT16432,Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors,2021-03-29,2025-01-13,1386 days,Recruiting,Interventional
AAAT8817,IMPACT Trial: Intervention to iMProve AdherenCe Equitably,2021-08-31,2026-10-31,1887 days,Recruiting,Interventional
19-07020533,Prospective Randomized Study of Accelerated Radiation Therapy (PRART),2019-11-21,2025-12-31,2232 days,Recruiting,Interventional
PSIBBR,Prepectoral and Subpectoral Implant-based Breast Reconstruction,2021-01-01,2022-11-30,698 days,Unknown status,Interventional
THRIVORSBH-01,Physical Activity Platform to Improve Bone Health in Cancer Survivors,2019-01-21,2020-03-01,405 days,Completed,Interventional
20190516,Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib,2020-03-01,2021-06-28,484 days,Completed,Interventional
RECHMPL20_0614,Assessment of Cryotherapys Analgesic Impact in Anti-aromatase-induced Arthralgia,2023-05-01,2025-03-01,670 days,Not yet recruiting,Interventional
NNF19OC0057928,"PreoperatIve MRI to Obtain Adequate Resection Margins in Breast Conserving Surgery, (PRIMAR) Trial",2021-02-01,2026-08-31,2037 days,Recruiting,Interventional
RD19/121361,Role of ABUS as an Alternative to Breast MRI in Assessing Response to Neoadjuvant Chemotherapy,2019-08-22,2022-06-30,1043 days,Unknown status,Interventional
BRAVEHeartV1,Breast Radiotherapy Audio Visual Enhancement for Sparing the Heart,2018-09-15,2023-08-01,1781 days,"Active, not recruiting",Interventional
R/19.08.578,Reconstruction of Partial Mastectomy Defects With Pectoralis Myo-glandular Local Flap.,2019-08-24,2022-02-28,919 days,Unknown status,Interventional
DHP107_Bioimaging,A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor,2018-07-03,2018-12-24,174 days,Completed,Interventional
18-5029,Evaluating Positron Emission Mammography Imaging of Suspicious Breast Abnormalities,2019-12-17,2021-12-01,715 days,Recruiting,Interventional
201902048MINC,Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ,2019-04-30,2025-12-31,2437 days,Recruiting,Interventional
050811,Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer,2018-11-01,2020-12-01,761 days,Unknown status,Interventional
0594,The Genomic Medicine at VA Study,2020-07-17,2025-09-30,1901 days,Recruiting,Interventional
APHP201173,BENEFIT OF MECHANICAL ISCHEMIC PRECONDITIONING ON TOLERANCE OF ADIPOSE TISSUE TO ISCHEMIA REPERFUSION OF TYPE DIEP (DEEP INFERIOR EPIGASTRIC PERFORATOR) FREE FLAPS.,2022-05-01,2024-05-01,731 days,Not yet recruiting,Interventional
2019-001,Evolution of the Physical Condition in Treated Cancer Patients,2019-09-17,2021-06-01,623 days,Unknown status,Interventional
19-315,Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment,2019-12-20,2024-12-01,1808 days,Recruiting,Observational
UMCC 2019.125,Altering Lipids for Tolerance of Aromatase Inhibitor Therapy,2020-07-28,2023-05-01,1007 days,"Active, not recruiting",Interventional
2022P000354,Evaluating the Impact of an Equity Focused Dashboard and Clinical Support,2022-03-24,2023-06-30,463 days,Recruiting,Interventional
SB-2101,Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy,2022-05-25,2025-04-30,1071 days,Recruiting,Observational
00001137,Improving Genetic Counseling for BRCA+ Mothers,2020-07-01,2025-12-31,2009 days,Recruiting,Interventional
2017/2805,Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery,2018-01-03,2023-12-31,2188 days,"Active, not recruiting",Observational
C3661001,A Study of PF-06873600 in People With Cancer,2018-03-07,2024-11-28,2458 days,"Active, not recruiting",Interventional
4-2020-0430,The Effects of Perioperative PECS Block During Robotic Breast Surgery and Breast Reconstruction,2020-07-08,2021-10-10,459 days,Completed,Interventional
N16PRB,Preoperative Breast Irradiation,2018-03-12,2018-08-09,150 days,Terminated,Interventional
CASE10119,"Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography",2022-03-15,2024-08-01,870 days,Recruiting,Interventional
21-012300,Tonation Breathing Technique Method to Ease Aromatase Inhibitor-induced Joint and/or Muscle Pain,2022-02-22,2024-03-15,752 days,Recruiting,Interventional
Breast MRI,Non-mass Enhancement in Breast MRI,2020-03-01,2021-09-01,549 days,Unknown status,Observational
KY-Q-2021-182,Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis,2022-03-01,2024-12-31,1036 days,Recruiting,Interventional
DOLPHIN,Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment,2021-02-18,2023-12-31,1046 days,Recruiting,Observational
METC20-099,External Vacuum Expansion: Evaluation in Breast Reconstructive Surgery Evaluation in Breast Reconstructive Surgery,2021-07-12,2026-10-01,1907 days,Recruiting,Interventional
D8534C00001,Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6),2021-06-30,2027-11-26,2340 days,Recruiting,Interventional
NUV-422-03,Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC,2022-09-01,2026-09-01,1461 days,Withdrawn,Interventional
CLEE011ARU01,"A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With RisargÂ®, PiqrayÂ®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia",2021-07-27,2025-06-30,1434 days,Recruiting,Observational
FIS-APBI-2019-02,Accelerated Partial Irradiation of the Breast: New Altered Fractionation,2019-10-15,2026-06-15,2435 days,Recruiting,Observational
17/0774,Extended Follow up of the TARGIT-A Trial,2018-08-16,2023-01-31,1629 days,Recruiting,Observational
OSU-18094,Evaluation of Perforator Phase Contrast Angiography in Developing Surgery Plans for Patients With Breast Cancer Undergoing Breast Reconstruction With Free-Flap Methods After Mastectomy,2023-01-01,2024-07-31,577 days,Withdrawn,Interventional
21-3100.cc,Second Opinions in Oncology,2021-05-14,2024-06-01,1114 days,"Active, not recruiting",Observational
10840098-604.01.01-E.184,"Effectiveness of PNF Training for Improving for Muscle Strength, Function, and Pain After Axillary Lymph Node Dissection",2019-12-12,2021-07-01,567 days,Completed,Interventional
Breast Cancer Chemotherapy,Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses,2020-08-03,2022-11-03,822 days,Recruiting,Interventional
STUDY02001039,"21DIF039: Prone to Supine Breast MRI II, P2S2 Breast MRI Trial",2022-03-15,2022-06-15,92 days,Not yet recruiting,Interventional
CSCS,Cognitive Stimulation and Chemobrain. An Innovative Intervention for Cancer Survivors,2022-06-03,2023-12-01,546 days,Recruiting,Interventional
2020/6422,"Effects of Bromelain and Boswellia Serrata Casperome With Centella Asiatica and Vitamins on Edema, Paresthesia and Postoperative Pain After Quadrantectomy With or Without Sentinel Lymph Node Biopsy.",2020-12-31,2022-01-31,396 days,Unknown status,Interventional
2022-0150,A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care,2022-08-25,2023-12-31,493 days,Recruiting,Interventional
2007-0003,Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism,2019-01-01,2021-01-01,731 days,Withdrawn,Interventional
2-028-22,Chemotherapy Induced Cognitive Impairment,2022-12-15,2024-06-30,563 days,Recruiting,Observational
CASE2119,A Study of the Use of AirXpanders AeroForm in Patients Undergoing Post-Mastectomy Radiation Therapy,2019-07-15,2022-06-01,1052 days,Withdrawn,Interventional
GEN-602-CT-101,Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer,2019-03-01,2023-12-01,1736 days,"Active, not recruiting",Interventional
STUDY00000228,RCT Comparing ESPB Solutions in Breast Surgery,2020-12-04,2023-12-01,1092 days,Recruiting,Interventional
PRESIONA20,Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program,2021-01-01,2024-01-01,1095 days,Recruiting,Interventional
IPAC,Optimizing the Management of Patients With Oral Therapy,2018-03-19,2021-05-22,1160 days,Unknown status,Interventional
CASE5122,Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi ScoutÂ®,2023-05-01,2026-11-01,1280 days,Not yet recruiting,Interventional
CTMS# 18-0135,Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy,2019-01-16,2024-12-01,2146 days,Suspended,Interventional
3734,Assessment of the Breast Cosmesis Using Deep Neural Networks: an Exploratory Study (ABCD),2021-10-04,2026-09-01,1793 days,Recruiting,Observational
6077,Multicentric Study for External Validation of a Deep Learning Model for Mammographic Breast Density Categorization,2021-09-01,2022-07-01,303 days,Not yet recruiting,Observational
2022LS100,Assessing the Time Demands of Cancer,2023-05-01,2030-12-31,2801 days,Not yet recruiting,Observational
STX-478-101,First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor,2023-04-01,2026-06-01,1157 days,Recruiting,Interventional
18-486,Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease,2019-01-16,2024-01-01,1811 days,Recruiting,Interventional
2019-02661,Added Value of Preoperative Contrast Enhanced Mammography in Staging of Malignant Breast Lesions,2020-11-02,2023-12-31,1154 days,Recruiting,Interventional
110181,Probiotics and Breast Health,2019-07-02,2021-12-31,913 days,Completed,Interventional
IRB-55153,"Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts",2021-04-28,2023-04-15,717 days,Recruiting,Interventional
GS3,GlobalSurg 3: Quality and Outcomes in Global Cancer Surgery,2018-04-01,2018-11-30,243 days,Unknown status,Observational
20953,"Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer",2021-03-31,2025-06-30,1552 days,Withdrawn,Interventional
QT MG PRE Phase 1,Understanding Patient Experience and Preferences for the QT Scanner Compared to Mammography,2019-08-06,2022-12-30,1242 days,Suspended,Observational
MC1932,TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol,2019-08-21,2025-09-30,2232 days,Recruiting,Interventional
2018-A011828-47,Assessment of Health Related Quality of Life in Women Who Underwent Breast Reconstruction After Radical Surgery,2019-05-04,2025-05-04,2192 days,Recruiting,Observational
EXPLLN21-01,A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG,2023-05-01,2025-03-01,670 days,Not yet recruiting,Interventional
22-457,Losartan in Prevention of Radiation-Induced Heart Failure,2023-01-01,2023-12-01,334 days,Not yet recruiting,Interventional
GW10029,"Assessing the Sensitivity of ""SureTouchâ¢"" in Women Undergoing Diagnostic and Screening Mammography",2019-01-04,2021-02-10,768 days,Terminated,Interventional
GCC1950,First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies,2022-02-14,2026-11-01,1721 days,Recruiting,Interventional
2020-0501,Contrast-Enhanced Mammography for the Evaluation of Mammographic Microcalcifications,2021-03-23,2023-04-30,768 days,Recruiting,Observational
Erector block after mastectomy,Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy.,2023-01-01,2023-08-30,241 days,Recruiting,Interventional
2021-0025,Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge,2021-04-15,2024-04-30,1111 days,Recruiting,Interventional
HCI148669,Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System,2022-08-02,2027-08-01,1825 days,Recruiting,Interventional
CBYL719CKR01,A Post Marketing Surveillance on Piqray in Korea,2022-06-29,2027-05-12,1778 days,Recruiting,Observational
21/59848,Lymphaticovenous Anastomosis as Treatment for Lymphedema,2022-05-11,2024-01-31,630 days,Recruiting,Interventional
221-005,Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin Â®,2019-11-13,2020-09-11,303 days,Completed,Interventional
RECHMPL20_0005-UF7919,Hepatitis C Screening Paired With Mammography,2022-03-23,2025-03-23,1096 days,Recruiting,Observational
P.T.REC/012/002615,Aquatic Versus Land Based Exercise on Lymphedema Post Mastectomy,2018-07-01,2019-11-30,517 days,Completed,Interventional
INT31/19,Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases,2019-10-15,2022-03-31,898 days,Unknown status,Interventional
Telerehab CH Usability,Telerehabilitation Cognitive Impairments Following Chemotherapy Usability Study,2021-06-07,2021-12-31,207 days,Completed,Observational
ICO-N-2018-15,Delayed Breast Reconstruction by Prepectoral Implant After Lipo-preparation (RM2prepec),2019-12-24,2023-12-24,1461 days,"Active, not recruiting",Observational
B00394,Automated Low Dose Risk Assessment Mammography (ALDRAM),2019-02-22,2023-02-16,1455 days,Completed,Interventional
CKMW-1801,Compass Course: Efficacy Study,2018-03-02,2021-05-01,1156 days,Completed,Interventional
EGC101,A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers,2022-05-16,2023-01-24,253 days,Completed,Interventional
69HCL20_1018,Remediation for Mild Cognitive Deficits After Cancer,2021-12-17,2025-07-17,1308 days,Recruiting,Interventional
300.08-2018-Samsungmedison-S,Breast Ultrasound Image Reviewed With Assistance of Deep Learning Algorithms,2018-09-20,2020-01-31,498 days,Unknown status,Interventional
ICO-A-2020-10,Electrotherapy in the Management of Myofascial Syndrome,2022-01-05,2024-04-01,817 days,Recruiting,Interventional
INT157/17,Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial,2018-07-01,2020-12-31,914 days,Unknown status,Interventional
13155,ciNPT in Autologous Abdominal Tissue Breast Reconstruction,2021-10-01,2022-10-01,365 days,Not yet recruiting,Interventional
BO40933,"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.",2019-06-11,2022-01-04,938 days,Completed,Interventional
IRB20-0528,Low-dose Imaging Technique (LITE),2020-08-24,2020-08-24,0 days,Withdrawn,Interventional
2018-0345-1105,Feasibility of Preoperative Tattooing of Percutaneously Biopsied Axillary Lymph Node: A Quasi Experimental Pilot Study,2019-03-27,2020-12-31,645 days,Unknown status,Observational
NL67696.068.18,Functional MRI Study Reconstructed Breasts,2020-02-11,2021-12-31,689 days,Unknown status,Interventional
UW17032,Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention,2019-11-19,2020-03-10,112 days,Terminated,Interventional
MedOPP321,"ABemaciclib, ET Â± paclItaxel in aGgressive HR+/HER2- MBC trIaL",2021-06-02,2024-05-01,1064 days,Recruiting,Interventional
RECHMPL21_0379,Cancer Predictive Score on Breast MRI,2021-01-01,2022-09-30,637 days,Enrolling by invitation,Observational
2017-8737,Post-op Outcomes of Enhanced Energy Delivery Dissection for Mastectomy With Immediate Breast Reconstruction,2018-08-15,2019-10-15,426 days,Unknown status,Interventional
IRB-53132,LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy,2021-09-10,2030-06-01,3186 days,Suspended,Interventional
AP2204-50104,Efficacy of Serratus Anterior Plane Block With Dexmedetomidine During Breast Surgery,2022-05-10,2023-05-25,380 days,Recruiting,Interventional
5160378,Effect of Resveratrol on Serum IGF2 Among African American Women,2019-04-24,2024-06-30,1894 days,Suspended,Interventional
R.21.11.1523,Comparison of Different Volumes Spread of Erector Spinae Block in Post Mastectomy Pain Syndrome Management,2021-12-12,2022-09-01,263 days,Recruiting,Interventional
CYP003,A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers,2023-03-21,2025-02-01,683 days,Recruiting,Interventional
315581,Randomised Trial Comparing Biological Matrices With Synthetic Meshes,2022-08-01,2025-07-31,1095 days,Not yet recruiting,Interventional
2022000438,Clinical Outcomes and Patient Satisfaction With Use of the Amma System,2022-08-22,2024-10-01,771 days,Recruiting,Observational
CTB in Breast surgery,Ultrasound Guided Costotransverse Block for Breast Cancer Surgery,2020-01-06,2020-04-29,114 days,Completed,Interventional
RS1307/20,Prognostic Relevance of Coagulation Activation in RIsk Assessment and Stratification,2020-01-21,2023-12-31,1440 days,Recruiting,Observational
H-18041465,Pain Phenotyping of Patients With Bone Cancer Pain,2019-02-05,2023-02-01,1457 days,Unknown status,Observational
RIS42756,Remote Time-restricted EAting DeliverY,2022-07-07,2023-07-06,364 days,Recruiting,Interventional
18-294,"Evaluation of an Online, Remote Cognitive Battery for Use in Cancer Survivorship",2018-09-11,2024-09-01,2182 days,"Active, not recruiting",Observational
YH32367-101,Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor,2022-08-26,2026-10-06,1502 days,Recruiting,Interventional
HP-00088085,GammaPod Registry and Quality of Life Nomogram,2019-01-03,2027-12-01,3254 days,Recruiting,Observational
2020-0974,Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics,2020-12-15,2023-10-31,1050 days,Recruiting,Observational
2021.127,Music Intervention for Preoperative Anxiety and Acute Pain Among Mastectomy Patients,2021-06-05,2022-03-27,295 days,Completed,Interventional
ShantouCH,Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery,2020-08-20,2024-01-01,1229 days,Recruiting,Interventional
HYACOM,"Efficacy of Preparation in Self-Hypnosis by Anchoring Versus Conversational Hypnosis, Used Alone or Combined, in Patients Undergoing Breast Macrobiopsies",2022-10-11,2024-07-01,629 days,Recruiting,Interventional
NL82061.096.22,Evaluating the Use of Magnetic Resonance Imaging and Contrast Enhanced Mammography After MagTraceÂ® Use,2022-11-23,2023-03-31,128 days,Not yet recruiting,Observational
36264PR116/2/23,Vitamin C on Acute and Chronic Post Mastectomy Pain,2023-04-01,2024-12-01,610 days,Recruiting,Interventional
MCC-20335,Evaluation of EnVisio SmartClip for Intraoperative Localization of Breast Masses,2020-10-27,2023-11-01,1100 days,Recruiting,Observational
00101494,Technology-Based Cancer Screening Intervention,2022-01-04,2025-07-01,1274 days,Enrolling by invitation,Interventional
ETK00-2020-0103,Effects of Clinical Pilates and Yoga Training in Lymphedema,2021-10-29,2023-02-14,473 days,Completed,Interventional
DIVA-001,"Randomized, Controlled Trial With Hybrid Fractional Laser",2018-08-10,2021-06-15,1040 days,Completed,Interventional
PRO00030436,The Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure,2018-03-03,2021-03-21,1114 days,Completed,Interventional
JS2021-6-1,Hypofractionated Post Mastectomy Radiation With Two-Stage Expander/Implant Reconstruction,2021-04-08,2025-04-30,1483 days,Recruiting,Interventional
20180335,An Investigator Initiated Study of Intra-Operative Radiation Therapy (IORT) Using the XoftÂ® AxxentÂ® eBx System,2019-01-11,2029-08-01,3855 days,Recruiting,Interventional
DRBX201901/PRO,A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection,2019-07-04,2019-12-23,172 days,Completed,Interventional
21-04,Performance Assessment of the Fluorescence Technique Alone in the Search for the Sentinel Node in Breast Surgery,2022-12-05,2024-07-15,588 days,Recruiting,Interventional
A221505,Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer,2018-02-01,2035-08-01,6390 days,"Active, not recruiting",Interventional
UC-0107/1803,Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast,2019-05-10,2034-11-13,5666 days,Recruiting,Interventional
SHS-An-1-2022,Nociception Level Monitor (NOL) During Guided Analgesic Delivery in Breast Surgeries,2022-01-01,2025-03-01,1155 days,Enrolling by invitation,Interventional
R01CA249419,The Engaging Primary Care in Cancer Survivorship (EPICS) Study,2021-09-21,2025-05-31,1348 days,Enrolling by invitation,Interventional
STU 072016-058,Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity,2018-07-01,2023-03-01,1704 days,Enrolling by invitation,Interventional
22-0241,What is Optimal Post-operative Prophylactic Therapy in Irradiated Breasts Undergoing Repeat Surgery,2023-06-01,2025-12-31,944 days,Not yet recruiting,Interventional
DS1103-074,A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors,2023-04-10,2026-06-30,1177 days,Not yet recruiting,Interventional
NEUROTOX,Relationship Between Serum Interleukin-20 Level and Paclitaxel-associated Neuropathy,2022-01-01,2023-04-01,455 days,Recruiting,Observational
Biofeedback_based_music,Effects of Biofeedback-based Music Program Using a Smart Device Application on Perioperative Sleep Quality.,2023-02-02,2023-06-30,148 days,Not yet recruiting,Interventional
IRB-21-28,Can Chronic Post-surgical Pain be Reduced by Preserving Intercostobrachial Nerve During Axillary Lymph Node Dissection? : A Randomized Controlled Trial,2022-01-30,2022-10-01,244 days,Enrolling by invitation,Interventional
BREAST-Pyrotinib,Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC,2019-06-01,2023-12-01,1644 days,Not yet recruiting,Interventional
ELEGANT - ET18-262,Satisfaction & Efficacy of Compression Using Surgical Gloves in Chemo-induced Peripheral Neuropathies,2019-09-30,2023-09-30,1461 days,"Active, not recruiting",Observational
A5481065,Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCEÂ®,2018-02-08,2025-08-08,2738 days,Recruiting,Observational
L19-065,Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction,2022-06-01,2026-06-01,1461 days,Recruiting,Interventional
HP-00068503,Cardiac MRI Biomarker Testing (GCC 1618),2018-02-01,2022-09-09,1681 days,Terminated,Observational
TQB211-III-01,A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.,2018-11-11,2021-10-01,1055 days,Unknown status,Interventional
AP2110-30111,Erector Spinae Plane Block Versus Serratus Anterior Block on Post Mastectomy Pain Syndrome,2021-11-01,2022-12-30,424 days,Recruiting,Interventional
IRB202101449,UFPTI 2105-BR05: Improving Breast Radiotherapy Setup and Delivery Using Mixed-Reality Visualization,2022-08-02,2023-06-30,332 days,Recruiting,Interventional
NL72808.068.20,AFT: Introduction of a Full Breast Reconstructive Method,2020-12-09,2026-10-01,2122 days,Recruiting,Observational
IIT2021-01-Shiao-CSF1Ri,Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation,2023-03-30,2024-12-01,612 days,Not yet recruiting,Interventional
WHITE TEA,White Tea for Prevention of Chemotherapy Induced Mucositis,2020-09-02,2023-07-01,1032 days,"Active, not recruiting",Interventional
R17096,Intraoperative Tissue Identification by Analyzing Surgical Smoke,2019-10-09,2019-12-26,78 days,Completed,Observational
2017/15,Study of the Impact of DPD Activity on the Efficacy of Capecitabine,2020-07-20,2025-04-01,1716 days,Recruiting,Interventional
A222101,Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II),2023-03-31,2030-05-31,2618 days,Not yet recruiting,Interventional
AP2014-50103,Dexmedetomidine in Erector Spinae Block in Postoperative Analgesia,2021-07-01,2021-09-30,91 days,Completed,Interventional
DMT-2015.002,Delphinus SoftVueâ¢ ROC Reader Study,2018-09-23,2018-09-23,0 days,Completed,Observational
21-318,Use of an Interactive 3D Tool During Consultation for Breast Reconstruction Surgery,2021-08-23,2023-08-01,708 days,"Active, not recruiting",Interventional
KY2019,Recurrence Risk Evaluation by 21-gene Detection,2019-01-01,2019-02-01,31 days,Completed,Observational
S61864,Magnetic Seed Localisation for Nonpalpable Breast Lesions,2018-09-10,2019-05-23,255 days,Completed,Observational
IRAS 283017,Comparison of Patient Reported Outcome Measures Using the BREAST-Q Questionnaire in Patients Undergoing Pre Versus Sub-pectoral Implant Based Immediate Breast Reconstruction.,2019-09-01,2022-12-01,1187 days,Unknown status,Observational
BXU572940,Doxil/Caelyx BE Study,2023-08-01,2024-04-01,244 days,Not yet recruiting,Interventional
62/19-06-18,Guided Imagery & Music in Cancer,2018-07-01,2020-12-31,914 days,Unknown status,Interventional
ZUH-MICB-UMPR,The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery.,2019-11-29,2021-12-08,740 days,Completed,Interventional
20/WS/0110,Contrast-Free Magnetic Resonance Imaging for Breast Disease,2021-07-06,2024-07-01,1091 days,Recruiting,Observational
RG1007834,Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy,2021-07-10,2041-04-30,7234 days,"Active, not recruiting",Interventional
KCT001,"Clinical Evaluation of a Novel Wearable Compression Technology in the Treatment of Lymphedema, An Open-Label Controlled Study",2020-08-05,2021-05-28,296 days,Completed,Interventional
HE641269,Efficacy of Parecoxib Combined With Paracetamol in Mastectomy,2023-03-28,2023-05-10,43 days,Recruiting,Interventional
AIUR trial,The AIUR Trial: Surgical Gloves to Prevent Peripheral Neuropathy,2023-05-01,2026-02-01,1007 days,Not yet recruiting,Interventional
ATADEK 2021-14/18,Aromatherapy Methods in Reducing Anxiety Before Breast Biopsy,2021-08-01,2022-06-01,304 days,Recruiting,Interventional
S-20200094,Lymphedema Screening,2020-10-05,2021-10-01,361 days,Unknown status,Interventional
LBS-CA-PTL-033,HydroMARK Post-market Clinical Follow-up Study,2021-02-16,2023-12-01,1018 days,Recruiting,Observational
19-665,CONFIRM: Magnetic Resonance Guided Radiation Therapy,2021-05-01,2024-06-18,1144 days,Recruiting,Interventional
RECHMPL18_0244,Pre Pectoral Implant for Immediate Breast Reconstruction Using Single Port Endoscopy in Prophylactic Indication,2019-04-26,2026-10-22,2736 days,Recruiting,Interventional
TBio-4101-001,A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors,2023-01-17,2024-06-30,530 days,Recruiting,Interventional
UCCS19102,Memory and Attention Adaptation Training-Geriatrics (MAAT-G),2020-06-12,2023-03-01,992 days,Recruiting,Interventional
UCCS20127,Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II,2021-04-02,2024-09-01,1248 days,Recruiting,Interventional
U21-08-4519,Assessment of Cancer Related Brain Fog Using the Test of Strategic Learning,2022-08-01,2023-08-01,365 days,Recruiting,Observational
RCB: 2022-A01349-34,Algology in Oncology Osteopathic Support (ALGOS),2023-01-11,2024-12-08,697 days,Recruiting,Interventional
211820931,Urtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis,2018-05-02,2022-02-10,1380 days,Completed,Interventional
CTC-SMMiL-E-1901,Feasibility of a New Technology for Isolating Circulating Tumour Cells,2020-03-11,2023-12-01,1360 days,Recruiting,Interventional
LCI-BRE-VITD-001,A Study of High-Dose Vit D Versus Standard of Care Vit D Supplementation,2021-09-16,2024-12-01,1172 days,Recruiting,Interventional
CLEE011A2412B,Roll-over Study to Allow Continued Access to Ribociclib,2022-07-07,2028-02-16,2050 days,Recruiting,Interventional
PB-2020-01,ARGONAUT: Stool and Blood Sample Bank for Cancer Patients,2022-07-01,2025-12-31,1279 days,Recruiting,Observational
OX2022-203-01,Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors,2023-02-20,2027-04-01,1501 days,Recruiting,Interventional
2018-0561,"ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors",2019-01-24,2023-07-26,1644 days,"Active, not recruiting",Interventional
IRB00180383,e-CHEC-uP: Scaling up an Efficacious Cancer Screening Intervention for Women With Limited English,2019-07-14,2020-08-17,400 days,Completed,Interventional
ID-RCB: 2018-A03356-49,Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis,2019-07-04,2020-12-17,532 days,Completed,Interventional
2021/058,Novel Skin Care Product for the Management of Acute Radiodermatitis,2022-02-01,2023-06-01,485 days,Recruiting,Interventional
2011684,Radiofrequency Chip for Localization of Non-Palpable Breast Lesions,2018-10-18,2021-04-19,914 days,Completed,Interventional
CDK-002-101,"A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors",2020-09-15,2022-12-23,829 days,Completed,Interventional
SAPB for MRM 2.0,Serratus Anterior Plane Block for Modified Radical Mastectomy: Double-point VS Single-point,2021-12-01,2022-06-30,211 days,Recruiting,Interventional
2020_16,"Metabolism, Circadian Rhythms and Ovarian Function",2022-02-24,2025-02-01,1073 days,Recruiting,Observational
TJ107001STM202,Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors,2021-12-22,2024-02-01,771 days,Recruiting,Interventional
2015C0090,Tango for Neuropathy Among Breast Cancer Survivors,2021-08-15,2023-08-14,729 days,Recruiting,Interventional
Study-21-00112,Mammography and Breast Arterial Calcification: An Information-Sharing Trial,2021-09-29,2026-03-01,1614 days,Recruiting,Interventional
NeuroMod-PCCI,Cognitive Training and Brain Stimulation in Women With Post-chemotherapy Cognitive Impairment,2021-11-02,2023-08-01,637 days,Recruiting,Interventional
2020-013-00US3,A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors,2021-08-09,2024-03-01,935 days,Recruiting,Interventional
D8530C00004,"A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833",2020-09-17,2021-01-07,112 days,Completed,Interventional
19-5250.0,Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy,2019-11-01,2022-11-01,1096 days,Suspended,Interventional
STU 2019-1099,Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity,2019-12-17,2023-12-01,1445 days,Suspended,Interventional
2020.253 NL72539.029.20,Supervised Exercise to Promote Infiltration of NK-cells Into the Tumor,2021-01-06,2022-07-25,565 days,Completed,Interventional
A5481173,Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies,2022-07-07,2026-04-19,1382 days,Recruiting,Interventional
RCT Pristina 2/TR,Self-compression Mammography in Clinical Practice,2018-01-25,2020-12-31,1071 days,Completed,Interventional
2021-0568-001,A Study to Reduce Persistent Post-mastectomy Pain Using Opioid-free Anesthesia,2021-12-16,2025-10-31,1415 days,Recruiting,Interventional
STUDY00143316,Sexual Health Empowerment for Womens Health,2019-11-11,2024-03-31,1602 days,"Active, not recruiting",Interventional
2019P001434-1,Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey,2020-03-17,2020-06-29,104 days,Completed,Observational
19-238,Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction,2019-07-05,2023-07-01,1457 days,Recruiting,Interventional
FDRT-BC007,Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery,2018-07-01,2028-06-30,3652 days,Recruiting,Interventional
PMPS 1,Incidence and Factors Affecting the Development and Outcome of Post Mastectomy Pain Syndrome,2021-08-01,2022-09-01,396 days,Not yet recruiting,Observational
2004-219-1119,Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy,2020-07-13,2021-08-15,398 days,Completed,Interventional
2000031319,The In4M Study: Integrating 4 Measures to Assess Physical Function in Cancer Patients,2022-01-27,2024-08-01,917 days,Recruiting,Observational
DS1062-A-J101,First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01),2018-01-31,2025-01-01,2527 days,Recruiting,Interventional
CMUH110-REC1-122,Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Radiation CareÂ® Gel,2021-08-01,2022-06-01,304 days,Recruiting,Interventional
IIT-ePRO,A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys,2022-03-30,2023-10-01,550 days,Recruiting,Interventional
ICO-2020-22,"Breast Reconstruction by Exclusive Lipomodulin : Feasibility, Evaluation of the Aesthetic Result and Quality of Life",2020-11-26,2021-02-05,71 days,Completed,Observational
22-091,Culturally Aware AET Non-Initiation Intervention,2022-12-01,2023-07-01,212 days,Not yet recruiting,Interventional
UTK-IRB-22-07195,Womens Interventions for Sexual Health: WISH,2022-11-22,2023-09-01,283 days,Recruiting,Interventional
ERC#2020-3379-10190,Outcomes of Local Perforator Flaps in Oncoplastic Surgery,2020-04-18,2021-06-30,438 days,Completed,Observational
PROICM 2018-07 BPR,Memory Perception Assessment in Central/Non-central Nervous System Cancers,2019-05-10,2023-10-30,1634 days,Recruiting,Interventional
5271,"SEroma Reduction pOst MAstectomy ""SEROMA Study""",2019-10-07,2022-07-01,998 days,Unknown status,Interventional
ZG01012019,Closed Incision Disposable Negative Pressure Wound Therapy in Immediate Postmastectomy Breast Reconstruction,2019-01-01,2021-07-01,912 days,Unknown status,Interventional
PO18091,Per-operative Exploration of the Peri-pancreatic Lymphatic Pathways During Pancreatic Surgical Resection,2018-10-22,2020-10-22,731 days,Unknown status,Interventional
22-197,The Effect of Acupuncture on Nerve Pain Caused by Taxane (Chemotherapy) Treatment,2022-07-11,2025-07-01,1086 days,Recruiting,Interventional
21-055,Study of the Safety of MRI Scans in People Who Have Breast Tissue Expanders After Mastectomy,2021-02-19,2024-02-19,1095 days,Recruiting,Observational
1955K,Multicentric Risk Evaluation of Autologous Fat Grafting Procedure,2019-06-01,2020-06-01,366 days,Unknown status,Observational
20-5111,The Person-centered Evolution of Radiotherapy Services in Ontario Study,2020-08-13,2024-08-01,1449 days,"Active, not recruiting",Interventional
PROICM 2020-06 BIO,Pain Monitoring After Breast Biopsy: Benefit of E-health,2021-02-09,2023-08-01,903 days,Recruiting,Interventional
IRB-46373,Phase 2 Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma,2019-03-22,2025-07-01,2293 days,Recruiting,Interventional
UPCC 21220,CTNNA1 Familial Expansion Study,2021-03-16,2024-01-01,1021 days,Recruiting,Observational
2019_NOV_CP_001,Evaluation Protocols for Isolation of Analytes From Urine for Future Oncology Applications,2020-06-18,2023-04-01,1017 days,Recruiting,Interventional
DEGENCA,"Feasibility Study of a Molecular Karyotype Using a Very High-throughput Sequencing Approach, the ""Massive Parallel Sequencing"" on Circulating Tumor DNA",2018-06-14,2021-06-01,1083 days,Unknown status,Interventional
IRB-2022- 1451,Axillary Versus Primary Breast Approach for Second-stage Breast Reconstruction,2022-12-01,2024-12-01,731 days,Not yet recruiting,Interventional
ASO.RianGen.22.02,Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery,2022-09-07,2023-11-07,426 days,Enrolling by invitation,Interventional
19-00222,Pilot Usability and Feasibility Testing on Kinect-Enhanced Training System for Lymphatic Exercises,2019-06-01,2019-09-01,92 days,Completed,Interventional
C4431001,A Study of PF-07260437 in Advanced or Metastatic Solid Tumors,2021-10-07,2025-09-25,1449 days,Recruiting,Interventional
M336,Comparison of Erector Spinae Plane Block With Serratus Anterior Plane Block for Breast Surgery,2018-08-01,2019-09-15,410 days,Completed,Interventional
MAGREES,Effectiveness and Safety of Preoperative Magnetic Detection of Non-palpable Breast Lesions,2022-03-20,2023-03-06,351 days,Completed,Observational
KIA 2018/155,The Effect of Thoracal Paravertebral Block on Seroma Reduction in Breast Surgery,2018-09-01,2019-02-26,178 days,Completed,Interventional
B-1206-158-005,Pilot Study of Skin Quality Improvement After Adipose-drived Stem Cell Transfer in Irradiated Breasts,2020-12-01,2021-12-30,394 days,Withdrawn,Interventional
190311,Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction,2022-10-20,2025-03-31,893 days,Recruiting,Interventional
20-021,Does Immediate Lymphatic Reconstruction Decrease the Risk of Lymphedema After Axillary Lymph Node Dissection,2020-01-22,2024-01-01,1440 days,Recruiting,Interventional
202200395A3,"Effect of Helmet Type, Home-use Low-level Light Therapy Device for Chemotherapy-induced Alopecia",2022-08-17,2025-12-31,1232 days,Recruiting,Interventional
PECS in Breast Cancer Surgery,PECS Block With Bupivacaine Vs Bupivacaine and Dexmedetomidine in Modified Radical Mastectomy,2020-03-01,2020-07-01,122 days,Unknown status,Interventional
HREBA.CC-19-0354,Protein Needs Study,2021-04-26,2025-12-31,1710 days,Recruiting,Interventional
Analgesia in breast surgey,Combined PECS II and Transversus Plane Blocks Versus Erector Spinae Block in Modified Radical Mastectomy,2021-02-08,2022-12-01,661 days,Unknown status,Interventional
159-2019,Magnetic Occult Lesion Localization Instrument (MOLLI) Guidance System for Breast Lesion Localization,2021-05-16,2023-12-31,959 days,Recruiting,Interventional
9778,MRI Characterization of Mammographically Detected DCIS,2018-04-20,2032-04-01,5095 days,Recruiting,Observational
LCCC1920,Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention,2019-10-30,2022-06-06,950 days,Completed,Interventional
MCC-19650,Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1,2019-01-10,2022-04-11,1187 days,Terminated,Interventional
2018-05-0009,Living Well After Breast Surgery,2019-02-18,2021-06-11,844 days,Completed,Interventional
STU00214745,Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage,2022-07-12,2023-07-01,354 days,Recruiting,Interventional
DCIS Cryo,Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ,2021-11-01,2026-11-01,1826 days,Recruiting,Interventional
ENTheR,Exploratory Study on Therapy for Breath Hold in Radiotherapy,2019-04-18,2020-01-03,260 days,Completed,Interventional
Michal Nissim 2,"Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer Patients",2023-04-01,2027-08-30,1612 days,Recruiting,Interventional
IUSCC-0533,Trial of Oral Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias,2018-12-14,2018-12-14,0 days,Withdrawn,Interventional
Version 1.1.6,Magnetic Occult Lesion Localization and Imaging (MOLLI),2018-05-28,2020-01-01,583 days,Completed,Interventional
GALENO 1,Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies,2019-06-20,2021-09-01,804 days,Unknown status,Interventional
MMSTD1Pecs2,Establishing Technique for PECS2 Catheter Insertion,2018-11-01,2019-11-30,394 days,Completed,Interventional
875329,Training Data Collection & AI Development,2022-07-31,2023-04-10,253 days,"Active, not recruiting",Interventional
ST-067-001,"Phase 1a and Phase 2 Study for PK, PD, Safety and Preliminary Efficacy of ST-067",2021-08-06,2025-01-30,1273 days,Recruiting,Interventional
H-40045,Scalable Communication Modalities for Returning Genetic Research Results,2023-03-06,2024-06-01,453 days,Recruiting,Interventional
SYSKY-2023-122-02,Clinical Value of Breast High-Resolution MR Ductography in Patients With Pathological Nipple Discharge,2023-03-02,2024-05-30,455 days,Recruiting,Interventional
TRV-002,Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs,2022-12-01,2024-06-01,548 days,Recruiting,Observational
KOU KAEK 2018/487,Comparison of Bi-level Erector Spine Plane Block and Combined Pectoral I-II Block in Breast Surgery,2020-01-01,2021-01-15,380 days,Completed,Interventional
TREM-1,Pilot Study of the Predictive Value of TREM1 Expression and Activation in Inflammation and Radio-induced Mammary Fibrosis,2022-04-01,2024-12-31,1005 days,Recruiting,Interventional
RC31/17/0335,Quality of Life in Patients With Standard External Compared to Custom-made Breast Prosthesis.,2021-01-28,2022-02-01,369 days,Unknown status,Interventional
201912245RINB,Effects on Recovery of Postoperative Gastrointestinal Function With Multimodal Analgesia,2020-03-23,2025-12-31,2109 days,Not yet recruiting,Interventional
KND-QX-CXXT,Clinical Study of Vascular Imaging Evaluation of Computed Tomography Photoacoustic Breast Imaging System,2021-03-31,2021-12-31,275 days,Unknown status,Observational
ALTERTASTE,Improving Food Pleasure and Intake of Oncology Patients Receiving Chemotherapy,2021-07-01,2022-12-01,518 days,Unknown status,Observational
CUT_DN_02,Prevention of Radiodermatitis in Breast and Head and Neck Cancer Patients in Cyprus,2022-12-01,2023-06-01,182 days,Not yet recruiting,Interventional
Pro00052823,Tissue Expansion in Breast Reconstruction Without Drains,2019-02-25,2020-10-02,585 days,Completed,Observational
PKUPH10B001,Comparison of pCR Rate After Neadjuvant Chemotherapy Guided by Result of in Vitro Cell Culture Drug Sensitivity or Physicians Choice,2019-12-01,2021-12-01,731 days,Unknown status,Interventional
19.58/ONCO19.08,PBMT for the Management of CIA ( HAIRLASER ),2020-06-17,2022-12-31,927 days,Recruiting,Interventional
CCS1477-01,Study to Evaluate CCS1477 in Advanced Tumours,2018-07-23,2024-03-01,2048 days,Recruiting,Interventional
CIRCADIAN,Chemotherapy-induced Circadian Rhythm Disruption,2019-12-14,2023-02-01,1145 days,Recruiting,Observational
CO-338-098,A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR),2019-06-28,2022-04-22,1029 days,Terminated,Interventional
UBP-A103-HER2,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers",2018-03-05,2019-04-02,393 days,Completed,Interventional
UMCC 2021.071,Developing a Psychosexual Educational Partners Program: PEPP A Feasibility Study,2022-03-15,2022-08-29,167 days,Completed,Interventional
Pro00040035,Home-Based Physical Activity Intervention for Taxane-Induced CIPN,2020-08-14,2024-09-30,1508 days,Recruiting,Interventional
18-6047,The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease,2019-09-11,2023-09-01,1451 days,Recruiting,Interventional
Real-HER2,Real World Study on the Efficacy and Safety of Anti-HER2 Therapy,2020-06-01,2022-10-01,852 days,Recruiting,Observational
PI2018068,Peer Support Program in Cancer Patients Elkar Laguntza,2020-06-01,2023-12-31,1308 days,Recruiting,Interventional
CBCSG-040,Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoopÂ® Bra(COSTA),2018-06-26,2023-12-31,2014 days,Recruiting,Interventional
Metimedi-202,OMT-111 for Terminal Stage Solid Tumors,2020-10-01,2022-10-01,730 days,Unknown status,Interventional
NUV-422-02,Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors,2020-12-08,2022-08-31,631 days,Terminated,Interventional
UBT 2022-01,A Clinical Investigation to Confirm the Ability of MammoWave in Breast Lesions Detection,2023-01-07,2024-05-31,510 days,Recruiting,Interventional
2020-A01534-35,A Proximity-incentive Strategy for Cervical Cancer Screening,2021-09-16,2025-03-01,1262 days,Recruiting,Interventional
181367,Physical Activity Intervention for Young Cancer Survivors,2019-09-01,2020-09-30,395 days,Completed,Interventional
PRO00041443,Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction,2022-03-01,2026-07-01,1583 days,Recruiting,Interventional
19SM5221,Development and Validation of a Tumour Oxygenation Monitoring Probe,2019-08-09,2020-06-01,297 days,Unknown status,Observational
METCZ20190024,The Risk of Postoperative Wound Complications Following the Use of Negative Pressure Wound Therapy in Patients Undergoing Mastectomy,2019-05-31,2020-06-01,367 days,Completed,Interventional
22-01024342,Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation,2023-04-01,2028-12-01,2071 days,Not yet recruiting,Interventional
PUMA-NER-9501,HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib,2019-03-14,2021-01-21,679 days,Terminated,Observational
SY-5609-101,"A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors",2020-01-23,2024-07-01,1621 days,"Active, not recruiting",Interventional
MCC-20487,Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease,2020-12-10,2024-11-01,1422 days,Recruiting,Interventional
DWI breast cancer,Diffusion Magnetic Resonance Imaging in Mamographically Detected Asymmetric Densities,2018-12-01,2019-10-01,304 days,Unknown status,Observational
2022/73,The Effect of the Motivational Interviewing Technique on Breast and Cervical Cancer Screenings,2022-04-30,2022-10-30,183 days,Not yet recruiting,Interventional
TBMZ-Radio-boron gel,Preventive Effect of Boron-based Gel on Radiation Dermatitis,2019-02-04,2019-12-21,320 days,Completed,Interventional
0141-19-RMB,Characterization of Skin Microbiome Profile and its Correlation to Radiation Dermatitis,2020-11-01,2021-11-01,365 days,"Active, not recruiting",Observational
BT5528-100,Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression,2019-11-07,2024-12-31,1881 days,Recruiting,Interventional
2021P000209,Mapping and Quantifying Lymphatic Drainage of the Arms Alternate Pathway,2022-04-01,2025-08-01,1218 days,Recruiting,Observational
REaCT-TEMPO,Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance,2023-04-01,2029-04-01,2192 days,Not yet recruiting,Interventional
SYSKY-2022-117-01,Endoscopic Breast Conserving Surgery With Intra-operative Navigation System,2022-01-01,2024-12-01,1065 days,Recruiting,Interventional
IRB 22-211,Global Cardio Oncology Registry,2022-07-01,2027-07-01,1826 days,Recruiting,Observational
PROT-P2-024,M5 vs. M6 Comparison Study With a Sub Study Into the Dielectric Constant of Aspirated Cyst Fluid,2019-02-19,2020-01-23,338 days,Completed,Interventional
2022-0454,Vapocoolant Analgesia for Breast Lymphoscintigraphy,2023-03-01,2023-08-31,183 days,Recruiting,Interventional
Pro00101109,Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS),2021-10-12,2022-01-31,111 days,Completed,Interventional
22-071,A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction,2022-03-23,2024-03-01,709 days,Recruiting,Interventional
ZL-2306-006,A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment,2020-02-03,2022-03-02,758 days,Terminated,Interventional
OTT-15-02,"Tumor Bed Dose Delivery Using A Breast Specific Radiosurgery Device, The Gammapod: (A Clinical Feasibility Study)",2021-01-01,2022-01-01,365 days,Unknown status,Interventional
CONFIDENCE-01,CONFIDENCE Registry,2020-09-11,2024-09-30,1480 days,Enrolling by invitation,Observational
K 2020-9716,[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors,2022-11-23,2025-12-31,1134 days,Recruiting,Interventional
NCC20180327,Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion,2019-10-15,2021-06-15,609 days,Unknown status,Interventional
3121_MATFIH22,"First-in-human, Study of MATTISSEÂ® Tissue Engineering Chamber in Adult Female Patients Undergoing Immediate Breast Reconstruction After Mastectomy for Cancer",2022-07-01,2025-10-31,1218 days,Recruiting,Interventional
Modi-1-001,"Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer",2022-04-07,2026-06-30,1545 days,Recruiting,Interventional
20-437,Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement,2021-05-17,2023-04-01,684 days,"Active, not recruiting",Interventional
16-01,Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging,2018-09-10,2021-09-01,1087 days,Terminated,Interventional
IEO 1002/,Evaluation of the Effectiveness of Prepectoral Breast Reconstruction,2019-09-03,2023-12-31,1580 days,Recruiting,Interventional
3271,PBI for Breast In Situ Carcinoma of Intermediate Low Risk as Local Adjuvant Treatment,2023-01-09,2029-12-01,2518 days,Recruiting,Interventional
21-559,Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study,2022-10-31,2025-01-31,823 days,Recruiting,Interventional
LCCC2139,Comparison of CE-DBT and MRI in Patients With Known Breast Lesions,2023-03-13,2024-10-01,568 days,Recruiting,Interventional
NK-101,FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors,2018-01-18,2020-12-15,1062 days,Completed,Interventional
1903399639,High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT),2022-12-01,2024-04-01,487 days,Not yet recruiting,Interventional
18-00684,Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP),2018-07-31,2023-10-23,1910 days,"Active, not recruiting",Observational
MCC-19-15167,Improving Uptake of Genetic Cancer Risk Assessment in African American Women- Video,2021-11-01,2023-12-31,790 days,Recruiting,Interventional
CASE5117,Drain-Less Abdominally Based Breast Reconstruction Using Lysine-Derived Urethane Adhesive,2020-11-01,2021-09-01,304 days,Withdrawn,Interventional
CASE10117,Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction,2018-03-30,2020-07-01,824 days,Withdrawn,Interventional
Medipol Hospital 18,ESPB and RIB for Pain Management Following Mastectomy Surgery,2021-02-16,2021-12-20,307 days,Completed,Interventional
18-431,Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung,2019-01-16,2024-01-01,1811 days,"Active, not recruiting",Interventional
SPI-POZ-203,A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies,2019-12-23,2022-03-29,827 days,Terminated,Interventional
STUDY21070030,CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study,2022-02-01,2026-11-01,1734 days,Recruiting,Interventional
E2018124,Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction Patients,2018-06-16,2021-10-31,1233 days,Unknown status,Interventional
2140-002,A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002),2020-10-07,2023-08-15,1042 days,"Active, not recruiting",Interventional
2019(S073),Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Breast Nodules,2019-01-18,2020-02-18,396 days,Unknown status,Observational
21-288,A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer,2021-09-14,2024-09-14,1096 days,Recruiting,Interventional
OSU-21198,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,2021-12-01,2022-06-15,196 days,Completed,Observational
RadOnc,Combined Optical and Infrared Imaging for Early Prediction of Erythema During Breast and Chestwall Radiotherapy,2020-07-01,2022-12-01,883 days,Unknown status,Interventional
INX-315-01,"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer",2023-03-28,2026-06-01,1161 days,Recruiting,Interventional
228012,Impact of Topical Tranexamic Acid in Breast Reconstruction,2023-03-30,2024-09-30,550 days,Recruiting,Interventional
JSKN003-101,First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors,2022-09-02,2024-12-30,850 days,Recruiting,Interventional
20-275,Testing a New Imaging Agent to Identify Cancer,2020-11-30,2024-11-30,1461 days,Recruiting,Interventional
018-781,DWIBS-MRI: An Adjunct to the Traditional Diagnostic Breast Imaging Evaluation,2019-03-11,2024-03-11,1827 days,Recruiting,Observational
IGAR-TO-007,IGAR-Breast TeleOp Trial,2019-01-01,2019-12-31,364 days,Unknown status,Interventional
Laser LabCorp #001,Real-time Diagnosis and Visualization of Tumor Margins in Excised Breast Specimens Using Zenith FLIM Diagnostics,2021-12-15,2022-11-02,322 days,Suspended,Interventional
2020-04936,Mammography Screening With Artificial Intelligence (MASAI),2021-04-12,2025-04-12,1461 days,"Active, not recruiting",Interventional
NCC2962,Multi-center Study of Deep Learning AI in Breast Mass,2021-08-12,2023-08-31,749 days,Recruiting,Observational
IRB-50877,Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution,2023-01-01,2023-12-01,334 days,Not yet recruiting,Interventional
PER-19-04,Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.,2021-12-01,2023-09-01,639 days,Recruiting,Interventional
KL166-I-01-CTP,A Study of A166 in Patients With Advanced Solid Malignant Tumors,2018-08-09,2023-12-31,1970 days,Recruiting,Interventional
PROTOCOL-P2-054,The ABC Study: Assessment of Breast Density Classification,2022-02-16,2022-10-31,257 days,Recruiting,Interventional
254-18,Reconstructions With Back Donor Site Flaps and Validation of Quality of Life Scales,2020-08-01,2025-12-31,1978 days,Recruiting,Interventional
MIP-2019-001,BIOpsychosocial Approach of the CAncer-RElated FAtigue (BIOCARE FActory),2021-01-15,2024-06-15,1247 days,Not yet recruiting,Interventional
B076201420067,Zhongnan Hospital of Wuhan University,2021-03-15,2022-12-31,656 days,Unknown status,Interventional
21051,Incorporating ePrognosis for the Encouragement of Smarter Screening for Breast and Colorectal Cancer in Older Adults,2021-08-24,2022-06-30,310 days,Completed,Interventional
DE-17-17,Clinical Investigation to Evaluate the Ability of MammoWave in Breast Lesions Detection,2020-09-16,2021-08-20,338 days,Completed,Interventional
CLINP-001013,Retrospective Data Collection on the Use of Motiva Flora TE in Breast Reconstruction,2023-01-01,2023-04-01,90 days,Not yet recruiting,Observational
201701045,Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach,2018-01-09,2018-10-24,288 days,Completed,Interventional
ICO-2021-05,"Retrospective and Prospective Evaluation of Scapulohumeral Comfort, Aesthetic Result and Quality of Life",2022-02-21,2025-02-21,1096 days,Recruiting,Observational
E20210210,Breast Mesh Used in Two-staged Breast Reconstruction,2021-08-01,2026-08-01,1826 days,Recruiting,Interventional
735CLD Rev.04,The ClearCoastâ¢ Magnetic Resonance Outcome PMS Study,2021-06-24,2025-01-01,1287 days,Recruiting,Observational
CLP-0004,A Retrospective Breast Reconstruction Study,2019-11-20,2022-06-01,924 days,Completed,Observational
EMC-0124-18,Evaluation of the SmartBx System for Breast Biopsy,2019-06-10,2019-09-01,83 days,Completed,Interventional
LYL797-101,A Study to Investigate LYL797 in Adults With Solid Tumors,2022-03-29,2026-09-01,1617 days,Recruiting,Interventional
2834,TIVA Admnistration and Autologous Fat Transfer in Breast Reconstruction,2019-09-01,2020-03-30,211 days,Completed,Interventional
IC 2021 07,Opioid Free Versus Opioid Based Anaesthesia for Secondary Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.,2022-12-07,2026-03-15,1194 days,Recruiting,Interventional
APHP220816,Cognitive Processing Slowness as a Marker of Cognitive Impairment in Non-central Nervous System Cancer Patients,2023-04-01,2026-04-01,1096 days,Not yet recruiting,Observational
GEN1B-01,Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications,2018-12-19,2020-12-30,742 days,Suspended,Interventional
IIT2018-25-MITA-NEOBREADS,NEOBREADS: Neoadjuvant Breast Diet Study,2019-03-21,2021-08-17,880 days,Terminated,Interventional
GOG-8023,Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer,2100-01-01,,,Not yet recruiting,Observational
2020-00493,Red Bull Energy Drink Intake After Autologous Microsurgical Breast Reconstruction,2020-05-11,2023-01-01,965 days,Completed,Interventional
20210817-01H,TAP vs QL for Postoperative Analgesia After DIEP Free Flap Breast Reconstruction,2022-04-01,2023-03-01,334 days,Not yet recruiting,Interventional
CIRB Ref. No: 2019/2090,Accessible Cancer Care to Enable Support for Survivors Programme,2019-10-01,2021-10-01,731 days,Unknown status,Interventional
20295,Dermacell ADM Without Basement Membrane,2018-09-01,2021-05-01,973 days,Unknown status,Interventional
TO-TAS0728-101,A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities,2018-04-06,2022-06-09,1525 days,Terminated,Interventional
124.03-2017-GES-0005,Patient-Assisted Compression in 3D - Impact on Image Quality and Workflow,2018-01-04,2018-01-09,5 days,Completed,Interventional
IIT2018-21-AMERSI-BREADS,BREADS: Breast Adjuvant Diet Study,2020-02-04,2023-03-30,1150 days,Terminated,Interventional
PSG SOMAVAC,Evaluation of SOMAVAC 100 Sustained Vacuum System,2021-05-01,2022-10-30,547 days,Completed,Observational
FMSU2017-003,Fujifilm Feature Comparison Reader Study to Compare Old vs New Processing,2018-06-30,2018-11-19,142 days,Completed,Observational
3-2021-0468,Pectoralis Nerve Block and Quality of Recovery in Mastectomy Patients,2022-02-23,2025-03-24,1125 days,Recruiting,Interventional
IB 2019-01,Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors,2021-03-31,2025-03-01,1431 days,Recruiting,Interventional
2022-010,F-Tryptophan PET/CT in Human Cancers,2022-09-29,2024-12-31,824 days,Recruiting,Interventional
Reader-02 Study,Optoacoustic Images Versus ImagioÂ® Ultrasound,2019-07-30,2019-11-03,96 days,Completed,Interventional
20-03,"A Prospective, Multi-site Clinical Study to Collect User Feedback Using AffirmÂ® Contrast Biopsy",2021-03-05,2022-08-18,531 days,Completed,Interventional
YWBC-002,Prevention and Treatment of Pyrrolitinib-associated Diarrhea,2020-05-16,2023-04-30,1079 days,Recruiting,Interventional
PER-19-03,Wide-field Optical Coherence Tomography Imaging of Excised Breast Tissue.,2020-08-03,2021-07-27,358 days,Completed,Observational
2018-4107,Does a Preoperative Prophylactic Antibiotic Reduce Surgical Site Infection Following Wire-localized Lumpectomy,2018-04-07,2019-12-10,612 days,Completed,Interventional
2019-1176,Patient-Specific Decision Aid System for Shared Decision Making About Breast Reconstruction,2020-10-13,2022-12-31,809 days,Recruiting,Interventional
2021-0290,Effect of Neurotization on QoL and Sensory Restoration,2023-04-01,2024-01-01,275 days,Not yet recruiting,Interventional
0180910/16,The Combination of PECS II Block and Parasternal Block for Radical Mastectomy,2018-12-01,2019-04-12,132 days,Completed,Interventional
ETNA-CRCI,Development and Validation of a Novel Functional Eye-Tracking Software Application for Cancer-related Cognitive Impairment (CRCI),2022-03-30,2025-01-20,1027 days,Recruiting,Observational
INTRUSION,INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701,2023-02-01,2025-05-01,820 days,Not yet recruiting,Interventional
2019-A00121-56,Analgesia Nociception Index (ANI) After Unilateral Radical Mastectomy as an Evaluation of Paravertebral Block Failure,2019-05-02,2023-06-01,1491 days,"Active, not recruiting",Observational
2018-9409,Intra-Operative Radiation Registry,2018-08-09,2024-08-09,2192 days,Recruiting,Observational
R.22.09.1830,Comparison of Analgesic Efficacy of Ultrasound Guided Rhomboid Intercostal Block Versus Serratus Anterior Plane Block for Mastectomy Surgery,2022-09-01,2022-12-30,120 days,Recruiting,Interventional
SCOUT2021,Streamlined Localization Using SCOUTÂ® at Biopsy (STREAMLoc ),2022-04-01,2024-03-01,700 days,Recruiting,Interventional
PROICM 2019-07 PRE,Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction,2020-12-11,2027-06-01,2363 days,Recruiting,Interventional
2022-A01940-43,Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL,2023-04-01,2024-10-01,549 days,Not yet recruiting,Interventional
Reader-01,"Imagio Feasibility Multi-Reader, Multi-Case Study",2018-11-13,2018-12-09,26 days,Completed,Interventional
2020-0980,What Women Want: Real Time Results During Screening Mammography in the Era of Patient-Experience Driven Care,2021-01-21,2023-10-31,1013 days,Recruiting,Observational
STUDY00025461,Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms,2023-04-17,2023-06-23,67 days,Not yet recruiting,Interventional
19D.203,Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings,2020-06-23,2023-01-27,948 days,Completed,Interventional
BCD-178-1,"A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or PerjetaÂ® in Healthy Volunteers",2022-08-08,2024-01-31,541 days,"Active, not recruiting",Interventional
2019P003607-11,Data Analysis for Drug Repurposing for Effective Alzheimers Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole,2022-11-01,2023-02-01,92 days,"Active, not recruiting",Observational
SHR6390-I-114,Study of SHR6390 in Renal Insufficiency and Healthy Subjects,2022-12-18,2023-09-28,284 days,Recruiting,Interventional
19-005445,Determining Molecular Drivers of Radiation Dermatitis,2021-02-21,2024-03-01,1104 days,Enrolling by invitation,Observational
2204MDJ,Testing Video Information About Mammography Screening,2020-06-16,2020-07-30,44 days,Unknown status,Interventional
mastectomy regional anesthesia,Regional Anesthesia for Modified Radical Mastectomy With Axillary Lymph Node Dissection,2020-04-01,2023-01-31,1035 days,Completed,Interventional
PECS 2019,The Analgesic Efficacy of the Pectoral Nerves Block Versus Local Anesthetic Infiltration After Mastectomy,2019-11-01,2021-06-30,607 days,Unknown status,Interventional
R-2017/UEM11,Acute Effect of Chromatic Environment During Chemotherapy,2018-04-15,2020-12-15,975 days,Unknown status,Interventional
IBIO-302,Food Effect Study of D-0502 Tablet in Healthy Volunteers,2018-10-23,2019-04-17,176 days,Completed,Interventional
LAE203CN2101,PhI to Solid Tumors and PhII to Locally Advanced or mTNBC,2021-06-12,2024-07-30,1144 days,Recruiting,Interventional
SN132D CSP final version 6.0,A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer,2019-08-23,2022-11-30,1195 days,Completed,Interventional
2022-1151,Implementation of Population Breast Cancer Genetic Services in Federally Qualified Health Centers (FQHC),2023-08-01,2027-12-01,1583 days,Not yet recruiting,Interventional
CIRB Ref. No: 2017/3139,Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS),2018-06-18,2022-09-01,1536 days,Recruiting,Observational
LCCC1754,UNC Pleural Fluid Registry,2018-01-24,2050-01-24,11688 days,Recruiting,Observational
Tomosymthesis,Tomosymthesis for Breast Mass Lesion Characterization,2021-09-01,2023-10-01,760 days,Not yet recruiting,Observational
NINTAU,ConquerFear-Group: A Psychological Intervention for Fear of Cancer Recurrence,2019-10-21,2022-06-22,975 days,Completed,Interventional
BCA-AI,Development of Artificial Intelligence System for Detection and Diagnosis of Breast Lesion Using Mammography,2018-04-05,2020-05-04,760 days,Completed,Observational
21-002713,3D Ultrasound Microvessel Imaging for Breast Masses,2021-08-19,2024-04-20,975 days,Recruiting,Interventional
LIVFOU-930411,Pectoral Nerves Block vs Wound Infiltration for Partial Mastectomy - a Prospective Randomized Trial.,2021-02-19,2022-05-01,436 days,Completed,Interventional
21-BI-1607-01,BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors,2022-07-28,2026-12-01,1587 days,Recruiting,Interventional
20-378,Researching the Effect of Exercise on Cancer,2020-10-02,2024-10-02,1461 days,Recruiting,Interventional
2019-A0872-55,Study on Skin Toxicities Induced by Cancer Treatments,2020-11-25,2024-07-25,1338 days,Recruiting,Interventional
CAAA504A12101,Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress Î±vÎ²3 and Î±vÎ²5 Integrins.,2021-10-14,2023-11-10,757 days,Recruiting,Interventional
20190701041GH,Antler Plate on Preventing Mammary High-risk Lesions From Malignant Development,2020-06-01,2025-06-01,1826 days,Recruiting,Observational
D6900C00001,First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies,2021-10-18,2025-06-30,1351 days,Recruiting,Interventional
HNCH-BC004,A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity,2020-08-28,2022-04-21,601 days,Completed,Interventional
CMUH106-REC2-117,Evaluation of the Efficacy of Acupuncture in Chemotherapy Induced Peripheral Neuropathy,2018-06-27,2020-10-10,836 days,Unknown status,Observational
20200491,Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences,2021-07-01,2024-12-31,1279 days,Recruiting,Interventional
2019-06214,Psychological Effects of Implant Loss,2020-03-01,2025-12-31,2131 days,Recruiting,Observational
LS2023012,Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy,2023-01-01,2024-01-01,365 days,Recruiting,Interventional
PRO2021-1428,Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer,2022-01-01,2026-12-31,1825 days,Not yet recruiting,Interventional
ZN-A-1041-101,Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors,2020-10-15,2024-06-30,1354 days,Recruiting,Interventional
HCC 21-265,"Dignity, Legacy, Advocacy, and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community",2022-03-13,2025-06-01,1176 days,Recruiting,Interventional
HNCH-BC007,GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel,2020-09-09,2022-08-22,712 days,Withdrawn,Interventional
2020-0498,Myofascial Release or Trigger Point Injections for the Reduction of Post-Mastectomy Pain Syndrome,2022-03-23,2022-03-23,0 days,Withdrawn,Interventional
NBE-002-01,NBE-002 in Patients With Advanced Solid Tumors,2020-06-19,2025-12-01,1991 days,"Active, not recruiting",Interventional
PROT002 - Test Plan 01 Rev A,Blue Note Therapeutics Product BNT 103 Usability and User Engagement,2021-09-01,2021-12-31,121 days,Completed,Interventional
1B-22-2,"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors",2023-01-09,2026-01-09,1096 days,Recruiting,Interventional
Gen 2 - 01,Clinical Evaluation of Opto-Acoustic Image Quality With the Gen 2 Imagio System,2021-08-19,2022-02-17,182 days,Completed,Interventional
PROT001,Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment,2021-05-15,2022-09-01,474 days,Terminated,Interventional
MW05-2020-CP301,Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF,2020-09-21,2022-11-05,775 days,Completed,Interventional
BYON5667.002,Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985,2022-01-10,2024-12-31,1086 days,"Active, not recruiting",Interventional
UZBRU_VHH2_1,Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT,2019-11-05,2023-04-01,1243 days,Recruiting,Interventional
v24-9-2017,Psyhosomatic Medicine in Oncologic and Cardiac Disease Study,2018-03-27,2022-12-01,1710 days,Unknown status,Observational
19-007547,"Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial",2020-09-01,2024-12-31,1582 days,"Active, not recruiting",Interventional
Pro00092817,VR Ultrasound Guided Breast Localization,2021-01-13,2022-01-07,359 days,Completed,Interventional
Pro00112215,The Use of Virtual Reality During Breast Ultrasound-Guided Biopsy Procedures,2021-09-15,2022-10-01,381 days,Enrolling by invitation,Interventional
Ageing-NIO,"Examining and Comparing the Temporal Changes and Results of Cosmetic, Quality of Life and Patient Satisfaction Achieved With Immediate and Delayed-immediate Implant-based Breast Reconstruction Procedures and Contralateral Symmetrization Techniques",2020-04-27,2027-04-10,2539 days,Recruiting,Observational
M16-573,A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors,2018-07-13,2023-04-30,1752 days,"Active, not recruiting",Interventional
5R44CA203608,LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge),2020-10-26,2024-02-15,1207 days,Recruiting,Interventional
ACROPOLI (SOLTI-1904),Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors,2021-04-12,2024-12-11,1339 days,"Active, not recruiting",Interventional
NL52329.075.15,Intra-individual Comparison of Conventional and Digital PET/CT Scanners,2018-01-08,2019-09-13,613 days,Completed,Interventional
DPCVC,Diagnostic Power Comparison Between VOCs and CTCs,2019-06-15,2020-12-31,565 days,Unknown status,Observational
AAAT2490,AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc,2022-05-03,2026-12-01,1673 days,Recruiting,Interventional
0S-20-6,Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy,2020-12-18,2024-06-18,1278 days,Recruiting,Observational
SRNSM,"Examining the Cosmetic Results, Quality of Life and Patient Satisfaction Achieved With Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction, and Comparing it to Classic Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgeries",2020-04-18,2027-04-05,2543 days,Recruiting,Observational
CMP-001-009,A Trial to Find Out if Vidutolimod Together With Cemiplimab is Safe and if it Works in Adult Participants With Advanced Cancer or Metastatic Cancer,2021-11-30,2027-03-07,1923 days,Recruiting,Interventional
5890-001,Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001),2018-02-18,2024-10-25,2441 days,"Active, not recruiting",Interventional
SS-SP01-201904,Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents,2020-07-18,2022-12-31,896 days,Recruiting,Interventional
H19-03343,Carbon-Fibre Accessory (CARA) for Supine Breast Positioning to Reduce Toxicity in Whole Breast Radiotherapy,2020-06-11,2024-12-31,1664 days,Recruiting,Interventional
BPI-2358-106 phase 3,Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia,2019-10-23,2025-09-25,2164 days,"Active, not recruiting",Interventional
EK 1623/2020,Dose-staged Gamma Knife Radiosurgery Versus Microsurgical Resection,2020-07-01,2023-12-01,1248 days,Recruiting,Interventional
TRX518-004,A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors,2019-05-20,2020-07-14,421 days,Terminated,Interventional
20200110,Study of the Effects of Transcutaneous Vagus Nerve Stimulation on Cancer Patients,2020-04-03,2021-12-30,636 days,Recruiting,Interventional
ASPB vs ESBP for mastectomy,Comparison Between Serratus Anterior Plane Block and Erector Spinae Plane Block for Mastectomy,2019-10-01,2020-07-30,303 days,Completed,Interventional
2018-01,Quantitative Evaluation of the Breasts Morphological Variations During Radiotherapy: MorphoBreast3D,2018-02-22,2020-05-07,805 days,Completed,Interventional
TYKM1602101,A Study of TY-302 in Patients With Advanced Solid Tumors,2020-12-07,2023-12-01,1089 days,Recruiting,Interventional
BrUOG 351,BrUOG 351: PRE-OPERATIVE APBI USING NIBB,2019-03-01,2020-01-21,326 days,Withdrawn,Interventional
PI-3958,Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit?,2019-02-02,2021-01-30,728 days,Completed,Observational
KL264-01,"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies",2020-02-28,2025-12-01,2103 days,Recruiting,Interventional
Medipol Hospital 26,Different Volumes of Erector Spinae Plane Block for Breast Surgery,2022-01-27,2023-03-30,427 days,Recruiting,Interventional
NeoVAB,Evaluation of the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB),2019-06-07,2021-08-30,815 days,Unknown status,Interventional
16-136,Ipilimumab and Nivolumab in Leptomeningeal Metastases,2018-02-15,2021-07-22,1253 days,Completed,Interventional
SGN228-001,A Study of SGN-CD228A in Advanced Solid Tumors,2019-09-03,2023-03-09,1283 days,Terminated,Interventional
1612017795,Web-based Family History Tool,2019-09-09,2022-12-31,1209 days,Completed,Interventional
7902-005,Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005),2019-02-12,2023-12-22,1774 days,"Active, not recruiting",Interventional
UUBreast02,PREMs on PROMs in Breast Disease (PREMs_PROMs),2019-09-01,2021-04-30,607 days,Completed,Interventional
2021-0842,Single Step Lesion Annotation and Localization of Suspicious Breast Lesions,2022-04-11,2023-11-01,569 days,Recruiting,Interventional
GN19HS442,"Augmented Reality (AR): The Future of ""Patient Information Leaflets",2020-11-30,2022-03-30,485 days,Recruiting,Interventional
06-2020/1,Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory,2020-01-13,2022-05-01,839 days,Completed,Observational
MCC-21622,Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies,2023-01-12,2026-01-01,1085 days,Recruiting,Interventional
SIBP-03-01,A Phase â a Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.,2020-10-26,2023-10-26,1095 days,Recruiting,Interventional
IRB00047335,Speeding Recovery From Pain and Opioid Use,2018-11-01,2020-06-01,578 days,Withdrawn,Interventional
217510,Microbiome and Association With Implant Infections,2021-09-28,2025-12-31,1555 days,Recruiting,Interventional
RIN20230039,Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure,2023-05-01,2024-02-01,276 days,Not yet recruiting,Interventional
4-2019-0834,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,2020-05-14,2022-12-04,934 days,"Active, not recruiting",Observational
UI/EC/20/0275,The Effect of Octreotide on Wound Drainage After Mastectomy,2020-12-18,2021-12-02,349 days,Completed,Interventional
AB-201-01,A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors,2023-03-01,2027-04-01,1492 days,Not yet recruiting,Interventional
IOM-040369,Patient Preference for Pegfilgrastim (NeulastaÂ®) Application Forms,2018-06-25,2019-09-10,442 days,Completed,Interventional
233,Effect of tDCS of the Motor Cortex on Chemotherapy Induced Nausia and Vomiting,2018-01-01,2019-09-01,608 days,Unknown status,Interventional
TQB3616-I-02,Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects,2021-07-06,2021-08-30,55 days,Completed,Interventional
MAR-BAS-18-005,The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy,2020-10-07,2024-08-01,1394 days,Recruiting,Interventional
107709,Acupuncture Treatment of Chemotherapy-Induced Peripheral Neuropathy in Women,2019-11-05,2020-08-12,281 days,Terminated,Interventional
20-1456,Improving Cancer Screening and Follow-up in Community Health Centers,2023-04-01,2023-09-30,182 days,Not yet recruiting,Interventional
UTN: U1111-1278-1680,CPAP for Motion Management in Breast Radiotherapy; and Lung & Liver SABR,2022-07-01,2023-07-01,365 days,Not yet recruiting,Interventional
19-104,The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting,2021-08-30,2023-10-30,791 days,Recruiting,Interventional
MASCT-I-1003,A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor,2018-04-19,2020-07-01,804 days,Unknown status,Interventional
REC/RCR&AHS/22/0511,Effects Of Lymphatic Drainage on Axillary Web Syndrome,2022-04-15,2023-01-05,265 days,Recruiting,Interventional
18-264,Enhancing Cancer Prevention and Control Pathways-Native Health Initiative,2021-06-01,2023-12-01,913 days,Recruiting,Interventional
KY20202093-F-1,Clinical Study of 68Ga Labeled HER2 Affibody Analogues,2022-06-01,2023-12-01,548 days,Not yet recruiting,Interventional
P050001 TiLOOPÂ® Bra Pocket,"Post Market Clinical Follow Up to ""Patient Reported Outcome"" Using a Titanised Polypropylene Mesh (TiLOOPÂ® Bra Pocket)",2019-07-04,2023-03-01,1336 days,"Active, not recruiting",Observational
2021-0262,Home Based Exercise for Patients With Breast or Prostate Cancer (The BENEFIT-CA Study),2022-04-07,2023-12-30,632 days,Recruiting,Interventional
H18-02014,CARA Treatment Pilot Study for Breast Positioning,2018-10-08,2019-11-18,406 days,Completed,Interventional
262180,Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane,2021-09-14,2025-06-01,1356 days,Recruiting,Interventional
IRB19-2074,Abbreviated MRI Protocol: Initial Experience With DotaremÂ® (Gadoterate Meglumine),2020-07-13,2023-04-01,992 days,Recruiting,Interventional
TG1819ONC,A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors,2020-04-21,2024-01-01,1350 days,Recruiting,Interventional
STUDY00018917,The PAI Trial for Breast and Colon Cancer Survivors,2022-04-12,2022-04-12,0 days,Withdrawn,Interventional
STUDY00002789,CONTIGO - Informing Latinas About HBOC Risk,2021-06-01,2025-12-31,1674 days,Enrolling by invitation,Interventional
S66520,Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of GSM in Patients Using Aromatase Inhibitors,2022-12-27,2025-12-01,1070 days,Recruiting,Interventional
P.T.REC/012/002677,Effectiveness of Low Level Laser Therapy on Insulin Resistance and Inflammatory Biomarkers,2020-07-01,2023-09-01,1157 days,Recruiting,Interventional
ISPY-P1.01,ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer,2021-07-28,2021-11-17,112 days,Withdrawn,Interventional
NCI-2017-01921,Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery,2018-10-31,2023-02-22,1575 days,"Active, not recruiting",Interventional
"2016-051-000001, 1835",Investigating Public Enthusiasm for Mammography Screening in Denmark,2020-11-06,2021-01-04,59 days,Completed,Interventional
CF21163B,Clinical Outcome of Extracorporeal Shock Wave Therapy in Patient With Axillary Web Syndrome,2021-10-13,2024-08-31,1053 days,Recruiting,Interventional
D-FR-01072-002,"Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)",2019-05-14,2019-10-10,149 days,Terminated,Interventional
Breast-Nektaria,The Impact of Pecs Blocks on Postmastectomy Pain Syndrome,2020-08-01,2022-03-31,607 days,Completed,Interventional
1413727,An Intimacy Intervention for Couples Completing Breast or Prostate Cancer,2019-12-09,2020-12-31,388 days,Completed,Interventional
1049/2018,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,2018-05-18,2021-02-28,1017 days,Completed,Observational
20200426,Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants,2021-09-09,2021-10-10,31 days,Completed,Interventional
VALO-001,START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer,2023-02-02,2024-01-01,333 days,Recruiting,Interventional
IMU R204/2017,Perioperative Oral Nutrition Supplementation in Malnourished Surgical Cancer Patients,2018-12-26,2021-06-30,917 days,Completed,Interventional
LCCC1915,3-D Super Resolution Ultrasound Microvascular Imaging,2022-05-26,2024-10-01,859 days,Recruiting,Interventional
RiphahIU Shafaq,Effects of Active Release Technique (ART) on Pectoralis Minor Tightness in Post Mastectomy Women.,2022-08-10,2023-01-15,158 days,Completed,Interventional
CRX100-001,Study of CRX100 in Patients With Advanced Solid Tumors,2021-01-08,2025-03-01,1513 days,Recruiting,Interventional
HREBA.CC-20-0077,Time-restricted Eating in Survivors Trial,2020-08-05,2021-07-28,357 days,Completed,Interventional
TST-9-H,Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors,2022-11-10,2024-01-10,426 days,Withdrawn,Interventional
OCOG-2022-RAPID2,A Randomized Trial of Five Fraction Partial Breast Irradiation,2022-10-01,2031-07-01,3195 days,Not yet recruiting,Interventional
20181004,Mindful After Cancer: A Mindfulness-based Therapy Intervention for Sexual Health After Cancer,2019-07-01,2020-10-05,462 days,Completed,Interventional
18-571,EHR-embedded OCDT in Breast or GI Cancer,2019-03-13,2021-11-23,986 days,Completed,Interventional
R19-159,Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction,2021-07-14,2023-09-29,807 days,"Active, not recruiting",Interventional
2018B0521,Southeast Asian Womens Health Project,2020-10-16,2023-09-01,1050 days,Recruiting,Interventional
287482,ARTISS a Single-centre Randomised Control Study,2022-02-01,2023-08-01,546 days,Recruiting,Interventional
HR-BLTN-DDI-07,Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects,2022-03-08,2022-08-02,147 days,Completed,Interventional
201612723,NR in Chemo-induced Peripheral Neuropathy,2019-11-08,2022-02-24,839 days,Terminated,Interventional
2012285106,Dedicated Breast CT for Quantitative Breast Density Measurements in Mexican-origin Women in Southern Arizona,2022-04-28,2023-07-30,458 days,Recruiting,Observational
AWS,Effects of a Manual Therapy Program to Reduce the Evolution Time of Axillary Web Syndrome,2021-12-01,2023-12-04,733 days,Recruiting,Interventional
2022-0328,"Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics",2022-11-23,2023-06-01,190 days,Recruiting,Interventional
20/007-E_TFM,Study of the Effectiveness of Supervised vs. Non-Supervised Therapeutic Exercise in Cancer Patients,2020-06-01,2021-11-01,518 days,Unknown status,Interventional
Internal Code 012-23,Efficacy and Safety of Supervised Therapeutic Exercise in Cancer Patients With and Without Concurrent Treatment.,2023-06-01,2025-09-01,823 days,Not yet recruiting,Interventional
0352-2189,"A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis",2023-04-25,2024-06-10,412 days,Not yet recruiting,Interventional
HCI128055,[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma,2020-12-11,2024-06-30,1297 days,Recruiting,Interventional
180097,Olaparib in People With Malignant Mesothelioma,2018-07-11,2020-10-21,833 days,Completed,Interventional
190134,Vaccine Response With NT-I7,2023-05-01,2025-05-19,749 days,Recruiting,Interventional
TH1902-CTR-0001,TH1902 in Patients With Advanced Solid Tumors,2021-03-04,2023-03-01,727 days,"Active, not recruiting",Interventional
18112,64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy,2021-11-03,2023-12-01,758 days,Recruiting,Interventional
KY20172047-1,Safety Study of 3D Printing Personalized Biodegradable Implant for Breast Reconstruction,2018-07-30,2025-12-30,2710 days,Recruiting,Interventional
BREAST HEMATOMA,Vacuum-Assisted Evacuation (VAE) Of Symptomatic and/or Voluminous Breast Haematomas Following Surgeries And Percutaneous Procedures: a Retrospective Analysis,2022-10-01,2022-12-15,75 days,Completed,Observational
mRNA-2752-P101,Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies,2018-11-27,2025-04-01,2317 days,Recruiting,Interventional
1380800-R,Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments,2022-04-25,2023-12-31,615 days,Recruiting,Interventional
7621,Opening the Conversation Study,2021-09-01,2024-12-31,1217 days,Recruiting,Interventional
TomBakerCC,Mobile App Postoperative Home Monitoring After Enhanced Recovery Oncologic Surgery,2019-06-10,2021-04-16,676 days,Completed,Interventional
SVIFT Nodal Trial,Breast Fractionation Study - Standard Versus Investigational Fractionation Trial - Nodal Radiation,2021-06-01,2027-12-31,2404 days,Recruiting,Interventional
CASE1Z21,Patient Recall of Cancer Screening and Diagnosis,2023-06-01,2024-06-01,366 days,Recruiting,Interventional
IRB00075787,Mastectomy Flap Temperature Study,2022-09-29,2023-10-01,367 days,Recruiting,Interventional
HB-AT-001,Radiation Therapy (HB-001) by Alpha-particle Sources for Recurrent Malignant Solid Tumors in Japan,2019-05-25,2022-05-27,1098 days,Completed,Interventional
D161100000816006,Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion,2018-09-08,2019-12-31,479 days,Completed,Observational
ART4215C001,A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors,2021-09-13,2025-08-01,1418 days,Recruiting,Interventional
Duke-NUS,Marital Satisfaction and Sexual Health of Female Cancer Patients in Singapore,2018-11-01,2022-07-01,1338 days,Recruiting,Interventional
226947,SS-INQ Information Needs Questionnaire in SjÃ¶grens Syndrome,2018-10-12,2021-07-21,1013 days,Completed,Observational
SKNA pilot,Measurement of the Skin Sympathetic Nerve Activity,2018-08-31,2018-11-01,62 days,Completed,Interventional
IIT2018-05-ASHER-IMPROV2,LOL: Its All Improv After Cancer!â¢,2019-08-02,2025-07-01,2160 days,"Active, not recruiting",Interventional
OU-SCC Virtual Reality,Virtual Reality Software to Reduce Stress in Cancer Patients,2023-04-01,2025-04-01,731 days,Not yet recruiting,Interventional
2020-A03205-34,"Meditation and Cancer, Pilot Feasibility Study (MAEva Pilot Study)",2021-09-01,2022-12-01,456 days,Recruiting,Interventional
OPERA2,OperaÂ® for Aromatase Inhibitor-related Arthralgia Management (AIA),2018-11-01,2019-11-01,365 days,Completed,Interventional
TaiHao BR-USCAD VT 20-249,Evaluation of TaiHao Breast Ultrasound Diagnosis Software,2020-08-15,2020-11-01,78 days,Completed,Interventional
201907039,RANKL Inhibition and Mammographic Breast Density,2019-08-27,2026-08-31,2561 days,Recruiting,Interventional
UMCC 2021.004,Sleep Coach: A Mobile App to Address Insomnia Symptoms Among Cancer Survivors,2021-05-12,2022-08-08,453 days,Completed,Interventional
UPMREB 2021-140-01,Bacterial Cellulose-monolaurin Hydrogel for Acute Radiation Dermatitis,2021-09-01,2022-12-01,456 days,Recruiting,Interventional
15/LO/1038 BRACELET,Breast: Recovery After Axillary Node Clearance - Evaluating Limbs With E-Technology (the BRACELET Study),2018-04-23,2021-12-30,1347 days,Unknown status,Observational
KS01,Serratus Plane Block vs Erector Spinae Plane Block on Postoperative Analgesia in Patients Undergoing Unilateral Breast Surgery,2019-05-01,2019-10-01,153 days,Completed,Interventional
MS-268-2019,Effectiveness of Ultrasound Guided Erector Spinae Plane Block Against Ultrasound Guided Serratus Anterior Block in Modified Radical Mastectomy,2020-01-10,2020-05-20,131 days,Completed,Interventional
BoCCE,Biopsy of Calcifications Under Contrast Enhancement Guide (BoCCE),2021-07-24,2022-12-01,495 days,Unknown status,Interventional
875329B,Real-Life Pilot Feasibility Study (LC_RLP_PUC1),2023-01-15,2023-10-15,273 days,Recruiting,Interventional
MS-536-2021,Dexmedetomidine Versus Dexamethasone as Adjuncts in Erector Spinae Plane Block in Modified Radical Mastectomy,2020-12-15,2022-03-15,455 days,Completed,Interventional
Gyn F-Chem,Effects of Music or Hypnotherapy on Cancer Patients During Chemotherapy,2018-02-01,2021-11-01,1369 days,Terminated,Interventional
PROICM 2019-06 COH,Management of Perioperative Anxiety by the Cardiac Coherence Technique Coupled With a Hypnosis Session,2020-02-14,2022-01-14,700 days,Completed,Interventional
NCCH1905,Asian Multicenter Prospective Study of ctDNA Sequencing,2021-11-01,2024-12-31,1156 days,Recruiting,Observational
D3614C00004,A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body,2021-02-01,2021-03-25,52 days,Completed,Interventional
1449,Pre-pectoral Versus Sub-pectoral Implant Placement in Immediate Breast Reconstruction,2019-08-22,2023-12-30,1591 days,Recruiting,Interventional
RocuMAST,Effect of Rocuronium on BIS Values,2023-01-03,2023-03-31,87 days,Recruiting,Observational
CHD22_0002,Interest of Virtual Reality on Anxiety Before the Planning CT Scan in Radiotherapy,2022-10-05,2024-08-01,666 days,Recruiting,Interventional
CLINP-001001,Motiva Flora Tissue Expander PMCF,2020-12-14,2023-06-15,913 days,Recruiting,Interventional
1920306,Purpose in Life Survey,2022-08-01,2024-08-31,761 days,Enrolling by invitation,Observational
17-VIN-0855,A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition,2018-05-01,2018-11-01,184 days,Unknown status,Interventional
2022-01423-01,Optimizing Postoperative Recovery After Breast Reconstruction With Autologous Tissue (BestDIEP),2022-05-02,2026-12-31,1704 days,Recruiting,Observational
2019-0557,Novel Application of Indocyanine Green as a Biomarker to Identify Tissue Necrosis in Mastectomy Patients,2019-09-25,2019-12-19,85 days,Completed,Interventional
Breast 2019,PCR Based CEUS in BI RADS 4A Nodules,2019-04-01,2021-12-30,1004 days,Unknown status,Observational
D0817C00098,Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib,2020-08-04,2025-01-08,1618 days,Enrolling by invitation,Interventional
2017-377,The Effect of Double Injection Erector Spinae Plane Block on Postoperative Pain Following Breast Surgery,2018-02-03,2018-03-07,32 days,Completed,Interventional
IZKSZ3_188408 / 1,The DIALOGUE Study: Swiss-Korean Billateral Collaboration,2022-04-15,2024-12-31,991 days,Recruiting,Interventional
2018-94,Comparison of Erector Spinae Plane Block With Thoracic Paravertebral Block for Breast Surgery,2018-03-28,2018-08-20,145 days,Completed,Interventional
ORIN1001-C1,Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.,2020-07-01,2023-06-30,1094 days,"Active, not recruiting",Interventional
UMCC 2020.041,Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias,2021-04-16,2023-02-01,656 days,Recruiting,Interventional
H-42207 GAIL-N,C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N),2019-04-23,2038-12-01,7162 days,Recruiting,Interventional
Esogu Anesthesia,Comparison of Erector Spina Plane Block and Thoracic Epidural Block,2021-01-11,2021-03-31,79 days,Completed,Interventional
TED16925,Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors,2021-08-16,2025-10-31,1537 days,Recruiting,Interventional
Telerehab CH Feasibility,Telerehabilitation Cognitive Impairments Following Chemotherapy Feasibility Study,2022-02-09,2022-09-30,233 days,Recruiting,Interventional
RPC006,A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.,2021-01-20,2023-07-28,919 days,"Active, not recruiting",Interventional
BEX15859,"Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women",2021-06-15,2021-08-19,65 days,Completed,Interventional
waitingroom,Anxiety on the First Day of Chemotherapy,2020-11-01,2022-03-03,487 days,Unknown status,Interventional
CP-10-001,In Vivo Smart Biopsy Device Protocol In Radiology,2019-03-14,2020-03-31,383 days,Unknown status,Interventional
REB16-1463,Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors,2020-10-01,2023-01-01,822 days,Unknown status,Interventional
UF-STO-ETG-003,Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types,2021-11-03,2024-12-01,1124 days,Recruiting,Interventional
UMCC 2020.157,Lighting Intervention for Cancer-related Fatigue,2021-07-15,2023-03-09,602 days,Completed,Interventional
OnkoFit II,Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy,2020-08-01,2025-08-01,1826 days,Recruiting,Interventional
R7075-ONC-2009,REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors,2020-12-21,2026-04-01,1927 days,Recruiting,Interventional
CART-TnMUC1-01,A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers,2019-10-10,2022-12-02,1149 days,Terminated,Interventional
PT06-01,A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors,2020-09-01,2021-12-30,485 days,Unknown status,Interventional
2019/2944,Cryotherapy in Breast B3 Lesions,2021-09-15,2022-10-15,395 days,Recruiting,Interventional
SPI-POZ-501,A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib,2018-10-05,2026-04-05,2739 days,"Active, not recruiting",Interventional
LCB-1801-001,A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers,2022-04-29,2025-09-30,1250 days,Recruiting,Interventional
PECS vs SAP,Comparing the Quality of Analgesia With Pectoral Nerve Block and Serratus Plane Block in Modified Radical Mastectomy,2022-04-01,2022-07-30,120 days,Completed,Interventional
2020-000495-37,"Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer",2020-11-12,2022-09-19,676 days,Completed,Interventional
2018-0175,Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo,2019-07-01,2021-12-01,884 days,Unknown status,Interventional
2021-082,DIEP Flap Surgery and Intraabdominal Pressure,2021-04-19,2022-01-25,281 days,Completed,Observational
012018CONTROL,Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines,2019-01-01,2023-02-28,1519 days,"Active, not recruiting",Interventional
18232,Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY),2019-07-03,2024-03-31,1733 days,Recruiting,Observational
R19258,The LYSA (Linking You to Support and Advice) Trial,2021-03-13,2023-09-01,902 days,"Active, not recruiting",Interventional
2020/03FEV/065,Mechanically-Assisted and Non-Invasive Ventilation for Breathing-related Tumor Motion Mitigation.,2020-07-03,2022-09-30,819 days,Unknown status,Interventional
2012-001-108,Ramosetron on Late PONV (Postoperative Nausea and Vomiting),2020-12-17,2021-10-31,318 days,Completed,Interventional
HREC/74777/Alfred-2021,Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial,2022-07-27,2028-02-01,2015 days,Recruiting,Interventional
7905,Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief,2020-12-04,2023-01-01,758 days,Recruiting,Interventional
ARX788-1711,"A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)",2018-03-20,2023-12-01,2082 days,"Active, not recruiting",Interventional
69HCL18_0492,Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture),2023-02-14,2024-12-01,656 days,Recruiting,Interventional
BB-1701-101,A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors,2020-07-28,2023-12-01,1221 days,Recruiting,Interventional
D9720C00001,Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies,2020-11-12,2026-01-15,1890 days,Recruiting,Interventional
XuanWuH-NK,Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killerï¼NKï¼Cells,2018-10-26,2022-09-30,1435 days,Unknown status,Interventional
FPX-01-01,A Phase 1/2 Study of [225Ac]-FPI-1434 Injection,2019-01-17,2026-06-01,2692 days,Recruiting,Interventional
RAPA-201-STP-01,RAPA-201 Therapy of Solid Tumors,2021-08-01,2024-12-31,1248 days,Recruiting,Interventional
HC-404-FCP-2011,A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD),2021-06-08,2024-03-08,1004 days,Recruiting,Interventional
assuitu faculty of medicine,Outcomes of Breast Conservative Surgery for Post Chemotherapy Tumour Size After Response to Neoadjuvant Chemotherapy,2021-06-01,2024-12-01,1279 days,Recruiting,Interventional
STUDY00015358,Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact,2021-03-18,2025-02-14,1429 days,"Active, not recruiting",Interventional
ONCX-NAV-G201,A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors,2022-08-05,2024-12-15,863 days,Recruiting,Interventional
CRUKD/22/002,HMBD-001 in Advanced HER3 Positive Solid Tumours,2021-11-10,2026-09-01,1756 days,Recruiting,Interventional
042201,Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted,2022-09-19,2027-03-01,1624 days,Recruiting,Interventional
DCC-2036-01-004,A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors,2019-01-02,2022-11-01,1399 days,"Active, not recruiting",Interventional
NM1F-T1-01,"A First-in-human, Phase I, Open-label, Multicenter Study of NM1F Administered as Monotherapy and in Combination With Pembrolizumab to Patients With Advanced Solid Tumors.",2023-03-01,2026-09-01,1280 days,Not yet recruiting,Interventional
213409,A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study,2021-04-16,2025-11-13,1672 days,"Active, not recruiting",Interventional
ICO-2020-06,Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ,2021-02-03,2033-08-01,4562 days,Recruiting,Interventional
OMO-103-01,"Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours",2021-04-28,2024-12-01,1313 days,"Active, not recruiting",Interventional
849679,RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR),2022-04-14,2024-02-01,658 days,Recruiting,Interventional
UC-0101/1709,Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours,2018-06-20,2024-12-30,2385 days,"Active, not recruiting",Interventional
4-2020-0165,Prospective Study of MAstectomy With Reconstruction Including Robot Endoscopic Surgery,2020-04-08,2030-04-07,3651 days,Recruiting,Observational
ZN-A-1041-101-US,A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors,2020-10-15,2023-11-30,1141 days,Recruiting,Interventional
UW21084,Self-administered Acupressure to Improve Cancer-related Fatigue Among Cancer Patients Undergoing Chemotherapy,2022-06-01,2025-05-01,1065 days,Recruiting,Interventional
IRB#56402,Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study,2021-08-25,2023-12-01,828 days,Enrolling by invitation,Observational
TAEK-VAC-HerBy-001,TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer,2020-08-10,2026-06-01,2121 days,Recruiting,Interventional
C4161001,PF-07104091 as a Single Agent and in Combination Therapy,2020-09-16,2026-01-07,1939 days,Recruiting,Interventional
MORAb-202-G000-201,"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRÎ±)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types",2020-08-06,2025-03-31,1698 days,Recruiting,Interventional
18-27025,SCOPE-Chinese Women Study,2020-07-20,2021-12-30,528 days,Completed,Interventional
APHP210583,Personalized Estimation of Doses Delivered During Image Guided Radiation Therapy Tests,2023-05-15,2025-05-14,730 days,Not yet recruiting,Observational
19-652,"Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers",2020-12-01,2024-12-31,1491 days,"Active, not recruiting",Interventional
BESTa,"Development, Implementation and Evaluation of an Individual Decision Aid in Swedish Cancer Screening Programs",2023-03-01,2024-12-31,671 days,Recruiting,Interventional
SOLTI-1804,HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a),2019-12-13,2024-12-15,1829 days,Recruiting,Interventional
M19-037,"A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors",2019-05-21,2023-11-12,1636 days,"Active, not recruiting",Interventional
2020-00256; ch18Weber4,Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy OPBC-02PREPEC,2020-07-28,2033-03-01,4599 days,Recruiting,Interventional
OSU-21313,A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer,2022-04-06,2024-12-31,1000 days,Recruiting,Interventional
AN0025S0103,AN0025 and Pembrolizumab Combination in Advanced Solid Tumors,2020-08-20,2025-11-28,1926 days,Recruiting,Interventional
202202104,Implementation of a Health System Intervention to Improve Quality of Cancer Care for Rural Patients,2023-01-20,2026-12-01,1411 days,Recruiting,Interventional
Medipol Hospital 9,Pectoral Nerve Block Type-II and Rhomboid Intercostal Block for Pain Management Following Mastectomy Surgery,2020-03-23,2021-02-20,334 days,Completed,Interventional
69HCL18_0369,Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients,2018-12-04,2028-01-04,3318 days,Recruiting,Interventional
2019/629,Breast Density Measurements in Digital Mammography and Breast Tomosynthesis Systems of Different Pixel Size,2019-10-01,2020-08-01,305 days,Unknown status,Observational
200023,Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors,2020-10-27,2023-12-31,1160 days,Recruiting,Interventional
RB-vs-RG-BCS,"Comparison of the Cosmetic Results, Quality of Life and Patient Satisfaction Achieved With Round-block and Retroglandular Oncoplastic Breast Conserving Surgeries",2020-04-18,2027-04-05,2543 days,Recruiting,Observational
CHANCES-IPC 2021-008,A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors,2022-01-21,2025-02-01,1107 days,Recruiting,Interventional
17-694,Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia,2018-05-10,2019-06-28,414 days,Terminated,Interventional
SLS17-201/MK3475-770,Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers,2019-06-28,2023-04-30,1402 days,"Active, not recruiting",Interventional
AP2207-30110,Dexmedetomidine vs Dexamethasone as Adjuvant to Bupivacaine in Bilevel Erector Spinae Plane Block in Breast Surgeries,2022-10-27,2023-11-10,379 days,Recruiting,Interventional
FZPL-â¢-301-OC,A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients,2019-04-30,2022-12-31,1341 days,"Active, not recruiting",Interventional
2015-KAEK-64-22-09,High Intensity vs Low Intensity Resistive Exercise In Patient With Upper Extremity Lymphedema,2022-11-15,2023-02-07,84 days,Completed,Interventional
2022-0329,Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.,2022-11-18,2023-05-31,194 days,Recruiting,Interventional
CLODIS,Local Compression Seroma DIminution Objective (CLODIS),2018-11-18,2020-10-01,683 days,Unknown status,Interventional
KE-0254/92/2018,ESP in Breast Surgery Due to Cancer,2021-02-01,2021-08-17,197 days,Completed,Interventional
G423 Multi TP,Improving Cancer Outcomes Through Personalized Care Planning and Symptom Management.,2021-02-16,2021-11-01,258 days,Completed,Interventional
2019-001982-34,Measuring Oncological Value of Exercise and Statin,2023-04-17,2027-12-31,1719 days,Not yet recruiting,Interventional
201803061RIND,Ventilation Efficacy of Size 3 or Size 4 I-gel in Female Patient Weighing 50 to 60 Kilograms,2018-05-28,2019-05-01,338 days,Unknown status,Interventional
192004,"KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer",2022-09-26,2028-12-31,2288 days,Recruiting,Interventional
RIPH3-RNI18/NEUROTAX,Involvement of SK3 Calcium Channel in Taxane Neuropathy,2019-02-06,2020-06-12,492 days,Completed,Observational
22339,Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors,2023-06-06,2024-10-31,513 days,Not yet recruiting,Interventional
TAS2940-101,A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer,2021-09-16,2025-06-01,1354 days,Recruiting,Interventional
Bio2738,Shoulder Rehabilitation Using a Mobile App Following Breast Reconstruction,2022-04-28,2023-05-01,368 days,Recruiting,Interventional
20252,Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety,2019-10-30,2021-02-16,475 days,Completed,Interventional
2021-PrMa-RWiberg,"Prophylactic Mastectomy: Prospective Evaluation of the Correlation Between Skin Flap Thickness, Residual Glandular Tissue and Skin Necrosis by Imaging and Clinical Examination",2022-08-25,2027-12-31,1954 days,Recruiting,Observational
STM-IRB-22B-001,Development and Testing of a TTDSS for Cancer Patients,2022-07-25,2024-04-06,621 days,Recruiting,Interventional
69HCL20_0346,Impact of the COVID-19 Pandemic in Gynecological Oncology,2020-05-06,2020-11-30,208 days,Completed,Observational
21-5539,Rehabilitation for People With Advanced Cancer,2022-12-02,2024-04-30,515 days,Recruiting,Interventional
2018-1361,Physical Activity Promotion for Breast and Endometrial Cancer Survivors,2020-09-08,2024-11-01,1515 days,"Active, not recruiting",Interventional
MC1713,A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ,2019-04-01,2023-06-01,1522 days,Recruiting,Interventional
HREBA.CC-18-0028,The ONE-MIND Study: Evaluating the Efficacy of Online Mindfulness-Based Cancer Recovery During Chemotherapy Treatment,2018-06-01,2024-01-01,2040 days,Recruiting,Interventional
E-SN@P PROJECT-IPC 2017-029,Assessment of Outpatient Digital Follow-up of Patients Over 70 Years of Age Undergoing Chemotherapy Treatment,2020-12-30,2023-12-30,1095 days,Not yet recruiting,Interventional
PASCA,A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.,2020-12-24,2028-04-24,2678 days,Recruiting,Interventional
H-49731,Improving Comprehensive Care of Cancer Patients,2022-04-01,2025-06-01,1157 days,Recruiting,Interventional
BrUOG 390,BrUOG 390: Neoadjuvant Treatment With Talazoparib,2021-03-29,2027-01-01,2104 days,"Active, not recruiting",Interventional
EC/2018/0315,Hormone Replacement Trial Against ALzheimers Disease,2018-04-17,2023-12-31,2084 days,Recruiting,Interventional
CIMS-2019-01,4FMFES-PET Imaging of Endometrial and Ovarian Cancers,2018-09-01,2023-08-31,1825 days,Recruiting,Interventional
XL102-101,Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101),2021-02-10,2024-10-01,1329 days,Recruiting,Interventional
Dnr 2019-04151,Exercise as Medicine for People With Cancer Sweden,2022-01-11,2024-11-01,1025 days,Recruiting,Interventional
2021-001624-17,Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy,2022-02-25,2027-12-01,2105 days,Recruiting,Interventional
GCO 21-0012,Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials,2022-12-24,2025-04-01,829 days,Recruiting,Interventional
2018-0004,Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery,2019-05-02,2024-04-30,1825 days,Recruiting,Interventional
TJ-IRB20211129,68Ga-HER2 Affibody PET/CT Imaging for HER2-Positive Cancer Patients,2021-12-18,2025-12-30,1473 days,Recruiting,Observational
823981A,Oncology Episode Payment Model in Hawaii,2018-08-01,2025-01-31,2375 days,"Active, not recruiting",Interventional
NIT-110 (KEYNOTE PNA60),NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors,2020-06-10,2024-05-20,1440 days,Recruiting,Interventional
69HCL19_0731,"Identify the Obstacles to Early Diagnosis of Cancer in Patients Over 75 Years Old, on an Outpatient Basis",2020-05-08,2020-10-02,147 days,Completed,Observational
BT-001.01,A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors,2021-02-25,2025-04-30,1525 days,Recruiting,Interventional
EAQ161CD,Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting,2019-01-08,2023-12-01,1788 days,"Active, not recruiting",Observational
Pro00106186,Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study),2021-09-20,2023-01-09,476 days,Completed,Interventional
G-5097-2019,Evaluation of Postoperative Nausea and Vomiting Incidence in Patients With Mastectomy Surgery According to Apfel Risk Scoring System,2020-06-01,2020-08-31,91 days,Completed,Observational
Laser treatment,Laser Treatment of Genito-urinary Syndrome in Women,2022-10-01,2026-12-31,1552 days,Not yet recruiting,Interventional
NIMAO/2016/PC-01,Kinetics of Perioperative Circulating DNA in Cancer Surgery,2018-01-22,2018-11-11,293 days,Completed,Observational
IIT-2021-CANINE,To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment,2021-02-23,2025-03-28,1494 days,"Active, not recruiting",Observational
PROICM 2017-05 BAL,Analysis of Circulating Tumor Markers in Blood,2018-05-29,2023-05-29,1826 days,Recruiting,Interventional
Breast Biopsy,The Effect of Education Given at Different Times Before a Breast Biopsy,2020-08-01,2020-10-30,90 days,Completed,Interventional
2018P000084,Evaluation of ADM Soft Tissue Reinforcement,2020-04-01,2022-04-01,730 days,Unknown status,Observational
IRB00167074,Sensory Restoration After DIEP Flap Neurotization,2020-12-01,2025-12-31,1856 days,Recruiting,Interventional
GOP,Goserelin for Ovarian Protection in Premenopausal Patients Receiving Cyclophosphamide,2018-03-01,2020-03-01,731 days,Unknown status,Interventional
NIP IT!,Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!),2022-07-20,2026-06-01,1412 days,Recruiting,Observational
CDKY709A12101C,Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.,2019-05-07,2025-05-16,2201 days,"Active, not recruiting",Interventional
IRB#21-001169,Postoperative Opt-In Narcotics Treatment in Breast,2022-01-01,2023-01-01,365 days,Not yet recruiting,Interventional
PRO 1676,A Digimed Oncology PharmacoTherapy Registry,2019-09-06,2022-03-01,907 days,Unknown status,Observational
Pro00102260,Hypertension Management in Cancer Patients,2019-12-10,2020-06-03,176 days,Terminated,Interventional
19829,"A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein",2020-07-02,2024-04-30,1398 days,"Active, not recruiting",Interventional
00011271,HeartPhone Cancer Survivors Trial 2019,2019-04-23,2020-12-31,618 days,Terminated,Interventional
CE3220.,Efficacy of the MepitelÂ® Film on the Prevention of Radiodermatitis in the Inguinal Fold.,2021-01-01,2025-01-01,1461 days,Not yet recruiting,Interventional
METCZ20220056,EvaLuating negAtive pressUre Wound theRapy in brEast coNserving Surgery,2023-02-01,2023-12-01,303 days,Not yet recruiting,Interventional
RC31/17/0350,Use of Compression Bandages in the Prevention of Post-mastectomy Lymphoceles,2021-08-16,2022-11-01,442 days,Recruiting,Interventional
19-179,Acupuncture Pilot Study for Cancer-related Cognitive Function,2019-07-01,2023-07-01,1461 days,"Active, not recruiting",Interventional
180276,Promotora Navigator - Culturally Appropriate Patient Navigator,2018-06-07,2018-10-15,130 days,Completed,Interventional
213353,Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer,2019-10-03,2022-01-12,832 days,Terminated,Interventional
ebeddows,Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy,2020-07-08,2024-12-31,1637 days,Recruiting,Interventional
IFCT-1703,Her2-positive Lung Cancer Treated With Dedicated Drug,2019-05-17,2023-07-01,1506 days,"Active, not recruiting",Interventional
69HCL17_0642,Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study,2019-11-28,2022-10-01,1038 days,Recruiting,Observational
CS001-SA,Safety Assessment of P2Et Extract in Healthy Voluntary Subjects in Colombia,2019-04-30,2020-05-01,367 days,Unknown status,Interventional
MSK8/22,The Effect of Rhomboid Intercostal Block and Serratus Anterior Plane Block on Postoperative Respiratory Functions,2022-09-21,2023-04-14,205 days,Completed,Interventional
JAB-2485-1001,JAB-2485 Activity in Adult Patients With Advanced Solid Tumors,2022-12-20,2026-08-01,1320 days,Recruiting,Interventional
PVMEDCT202201,Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk,2022-09-30,2023-06-30,273 days,Recruiting,Observational
BA3021-001,CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2),2018-06-27,2023-06-30,1829 days,Recruiting,Interventional
2020-05-001B,Regional Anesthesia in Breast Surgery,2020-12-01,2021-11-30,364 days,Unknown status,Interventional
13104,Tranexamic Acid for Alloplastic Breast Reconstruction,2022-08-01,2024-08-01,731 days,Not yet recruiting,Interventional
PRT2527-01,A Study of PRT2527 in Participants With Advanced Solid Tumors,2022-02-14,2023-12-01,655 days,Recruiting,Interventional
RECHMPL22_0024,Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC),2022-06-16,2024-09-01,808 days,Recruiting,Interventional
120134,NPWT for Abdominal Incisions in DIEP Reconstructions: A RCT,2023-09-01,2025-10-01,761 days,Withdrawn,Interventional
21-369,A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer,2021-09-20,2023-09-20,730 days,Recruiting,Interventional
Pro00078230,Erector Spinae Plane Block Versus Paravertebral Block,2018-05-29,2021-04-27,1064 days,Completed,Interventional
18-000948,Investigating Magnesium Glycinate in Structure/Function Role of Hot Flashes.,2018-07-24,2021-04-10,991 days,Completed,Interventional
20-08,Prospective Case Collection Study for New Mammography Technologies,2021-12-10,2025-12-01,1452 days,Recruiting,Interventional
AP2001-50504,Erector Spinae Block Versus PECS Block Type II for Breast Surgeries,2020-03-19,2021-03-10,356 days,Completed,Interventional
FMBSURECS/30042019/Ali,Efficacy of Serratus Anterior Plane Block Mastectomy,2019-05-07,2019-12-01,208 days,Completed,Interventional
21-192,TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance),2021-08-01,2022-11-01,457 days,Completed,Interventional
SBT6290-101,A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors,2022-03-01,2022-03-31,30 days,Withdrawn,Interventional
SAHZhejiangU 123,Added Value of Contrast-enhanced Ultrasound for BI RADS 4A Nodules,2019-01-01,2021-12-31,1095 days,Unknown status,Observational
CRYO for Mastectomy (DoD),Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Postoperative Pain After Mastectomy,2022-09-15,2026-05-14,1337 days,Enrolling by invitation,Interventional
FMASUMD45/2021,Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity,2021-06-01,2023-06-01,730 days,Recruiting,Interventional
PT3465,Effect of Thera Band Exercises on Adhesive Capsulitis Post Mastectomy,2021-01-10,2022-01-05,360 days,Completed,Interventional
Lishui Peoples Hospital,Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors,2019-02-13,2021-12-31,1052 days,Unknown status,Interventional
HAN2014005-CT02,"Evaluation of the Efficacy and Safety of A High Molecular Weight, Natural Hyaluronic Acid Vaginal Gel in Women With Genitourinary Syndrome of Menopause",2020-03-01,2022-08-13,895 days,Completed,Interventional
SHEBA-19-6136-RS-CTIL,Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors,2020-02-24,2022-12-30,1040 days,Unknown status,Interventional
2021/01159,Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI,2022-06-01,2027-04-04,1768 days,Not yet recruiting,Interventional
GS-US-417-5937,Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants,2020-11-04,2021-01-13,70 days,Completed,Interventional
SOGUG-2016-A-IEC(PRO)-12,Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL),2018-02-06,2022-05-12,1556 days,Completed,Interventional
CCR5653,Accelerated Body Diffusion-Weighted MRI Using Artificial Intelligence,2022-05-06,2025-04-01,1061 days,Enrolling by invitation,Observational
PPP005-Ph2/3-01,Cannabis Oil and Radiation Therapy for the Management of Pain,2018-03-14,2018-11-30,261 days,Terminated,Interventional
AAAS9968,Hair Care Product Use Among Women Of Color,2021-03-31,2023-07-01,822 days,Recruiting,Interventional
METCZ2019016,Seroma Reduction and Drain Free Mastectomy,2020-06-26,2023-12-01,1253 days,Recruiting,Interventional
1190532,Chilean Maternal & Infant Cohort Study II (CHiMINCs-II),2019-06-01,2023-04-30,1429 days,"Active, not recruiting",Observational
HSL 2016-83,Determination of Autonomic Responses to the Exposure of Low Energy Electromagnetic Fields With Frequency Modulation in Patients With Advanced Hepatocellular Carcinoma and Healthy Individuals.,2018-02-15,2020-02-16,731 days,Unknown status,Interventional
IMM2902-101,"IMM2902, a HER2/SIRPÎ± Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors",2022-06-20,2024-12-01,895 days,Recruiting,Interventional
NOX66-005,A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors,2021-10-25,2024-02-28,856 days,Recruiting,Interventional
CCR5063,Evaluation of an Educational Intervention for Women With Breast Pain,2019-05-31,2019-09-30,122 days,Unknown status,Interventional
BGB-3111-108,A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects,2018-06-07,2018-07-02,25 days,Completed,Interventional
2020/14MAI/273,Serum Neurofilament Light (NFL) in Surgery Under General Anaesthesia (GA) Compared to Surgery With Hypno-analgesia (Hyp),2020-09-01,2023-02-28,910 days,Recruiting,Interventional
B4T2-PRC-IIT-001,A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors,2022-09-14,2026-12-31,1569 days,Recruiting,Interventional
PROACTIVE,"Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness",2021-12-15,2025-12-31,1477 days,Recruiting,Interventional
2017-02028,"Efficacy of the ""Consilium"" Smartphone App for Detecting Symptoms and Treatment Side Effects in Cancer Patients",2018-03-05,2020-10-10,950 days,Terminated,Observational
JS001-PMS-CO1,Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .,2020-02-15,2023-07-05,1236 days,Not yet recruiting,Observational
875351,Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project,2021-02-01,2023-12-31,1063 days,Recruiting,Interventional
CX-839-011,Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors,2019-05-20,2020-07-29,436 days,Terminated,Interventional
Pro00037562,Apple Womens Health Study,2019-11-14,2029-11-01,3640 days,Recruiting,Observational
16-010491,Preventing Lymphedema in Axillary Lymph Node Dissection,2018-04-10,2024-02-01,2123 days,"Active, not recruiting",Interventional
INT17676,A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects,2021-07-27,2022-10-28,458 days,Completed,Interventional
829785,Effect of PARP Inhibitors on Glomerular Filtration Rate,2020-02-03,2021-07-01,514 days,Terminated,Observational
ESG401-101,Study of ESG401 in Adults With Solid Tumors,2021-09-14,2025-04-01,1295 days,Recruiting,Interventional
GS-US-382-1587,Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels,2022-08-19,2023-11-01,439 days,Recruiting,Interventional
20221202,Primary Lesion Treatment for Bone Metastases,2023-03-01,2026-03-01,1096 days,Not yet recruiting,Interventional
KSCM-CRD-001,KeraStat(R) Cream for Radiation Dermatitis,2018-04-11,2018-11-06,209 days,Completed,Interventional
201707042,Diagnostic US for Reduction of Benign Breast Biopsies Using US-guided Optical Tomography,2018-12-13,2024-11-30,2179 days,Recruiting,Interventional
201810102MINC,Does Letrozole Improve Pregnancy Outcome in Fresh Embryo Transfer IVF/ICSI Cycle?,2019-04-25,2021-04-08,714 days,Unknown status,Interventional
IRB 20-488,CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer,2020-07-14,2023-08-01,1113 days,"Active, not recruiting",Observational
GO-1,SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients Own Stem Cells,2021-01-13,2025-12-01,1783 days,Recruiting,Interventional
1237087,A Mind-Body Intervention for Hot Flash Management,2018-11-15,2023-08-01,1720 days,Recruiting,Interventional
P.T.REC/012/003747,Aerobic Training and Diet on the Immune System in Postmastectomy Patients Receiving Chemotherapy,2022-05-20,2023-03-28,312 days,Recruiting,Interventional
GIHSYSU-26,"RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer",2022-12-15,2025-12-25,1106 days,Not yet recruiting,Interventional
BRCA-ACP.2022,Acupuncture With/Without Self-acupressure for Post-oophorectomy Hot Flashes in BRCA Carriers,2023-11-01,2024-12-31,426 days,Not yet recruiting,Interventional
20,Early Detection of Heart Problems in Cancer Patients Receiving Chemotherapy,2020-03-01,2020-05-28,88 days,Withdrawn,Observational
JK08.1.01,"A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer",2022-10-17,2026-02-20,1222 days,Recruiting,Interventional
NC762-01,A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors,2021-06-30,2024-10-01,1189 days,Recruiting,Interventional
PARPA-293-001,Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors,2019-11-25,2023-12-30,1496 days,Recruiting,Interventional
17237,HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases,2018-08-31,2023-08-31,1826 days,Recruiting,Interventional
209514,Pilot Study of Pancreatic Cancer Screening,2022-01-20,2032-01-31,3663 days,Recruiting,Observational
INT 36/18,Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients,2018-12-03,2023-12-01,1824 days,Recruiting,Interventional
MER-XMT-2056-1,A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2,2023-01-24,2025-11-01,1012 days,Suspended,Interventional
Klotho _ LRP-6 _ GC,Klotho _ LRP-6 _ Gastric Adenocarcinoma,2023-04-01,2024-04-01,366 days,Not yet recruiting,Observational
ZL-2306-912 ALTER-OC-02,Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors,2021-04-01,2023-02-28,698 days,Unknown status,Interventional
CEP1:4/2016,BRCA Main Home Nutritional Intervention-random Study,2018-06-01,2020-05-31,730 days,Unknown status,Interventional
Chemobrain Study,Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies,2021-03-01,2023-09-01,914 days,Not yet recruiting,Interventional
XB002-101,Study of XB002 in Subjects With Solid Tumors (JEWEL-101),2021-06-07,2024-10-07,1218 days,Recruiting,Interventional
KlusPharma,Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene,2018-07-16,2022-12-01,1599 days,"Active, not recruiting",Interventional
AJIRB-MED-THE-18-236,Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG,2018-11-06,2021-03-24,869 days,Completed,Interventional
20/PR/0222,Precision Medicine for Liver Tumours With Quantitative Magnetic Resonance Imaging and Whole Genome Sequencing,2021-02-18,2023-08-01,894 days,"Active, not recruiting",Observational
JTU-6H-20210227001,Comparison Between IORT and Postoperative Radiotherapy in Breast Conserving Surgery,2021-03-01,2025-02-28,1460 days,"Active, not recruiting",Interventional
69HCL22_0275,Control Cohort CTRL COH,2022-09-16,2027-09-16,1826 days,Not yet recruiting,Interventional
REPLAMOD,Histological Modifications of Postmenopausal Vaginal Mucosa After Repeated Carbon Dioxide (CO2) Laser Treatment,2019-12-03,2021-12-01,729 days,Completed,Interventional
BTC-HER2,Trastuzumab in HER2-positive Biliary Tract Cancer,2019-06-01,2021-01-04,583 days,Completed,Interventional
CASE2117,Sensation After Nipple Sparing Mastectomy and Breast Reconstruction With or Without Neurotized Free Tissue Transfer,2018-10-01,2020-10-01,731 days,Withdrawn,Interventional
GOUDET 2018,Study and Monitoring of Multiple Endocrine Neoplasia Type 1,2019-04-05,2029-11-01,3863 days,Recruiting,Observational
H-38855,Ruxolitinib for Premalignant Breast Disease,2018-05-13,2025-01-01,2425 days,Recruiting,Interventional
FF-2018-084,Does Pecs II Block Reduce the Incidence of Post Mastectomy Pain Syndrome (PMPS)? A Cross Sectional Study,2018-03-06,2019-02-20,351 days,Completed,Observational
2018-03,SENTINEL LYMPH NODE BIOPSY AFTER NEOADJUVANT CHEMOTHERAPY,2018-01-31,2023-01-31,1826 days,Unknown status,Observational
4-2019-0648,Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy,2020-06-23,2023-03-01,981 days,Unknown status,Interventional
TG-iConquerFear,Reducing Fear of Cancer Recurrence in Danish Colorectal Cancer Survivors,2023-04-01,2025-09-01,884 days,Not yet recruiting,Interventional
P2101,The AUS-PREDICT Registry for DCIS Patients With DCISionRT Testing,2021-07-02,2034-05-01,4686 days,Recruiting,Observational
TCM-padia001,Clinical Study on Prevention and Treatment of Pyrotinib Associated Diarrhea With Traditional Chinese Medicine,2021-10-08,2022-10-08,365 days,Recruiting,Interventional
GO43860,"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",2022-10-20,2025-10-31,1107 days,Recruiting,Interventional
C/35/2017,MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour,2019-04-10,2022-12-31,1361 days,"Active, not recruiting",Interventional
2018-003115-21,Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors,2020-09-01,2024-12-05,1556 days,Withdrawn,Interventional
EC29,Auto-Adjustable MOBIDERMÂ® Autofit NIGHT-time Compression Armsleeve in the Upper Limb LYMphedema in Maintenance Phase,2020-07-01,2023-12-01,1248 days,Recruiting,Interventional
2021/117,Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Alopecia,2022-02-28,2030-01-01,2864 days,Recruiting,Interventional
HS-10502-101,A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors,2023-04-01,2026-10-01,1279 days,Not yet recruiting,Interventional
Health consortium maresme,Use of Glubran 2 Â® in Axillary Lymphadenectomy Without Drain,2022-04-01,2026-06-01,1522 days,Recruiting,Interventional
STUDY00023183,Humidified Forest Oils for Immune System Recovery in Stage I-III Breast or Prostate Cancer,2022-07-19,2023-12-31,530 days,Enrolling by invitation,Interventional
201903142,Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors,2019-05-29,2025-12-31,2408 days,Recruiting,Observational
DCC-2036-01-003,A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors,2018-09-19,2022-10-01,1473 days,"Active, not recruiting",Interventional
E-19-3943,Erector Spina Plane Block Versus Deep Serratus Anterior Plane Block for Post Mastectomy Analgesia,2019-07-07,2020-02-26,234 days,Completed,Interventional
CASE6118,Free Flap Breast Reconstruction Using Virtual Surgical Planning and 3-D Modeling,2020-12-01,2023-12-01,1095 days,"Active, not recruiting",Interventional
MCART-006,Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases,2022-10-30,2024-12-31,793 days,Recruiting,Interventional
ONC-392-001,"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",2020-09-16,2024-12-31,1567 days,Recruiting,Interventional
PRO1184-001,PRO1184 for Advanced Solid Tumors,2022-12-07,2025-09-01,999 days,Recruiting,Interventional
2021-04840,Lymphedema After Urologic Surgery,2022-03-14,2030-01-01,2850 days,Recruiting,Observational
BPI-2358-105 phase 3,Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3,2018-05-29,2021-02-08,986 days,Completed,Interventional
HCC 20-064,Telehealth and Memory Study,2021-03-18,2025-05-31,1535 days,Recruiting,Interventional
E-19-773,"A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan",2019-10-23,2023-12-01,1500 days,Recruiting,Interventional
STUDY00003387,Exercise and Nutrition Interventions During Chemotherapy K07,2019-04-15,2024-06-01,1874 days,Recruiting,Interventional
SBT6050-201,A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers,2022-02-08,2022-07-07,149 days,Terminated,Interventional
MCART-002,Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis,2021-03-12,2024-01-01,1025 days,Recruiting,Interventional
ARRAY-818-103,Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors,2018-01-02,2023-04-30,1944 days,"Active, not recruiting",Interventional
Niraparib-5001,A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea,2020-03-16,2024-12-01,1721 days,Recruiting,Observational
LINDA,Study To Evaluate The Sensitivity Of The Linda Thermal Device,2021-08-30,2023-01-30,518 days,Recruiting,Observational
MC210302,Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer,2021-07-01,2023-03-08,615 days,Completed,Interventional
QSPainRelief-patientCNS,"QSPainRelief-patientCNS : Clinical Biomarkers of Nociception, Sedation and Cognition",2021-03-15,2024-09-30,1295 days,Not yet recruiting,Interventional
CARTIER,Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial),2019-08-02,2025-11-30,2312 days,Recruiting,Interventional
The Swedish DIRECT study,Direct Information to At-risk Relatives,2020-02-06,2025-12-31,2155 days,Enrolling by invitation,Interventional
CKAF156A2104,"Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir",2022-03-09,2022-10-17,222 days,Completed,Interventional
B3271007,Safety and Efficacy of Trastuzumab BS,2023-08-31,2025-09-08,739 days,Not yet recruiting,Observational
Elasto Trial,Comparison of Real-time and Shear Wave Elastography,2018-03-01,2022-12-31,1766 days,"Active, not recruiting",Interventional
Soh-Med-22-09-01,Ultrasonography Screening for Breast Lesions During Pregnancy and Lactation,2022-11-01,2024-06-01,578 days,Not yet recruiting,Observational
N201810002,Spirulina (FEM-102) Supplement to Chronic Hepatitis B Patients,2019-10-29,2020-11-30,398 days,Completed,Interventional
MastoVit150,Possibilities of Phytomedicine in Monotherapy of Benign Breast Diseases,2020-01-11,2022-06-10,881 days,Completed,Interventional
OCOG-2021-ELISA,Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS),2022-11-23,2035-05-31,4572 days,Recruiting,Observational
CASE1219,Incomplete Follow Up After Positive FIT or Stool DNA Testing: A Multimethod Approach,2019-09-01,2024-12-01,1918 days,Recruiting,Interventional
CHIRCOLREC-IPC 2018-017,Prospective Database for Colonic or Rectal Resection Surgery Patients,2021-03-01,2071-12-01,18537 days,Not yet recruiting,Observational
RELI/19/Der-Rdt/001,Efficacy and Tolerability Evaluation of a Topical MD Based on SHBF in Management of Radiodermatitis.,2020-11-02,2023-02-16,836 days,Completed,Interventional
GS-US-467-5643,"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies",2021-09-15,2028-05-01,2420 days,Recruiting,Interventional
PRO00031416,Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors,2019-06-01,2023-06-30,1490 days,Recruiting,Interventional
7635,Cannabinoids for Taxane Induced Peripheral Neuropathy,2019-09-01,2021-08-30,729 days,Terminated,Interventional
VAC for HPV,Video-Assisted Counseling for HPV Vaccination,2018-08-30,2019-06-30,304 days,Unknown status,Interventional
ONCB-006-19F,Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer,2023-07-03,2027-04-01,1368 days,Not yet recruiting,Interventional
70781,Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover,2022-03-21,2026-08-31,1624 days,Recruiting,Interventional
1407426,Family History Study on Cancer Risk,2020-07-01,2025-08-31,1887 days,Recruiting,Interventional
PRS-343-PCS_08_18,PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors,2018-08-21,2021-07-01,1045 days,Unknown status,Interventional
NL72939.078.20,Bilateral Prophylactic Mastectomy; Should we Preserve the Pectoral Fascia?,2022-01-01,2023-12-01,699 days,Recruiting,Interventional
HCI105691,Fatigue Interventions in Cancer (Exercise Intervention),2018-02-26,2023-02-01,1801 days,"Active, not recruiting",Interventional
49/20 b,Breast Reconstruction in Previously Irradiated Breast,2020-06-06,2021-01-25,233 days,Completed,Observational
AP2007-50104,Comparison of Duloxetine Versus Pregabalin,2020-12-20,2021-04-01,102 days,Unknown status,Interventional
PRO00032593,Virtual Reality Education Program to Reduce Anxiety During Radiation Therapy,2019-08-12,2020-04-14,246 days,Terminated,Interventional
H00020209,Dotarem vs Gadobutrol Contrast for Breast MRI,2021-03-01,2024-02-28,1094 days,Recruiting,Interventional
ROR2103,"Evaluating Patient Reported Outcomes in Radiation Therapy, The PRO-RT Study",2022-03-02,2023-12-30,668 days,Recruiting,Observational
BG01-2002,Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors,2021-01-22,2023-12-30,1072 days,Recruiting,Interventional
Rhomboid,Analgesic Effects of Rhomboid Block,2019-06-01,2021-08-20,811 days,Recruiting,Interventional
KY-2021-012,A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2,2022-06-30,2024-12-31,915 days,Not yet recruiting,Observational
49/20,Adjuvant Radiotherapys Effect on One and Two Stages Prosthetic Breast Reconstruction and on Autologous Reconstruction,2020-06-06,2021-01-25,233 days,Completed,Observational
GC101 TIL-ST-01,A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors,2022-07-30,2025-04-30,1005 days,Recruiting,Interventional
IM014-032,Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants,2020-08-02,2020-10-26,85 days,Completed,Interventional
CEEGOG EX-02,Tracers for Endometrial Cancer Sentinel Node Labeling,2021-01-01,2024-01-01,1095 days,Recruiting,Interventional
93 /1801/2021,Lifting Effect on Recovery After Mastectomy,2022-09-01,2024-12-01,822 days,Not yet recruiting,Interventional
2020-3627-1407,"SSI Rates in Patients Undergoing Mastectomy Without Reconstruction- A Multicenter, Double-blinded RCT.",2020-11-01,2022-12-31,790 days,Unknown status,Interventional
OTH267,Iraqi Trial for Lung Cancer Screening,2018-06-01,2022-04-01,1400 days,Unknown status,Interventional
Pro00054854,The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors,2021-11-22,2028-09-14,2488 days,Recruiting,Observational
MF 22-02,Idiopathic Granulomatous Mastitis Combination Therapy,2022-04-16,2023-09-01,503 days,Recruiting,Interventional
2019-0989,Trastuzumab Biosimilar (SamfenetÂ®) Plus Treatment of Physicians Choice (TPC) in Patients With HER2-positive Solid Tumor,2019-12-30,2019-12-30,0 days,Unknown status,Interventional
UCSD IIT 150729,Histology-Independent Study of Palbociclib in Patients With Advanced Cancer,2018-07-01,2024-02-01,2041 days,Withdrawn,Interventional
P.T.REC/012/003464,Impact of Scapular Mobilization And Strengthening Exercises on Shoulder Function Post Mastectomy,2022-01-01,2022-07-20,200 days,Completed,Interventional
GCT1047-01,GEN1047 for Solid Tumors - First in Human (FIH) Trial,2021-12-13,2025-08-12,1338 days,Recruiting,Interventional
BPX603-201A,Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors,2020-12-07,2027-01-02,2217 days,Suspended,Interventional
KEEP-G 07,Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer,2022-08-01,2025-07-01,1065 days,Recruiting,Interventional
2021-0611,"Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases",2022-01-20,2025-04-30,1196 days,Recruiting,Interventional
13022260-300-180785,Effect of Exercise in the Management of Peripheral Neuropathy,2020-09-01,2023-04-30,971 days,"Active, not recruiting",Interventional
INCB 123667-101,Study of INCB123667 in Subjects With Advanced Solid Tumors,2022-07-05,2026-07-30,1486 days,Recruiting,Interventional
ICO-2020-19,Clinico-biological Data Collection Study of Metastatic Lung Cancer,2023-04-12,2031-10-01,3094 days,"Active, not recruiting",Interventional
CRUKD/21/004- Treatment Arm 4,"DETERMINE Trial Treatment Arm 4: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations",2023-03-07,2029-10-01,2400 days,Recruiting,Interventional
NU22-09-00539,Prostate Cancer Screening With Abbreviated MRI Protocol,2022-05-01,2025-12-31,1340 days,Recruiting,Interventional
2019-A03336-51,Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy,2020-09-28,2023-12-01,1159 days,Recruiting,Interventional
09.2020.125,Efect of Erector Spina Plane Block on Mastectomy,2020-11-01,2021-02-25,116 days,Completed,Interventional
ANAE-341-19,Improving Tissue Oxygenation in Breast Reconstruction Surgery,2019-07-12,2023-12-01,1603 days,Recruiting,Interventional
01-2/141 27,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,2020-07-01,2020-08-01,31 days,Completed,Interventional
KF2019#1,KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug,2022-05-11,2022-12-31,234 days,Recruiting,Interventional
Vein-project,Training of Arms to Reduce Pain With Peripheral Venous Catheter,2023-02-28,2025-12-31,1037 days,Recruiting,Interventional
thoracic sympathectomy,Radiofrequency Thoracic Sympathectomy for Chronic Postmastectomy Pain; Randomized Placebo Controlled Study,2018-04-01,2020-01-01,640 days,Completed,Interventional
20-240,Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases,2021-09-15,2026-02-01,1600 days,Recruiting,Interventional
Debio 1143-106,Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143,2019-04-08,2022-04-06,1094 days,Completed,Interventional
457,Diagnostic Value of Bronchoscopic and Thoracoscopic Frozen Section Biopsies in Patients With Pleuropulmonary Tumors,2022-06-15,2023-12-30,563 days,Not yet recruiting,Interventional
D8410C00001,Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies,2022-06-24,2025-11-17,1242 days,Recruiting,Interventional
229510,Combination Therapy in Cancers With Mutations in DNA Repair Genes,2023-04-01,2027-12-31,1735 days,Not yet recruiting,Interventional
034-2020,Radiomic Analysis for Predicting Treatment Response and Clinical Outcomes in Malignancies,2020-03-02,2025-03-01,1825 days,"Active, not recruiting",Observational
38RC17.291,EssaiClinique_CBSM,2018-09-01,2020-02-01,518 days,Terminated,Observational
Estim Breast,Electrical Stimulation for Improving Postoperative Breast Sensation,2023-07-01,2025-08-31,792 days,Not yet recruiting,Interventional
YS-RVON-001,Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors,2022-01-14,2023-12-01,686 days,Recruiting,Interventional
228-17-EP,Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study,2018-01-22,2020-11-25,1038 days,Completed,Observational
RG1006143,Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization,2020-11-18,2022-06-30,589 days,Completed,Interventional
ZL-2306-914,Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma,2021-02-01,2023-07-30,909 days,Recruiting,Interventional
2019-8890,Clinical Evaluation of CEM-guided Biopsy,2019-10-08,2021-10-06,729 days,Completed,Observational
2021-KY-073,The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort Study,2022-04-01,2025-03-30,1094 days,Recruiting,Observational
SNK01-102,Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers,2021-03-01,2023-02-01,702 days,Withdrawn,Interventional
C4551001,Study of PF-07248144 in Advanced or Metastatic Solid Tumors,2020-11-16,2026-11-08,2183 days,Recruiting,Interventional
ONT-380-011,Effects of Tucatinib on Cardiac Repolarization in Healthy Participants,2018-12-06,2019-03-11,95 days,Completed,Interventional
KCSG-ST18-20,AZD8186 and Paclitaxel in Advanced Gastric Cancer,2019-05-14,2022-12-31,1327 days,Unknown status,Interventional
HCC 20-117,GIST and Memory and Attention Adaptation Training,2021-01-12,2024-06-01,1236 days,Recruiting,Interventional
EXGEFATU,"Diagnostic Value of Exome/ Genome Sequencing, Conventional Methods in Rare Diseases and Familial Tumor Syndromes",2021-02-18,2023-10-01,955 days,Recruiting,Observational
HEM-ONCO-013,CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer,2021-07-01,2024-07-01,1096 days,Recruiting,Interventional
FESPET,FESPET Study: Female EStrogen recePtor in Endometrial Cancer Treatment,2020-01-01,2021-12-01,700 days,Unknown status,Observational
22-501,Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC),2022-11-28,2025-12-31,1129 days,Enrolling by invitation,Interventional
STUDY00002021,Study of Sulphoraphane in Chronic Kidney Disease,2022-05-02,2023-12-01,578 days,Recruiting,Interventional
OLATRA,Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma,2018-06-21,2022-07-27,1497 days,Completed,Interventional
ELVN-002-001,ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer,2023-03-20,2026-07-01,1199 days,Recruiting,Interventional
FN-1501-UP1,A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML,2018-07-23,2022-02-11,1299 days,Terminated,Interventional
ILYAD1_2019,Initiative in LYon for Lung cAncer Screening Development - Prevalence Study,2020-10-31,2021-01-14,75 days,Completed,Observational
RBN-2397-19-001,"Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors",2019-08-01,2023-07-31,1460 days,Recruiting,Interventional
STUDY00000334,Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers,2019-06-04,2020-10-01,485 days,Completed,Interventional
OPT-IN Research Protocol,"Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring",2022-10-06,2023-12-06,426 days,Recruiting,Interventional
2017-A02018-45,OncoSNIPE - Study of Molecular Profiles Associated With the Development of Resistance in Solid Cancer Patients,2018-01-06,2023-03-31,1910 days,Unknown status,Interventional
CX-5461-04,"Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation",2021-09-08,2024-06-01,997 days,Recruiting,Interventional
919/2020/Oss/IOR,"Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma",2021-03-10,2024-12-31,1392 days,Recruiting,Observational
MC16C2,Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors,2019-03-01,2021-02-22,724 days,Completed,Interventional
NL75863.068.21,Magtrial: MagtraceÂ® as Tracer for Sentinel Lymph Node Detection in Early Stage Epithelial Ovarian Cancer,2022-06-01,2024-10-01,853 days,Not yet recruiting,Interventional
20-009,Pre-consultation Compassion Among Patients Referred to a Cancer Center,2021-06-01,2022-08-01,426 days,Recruiting,Interventional
PUMCH-NM-11/041,68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis,2021-11-01,2022-12-01,395 days,Recruiting,Interventional
ISU104-001,"Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors",2018-04-27,2021-12-31,1344 days,"Active, not recruiting",Interventional
SLNB,Sentinel Lymph Node Biopsy in Rectal Cancer,2023-05-01,2025-12-01,945 days,Not yet recruiting,Interventional
BR/2019/487,Binaural Music Study,2020-01-14,2020-03-31,77 days,Completed,Interventional
ATADEK/2022.11,Genital Laser Treatment in Postmenopausal Patients,2022-12-01,2023-12-01,365 days,Not yet recruiting,Interventional
60116787-020/34123,Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients,2022-09-15,2023-02-15,153 days,Completed,Interventional
BARBEN 2020,Impact of Age and Geriatric Co-morbidities on Lymphocyte Phenotype in Patients 70 Years of Age and Older,2021-11-01,2021-11-01,0 days,Withdrawn,Observational
CHUB-Hystocor,Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer,2018-07-10,2020-03-02,601 days,Withdrawn,Interventional
BLU-222-1101,(VELA) Study of BLU-222 in Advanced Solid Tumors,2022-04-07,2026-09-30,1637 days,Recruiting,Interventional
Soh-Med-22-09-16,Role of IMP3 Expression in Colorectal Carcinoma: An Immunohistochemical Study,2022-10-01,2023-06-01,243 days,Recruiting,Observational
Shengjing-LJY05,The Effect of Gravity on the Occurrence of Lactational Mastitis,2022-01-01,2024-01-31,760 days,Recruiting,Observational
CHUBX 2015/17,Dynamic Contrast Enhanced Ultrasound for Predict and Assess Rectal Cancer Response After Neo-adjuvant Chemoradiation - RECT,2018-06-18,2019-01-08,204 days,Completed,Interventional
1766419-7,Storytelling Intervention for African Americans Living With Hypertension,2022-07-14,2023-02-13,214 days,Recruiting,Interventional
NUV-868-01,NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors,2022-03-29,2026-02-01,1405 days,Recruiting,Interventional
436,Effects of Clinical Pilates Exercises in Patients With Rheumatoid Arthritis,2018-12-24,2019-10-01,281 days,Unknown status,Interventional
200155,"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta ""Trap""/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)",2020-11-24,2024-05-31,1284 days,"Active, not recruiting",Interventional
2021-BRV-004,Scaffold-guided Breast Surgery,2022-06-15,2026-06-20,1466 days,Recruiting,Interventional
PREDICT,The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor,2019-11-12,2023-01-16,1161 days,"Active, not recruiting",Observational
EJC001,Compassion Meditation for Cancer Survivor-Caregiver Dyads,2018-03-14,2020-01-11,668 days,Completed,Interventional
CHU-426,Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies,2019-01-14,2019-03-23,68 days,Completed,Observational
PHOX-CLI_001,"First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours",2022-07-18,2026-07-31,1474 days,Recruiting,Interventional
NICSO,NICSO National Study: Physician - Nurse Monitoring Project About Oncological Adverse Events,2018-03-01,2022-01-31,1432 days,Completed,Interventional
BJK-Z-F18HN-202010-YZGK,Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTcâMDP-BSÂ±SPECT,2021-03-29,2022-06-02,430 days,Completed,Interventional
A-ER-109-415,Effect of Reconditioning Exercise on Older Adults With Urinary Tract Cancer Following Curative Surgery,2021-08-11,2022-05-20,282 days,Recruiting,Interventional
2-107-05-162,Investigation of the Strategy of Preventing Post-operative Opioid-induced Hyperalgesia,2019-01-11,2019-12-31,354 days,Unknown status,Interventional
IRAS307166,How Does Skin Tone Affect Quantitative Photoacoustic Imaging,2022-10-01,2023-10-15,379 days,Not yet recruiting,Observational
20.60-onco20.07,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,2020-08-03,2021-03-22,231 days,Completed,Interventional
YBCSG-21-04,Granisetron Transdermal Patch for Prophylaxis of Delayed CINV,2021-06-10,2023-12-30,933 days,Not yet recruiting,Interventional
SamanRostambeigi,Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity,2020-11-12,2021-12-02,385 days,Completed,Interventional
20190131,Study of AMG 650 in Adult Participants With Advanced Solid Tumors,2020-03-11,2023-02-15,1071 days,Completed,Interventional
999916161,The Role of Emotions and Regulatory Focus in Decision Making That Involves Risk Tradeoffs,2019-06-05,2019-06-17,12 days,Withdrawn,Observational
IRB00038262,"The Effect of Nitroglycerin Ointment, Fluorescent Angiography, and Incisional Negative Pressure Wound Therapy on Mastectomy Skin Flap Perfusion-Related Problems",2018-01-30,2019-03-12,406 days,Terminated,Interventional
IRB00095260,Efficacy of Massage for the Treatment of Cancer-Related Fatigue (CRF) in Prostate Cancer Survivors,2018-01-22,2019-03-31,433 days,Completed,Interventional
TapeK_Gesso_ABM_PSO,Taping to Control Edema in Patients With Forearm Plaster for Wrist Fracture.,2021-06-25,2023-03-23,636 days,Completed,Interventional
29BRC18-0005 (VinMetAtezo),Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer,2019-01-24,2022-02-23,1126 days,Completed,Interventional
1000-1,Womens Assessed Cardiovascular Evaluation With MCG,2020-10-15,2022-07-21,644 days,Completed,Observational
OPTIMUM,Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy,2022-04-01,2024-10-30,943 days,Recruiting,Interventional
R-17-360,Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy,2018-01-11,2020-03-01,780 days,Unknown status,Observational
2017-003582-10,Immunotherapy In Locally Advanced Rectal Cancer,2019-04-01,2023-12-01,1705 days,"Active, not recruiting",Interventional
BIC4VMR,Breakthrough Improvement Collaborative for Ventral Mesh Rectopexy,2023-03-01,2025-03-01,731 days,Not yet recruiting,Observational
2017_43,Impact of Supportive Care on the Experience of Hospitalization of Patients Staying in the Protected Area of the Department of Blood Diseases,2019-03-15,2024-03-01,1813 days,Recruiting,Interventional
4397,Social Risk Factors and Discrimination in Cancer Survivorship,2022-05-05,2026-09-30,1609 days,Recruiting,Interventional
00000001,Effects of Selected Exercise Program on Microcirculation and Lymphedema in Postmastectomy Patients,2022-03-01,2022-05-01,61 days,Not yet recruiting,Interventional
IRB-2019-118,Aesthetic Effect of Steri-Strip Orientation on Healing and Scar Appearance in Breast Surgery,2020-11-01,2023-04-15,895 days,Recruiting,Interventional
RGC-1501-001,Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy,2023-07-01,2025-06-30,730 days,Not yet recruiting,Interventional
19CX5601,PROState Pathway Embedded Comparative Trial,2020-09-08,2022-08-31,722 days,Completed,Observational
20-03021615,FaCT Trial (Facilitated Cascade Testing Trial),2021-07-21,2023-11-01,833 days,Recruiting,Interventional
210026,Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma,2021-09-29,2028-06-01,2437 days,Recruiting,Interventional
702576,Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo,2020-11-01,2022-12-01,760 days,Recruiting,Interventional
MT-5111_001,Study of MT-5111 in HER2-positive Solid Tumors,2019-11-12,2025-05-01,1997 days,Recruiting,Interventional
APHP180576,18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma,2022-09-01,2027-09-01,1826 days,Not yet recruiting,Observational
2020-1255,High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies,2022-04-24,2025-01-31,1013 days,Recruiting,Interventional
RC2022_prg.15,Evaluation of the Effects of Orange Consumption on Carbohydrate and Lipid Metabolism in Subjects With MAFLD (Metabolic Associated Fatty Liver Disease),2023-03-01,2023-12-31,305 days,Recruiting,Interventional
IEO 1740,68Ga-DOTATOC Radio-Guided Surgery With Î²-Probe in GEP-NET,2022-05-12,2023-05-12,365 days,Recruiting,Observational
UW 19-436,A Resilience Promotion Program for Parents of Children With Cancer,2019-08-13,2020-07-21,343 days,Completed,Interventional
EDGE 000339,"SHIFTPLAN: an RCT Investigating the Effect of a Shift Work Intervention on Fatigue, Sleep and Health.",2022-10-01,2023-08-01,304 days,Not yet recruiting,Interventional
METCZ20210156,Exploring an Alternative Pre-operative SLN Mapping Method Using a Magnetic Tracer and MRI for Melanoma Patients,2022-09-01,2024-09-01,731 days,Recruiting,Interventional
2000031462,Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases,2023-02-21,2024-06-01,466 days,Recruiting,Interventional
METCZ20210103,Sentinel Lymph Node Mapping Using Magtrace and MRI in Healthy Subjects for Potential Use in Melanoma Patients,2021-08-01,2021-08-20,19 days,Completed,Interventional
2017/184 HP,VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer,2019-05-05,2022-11-05,1280 days,Unknown status,Interventional
20-002000,Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer,2021-04-08,2024-12-31,1363 days,"Active, not recruiting",Interventional
18.068,PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer,2018-12-01,2024-12-01,2192 days,Recruiting,Interventional
Soh-Med-22-03-01,IMP3 and PCNA Expression in Laryngeal Squamous Cell Carcinoma in Sohag Governorate,2022-06-01,2023-06-01,365 days,Recruiting,Observational
2020-3547,Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments,2020-11-04,2022-10-04,699 days,Completed,Interventional
CTM-N2D,Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Î³Î´ T Cells for Relapsed or Refractory Solid Tumour,2019-12-01,2021-03-01,456 days,Unknown status,Interventional
IMT-009-101,Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas,2022-11-28,2025-04-01,855 days,Recruiting,Interventional
B.30.2.ATA.0.01.00/1/6,Ultrasound-guided Paravertebral Block Versus Mid-point Transverse Process Pleura Block in Mastectomy Surgery,2020-03-26,2021-04-20,390 days,Completed,Interventional
SYSKY-2022-019-02,Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC,2022-06-28,2026-06-28,1461 days,Recruiting,Interventional
2019-02Obs-CHRMT,Psychological Determinants of the Therapeutic Observance of Osteoporotic Patients,2019-06-17,2022-01-31,959 days,Completed,Observational
CHGH-IRB:(864)110-10,The Effect of Nursing Education Intervention on Womens Health Literacy of Plasticizers,2021-09-01,2022-07-01,303 days,Recruiting,Interventional
PROT-CI2021,US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism,2022-03-09,2026-12-31,1758 days,Not yet recruiting,Interventional
CP-MGC018-01,MGC018 With or Without MGA012 in Advanced Solid Tumors,2018-11-21,2023-03-18,1578 days,Terminated,Interventional
RTX-224-01,RTX-224 Monotherapy in Patients With Solid Tumors,2022-01-12,2022-11-30,322 days,Terminated,Interventional
2021-A01625-36,Clinical and Cyto-histological Evaluation of Fractional CO2 Laser Treatment on Genito-Urinary Syndromes of Menopause Related to Vaginal Atrophy,2021-12-09,2025-01-15,1133 days,Recruiting,Interventional
SGNB7H4V-001,A Study of SGN-B7H4V in Advanced Solid Tumors,2022-01-12,2027-01-31,1845 days,Recruiting,Interventional
ShuangHoH,Smart Home Care of Cloud Base ECG on the Cardiotoxicity Prevention on the Cancer Patients.,2021-07-01,2023-06-30,729 days,Not yet recruiting,Observational
P130935,"Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy",2021-04-14,2022-04-01,352 days,Recruiting,Interventional
794/2020/Farm/IOR,Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse,2021-03-01,2027-07-01,2313 days,Recruiting,Interventional
2000029793,Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma,2023-02-24,2028-07-30,1983 days,Recruiting,Interventional
CMUH109-REC2-101,Evaluation of the Efficacy of Chinese Herbal Medicine in Patients With Obesity,2020-11-01,2021-11-01,365 days,Unknown status,Observational
RNI 2021 LEBRETON 3 (EVIGE),Evaluation of the Inter-center Variability of the Measurement of Thrombin Generation by the ST Genesia System,2022-09-07,2023-12-31,480 days,Recruiting,Observational
SBNK-YJ-2020-016-02,Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas,2020-11-03,2025-10-31,1823 days,Recruiting,Interventional
ThirdMMUb,Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors,2019-08-20,2023-10-20,1522 days,Not yet recruiting,Interventional
2693-CL-0307,A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause,2020-07-30,2022-06-13,683 days,Completed,Interventional
2020NZKY-062-01,The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease,2020-09-01,2022-03-01,546 days,Completed,Interventional
2021-13614,Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color,2022-10-24,2024-01-03,436 days,Recruiting,Interventional
MER-XMT-1660-1,A Study of XMT-1660 in Participants With Solid Tumors,2022-08-15,2026-01-01,1235 days,Recruiting,Interventional
no: P.T.REC/012/002774,"Aerobic Exercise With Diet Induces Hormonal, Metabolic, and Psychological Changes",2021-01-01,2023-05-20,869 days,Recruiting,Interventional
SBNK-YJ-2019-006-02,Study of Recombinant Human Endostatin Combined With Temozolomide and Irinotecan in Recurrent Gliomas,2020-02-13,2024-11-30,1752 days,Recruiting,Interventional
1648/2019,"Glucocorticoids, Immunotherapy and Radiosurgery for Brain Metastases",2019-11-01,2023-10-01,1430 days,Recruiting,Observational
2020/900/88,Assessment of the Efficacy of Injectable Hyaluronic Acid for Genitourinary Syndrome of Menopause,2021-04-01,2021-11-01,214 days,Completed,Interventional
DF1001-001,Study of DF1001 in Patients With Advanced Solid Tumors,2019-11-11,2025-12-01,2212 days,Recruiting,Interventional
STUDY00000224,Connecting Families to Overcome Ovarian Cancer,2021-07-24,2024-04-01,982 days,Recruiting,Interventional
2693-CL-0304,A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause,2019-07-10,2022-01-04,909 days,Completed,Interventional
ZUH-ITP-MBCS,ITP Block: Single or Multiple Injection?,2023-02-26,2023-03-05,7 days,Recruiting,Interventional
21-007867,Physical Activity Intervention for Hematopoietic Cell Transplant Recipients and Caregivers,2022-02-03,2023-11-30,665 days,"Active, not recruiting",Interventional
1 TP2AH000076-01-00,Evaluation of Momentary Affect Regulation - Safer Sex Intervention,2021-06-19,2024-06-30,1107 days,Recruiting,Interventional
Masters thesis,The Effect of Art-Based Mandala on Mental Health in Bone Marrow Transplant Patients,2022-01-15,2022-05-15,120 days,Completed,Interventional
22072,A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting,2022-11-03,2023-04-27,175 days,"Active, not recruiting",Observational
CPI-006-001,CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers,2018-04-25,2025-12-01,2777 days,"Active, not recruiting",Interventional
HKG-KZ-PRAD-103,"Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC",2018-06-01,2021-12-01,1279 days,Withdrawn,Observational
RG1001812,Effects of Alternative Healthy Eating Index-Based Diet on Inflammatory Markers and Breast Density in Healthy Participants,2019-10-28,2020-11-19,388 days,Completed,Interventional
25922,Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition,2023-02-15,2024-06-01,472 days,Not yet recruiting,Interventional
2693-CL-0305,A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause,2020-03-17,2022-04-20,764 days,Completed,Interventional
PET/CT in malignancy,Validity of Mediastinal Blood Pool SUV Ratio,2022-06-01,2023-12-30,577 days,Not yet recruiting,Observational
2021-A01570-41,Interventional Study on DEterminants and Factors of Physical ACtivity After Treatments in Oncology,2022-03-29,2023-10-01,551 days,Recruiting,Interventional
2693-CL-0302,A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2,2019-07-10,2021-04-23,653 days,Completed,Interventional
2693-CL-0301,A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause,2019-07-11,2021-08-11,762 days,Completed,Interventional
AssiutNT,Risk Assessment of Endometrial Hyperplasia and Endometrial Cancer,2021-09-01,2024-07-01,1034 days,Recruiting,Observational
PUMCH-NM-RR,68Ga-RM26-RGD PET/CT Imaging in the GRPR and Î±vÎ²3 Positive Tumor Patients,2022-08-16,2023-12-31,502 days,Recruiting,Interventional
HKG-Bng-HCC-100,HCC Screening Using DNA Methylation Changes in ctDNA,2018-08-20,2020-11-01,804 days,Completed,Observational
IX-2021-DS-LEARN,LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology,2023-01-31,2026-01-31,1096 days,Not yet recruiting,Observational
1-1-7-05-114,Decision Support for the Renal Replacement Therapy With End-stage Renal Disease,2019-04-18,2020-01-28,285 days,Completed,Interventional
Pro00101102,Cancer Treatment Decision-making in the HIV Population: an Observational Study of Physician-patient Interactions,2019-05-26,2020-03-16,295 days,Terminated,Observational
ALXN2040-HV-102,Potential Drug Interaction Between ALXN2040 and Rosuvastatin,2023-02-01,2023-04-05,63 days,Completed,Interventional
NL66650.041.18,The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study,2019-02-01,2024-02-01,1826 days,Recruiting,Observational
NCI-2020-01206,Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer,2020-07-14,2023-12-31,1265 days,Recruiting,Interventional
21083,Narrative Exposure Therapy to Reduce Symptoms of Traumatic Stress in Cancer Survivors,2022-03-04,2023-09-01,546 days,"Active, not recruiting",Interventional
STUDY00144314,KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural Practice,2020-11-18,2024-07-01,1321 days,Recruiting,Interventional
19-068,OPTimizing Treatment Focused Genetic Testing IN Cancer,2019-12-19,2028-12-31,3300 days,"Active, not recruiting",Interventional
69HCL21_0409,"CAncer, NUtrition and Taste 2",2022-01-27,2023-04-27,455 days,Recruiting,Interventional
HALO Dx 001,Phase I Human Analytics (HALO) Study,2022-03-16,2037-03-01,5464 days,Recruiting,Observational
D8532C00003,A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole,2022-10-04,2022-12-28,85 days,Completed,Interventional
UC-0107/1603,Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 3 Bone-only Metastases,2018-01-24,2027-07-24,3468 days,Recruiting,Interventional
AK_2021_HP,Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients,2022-05-18,2023-12-01,562 days,Enrolling by invitation,Interventional
C4391001,Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors,2020-09-23,2026-02-13,1969 days,Recruiting,Interventional
ICO-2020-14,"Evaluation of Different Smoking Cessation Protocols: Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy in Cancer Patients Scheduled for Surgery",2021-09-29,2023-09-01,702 days,Recruiting,Interventional
20-2458.cc,Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.,2021-02-05,2024-09-30,1333 days,Recruiting,Interventional
844554,TumorGlow Intraoperative Molecular Imaging (IMI),2023-12-23,2026-01-14,753 days,Not yet recruiting,Interventional
659/2017BO1,Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac,2018-05-09,2027-05-09,3287 days,Recruiting,Interventional
SYSU_AI01,Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics,2020-09-01,2020-09-01,0 days,Unknown status,Observational
XL092-001,A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors,2019-03-20,2024-11-01,2053 days,Recruiting,Interventional
HSC-SPH-20-1117,Accelerating the Implementation of a Breast and Cervical Cancer Screening and HPV Vaccination Intervention,2022-11-16,2024-09-29,683 days,Not yet recruiting,Interventional
B2017-113R,Tumor Landscape Pathological Diagnosis by Large Tissue Sections,2018-01-01,2021-06-30,1276 days,Unknown status,Observational
PH-FAPGA-01/22,A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors,2023-04-01,2024-01-01,275 days,Not yet recruiting,Interventional
FPA150-001,FPA150 in Patients With Advanced Solid Tumors,2018-03-27,2021-05-10,1140 days,Completed,Interventional
GCT1029-01,GEN1029 (HexaBodyÂ®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors,2018-04-30,2021-10-12,1261 days,Terminated,Interventional
STU-2019-0522,Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM),2020-02-01,2021-09-24,601 days,Completed,Observational
HEALED_CPS3,Health and Energy Through Active Living Every Day (HEALED) After Cancer Pilot Intervention for Cancer Survivors,2019-05-15,2019-10-01,139 days,Unknown status,Interventional
PJ-KS-KY-2019-134,The Clinical Study of Modern Therapies on Flora in Body Fluids and Blood of Malignant Tumor Patients,2019-12-20,2022-11-11,1057 days,Unknown status,Observational
PY314-1-01,A Study of PY314 in Subjects With Advanced Solid Tumors,2020-10-29,2023-10-28,1094 days,Recruiting,Interventional
LAUMCRH.YJ1.16/Jul/2019,Effect of Dexmedetomidine on the Duration of Pain Control in ESP Block for Breast Surgery,2019-07-17,2022-01-17,915 days,Unknown status,Interventional
DMT-2019.002,Delphinus SoftVueâ¢ ROC Reader Study (DMT SV RRS3),2020-02-08,2020-03-03,24 days,Completed,Observational
DMT-2019.001,Delphinus SoftVueâ¢ ROC Reader Study,2019-06-08,2019-07-02,24 days,Completed,Observational
AD10,KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method),2023-01-01,2023-12-01,334 days,Not yet recruiting,Observational
CASE7Y16,A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors,2018-03-14,2019-10-25,590 days,Completed,Observational
1474/19,Trigger Point Injections for Post-Mastectomy Pain Syndrome,2020-01-03,2023-12-03,1430 days,Recruiting,Interventional
CNZV930X2101,A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.,2018-07-18,2022-10-17,1552 days,Terminated,Interventional
TirolGESUND,"TirolGESUND: Baseline-controlled Comparison of the Effects of Fasting Dietary Intervention or Smoking Cessation Combined With Exercise in Healthy Female Tyrolean Volunteers Aged 30-60 on Epigenetic and Multi-omic Biomarkers of Health, Ageing, and Disease",2021-04-21,2023-08-01,832 days,"Active, not recruiting",Interventional
R20-3896L,PECS Block in Partial Mastectomy for Postoperative Pain Control,2019-09-01,2020-11-01,427 days,Unknown status,Interventional
69HCL19_0992,Interest of Virtual Reality to Prevent Cancer Patient Anxiety Before Chemotherapy or an Invasive Act,2020-10-07,2022-12-07,791 days,Recruiting,Interventional
201805930,Comparison of Pre-op and Post-op Pectoralis Nerve Block,2019-03-12,2021-10-31,964 days,Completed,Interventional
2018-0075,Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery,2018-10-08,2024-03-01,1971 days,Recruiting,Interventional
LOCAL/2020/DR-01,18F-DOPA-PET in Non-tumoral and Tumoral Brain Lesions,2020-01-01,2020-02-29,59 days,Completed,Observational
IRB-300003680,Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy,2020-07-06,2021-11-25,507 days,Completed,Interventional
HSC-MS-16-0467,Serratus Anterior Muscle Plane Block vsThoracic Paravertebral Block For Unilateral Mastectomies,2018-12-01,2019-12-01,365 days,Withdrawn,Interventional
PJ-KS-KY-2019-135,"Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy",2019-10-01,2021-10-01,731 days,Unknown status,Observational
2021/03-12,Effects of US-guided SAPB During Breast Surgery,2021-03-01,2021-09-30,213 days,Completed,Interventional
D0817R00010,OLAP (OLAparib Regulatory Post-marketing Surveillance),2021-02-01,2024-12-31,1429 days,Recruiting,Observational
201610,Predicting Chronic Pain Following Breast Surgery,2021-07-19,2023-12-31,895 days,Recruiting,Observational
VAR-2021-12,Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy,2022-12-20,2023-11-01,316 days,Recruiting,Interventional
WVU010518,Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy,2018-06-12,2021-12-31,1298 days,Terminated,Interventional
NUSMart NM,Evaluating the Relative Effectiveness of Two Front-of-pack Nutrition Labels,2018-07-31,2018-12-03,125 days,Completed,Interventional
XmAb22841-01,A Study of XmAbÂ®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors,2019-05-29,2023-02-16,1359 days,Completed,Interventional
PREDAPT,A Multicenter Cancer Biospecimen Collection Study,2020-02-05,2027-02-01,2553 days,Recruiting,Observational
SC103,Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors,2019-06-13,2023-12-01,1632 days,Recruiting,Interventional
ACE1702-001,ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors,2020-05-19,2024-06-01,1474 days,Recruiting,Interventional
RP12146-2101,"Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a PARP Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors",2021-10-05,2023-08-01,665 days,Recruiting,Interventional
RG1005815,"Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study",2020-02-19,2023-08-31,1289 days,Enrolling by invitation,Interventional
HH-PRT-0001,Development and Validation of Harbinger Health Test for Early Cancer Detection,2022-06-21,2025-07-03,1108 days,Recruiting,Observational
MP01,Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours,2024-01-01,2027-01-01,1096 days,Not yet recruiting,Interventional
AD07,GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescence PCR Method),2023-01-01,2023-12-01,334 days,Not yet recruiting,Observational
5688,Psychosocial Transitional Group Pragmatic Trial,2023-05-01,2024-12-31,610 days,Not yet recruiting,Interventional
RG1005140,"Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer",2021-10-18,2026-03-30,1624 days,Recruiting,Interventional
BT8009-100,Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumor Malignancies,2020-07-17,2025-12-01,1963 days,Recruiting,Interventional
HN20190929,PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma,2019-07-30,2022-07-30,1096 days,Recruiting,Interventional
STUDY00018000,EXERCISING TOGETHER for Couples Coping With Cancer,2019-01-18,2023-10-01,1717 days,"Active, not recruiting",Interventional
00003543,Comorbidities And Reducing inEquitieS,2021-05-05,2023-06-30,786 days,"Active, not recruiting",Interventional
OSU-19199,Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM),2020-11-17,2023-12-31,1139 days,Recruiting,Interventional
KB-0742-1001,A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma,2021-02-08,2025-12-01,1757 days,Recruiting,Interventional
GQ1001X2101,Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors,2020-07-07,2024-05-01,1394 days,Recruiting,Interventional
21820,"A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors",2022-10-11,2027-05-04,1666 days,Recruiting,Interventional
NL 70691.091.19,TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention,2020-03-01,2040-02-17,7292 days,Recruiting,Interventional
ORM-5029-01-001,Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors,2022-10-03,2025-10-01,1094 days,Recruiting,Interventional
NCI-2017-01232,PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery,2018-03-16,2024-03-27,2203 days,"Active, not recruiting",Interventional
PRT3645-01,A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors,2022-12-27,2024-12-01,705 days,Recruiting,Interventional
123glioma,Correlation Between SPECT/CT and IDH Mutation in Brain Glioma,2022-11-01,2023-12-01,395 days,Not yet recruiting,Observational
HMBD-002-V4C26-01,"A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab",2022-01-01,2025-01-01,1096 days,Recruiting,Interventional
NCH04-2020,"Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery",2020-07-01,2023-12-31,1278 days,Recruiting,Observational
BakircayU/D208,Chemotherapy-induced Peripheral Neuropathy (CIPN) on Motor and Sensory Function,2021-03-06,2022-05-15,435 days,Completed,Observational
RG1121550,Clinical Outcomes for Offering Genetic Testing in a Tiered Approach,2020-08-03,2021-12-31,515 days,Completed,Interventional
KYL[2020091],Surgical Intervention for Refractory Granulomatous Lobular Mastitis,2020-11-01,2027-06-30,2432 days,Recruiting,Interventional
TJ004309STM103,A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQÂ®) in Patients With Ovarian Cancer and Selected Solid Tumors,2021-11-02,2023-06-01,576 days,"Active, not recruiting",Interventional
AP1904-50102,Magnesium and Ketamine in Postoperative Analgesia,2019-11-01,2020-12-01,396 days,Completed,Interventional
GCT1044-01,A Study on the Safety of GEN1044 (DuoBodyÂ®-CD3x5T4) in Patients With Malignant Solid Tumors,2020-07-15,2021-10-29,471 days,Terminated,Interventional
SZMC-0216-22,A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC,2023-01-20,2028-12-31,2172 days,Not yet recruiting,Interventional
7465-CL-202,A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202),2020-03-09,2024-07-31,1605 days,"Active, not recruiting",Interventional
ELU-FRÎ±-1,A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRÎ±),2021-09-13,2025-03-15,1279 days,Recruiting,Interventional
IMP7068 - 101,The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors,2021-02-25,2023-08-30,916 days,Recruiting,Interventional
D0818R00008,A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer,2023-07-03,2023-09-15,74 days,Not yet recruiting,Observational
2000028592,Congenital Uterine Anomalies: Identifying Cancer Associations and Genetic and Environmental Factors to Improve Clinical Care,2021-07-14,2025-03-01,1326 days,Recruiting,Observational
D17062,Biomarkers in Chemotherapy-Induced Peripheral Neurotoxicity,2018-03-01,2022-02-14,1446 days,Completed,Interventional
SGNPDL1V-001,A Study of SGN-PDL1V in Advanced Solid Tumors,2022-10-25,2026-12-31,1528 days,Recruiting,Interventional
22/006-P,Palliative Care Costs for Outpatient Setting Management in Catalunya,2023-04-01,2024-03-31,365 days,Not yet recruiting,Observational
SAIL-002,Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity,2018-05-01,2018-10-24,176 days,Completed,Interventional
101,CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors,2021-02-02,2024-12-01,1398 days,Recruiting,Interventional
PREFER,PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine,2021-04-19,2023-04-01,712 days,Recruiting,Observational
C3881001,PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors,2018-10-04,2022-03-30,1273 days,Terminated,Interventional
TT420X1103,Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors,2021-07-14,2022-12-01,505 days,Recruiting,Interventional
RP2-001-18,Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors,2019-10-17,2023-07-01,1353 days,Recruiting,Interventional
M18HAR,Health After eaRly Menopause Due to Oophorectomy,2019-02-11,2022-01-01,1055 days,Unknown status,Observational
8259,PostmenopausAL heaLth And DIseAse (PALLADIA) Study,2021-10-01,2025-12-31,1552 days,Recruiting,Observational
20-458,Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients,2021-11-16,2025-08-01,1354 days,Recruiting,Observational
STUDY00020679,SMMART Adaptive Clinical Treatment (ACT) Trial,2022-12-01,2026-03-31,1216 days,Not yet recruiting,Interventional
M20COM,The Prospective Observational COMPRAYA Cohort Study,2021-06-18,2035-06-01,5096 days,Recruiting,Observational
21-508,Video Education With Result Dependent dIsclosure,2022-08-04,2026-09-01,1489 days,Recruiting,Interventional
CPG-01-001,COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.,2018-09-06,2023-12-01,1912 days,"Active, not recruiting",Interventional
TJCC-LC-20190108,Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC,2019-03-01,2020-12-01,641 days,Unknown status,Interventional
S1714,Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer,2019-03-01,2026-02-28,2556 days,"Active, not recruiting",Observational
2000026840,Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC,2023-05-01,2025-08-01,823 days,Not yet recruiting,Interventional
2020/2706,Impact of Measures Taken to Contain COVID-19 on Hospital Surgical Care Services and Clinical Outcomes,2020-08-01,2021-03-31,242 days,Completed,Observational
INCB 106385-102,INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors,2021-02-03,2023-12-29,1059 days,Recruiting,Interventional
GCT1046-01,GEN1046 Safety Trial in Patients With Malignant Solid Tumors,2019-05-14,2024-12-01,2028 days,Recruiting,Interventional
127-CL-01,Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors,2019-10-10,2023-08-30,1420 days,"Active, not recruiting",Interventional
Pro00077309,Prevent Cancer- Greenville,2018-11-08,2029-11-08,4018 days,Recruiting,Observational
KY1044-CT01,Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer,2019-01-28,2024-11-01,2104 days,Recruiting,Interventional
UAB30,A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer,2020-10-01,2024-08-01,1400 days,Recruiting,Interventional
MCC-20086,Developing and Testing a Spanish-Language Intervention to Reduce Cancer-Related Sleep Disturbance,2019-08-15,2021-04-09,603 days,Completed,Interventional
Oncoplastic breast surgeries,The Role of Lipofilling After Oncoplastic Breast Surgeries : Evaluation of Outcomes and Patient Satisfaction,2022-12-19,2024-09-01,622 days,Recruiting,Interventional
105909,Influence of Chemotherapy on Postural Control in Women With Cancer,2020-10-07,2022-12-31,815 days,Recruiting,Observational
XmAb20717-01,A Study of XmAbÂ®20717 in Subjects With Selected Advanced Solid Tumors,2018-07-10,2022-09-06,1519 days,Completed,Interventional
PBC017,Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer,2020-02-20,2024-04-30,1531 days,Recruiting,Interventional
19ON033,Vibrational Spectroscopy for Endometrial Cancer Diagnosis,2020-01-19,2024-11-01,1748 days,Recruiting,Observational
Parameters of resistence,Parameters Declaring PCO Infertile Patients Either Sensitive or Resistant to Different Doses of Clomiphene Citrate.,2021-01-01,2022-03-01,424 days,Recruiting,Observational
NCI-2017-01979,"Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery",2018-04-20,2018-04-20,0 days,Withdrawn,Interventional
NCI-2018-01375,"Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study",2019-04-09,2023-05-01,1483 days,"Active, not recruiting",Observational
Pro20170001392,"Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability",2018-03-08,2023-10-02,2034 days,Recruiting,Interventional
A005D-E01-201,[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR),2018-07-03,2019-07-05,367 days,Terminated,Interventional
A212102,Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection,2022-08-01,2025-02-01,915 days,Recruiting,Observational
TAP_Sett17,Kinesio Tex Tape in Reducing Edema and Seroma After Complex Reconstructive Breast Surgery,2018-04-03,2020-07-01,820 days,Unknown status,Interventional
CPO-100-US-101,Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors,2021-03-24,2025-03-01,1438 days,Recruiting,Interventional
IRB00058758,Paclitaxel Therapeutic Drug Monitoring in Cancer Patients,2019-11-11,2023-12-01,1481 days,Recruiting,Observational
20-117,Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors,2020-04-10,2024-04-01,1452 days,"Active, not recruiting",Interventional
19-002006,Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer,2019-05-16,2022-12-31,1325 days,"Active, not recruiting",Interventional
Plasticity Longitudinal cANcer,Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET),2021-11-16,2025-09-15,1399 days,Recruiting,Interventional
2021-025,Ask Questions (ASQ):Implementation of a Communication Intervention,2021-08-25,2023-08-01,706 days,Recruiting,Interventional
ATRC-101-A01,A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies,2020-02-11,2025-03-01,1845 days,Recruiting,Interventional
ST101-101,A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors,2020-07-01,2024-01-01,1279 days,Recruiting,Interventional
190143,Non-Viral TCR Gene Therapy,2023-05-01,2029-12-31,2436 days,Recruiting,Interventional
CYT-0851-01,A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors,2019-10-09,2023-12-01,1514 days,Recruiting,Interventional
MC210102,"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study",2022-03-31,2025-02-24,1061 days,Recruiting,Interventional
17573,A Study of Lasmiditan in Healthy Volunteers,2021-02-15,2021-07-06,141 days,Completed,Interventional
NCI-2020-13883,"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial",2021-03-05,2026-03-31,1852 days,Recruiting,Interventional
TT00420CN04,To Evaluate Efficacy and Safety of TT-00420 as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors,2022-04-13,2024-08-01,841 days,Recruiting,Interventional
ONCR-177-101,"Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors",2020-05-20,2028-07-01,2964 days,"Active, not recruiting",Interventional
SGNSTNV-001,A Study of SGN-STNV in Advanced Solid Tumors,2021-01-18,2026-03-31,1898 days,Recruiting,Interventional
2021-0299,Tumor Treating Fields Therapy in Combination With Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax,2022-04-29,2026-09-01,1586 days,Recruiting,Interventional
SKL27969C001,"Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients",2022-09-12,2024-09-01,720 days,Recruiting,Interventional
ACE-Pan tumor-02,ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02),2021-11-05,2022-04-20,166 days,Withdrawn,Interventional
HCC 20-266,Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC),2021-10-28,2029-12-01,2956 days,Recruiting,Interventional
2019-0239,Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives,2019-08-21,2022-12-31,1228 days,Recruiting,Observational
D9090C00003,A Study to Assess the Effect of Multiple Doses of AZD5462 on the Pharmacokinetics (PK) of Drugs in Healthy Participants,2022-06-30,2022-09-12,74 days,Completed,Interventional
FT500-101,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors,2019-02-15,2022-11-15,1369 days,Completed,Interventional
17364,A Study of LY3435151 in Participants With Solid Tumors,2019-10-28,2020-03-05,129 days,Terminated,Interventional
180043,Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy,2018-01-30,2019-09-30,608 days,Terminated,Observational
NCI-2020-06906,Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations,2020-12-29,2023-12-01,1067 days,Recruiting,Interventional
INT 48/21,Quantifying Systemic Immunosuppression to Personalize Cancer Therapy,2022-03-10,2024-05-17,799 days,Recruiting,Observational
IDE161-001,A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors,2023-03-01,2025-09-01,915 days,Not yet recruiting,Interventional
AK2018_1,18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer,2019-01-03,2019-11-18,319 days,Completed,Interventional
FT536-101,FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors,2022-05-31,2027-04-01,1766 days,Recruiting,Interventional
STUDY00000719,Adaptive Symptom Self-Management Immunotherapy Study,2023-05-01,2027-08-01,1553 days,Not yet recruiting,Interventional
DV001,The Effect of Androgen Receptor Polymorphism on Endometrial Cancer,2022-04-01,2024-04-01,731 days,Not yet recruiting,Observational
JZP712-201,Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors,2022-03-03,2024-06-23,843 days,Recruiting,Interventional
CancerDyads,Improving Survivorship Among Minority Cancer Dyads,2021-07-01,2024-12-31,1279 days,Withdrawn,Interventional
TMPS-101,Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors,2022-03-15,2025-07-01,1204 days,Recruiting,Interventional
IIBSP-ECV-2019-103,Study of Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2 Mutation Carriers (BRCA-HRT),2020-03-12,2023-10-01,1298 days,Recruiting,Observational
00000441,Same-Day Discharge After Nipple-sparing Mastectomy or Skin-sparing Mastectomy With Breast Reconstruction,2020-02-04,2022-02-04,731 days,Unknown status,Interventional
CCI-2003,Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC),2022-02-23,2025-11-01,1347 days,Recruiting,Interventional
SGNB6A-001,A Study of SGN-B6A in Advanced Solid Tumors,2020-06-08,2024-10-31,1606 days,Recruiting,Interventional
MLB-PK-001,A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer,2022-12-01,2024-12-01,731 days,Not yet recruiting,Interventional
XmAb23104-01,A Study of XmAbÂ®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3),2019-05-01,2025-09-01,2315 days,Recruiting,Interventional
2020-0439,Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors,2021-01-20,2025-02-03,1475 days,Recruiting,Interventional
CYH33-G102,Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.,2020-09-28,2024-01-28,1217 days,Recruiting,Interventional
20-410,Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer,2021-01-23,2023-12-01,1042 days,"Active, not recruiting",Interventional
202101,Comprehensive Outcomes for After Cancer Health,2022-06-23,2023-12-01,526 days,Recruiting,Interventional
NB-ND021 (NM21-1480)-101,A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors,2020-08-19,2025-01-01,1596 days,Recruiting,Interventional
SBT6050-101,A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors,2020-07-27,2022-12-01,857 days,"Active, not recruiting",Interventional
17-262-01,REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies,2018-03-15,2022-05-09,1516 days,Terminated,Interventional
UC-IMM-2101,Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO,2022-03-08,2025-03-07,1095 days,Recruiting,Interventional
ADCT-301-103,Study of ADCT-301 in Patients With Selected Advanced Solid Tumors,2018-11-09,2022-12-08,1490 days,Terminated,Interventional
170177,Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer,2018-04-11,2019-09-16,523 days,Terminated,Interventional
TPST-1120-001,TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers,2019-03-20,2024-06-23,1922 days,"Active, not recruiting",Interventional
180032,Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer,2018-01-31,2020-08-24,936 days,Completed,Interventional
VICC SUPP 2112,Improving Care After Inherited Cancer Testing,2022-08-05,2028-12-01,2310 days,Recruiting,Interventional
IB2022-03,Streamlined Geriatric and Oncological Evaluation Based On IC Technology,2023-04-01,2026-01-01,1006 days,Not yet recruiting,Interventional
PR148/21,Axillary Lymph Node Dissection vs Axillary Radiotherapy in Positive Sentinel Node After Neoadjuvant Therapy,2021-06-01,2026-06-01,1826 days,Recruiting,Interventional
2020-117,DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer,2021-02-10,2025-08-31,1663 days,Recruiting,Interventional
A9001502,Treatment Resistance Following Anti-cancer Therapies,2019-02-13,2020-12-14,670 days,Terminated,Interventional
NCI-2020-05428,"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer",2021-02-01,2023-12-31,1063 days,Recruiting,Interventional
2021-0175,Phase I Study of ZN-c3 and Bevacizumab Â± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors,2022-12-14,2022-12-14,0 days,Withdrawn,Interventional
CCT303-406-mST01,A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors,2020-07-09,2025-03-29,1724 days,Recruiting,Interventional
6B-20-1,18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases,2021-02-15,2025-02-15,1461 days,"Active, not recruiting",Interventional
NRG-BN009,Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery,2020-12-15,2030-01-31,3334 days,Recruiting,Interventional
TCR2-21-01,A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer,2022-06-21,2027-12-01,1989 days,Recruiting,Interventional
NCI-2020-05956,Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV,2020-11-04,2025-11-02,1824 days,Recruiting,Interventional
Pro9646,Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy,2019-06-25,2022-06-01,1072 days,Recruiting,Observational
CA052-002,A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors,2021-05-27,2026-09-15,1937 days,Recruiting,Interventional
IMX-110-001,IMX-110 in Patients With Advanced Solid Tumors,2018-02-15,2023-07-15,1976 days,Recruiting,Interventional
IIR 17-127,Measuring and Improving the Safety of Test Result Follow-Up,2018-10-01,2023-09-01,1796 days,"Active, not recruiting",Interventional
WPH 2201,A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler Heads,2022-08-15,2023-09-30,411 days,Not yet recruiting,Interventional
IRB20-0462,The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care,2022-02-07,2028-03-31,2244 days,Recruiting,Interventional
XmAb808-01,"Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAbÂ®808 in Combination With Pembrolizumab in Advanced Solid Tumors",2022-12-14,2027-12-01,1813 days,Recruiting,Interventional
2019-1091,Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases,2021-01-15,2025-05-01,1567 days,"Active, not recruiting",Interventional
INT156-19,Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment,2020-06-25,2023-02-28,978 days,Completed,Observational
02-MX-003,ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation,2021-09-07,2028-02-01,2338 days,Recruiting,Observational
VAR-2022-04,Evaluation of a Cone-beam CT Scanner for Image Guided Radiotherapy,2023-03-20,2024-02-01,318 days,Recruiting,Interventional
Phase 1 SV-101,Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors,2023-02-01,2023-12-31,333 days,Recruiting,Interventional
NYPC ERC# 2019-002,Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors,2022-01-24,2027-01-01,1803 days,Recruiting,Interventional
TTX-080-001,TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers,2020-07-14,2024-06-01,1418 days,Recruiting,Interventional
P.T.REC/012/003744,Endermologie Versus Negative Pressure Therapy on Postmastectomy Lymphedema,2022-06-29,2023-06-01,337 days,Recruiting,Interventional
P.T.REC/012/004199,Effect of Wii-console Based Exercise on Shoulder Range of Motion for Post-mastectomy Lymphedema Patients,2022-11-01,2023-06-01,212 days,Recruiting,Interventional
Doaa Atef,Virtual Reality Versus Proprioceptive Neuromuscular Facilitation on Postmastectomy Lymphedema,2018-06-30,2019-08-31,427 days,Completed,Interventional
09.2018.466,Reliability of Subcutaneous Echogenicity (SEG) Grade and Subcutaneous Echo-free Space (SEFS) Grade,2018-07-01,2018-08-13,43 days,Completed,Observational
0752-20-HMO,Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers,2022-04-01,2027-12-30,2099 days,Recruiting,Interventional
OCEL-01,A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers,2020-10-06,2022-11-01,756 days,Recruiting,Interventional
ILBS-VASMPCa-103,Effectiveness of Video Assisted Self Management Program on Chemotherapy Related Side Effects .,2021-11-01,2021-12-05,34 days,Completed,Interventional
NuTide:303,NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours,2023-02-01,2025-01-01,700 days,Not yet recruiting,Interventional
IC 2020-11_ALCINA4,Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4,2022-05-27,2027-11-30,2013 days,Recruiting,Interventional
AMT-151-01,AMT-151 in Patients With Selected Advanced Solid Tumours,2023-01-25,2024-10-30,644 days,Recruiting,Interventional
MDNA11-01,A Beta-only IL-2 ImmunoTherapY (ABILITY) Study,2021-08-27,2024-12-30,1221 days,Recruiting,Interventional
SGNTGT-001,A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer,2020-05-29,2025-04-30,1797 days,Recruiting,Interventional
PT199X1101,Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor,2022-06-23,2024-01-01,557 days,Recruiting,Interventional
GB1275-1101 (KEYNOTE-A36),GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma,2019-08-13,2022-04-11,972 days,Terminated,Interventional
IB2022-02,Cancer Risk Assessment in Patients With a Constitutional Alteration of the PTEN Gene,2023-02-07,2048-01-01,9094 days,Recruiting,Observational
INCAGN 2385-101,A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies,2018-06-18,2020-10-07,842 days,Completed,Interventional
IB 2017-01,A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors,2018-05-04,2025-12-31,2798 days,Recruiting,Interventional
INCAGN 2390-101,A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies,2018-09-24,2021-08-18,1059 days,Completed,Interventional
NU04,.Exercise and Follow-up After a Mastectomy,2018-01-01,2018-07-30,210 days,Completed,Interventional
STUDY00001436,Enhance the Use of Genetic Counseling and Testing in Latinas,2020-02-24,2022-01-31,707 days,Completed,Interventional
20430,HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics,2021-12-30,2024-12-31,1097 days,Recruiting,Interventional
STUDY00015588,Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial,2020-04-01,2026-02-27,2158 days,Recruiting,Interventional
IRB00092505,Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy,2023-05-01,2028-03-01,1766 days,Not yet recruiting,Interventional
NX-1607-101,A Study of NX-1607 in Adults With Advanced Malignancies,2021-09-29,2025-02-28,1248 days,Recruiting,Interventional
GLP-CDK-1009,Evaluation of GLR2007 for Advanced Solid Tumors,2020-07-15,2022-07-29,744 days,Completed,Interventional
0S-17-4,"Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer",2018-08-30,2020-09-24,756 days,Withdrawn,Observational
Teleclub_cam,Telerehabilitation in Oncology Patients,2020-07-01,2020-12-01,153 days,Unknown status,Interventional
AS-IRB-BM-17056,Taiwan Cancer Moonshot Project,2022-02-21,2035-12-31,5061 days,Recruiting,Observational
HZDH20-002,Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.,2021-03-04,2023-03-01,727 days,Recruiting,Interventional
Pro00100029,Calming Alternatives Learned During MRI-Guided Breast Biopsy,2018-10-16,2019-06-20,247 days,Completed,Interventional
2022-0712,Feasibility Study: IGNITE-TX (Identifying Texans at Risk for Hereditary Cancer) Intervention,2023-04-14,2027-10-31,1661 days,Recruiting,Interventional
2018-0439,Genetic Education in BRCA Families,2020-05-01,2024-06-30,1521 days,Enrolling by invitation,Interventional
CR109080,A Study of Lazertinib (JNJ-73841937) in Healthy Participants,2021-09-17,2022-02-10,146 days,Completed,Interventional
GIMI-IRB-20004,4SCAR-CD44v6 T Cell Therapy Targeting Cancer,2020-06-01,2023-12-31,1308 days,Recruiting,Interventional
2020-0079-E,Evaluation of the Effectiveness and Implementation of the BETTER Women Peer Health Coaching Program,2021-06-14,2024-04-01,1022 days,Recruiting,Interventional
2020-3,Experiment on the Use of Innovative Computer Vision Technologies for Analysis of Medical Images in the Moscow Healthcare System,2020-02-21,2024-01-01,1410 days,Recruiting,Observational
EOC317X1101,Study of EOC317 in Chinese Patients With Advanced Solid Tumors,2018-05-29,2020-11-29,915 days,Unknown status,Interventional
IRB00056774,Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors,2020-10-01,2024-03-07,1253 days,"Active, not recruiting",Interventional
EAQ202,Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials,2021-10-28,2025-01-25,1185 days,Recruiting,Interventional
SYNERGY-AI,SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry,2018-01-01,2025-06-01,2708 days,Recruiting,Observational
V937-013,A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013),2020-10-28,2023-07-31,1006 days,"Active, not recruiting",Interventional
10000045,"T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers",2022-03-08,2026-04-05,1489 days,Recruiting,Interventional
19-006717,Cancer Genetic Testing in Ethnic Populations,2019-12-13,2023-10-15,1402 days,Recruiting,Interventional
ATLAS-101,A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies,2020-08-12,2023-01-01,872 days,Recruiting,Interventional
19-151,Personalized Disease Prevention,2022-08-05,2025-06-30,1060 days,Recruiting,Interventional
21-00715,Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain,2022-01-04,2025-10-01,1366 days,Recruiting,Interventional
TAC01-HER2-03,TAC T-cells for the Treatment of HER2-positive Solid Tumors,2021-04-19,2025-02-01,1384 days,Recruiting,Interventional
UW17009,Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer,2018-01-17,2022-09-02,1689 days,Completed,Interventional
UMCC 2021.076,Methods for Increasing Genetic Testing Uptake in Michigan,2022-04-21,2027-03-01,1775 days,Recruiting,Interventional
H19-04010,Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity,2020-06-17,2024-10-01,1567 days,Recruiting,Interventional
F/N-R19-3893L,Effect of Hemp-CBD on Patients With CIPN,2020-05-27,2023-04-01,1039 days,"Active, not recruiting",Interventional
CRUKD/21/005,TT-702 in Patients With Advanced Solid Tumours.,2022-01-19,2025-09-01,1321 days,Recruiting,Interventional
Adela-EDMRD-001,cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease,2022-05-03,2026-12-01,1673 days,Recruiting,Observational
YXLL-KY-2022(057),Effect of Precise Grip Strength Training on PICC Catheter-Related Thrombosis in Cancer Patients,2022-07-10,2023-01-10,184 days,Completed,Interventional
ISI dV Xi-NSM,Robotic-Assisted da Vinci Xi Prophylactic Nipple-Sparing Mastectomy,2021-03-26,2028-12-30,2836 days,Recruiting,Interventional
16712,A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer,2018-04-10,2020-10-03,907 days,Completed,Interventional
HREBA.CC-20-0098,EXCEL: Exercise for Cancer to Enhance Living Well,2020-09-02,2027-12-31,2676 days,Recruiting,Interventional
IPO/PI134,Impact of Group Psychological Interventions on Extracellular Vesicles in People Who Had Cancer,2021-09-01,2021-09-01,0 days,Unknown status,Interventional
IMM2520-001,"IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors",2023-03-23,2025-10-26,948 days,Not yet recruiting,Interventional
Cancer Genetic Counseling.PSI,Assessment Psychological Distress for Cancer Heredity Test,2018-10-01,2021-12-31,1187 days,Unknown status,Observational
OM-GRPR-02,Safety and Tolerability of Â²Â¹Â²Pb-DOTAM-GRPR1 Â²Â¹Â²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors,2022-12-22,2025-01-01,741 days,Recruiting,Interventional
17493,A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors,2019-06-13,2024-08-24,1899 days,Recruiting,Interventional
LOXO-IDH-20002,Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations,2020-10-16,2023-05-01,927 days,"Active, not recruiting",Interventional
1623168,Healthy Moms: Prenatal Counseling for Postpartum Health,2021-02-01,2023-06-15,864 days,"Active, not recruiting",Interventional
11190071,Multimodal Assesment of Acute Cardiac Toxicity Induced by Thoracic Radiotherapy in Cancer Patients,2020-01-09,2023-10-31,1391 days,"Active, not recruiting",Observational
PACT-0101,A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors,2019-07-03,2022-08-12,1136 days,Suspended,Interventional
PROICM 2021-05 SER,Quantifying Systemic Immunosuppression to Personalize Cancer Therapy,2022-07-07,2024-03-01,603 days,Withdrawn,Interventional
IRB-300002068,Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health,2020-03-04,2024-08-31,1641 days,Recruiting,Interventional
0000-0001-5580-7256,Education Intervention in Patients With Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment.,2019-01-01,2021-05-01,851 days,Unknown status,Interventional
2017-0319,Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF,2018-12-18,2024-12-31,2205 days,Recruiting,Interventional
TRV-003,Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance,2022-07-15,2026-07-01,1447 days,Recruiting,Observational
ATOS-016R,Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density,2021-12-21,2025-12-31,1471 days,Recruiting,Interventional
HSP70CTC,Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells,2021-02-17,2022-05-01,438 days,Recruiting,Observational
Pro00104093,Assessing the Immunogenicity of pING-hHER3FL,2020-07-13,2024-12-01,1602 days,Recruiting,Interventional
VNC-236-101,Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer,2023-01-24,2024-12-01,677 days,Recruiting,Interventional
DB-1303-O-1001,A Study of DB-1303 in Advanced/Metastatic Solid Tumors,2022-01-31,2025-10-01,1339 days,Recruiting,Interventional
Metabolic Cancer 001,"Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer",2022-05-23,2027-09-23,1949 days,Withdrawn,Interventional
POWER,Potential of Moderate Whole Body Hyperthermia to Enhance Response,2023-02-01,2027-12-01,1764 days,Recruiting,Interventional
19-000756,Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues,2019-11-05,2031-10-17,4364 days,Recruiting,Interventional
7339-002,"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)",2018-12-12,2025-12-01,2546 days,Recruiting,Interventional
2018-001744-62,Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors,2019-04-12,2025-04-01,2181 days,Suspended,Interventional
20-533,Pembrolizumab And Lenvatinib In Leptomeningeal Metastases,2021-03-08,2022-12-01,633 days,Recruiting,Interventional
D9950C00001,First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours,2020-08-18,2023-05-02,987 days,"Active, not recruiting",Interventional
19-011472,"Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study",2020-06-30,2024-07-15,1476 days,"Active, not recruiting",Interventional
7684A-005,MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005),2021-09-16,2027-02-22,1985 days,Recruiting,Interventional
2017-0719,Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT,2018-07-10,2024-10-01,2275 days,Recruiting,Interventional
CBX-12-101,Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors,2021-05-03,2024-04-01,1064 days,Recruiting,Interventional
1801,9-ING-41 in Patients With Advanced Cancers,2019-01-04,2025-11-01,2493 days,Recruiting,Interventional
MOHCCN-O,Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O),2022-06-13,2026-10-01,1571 days,Recruiting,Observational
STU00209558,Plan to Thrive: Extending Cancer Survivorship Care Beyond the Clinic,2019-08-19,2019-12-31,134 days,Completed,Observational
IJB-IRAES-2020,Immunological Variables Associated to ICI Toxicity in Cancer Patients,2022-09-01,2024-12-01,822 days,Recruiting,Interventional
IRB00229163,Behavioral Weight Loss Program for Cancer Survivors in Maryland,2020-09-22,2023-06-30,1011 days,"Active, not recruiting",Interventional
ON-1002,"A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer",2019-08-09,2021-11-18,832 days,Completed,Interventional
SGN47M-001,A Safety Study of SGN-CD47M in Patients With Solid Tumors,2019-07-17,2020-09-14,425 days,Terminated,Interventional
TP-CA-001,Tempus Priority Study: A Pan-tumor Observational Study,2020-10-19,2030-10-19,3652 days,Recruiting,Observational
P-MUC1C-ALLO1-001,P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors,2022-02-15,2039-04-01,6254 days,Recruiting,Interventional
NTI1GSA,"Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid",2022-01-01,2023-12-01,699 days,Recruiting,Interventional
FT538-102,FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors,2021-10-15,2025-08-05,1390 days,Recruiting,Interventional
OHSN-REB#20170381-01H,Randomized Trial of eOncoNote,2018-02-05,2021-02-17,1108 days,Completed,Interventional
H-43405 VISTA,"Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors",2020-12-14,2038-12-30,6590 days,Recruiting,Interventional
QUILT-2.025,QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.,2018-08-10,2020-12-30,873 days,Unknown status,Interventional
ZZTIL-012,Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors,2021-01-01,2035-01-01,5113 days,Recruiting,Interventional
202211038RINA,Microscopy Imaging of Whole-mount Stained Human Tissues,2023-01-10,2024-12-31,721 days,Not yet recruiting,Observational
20201421,"With Love, Grandma (""Con CariÃ±o, Abuelita"") Pilot Study",2023-02-22,2024-05-31,464 days,Recruiting,Interventional
YSCH-01-0000,Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study,2021-11-30,2023-12-31,761 days,Recruiting,Interventional
SNB-101-101,"Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors",2020-10-21,2023-12-31,1166 days,Recruiting,Interventional
1224/2018,Cryotherapy vs. Cryocompression for Preventing Chemotherapy-induced-peripheral-neuropathy in Women Undergoing Chemotherapy,2020-02-03,2024-02-03,1461 days,Recruiting,Interventional
438-IO-101,Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors,2022-05-11,2024-06-01,752 days,Recruiting,Interventional
831-IO-101,Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors,2022-03-31,2024-12-01,976 days,Recruiting,Interventional
BHP0120,A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation,2020-11-18,2024-09-19,1401 days,Recruiting,Interventional
CDX527-01,A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies,2020-08-04,2023-04-01,970 days,"Active, not recruiting",Interventional
HREBA.CC-22-0196,LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study,2022-11-24,2024-05-30,553 days,Recruiting,Observational
Meet-URO 12,Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy,2019-08-27,2021-09-01,736 days,Completed,Interventional
NC318-01,A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors,2018-09-28,2023-04-01,1646 days,"Active, not recruiting",Interventional
STR-004-001,Strata PATHâ¢ (Precision Indications for Approved Therapies),2021-11-19,2029-11-19,2922 days,Recruiting,Interventional
Pro00103249,Symptom Management for YA Cancer Survivors,2020-01-22,2025-10-01,2079 days,Recruiting,Interventional
21850,Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors,2019-11-21,2025-06-30,2048 days,Recruiting,Interventional
180049,Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer,2018-09-06,2028-03-23,3486 days,Recruiting,Interventional
ARC-5 (AB928CSP0005),A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies,2018-07-24,2021-09-03,1137 days,Completed,Interventional
201809177,PROactive Evaluation of Function to Avoid CardioToxicity,2019-03-13,2023-03-02,1450 days,Terminated,Interventional
2020-2110,Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel,2020-02-14,2020-09-04,203 days,Completed,Interventional
AVS4TL - 0921,Avera/Sema4 Oncology and Analytics Protocol,2021-11-01,2026-12-31,1886 days,Recruiting,Observational
IIT2020-24-SHIRAZIP-BURN,The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors,2022-01-10,2024-03-09,789 days,Recruiting,Interventional
PY159-2-01,A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors,2020-11-10,2023-04-07,878 days,Recruiting,Interventional
C3651010,Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia,2021-05-11,2022-08-09,455 days,Completed,Interventional
Palliach,Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care,2021-02-01,2022-07-01,515 days,Unknown status,Interventional
DPM401,Study to Evaluate the Safety of Nanoxel M Inj.,2019-09-18,2024-08-01,1779 days,Recruiting,Observational
BR-DTX-OS-401,Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating Factor,2020-06-10,2021-06-24,379 days,Completed,Observational
TAK-500-1001,A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors,2022-04-26,2025-03-20,1059 days,Recruiting,Interventional
PRT1419-02,A Study of PRT1419 in Patients With Advanced Solid Tumors,2021-08-11,2023-02-06,544 days,Completed,Interventional
IIT2020-13-GRESHAM-ELLY,Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients,2020-12-02,2022-07-08,583 days,Recruiting,Interventional
2018-0663,Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients,2021-02-01,2023-07-31,910 days,Recruiting,Interventional
APHP190973,Integrated Care Pathway in Oncology (PASSION),2020-02-21,2022-12-31,1044 days,"Active, not recruiting",Observational
C3441037,A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors,2020-12-21,2022-07-22,578 days,Completed,Interventional
CE 07-14-2020,Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer,2021-03-01,2024-12-31,1401 days,Recruiting,Interventional
ELVCAP-001-01,Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors,2020-09-29,2023-06-01,975 days,"Active, not recruiting",Interventional
202100484,Early Ageing During Therapy in AYA Cancer Patients,2022-02-10,2023-10-01,598 days,Recruiting,Observational
143631,"Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.",2020-03-04,2021-07-15,498 days,Withdrawn,Interventional
ZZITICI-004,Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors,2018-11-01,2033-11-01,5479 days,Recruiting,Interventional
QBS-72S-1001,"Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S",2020-07-20,2022-12-22,885 days,Completed,Interventional
2440LM-002,DNX-2440 for Resectable Colorectal Liver Metastasis,2021-02-15,2023-12-31,1049 days,Recruiting,Interventional
MX-011-219,Project CADENCE (CAncer Detected Early caN be CurEd),2022-07-07,2025-05-01,1029 days,Recruiting,Observational
VISTA-101,A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101),2023-03-03,2024-12-31,669 days,Recruiting,Interventional
ZZICI3-015,Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors,2021-11-01,2025-10-30,1459 days,Recruiting,Interventional
ALS-6000-101,"A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours",2021-07-16,2023-06-30,714 days,Recruiting,Interventional
AA1809,Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors,2018-12-17,2022-01-19,1129 days,Completed,Interventional
PMV-586-101,The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE),2020-10-29,2026-07-14,2084 days,Recruiting,Interventional
R231-A14057,Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.,2020-09-01,2022-10-01,760 days,Completed,Observational
AMXT1501-102,Oral AMXT 1501 Dicaprate in Combination With IV DFMO,2022-11-29,2024-03-31,488 days,Recruiting,Interventional
201909133,Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers,2021-01-15,2023-09-30,988 days,Recruiting,Interventional
ROOT,The Registry of Oncology Outcomes Associated With Testing and Treatment,2021-05-05,2031-10-01,3801 days,Recruiting,Observational
BBI-355-101,"Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy, in Subjects With Tumors With Oncogene Amplifications",2023-04-24,2026-01-31,1013 days,Recruiting,Interventional
FPI-1966-101,A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours,2022-04-20,2026-12-01,1686 days,Recruiting,Interventional
MYCT001,The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology),2019-03-21,2024-03-12,1818 days,Recruiting,Observational
JAB-3312-1002,A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China,2020-06-10,2023-12-01,1269 days,Recruiting,Interventional
707-IO-101,Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies,2021-06-09,2025-07-01,1483 days,Recruiting,Interventional
UW18101,Immunonutrition and Carbohydrate Loading Strategies in Breast Reconstruction,2019-02-01,2021-11-01,1004 days,Completed,Interventional
JAB-3312-1001,"A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors",2019-09-26,2024-03-01,1618 days,Recruiting,Interventional
PAL-E602-001,Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01),2022-02-11,2025-06-01,1206 days,Recruiting,Interventional
340-74,CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC),2018-09-13,2021-03-01,900 days,Withdrawn,Interventional
PRO17070414,Self-Advocacy Serious Game in Advanced Cancer,2018-12-13,2021-03-18,826 days,Completed,Interventional
MAPreminder1,UCLA Health Patient Health Maintenance Text Reminder,2023-03-23,2024-06-30,465 days,Not yet recruiting,Interventional
MFLeong,RCT of Acceptance and Commitment Therapy Versus Mindfulness-based Stress Reduction in Head and Neck Cancer,2021-07-01,2024-06-30,1095 days,Not yet recruiting,Interventional
1100,NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy,2019-01-16,2028-05-30,3422 days,Recruiting,Interventional
MAPinitial,UCLA Health Patient Health Maintenance Outreach Text Message,2023-03-09,2024-06-30,479 days,Enrolling by invitation,Interventional
MAPreminder2,UCLA Health Patient Health Maintenance With Interactive Text Reminder,2023-05-23,2024-06-30,404 days,Not yet recruiting,Interventional
G190165,Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites,2019-07-30,2023-04-14,1354 days,"Active, not recruiting",Interventional
JSKN003-102,To Evaluate the Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors,2023-03-01,2025-12-31,1036 days,Not yet recruiting,Interventional
RAIN-3202,Milademetan in Advanced/Metastatic Solid Tumors,2021-11-01,2024-08-01,1004 days,Recruiting,Interventional
IN10018-010,IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients,2022-03-10,2024-12-31,1027 days,"Active, not recruiting",Interventional
05-2019,Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection,2020-05-04,2024-12-30,1701 days,"Active, not recruiting",Observational
56160922.7.3001.5274,Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds,2023-04-01,2024-04-01,366 days,Not yet recruiting,Interventional
PN #1082409C,Post Market Clinical Follow-up Study on da VinciÂ® Robotic-assisted Prophylactic Nipple Sparing Mastectomy With Breast Reconstruction,2022-01-18,2024-01-01,713 days,"Active, not recruiting",Observational
CH1701,CH1701 for Prevention and Treatment of Radiation Burns,2019-07-05,2020-12-01,515 days,Unknown status,Interventional
A222001,Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer,2021-07-30,2024-05-01,1006 days,Recruiting,Interventional
D0816C00020,Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients,2018-01-30,2022-03-10,1500 days,Completed,Interventional
K01CA190659,Culturally Appropriate Nutrition Communication for Mexican American Women,2019-03-25,2022-12-25,1371 days,"Active, not recruiting",Interventional
TOS-358-001,A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors,2023-02-15,2025-12-01,1020 days,Recruiting,Interventional
UW19-183,"The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence",2021-07-21,2023-12-31,893 days,Recruiting,Interventional
2011P002580-207,Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints,2021-03-10,2022-05-16,432 days,Completed,Observational
SI-B003-101,"A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors",2020-11-10,2023-05-01,902 days,Recruiting,Interventional
PROT004,Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer,2022-03-10,2022-12-15,280 days,"Active, not recruiting",Interventional
EK 1612/2018,Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing,2018-11-01,2022-06-30,1337 days,Completed,Interventional
202006168,Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome,2021-04-09,2023-10-31,935 days,Recruiting,Interventional
FT-003,"Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy",2019-06-11,2037-12-01,6748 days,Recruiting,Observational
BO41929,A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors,2021-05-24,2022-05-16,357 days,Terminated,Interventional
IRB202201399 -N-R,A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials,2023-01-01,2027-08-31,1703 days,Not yet recruiting,Interventional
FLX475-02,Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab,2018-09-25,2023-12-01,1893 days,Recruiting,Interventional
2019-A02135-52,Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine,2020-08-25,2029-09-15,3308 days,Recruiting,Interventional
18-504,Smartphone Technology to Alleviate Malignant Pain (STAMP),2018-11-01,2022-05-01,1277 days,Completed,Interventional
DB-1305-O-1001,First-in-human Study of DB-1305 for Advanced/Metastatic Solid Tumors,2022-07-19,2025-06-30,1077 days,Recruiting,Interventional
TAS0612-101,A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer,2020-10-15,2024-06-01,1325 days,Recruiting,Interventional
IIT2021-07-Atkins-CARMA,Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial,2022-10-07,2024-08-31,694 days,"Active, not recruiting",Interventional
1948-CL-0101,"A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors",2018-07-02,2023-06-30,1824 days,"Active, not recruiting",Interventional
CO-338-100,A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes,2019-11-21,2022-07-15,967 days,Terminated,Interventional
STUDY00020629,Identifying and Caring for Individuals With Inherited Cancer Syndrome,2020-03-09,2030-06-10,3745 days,Recruiting,Interventional
E7766-G000-101,Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101,2020-02-24,2022-07-26,883 days,Completed,Interventional
NRG-GU006,BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER,2018-04-27,2028-10-31,3840 days,"Active, not recruiting",Interventional
BBI-20201001,A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors,2020-02-24,2026-10-31,2441 days,Recruiting,Interventional
ZWI-ZW49-101,A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers,2019-04-15,2025-08-01,2300 days,Recruiting,Interventional
SAHoWMU-CR2021-02-404,Gastric Cancer Marker Detection and Its Kit Development,2021-01-01,2030-12-30,3650 days,Recruiting,Observational
BVAC-B-P1,Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care,2018-02-26,2019-05-13,441 days,Completed,Interventional
IDE397-001,Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion,2021-04-14,2024-06-30,1173 days,Recruiting,Interventional
MDK-703-102,A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors,2023-02-08,2025-09-01,936 days,Recruiting,Interventional
19-011444,Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ,2021-07-26,2026-12-31,1984 days,Recruiting,Interventional
ATTCK-34-01,Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers,2019-03-13,2020-03-12,365 days,Terminated,Interventional
BDTX-189-01,"A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.",2019-12-19,2022-09-16,1002 days,Terminated,Interventional
DB-1310-O-1001,A Study of DB-1310 in Advanced/Metastatic Solid Tumors,2023-04-07,2026-08-31,1242 days,Not yet recruiting,Interventional
NRG-GU009,"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial",2020-12-15,2033-12-31,4764 days,Recruiting,Interventional
7101,Womens Knowledges About Gynaecological Aftercare,2018-07-01,2019-07-01,365 days,Unknown status,Observational
17504,A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer,2020-01-16,2022-06-20,886 days,Completed,Interventional
DGD-44-065,Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years,2021-03-24,2028-12-31,2839 days,Recruiting,Interventional
22-OBU-SH-CA-II-019,Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy,2022-12-01,2024-10-01,670 days,Not yet recruiting,Interventional
20220586-01H,Reexamining Her Cardiovascular Risk - Ottawa WomeNs Longitudinal Cohort Study,2023-04-17,2024-05-24,403 days,Not yet recruiting,Interventional
D8532C00004,"Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers",2022-06-13,2022-12-13,183 days,Completed,Interventional
CLIN-17-008,Study of the Safety and Effectiveness of Motiva ImplantsÂ®,2018-04-06,2033-02-28,5442 days,"Active, not recruiting",Interventional
200-04,A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.,2021-02-26,2024-12-23,1396 days,Recruiting,Observational
Ad-p53-002,Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.,2018-10-01,2022-12-31,1552 days,Unknown status,Interventional
TUMAGNOSTIC(CP506-001),Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI,2023-04-01,2026-05-01,1126 days,Not yet recruiting,Interventional
20210104,A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression,2022-09-23,2026-07-28,1404 days,Recruiting,Interventional
01GS,Early Detection of Five Common Cancers Using the ctDNA Analysing Test,2022-04-10,2023-12-01,600 days,Recruiting,Observational
217228,First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors,2022-03-22,2025-12-29,1378 days,Recruiting,Interventional
CBP-1019-101,A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors,2023-03-14,2025-09-30,931 days,"Active, not recruiting",Interventional
FT516-102,FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors,2020-09-07,2023-01-27,872 days,Completed,Interventional
19-110,Minnesota Care Coordination Effectiveness Study,2021-06-14,2023-12-31,930 days,"Active, not recruiting",Observational
IMC-F106C-101,Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors,2020-02-25,2026-02-01,2168 days,Recruiting,Interventional
TK-Onko,Evaluation of a Oncology Day Care Unit Programme With Two Different Focuses,2020-07-14,2022-05-01,656 days,Completed,Interventional
Pro00103812,Neoadjuvant Immunotherapy in Brain Metastases,2020-11-04,2021-06-17,225 days,Terminated,Interventional
17894,Taking Time to Connect: A Study of Programs for Hispanic Mothers Diagnosed With Cancer and Their Children,2019-04-16,2022-09-30,1263 days,Completed,Interventional
M19-345,"Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors",2019-02-21,2024-04-11,1876 days,Recruiting,Interventional
21-00072,Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy,2021-04-26,2022-03-29,337 days,Completed,Interventional
20246,"Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants",2020-03-02,2020-12-07,280 days,Completed,Interventional
UW21090,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer,2021-11-17,2023-02-07,447 days,Completed,Interventional
18-222,GENetic Education Risk Assessment and TEsting Study,2019-05-08,2027-12-31,3159 days,"Active, not recruiting",Interventional
4830-001,Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001),2018-07-11,2025-11-04,2673 days,Recruiting,Interventional
2020-002766-14,Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab,2021-04-07,2027-03-01,2154 days,Recruiting,Interventional
17-01135,Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome,2019-03-01,2025-03-31,2222 days,Recruiting,Observational
2019-00134,Vitamin D3 - Omega3 - Home Exercise - HeALTHy Aging and Longevity Cohort,2019-11-26,2023-12-31,1496 days,Enrolling by invitation,Observational
AG0315OG/CTC0140,RegoNivo vs Standard of Care Chemotherapy in AGOC,2021-06-01,2026-06-01,1826 days,Recruiting,Interventional
63646,Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer,2022-06-24,2026-10-15,1574 days,Recruiting,Interventional
19-007,DECIDE: Developing Tools for Lung Cancer Screening Discussion Improvement,2019-03-22,2023-03-01,1440 days,Withdrawn,Observational
2018-01B,Stool Collection Sub-Study of Exact Sciences Protocol 2018-01,2020-07-21,2022-05-25,673 days,Completed,Observational
201617079.3,Accelerated Hypofractionated Whole Breast Irradiation Plus Sequential Boost Versus Concomitant Boost Following BCS,2018-06-01,2021-06-30,1125 days,Unknown status,Interventional
IOSI-COVID19-001,A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study,2021-02-25,2023-03-21,754 days,Completed,Observational
C4221015,A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer,2020-12-21,2026-11-15,2155 days,Recruiting,Interventional
ARRAY-818-202,An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer,2019-06-04,2024-06-30,1853 days,"Active, not recruiting",Interventional
0482-001,A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001),2019-06-19,2025-02-19,2072 days,Recruiting,Interventional
03.CP.0.3,Study to Evaluate VORTX Rx (Theresa),2018-03-21,2019-07-17,483 days,Completed,Interventional
GO42144,"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",2020-07-29,2024-11-30,1585 days,Recruiting,Interventional
Ordu55,Nutrition Education and Quality of Life in Cancer Cachexia,2022-03-01,2023-01-01,306 days,Not yet recruiting,Interventional
ORDU551,"Slimming Myokines, Cancers,Nutritional and Psychology Support",2022-08-01,2024-08-01,731 days,Not yet recruiting,Interventional
ONO-4059-09,Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study),2021-12-29,2026-07-01,1645 days,Recruiting,Interventional
19741,"Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",2019-09-30,2023-04-11,1289 days,"Active, not recruiting",Interventional
GOG-8030,Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199,2100-01-01,,,Not yet recruiting,Observational
JTX-8064-101,"Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors",2021-01-12,2024-01-01,1084 days,"Active, not recruiting",Interventional
IBC0966-I/IIa,Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors,2021-08-31,2025-12-01,1553 days,Recruiting,Interventional
"019/026/ICI, CEI/1330/18",Effect of Two Cognitive-Behavioral Interventions on Cervical Cancer Patients,2020-03-02,2022-02-15,715 days,Unknown status,Interventional
LCH-112020,Subzero and Scorpion Trial,2020-11-16,2023-09-01,1019 days,Recruiting,Interventional
HP-00070946,Exercise Effect on Chemotherapy-Induced Neuropathic Pain,2018-03-01,2023-06-01,1918 days,"Active, not recruiting",Interventional
18HLGENE03,Evaluation of the Adhesion to the GENEPY Network,2019-08-01,2020-12-31,518 days,Unknown status,Observational
FGCL-4592-898,A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies,2022-03-16,2023-05-12,422 days,Recruiting,Interventional
2000034075,Buprenorphine Integration Research and Community Health,2023-01-24,2026-05-31,1223 days,Recruiting,Interventional
CR108454,A Study of Participants With Advanced Prostate Cancer in Canada,2018-04-12,2026-07-09,3010 days,"Active, not recruiting",Observational
APHP180586,Evaluating Effectiveness of a Communication Facilitator : A Randomized Trial,2020-01-01,2021-06-01,517 days,Unknown status,Interventional
NCI-2020-07841,Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer,2021-01-04,2024-06-30,1273 days,Recruiting,Interventional
S60857,FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study,2019-03-13,2025-12-31,2485 days,Recruiting,Interventional
MO19/127559,Tolerance of Anti-Cancer Therapy in the Elderly,2020-11-01,2023-06-01,942 days,Recruiting,Observational
RPCR-breast 01,Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT),2022-08-15,2027-06-01,1751 days,Recruiting,Observational
T30-0002,Evaluation of Viatarâ¢ Oncopheresis System in Removing CTC From Whole Blood,2018-09-01,2019-05-01,242 days,Unknown status,Interventional
WP-2021-03,Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy,2022-06-01,2024-08-01,792 days,Not yet recruiting,Observational
CAMH2_1001,"A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer",2021-09-14,2025-01-17,1221 days,Recruiting,Interventional
CIRB Ref. No: 2019/2135,Health-related Quality of Life-intervention in Survivors of Breast and Other Cancers Experiencing Cancer-related Fatigue Using Traditional Chinese Medicine: The HERBAL Trial,2019-10-24,2022-06-09,959 days,Unknown status,Interventional
Nigeria World Cancer Walk 2022,"Step up to Health, Nigeria! Impact of 2022 World Cancer Day Walk on Health Behaviors Among Nigerians",2022-02-05,2022-02-05,0 days,Not yet recruiting,Interventional
NRG-HN010,"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer",2022-09-30,2028-07-31,2131 days,Recruiting,Interventional
D081SC00001Sub,Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort),2021-06-24,2026-03-31,1741 days,"Active, not recruiting",Interventional
FatebenefratelliH,Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging,2021-04-01,2030-12-31,3561 days,Recruiting,Observational
D081SC00001,Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer,2018-10-31,2022-10-30,1460 days,"Active, not recruiting",Interventional
2019P001434-2,Examining Validity and Reliability of the Shared Decision Making Process Survey in Adults With Depression,2020-04-29,2020-12-30,245 days,Completed,Observational
H18-02052,BREAST ADM Trial for Alloplastic Breast Reconstruction,2020-11-25,2021-12-31,401 days,Unknown status,Interventional
REG-114-2019,Histopathologic Effect of Calcium Electroporation on Cancer in the Skin,2020-04-20,2024-02-01,1382 days,Recruiting,Interventional
20-0270-E,Family History App in Personalized Medicine,2021-09-20,2023-12-01,802 days,"Active, not recruiting",Interventional
PRO00104179,Onco-primary Care Networking to Support TEAM-based Care,2021-06-14,2024-03-31,1021 days,Recruiting,Interventional
SJHH_PSPM,Post SBRT Pulmonary Metastasectomy (PSPM) Trial,2020-07-14,2023-12-31,1265 days,Recruiting,Interventional
823871-iGame,Digital Intervention for the Modification of Lifestyles (iGame),2021-09-01,2023-09-28,757 days,Not yet recruiting,Interventional
2018-0419,Pediatric Reporting of Adult-Onset Genomic Results,2020-11-25,2024-06-30,1313 days,Recruiting,Interventional
2019-00965,The SERENITY Study: Online Mindfulness-Based Cancer Recovery for Patients With Gynecological Cancer,2019-12-19,2022-09-30,1016 days,Completed,Interventional
COALESE/2021/103,Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy,2022-09-01,2024-03-01,547 days,Recruiting,Interventional
BC 09915,Lymphedema After Gyneco-oncologic Treatment,2022-06-01,2025-06-30,1125 days,Recruiting,Observational
7013,MRI in Ductal Carcinoma in Situ (DCIS),2018-02-26,2019-02-01,340 days,Unknown status,Observational
2017_71,PAGETEXÂ® Photodynamic Therapy Device for the Treatment of Extra Mammary Pagets Disease of the Vulva (EMPV).,2019-08-27,2024-08-01,1801 days,Recruiting,Interventional
22-200,"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer",2023-03-31,2032-03-25,3282 days,Not yet recruiting,Observational
PYC001,The Use of PycnogenolÂ® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments,2018-10-01,2020-09-15,715 days,Unknown status,Interventional
22-01516,NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation,2023-04-01,2026-10-01,1279 days,Not yet recruiting,Interventional
2U01HG007292-05,Cancer Health Assessments Reaching Many,2018-08-15,2023-12-31,1964 days,"Active, not recruiting",Interventional
20201224,Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate,2021-05-01,2024-12-01,1310 days,Not yet recruiting,Interventional
CTMS# 19-0069,Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0,2019-07-17,2023-06-03,1417 days,"Active, not recruiting",Interventional
E2019453,Bovine Pericardial Patch and TiLOOPÂ® Bra Mesh in Immediate Implant Breast Reconstruction.,2020-01-01,2022-12-31,1095 days,Unknown status,Interventional
21-103,A Study to Develop a Strategy to Increase Lung Cancer Screening in Women Who May Be at Risk for Lung Cancer,2021-04-09,2024-04-09,1096 days,"Active, not recruiting",Interventional
ABCSG C08,ABCSG C08-Exercise II: Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer,2019-02-14,2026-12-01,2847 days,Recruiting,Interventional
PCA001,Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer,2023-01-30,2027-04-01,1522 days,Recruiting,Interventional
CASE1121,Prepectoral vs Partial Subpectoral Two-Stage Implant-Based Breast Reconstruction,2023-04-01,2023-07-01,91 days,Not yet recruiting,Interventional
Nigeria Cancer Walk,"Step up to Health, Nigeria! Impact of World Cancer Day Walk on Health Behaviors Among Nigerians",2020-02-01,2020-02-01,0 days,Completed,Interventional
20172841,The PREDICT Registry for DCIS Patients With DCISionRT Testing,2018-02-27,2035-11-01,6456 days,Suspended,Observational
RC31/18/0440,Abatacept and the Risk of Cancer: a Case Non-case Analysis in VigiBase,2018-11-20,2019-06-28,220 days,Unknown status,Observational
SDLNOC,Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy,2021-06-01,2021-12-31,213 days,Recruiting,Observational
20-565,Comparing Two Different Surgical Techniques for Breast Reconstruction,2021-01-14,2021-12-13,333 days,Withdrawn,Interventional
Arabic BREAST-Q,Validity and Reliability of Arabic Version of Breast Questionnaire,2023-04-01,2023-07-01,91 days,Not yet recruiting,Interventional
UPCC 11919,Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients,2020-08-17,2024-01-01,1232 days,Recruiting,Interventional
2021-1211,Development of an Application-Based Digital Navigator for Perioperative Breast Surgery Patients,2022-02-28,2023-12-31,671 days,Recruiting,Observational
segmental thoracic TEA-spinal,US-guided Thoracic Spinal Epidural Anesthesia VS GA for Abdominal and Breast Surgeries,2022-03-01,2022-10-14,227 days,Completed,Interventional
IRB-22-34,Comparison of Patient Satisfaction in Post-operative Breast Surgery Patients Having Physical Clinic and Tele Clinic Follow up: A Randomized Controlled Trial,2022-12-01,2023-08-01,243 days,Enrolling by invitation,Interventional
PSCI-19-112,Diminish Chemotherapy Related Side Effects Through Patient Education,2021-03-24,2023-12-31,1012 days,Recruiting,Interventional
LSHBSWMBC,Screening of Cancer Through Novel Female Specific Biomarkers,2019-05-15,2019-12-31,230 days,Unknown status,Observational
2016-0463,REVOLVE or PureGraft Technique in Processing Fat Grafts for Patients Undergoing Breast Reconstruction,2018-02-13,2021-08-06,1270 days,Completed,Interventional
IIT-0013,MR Imaging Study Using the Northern Alberta Linac-MR (Northern LIGHTs - 1),2021-08-23,2023-08-01,708 days,Recruiting,Interventional
BND and RND,Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection,2018-01-01,2018-12-31,364 days,Unknown status,Interventional
TheNethersole,Effects of Music Intervention Combined With Progressive Muscle Relaxation in Cancer Patients,2022-03-08,2022-08-10,155 days,Completed,Interventional
1655,Cell-free DNA in Hereditary And High-Risk Malignancies,2018-07-01,2023-10-01,1918 days,Recruiting,Observational
N-111012422,Diet Effect on Cancer Treatment Outcome,2022-10-12,2023-12-14,428 days,"Active, not recruiting",Interventional
302,"177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)",2022-08-31,2024-12-31,853 days,Withdrawn,Interventional
MC01/01/19,Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE),2019-05-29,2022-05-01,1068 days,Unknown status,Interventional
Colorectal Cancer,Colorectal Cancer Awareness in Turkey,2019-05-01,2019-08-15,106 days,Unknown status,Observational
LCCC1748,Academic-Industrial Partnership for Translation of Acoustic Angiography,2019-03-25,2021-05-25,792 days,Completed,Interventional
1992110-1,Engaging Diverse and Underserved Communities in Cancer Awareness Training and Education,2023-03-07,2025-03-01,725 days,Recruiting,Observational
CSC-20200324,Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis,2020-03-30,2020-12-31,276 days,Unknown status,Observational
69HCL22_0466,Lung Cancer Screening Implementation Among Employees at Lyon Hospital,2022-09-13,2024-09-12,730 days,Not yet recruiting,Interventional
IMPACNEO,IMPACt of an Enhanced Screening Program on the Detection of Non-AIDS NEOplasms in HIV Patients,2019-11-11,2023-06-30,1327 days,Recruiting,Interventional
0029-20-ZIV,Smurf2 Gene Expression in Urinary Tract Tumors,2021-12-01,2023-12-01,730 days,Not yet recruiting,Observational
HKG-KZ-LNG-102,Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA,2018-07-01,2019-07-19,383 days,Terminated,Observational
GCO 19-2707,To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer,2020-10-01,2023-10-01,1095 days,Withdrawn,Interventional
LIFT project,Longitudinal Investigation of Cancer-related Fatigue and Its Treatment (LIFT Project),2021-08-20,2024-02-28,922 days,Recruiting,Observational
RECO_CT29A,Investigation of Urinary Biomarkers for the Detection of Prostate Cancer,2023-07-01,2024-04-01,275 days,Suspended,Interventional
S1614,Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors,2019-02-21,2027-02-28,2929 days,"Active, not recruiting",Interventional
INT 292/20,Lung Cancer Prevention Screening Programme in Italy,2022-09-17,2026-09-01,1445 days,Recruiting,Interventional
STUDY21020095,Efficacy of a Self-advocacy Serious Game Intervention,2022-08-22,2026-08-31,1470 days,Recruiting,Interventional
D967MC00001,A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations,2020-12-30,2028-01-17,2574 days,"Active, not recruiting",Interventional
UHHeidelberg,Decision Aid to Support Advanced Cancer Patients,2019-10-01,2023-04-01,1278 days,Recruiting,Interventional
R01CA205025,Understanding the Post-Surgical Non-Small Cell Lung Cancer Patients Symptom Experience,2019-06-04,2024-04-01,1763 days,Recruiting,Interventional
2019-PVSEP,Drugs for the Treatment of Multiple Sclerosis and Risk of Cancer: a Pharmacovigilance Analysis in Vigibase,2020-01-01,2020-03-01,60 days,Unknown status,Observational
HCB/2021/0130,Mapping Sentinel Lymph Node in Initial Stages of Ovarian Cancer,2021-01-01,2023-05-01,850 days,Recruiting,Interventional
TMHPO1763,A Pilot Study on HPV and Cervical Cancer Screening in Mumbai,2018-04-01,2018-05-01,30 days,Unknown status,Interventional
002.1,Telegenetics or In-Person Genetic Counselling,2021-02-01,2024-02-01,1095 days,Recruiting,Observational
LIFT,Longitudinal Investigation of Cancer-related Fatigue,2019-03-01,2025-06-01,2284 days,Withdrawn,Observational
2767,The Role of Vitamin D in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer,2020-09-01,2023-08-31,1094 days,Recruiting,Observational
APHP210359,Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of Prostate Cancer (HRPCa-II),2022-10-01,2027-11-01,1857 days,Not yet recruiting,Interventional
M16VIB,Vinorelbine in Advanced BRAF-like Colon Cancer,2018-03-01,2020-03-01,731 days,Unknown status,Interventional
EPOC1903,Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer,2020-12-01,2024-06-01,1278 days,"Active, not recruiting",Interventional
CASE2118,Integrated Imaging System for In Vivo Visualization of Free Flap Perfusion Using Indocyanine Dye,2019-11-22,2023-08-01,1348 days,Suspended,Interventional
PARALUC,Pneumonitis After Radiotherapy for Lung Cancer,2020-09-01,2024-06-01,1369 days,Recruiting,Interventional
CTC20200417,Influence of Opioids on Circulating Tumor Cells in Radical Cystectomy,2020-06-02,2021-01-21,233 days,Completed,Interventional
09.2019.1026,Prognostic Value of Body Composition in Lung Cancer,2019-01-01,2019-07-01,181 days,Completed,Observational
CASE4119,The Impact of Functional Medicine On Wound Healing From Delayed Autologous Breast Reconstruction,2021-11-01,2024-01-01,791 days,Recruiting,Interventional
EC/GOVT/24/IRB23,Comprehensive Digital Archive of Cancer Imaging-Radiation Oncology( CHAVI-RO ),2018-08-31,2021-02-28,912 days,Completed,Observational
CFTSp195,A Survey Exploring Health and Screening Tests in People Treated for Hodgkin Lymphoma,2021-06-01,2021-09-28,119 days,Completed,Observational
04/20,Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer,2020-05-11,2024-05-11,1461 days,Recruiting,Observational
29BRC20.0021,Screening for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism,2020-09-08,2028-09-08,2922 days,Recruiting,Interventional
MRI in urinary bladder tumors,Role of MRI in Assessment of the Urinary Bladder Wall Post Transurethral Tumor Resection,2023-04-01,2024-12-01,610 days,Not yet recruiting,Observational
CRUKD/21/004 - Treatment Arm 2,"DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition",2023-04-01,2029-10-01,2375 days,Not yet recruiting,Interventional
20201491,Culturally Tailored Nurse Coaching Study for Cancer Symptom Management,2021-09-23,2023-05-31,615 days,Recruiting,Interventional
32900654326,"TPVB, PECSB, ESPB for Postmastectmy Pain",2019-04-10,2021-08-10,853 days,Completed,Interventional
ReDA 13176,A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.,2023-04-01,2029-04-01,2192 days,Not yet recruiting,Interventional
64121317.4.1001.5330,Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial),2018-06-01,2022-03-01,1369 days,"Active, not recruiting",Interventional
3-2020-0038,Intraoperative Radiation Therapy for Resectable Pancreatic Cancer,2020-04-02,2026-04-01,2190 days,Recruiting,Interventional
2018PS02,Pharmacist and Data Driven Quality Improvement in Primary Care,2020-09-16,2021-06-30,287 days,Completed,Observational
